Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,0.72,620,DB00683,Midazolam
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,7.2,621,DB00683,Midazolam
,28747995,Ki,"Due to the inhibition of the particular intestinal CYP3A4, the obtained Ki values of 14 µM of propiverine (30 mg daily, IR) resulted in a predicted doubling of the AUC for midazolam (CYP3A4 substrate).",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,14,622,DB00683,Midazolam
,23777257,Km,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,33,1718,DB00683,Midazolam
,23777257,Vmax,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),1/[min],0.20,1719,DB00683,Midazolam
,23777257,inhibition constant,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,37,1720,DB00683,Midazolam
,23777257,maximum plasma concentration,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,10.5,1721,DB00683,Midazolam
,8500918,tmax,"In a supine position, the gastrointestinal absorption rate of flunitrazepam (tmax 0.6 h) was faster than that of midazolam (tmax 0.95 h).",Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500918/),h,0.6,1771,DB00683,Midazolam
,8500918,tmax,"In a supine position, the gastrointestinal absorption rate of flunitrazepam (tmax 0.6 h) was faster than that of midazolam (tmax 0.95 h).",Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500918/),h,0.95,1772,DB00683,Midazolam
,9512844,gamma,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,6.0,1964,DB00683,Midazolam
,9512844,IC50,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,2.1,1965,DB00683,Midazolam
,9512844,t1/2Keo,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,2.1,1966,DB00683,Midazolam
,11851636,clearance,"Interestingly there was no significant change in the clearance of lignocaine (6.4 vs 5.8 (95% CI for the difference -2.74, -1.51) ml kg-1 min-1).",Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851636/),kg·ml,6.4,2363,DB00683,Midazolam
,11851636,clearance,"Interestingly there was no significant change in the clearance of lignocaine (6.4 vs 5.8 (95% CI for the difference -2.74, -1.51) ml kg-1 min-1).",Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851636/),kg·ml,5.8,2364,DB00683,Midazolam
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,7.30,2403,DB00683,Midazolam
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,7.17,2404,DB00683,Midazolam
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,6.91,2405,DB00683,Midazolam
,24216249,apparent pA2,"The potency of flumazenil, estimated by apparent pA2 values (95% CI), was 7.30 (7.12, 7.49), 7.17 (7.03, 7.31), 6.91 (6.72, 7.10) and 6.80 (6.67, 6.92) at 15, 30, 60 and 120min after flumazenil administration, respectively.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),,6.80,2406,DB00683,Midazolam
,24216249,functional half life,"The functional half life of flumazenil, derived from potency estimates, was 57±13min.",Quantitative pharmacological analyses of the interaction between flumazenil and midazolam in monkeys discriminating midazolam: Determination of the functional half life of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24216249/),min,57,2407,DB00683,Midazolam
,2723115,total clearance,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),[ml] / [kg·min],3.34,3045,DB00683,Midazolam
,2723115,total clearance,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),[ml] / [kg·min],5.63,3046,DB00683,Midazolam
,2723115,total elimination rate constant,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),1/[h],0.400,3047,DB00683,Midazolam
,2723115,total elimination rate constant,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),1/[h],0.721,3048,DB00683,Midazolam
,2723115,elimination half-life,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,7.36,3049,DB00683,Midazolam
,2723115,elimination half-life,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,3.80,3050,DB00683,Midazolam
,2723115,bioavailability,The bioavailability of oral midazolam was significantly (P less than 0.05) higher in patients than controls (76% vs. 38%).,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),%,76,3051,DB00683,Midazolam
,2723115,bioavailability,The bioavailability of oral midazolam was significantly (P less than 0.05) higher in patients than controls (76% vs. 38%).,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),%,38,3052,DB00683,Midazolam
,2723115,-,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,32.4,3053,DB00683,Midazolam
,2723115,-,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,11.8,3054,DB00683,Midazolam
,2723115,half-life,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,32.4,3055,DB00683,Midazolam
,2723115,half-life,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,11.8,3056,DB00683,Midazolam
,18077730,95% inhibitory concentration,Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum).,Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18077730/),nM,33,3393,DB00683,Midazolam
,3425871,Elimination half-life,Elimination half-life ranged from 0.72 to 15.06 h.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,0.72 to 15.06,3654,DB00683,Midazolam
,3425871,Cl,Cl ranged from 2.5 to 12.8 ml/min per kilogram.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),[ml] / [kg·min],2.5 to 12.8,3655,DB00683,Midazolam
,3425871,t1/2el,Four patients (= 9%) had a t1/2el of 7-15 h; in 16 cases we found secondary concentration peaks.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,7-15,3656,DB00683,Midazolam
up to,3425871,half-life,"In accordance with others, we found some patients with a half-life of up to 15 h, which might reflect the influence of the anesthesia itself.",[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,15,3657,DB00683,Midazolam
,15618678,liver concentrations,"Meanwhile, the liver concentrations of itraconazole after single administration and repeated administration were 38.2 and 20.3 (nmol/g), respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),,38.2,5137,DB00683,Midazolam
,15618678,liver concentrations,"Meanwhile, the liver concentrations of itraconazole after single administration and repeated administration were 38.2 and 20.3 (nmol/g), respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),,20.3,5138,DB00683,Midazolam
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],2.26,5139,DB00683,Midazolam
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],3,5140,DB00683,Midazolam
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,8,5141,DB00683,Midazolam
,15618678,maximum metabolic reaction velocity (V(max)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],2.23,5142,DB00683,Midazolam
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,8,5143,DB00683,Midazolam
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),[nM] / [mg·min],1,5144,DB00683,Midazolam
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,7.86,5145,DB00683,Midazolam
,15618678,Michaelis-Menten constant (K(m)),"In vitro maximum metabolic reaction velocity (V(max)) and Michaelis-Menten constant (K(m)) of midazolam were increased from 2.26 to 3.84 (nmol/min/mg protein) and from 8.28 to 13.0 (microM) by single itraconazole treatment, respectively, and decreased from 2.23 to 1.17 (nmol/min/mg protein) and from 7.86 to 4.47 (microM) by repeated treatment, respectively.",Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618678/),μM,4.47,5146,DB00683,Midazolam
>,8924728,Recoveries,Recoveries were > 70%.,"Measurement by HPLC of midazolam and its major metabolite, 1-hydroxymidazolam in plasma of very premature neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924728/),%,70,5241,DB00683,Midazolam
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,8.79,5916,DB00683,Midazolam
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,20.17,5917,DB00683,Midazolam
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,16.18,5918,DB00683,Midazolam
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,17.66,5919,DB00683,Midazolam
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.51,8972,DB00683,Midazolam
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.34,8973,DB00683,Midazolam
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.32,8974,DB00683,Midazolam
,10073325,clearance,"Tirilazad clearance was significantly higher in premenopausal women (0.51 +/- 0.09 L/hr/kg) than in postmenopausal groups (0.34 +/- 0.07, 0.32 +/- 0.06, and 0.36 +/- 0.08 L/hr/kg, respectively) (p = 0.0001).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.36,8975,DB00683,Midazolam
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.64,8976,DB00683,Midazolam
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.47,8977,DB00683,Midazolam
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.49,8978,DB00683,Midazolam
,10073325,Midazolam clearance,"Midazolam clearance (0.64 +/- 0.12 L/hr/kg) was significantly higher in premenopausal women compared to postmenopausal groups (0.47 +/- 0.11, 0.49 +/- 0.11, and 0.53 +/- 0.19 L/hr/kg, respectively) (p = 0.037).",Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073325/),[l] / [h·kg],0.53,8979,DB00683,Midazolam
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],1400,9368,DB00683,Midazolam
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],583,9369,DB00683,Midazolam
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],416,9370,DB00683,Midazolam
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],296,9371,DB00683,Midazolam
,16615673,elimination t1/2,The first level likely represents a predistributional level with subsequent levels giving an elimination t1/2 of 17.38 h.,Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),h,17.38,9372,DB00683,Midazolam
,16615673,t1/2,The elimination of the parent drug corresponds to an approximate t1/2 of 15-20 h in this single case.,Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),h,15-20,9373,DB00683,Midazolam
,1804652,tmax,After IN administration the rapid onset of absorption was observed (tmax 12 min).,Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804652/),min,12,9399,DB00683,Midazolam
,1804652,half-life,After both routes of administration the half-life was similar (2.2 h IN and 2.4 h IV).,Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804652/),h,2.2,9400,DB00683,Midazolam
,1804652,half-life,After both routes of administration the half-life was similar (2.2 h IN and 2.4 h IV).,Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804652/),h,2.4,9401,DB00683,Midazolam
,1804652,bioavailability,The results are consistent with an estimated mean bioavailability of 55%.,Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804652/),%,55,9402,DB00683,Midazolam
,9856717,V1,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),l,32.2,9781,DB00683,Midazolam
,9856717,V2,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),l,53,9782,DB00683,Midazolam
,9856717,V3,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),l,245,9783,DB00683,Midazolam
,9856717,Cl1,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),[l] / [min],0.43,9784,DB00683,Midazolam
,9856717,Cl2,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),[l] / [min],0.56,9785,DB00683,Midazolam
,9856717,Cl3,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),[l] / [min],0.39,9786,DB00683,Midazolam
,9856717,elimination half-life,The calculated elimination half-life was 15 h.,Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),h,15,9787,DB00683,Midazolam
,28301431,hepatic,"The hepatic and intestinal extraction ratios for midazolam were 0.11 ± 0.06 and 0.64 ± 0.25, respectively; however, CYP3A4 activity was nearly 5-fold lower in our CD cohort compared with published data among healthy subjects.",CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301431/),,0.11,12020,DB00683,Midazolam
,28301431,in,"The hepatic and intestinal extraction ratios for midazolam were 0.11 ± 0.06 and 0.64 ± 0.25, respectively; however, CYP3A4 activity was nearly 5-fold lower in our CD cohort compared with published data among healthy subjects.",CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301431/),,0.11,12021,DB00683,Midazolam
,22190555,recovery times,"Median recovery times after approximately equieffective doses of remimazolam (0.10 and 0.15 mg/kg) and midazolam (0.075 mg/kg) were 10 and 40 minutes, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22190555/),min,10,12232,DB00683,Midazolam
,22190555,recovery times,"Median recovery times after approximately equieffective doses of remimazolam (0.10 and 0.15 mg/kg) and midazolam (0.075 mg/kg) were 10 and 40 minutes, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22190555/),min,40,12233,DB00683,Midazolam
,2933205,steady-state plasma concentration,Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004).,Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],56.7,12601,DB00683,Midazolam
,2933205,steady-state plasma concentration,Cimetidine significantly increased the mean (+/- SD) steady-state plasma concentration of midazolam from 56.7 +/- 7.8 to 71.3 +/- 19.6 ng/ml (P = 0.004).,Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],71.3,12602,DB00683,Midazolam
,2933205,steady-state midazolam concentration,"In contrast, the steady-state midazolam concentration after ranitidine dosing (61.8 +/- 6.8 ng/ml) did not differ significantly from that after placebo.",Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933205/),[ng] / [ml],61.8,12603,DB00683,Midazolam
,27511886,AUC0-∞,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[h∙ng] / [ml],210·0,13881,DB00683,Midazolam
,27511886,AUC0-∞,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[h∙ng] / [ml],313·9,13882,DB00683,Midazolam
,27511886,CL/F,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[l] / [h·kg],1·16,13883,DB00683,Midazolam
,27511886,CL/F,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[l] / [h·kg],0·88,13884,DB00683,Midazolam
,26380154,Oral bioavailability,Oral bioavailability (population mean value [RSE%] of 0.28 (7.1%)) showed 24-hour variation that was best parameterized as a cosine function with an amplitude of 0.04 (17.3%) and a peak at 12:14 in the afternoon.,Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26380154/),,0.28,13905,DB00683,Midazolam
,26380154,Clearance,Clearance (0.38 L/min (4.8%)) showed a minor 24-hour variation with an amplitude of 0.03 (14.8%) L/min and a peak at 18:50.,Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26380154/),[l] / [min],0.38,13906,DB00683,Midazolam
,3411438,AUC0-4,"The mean AUC0-4 value following sublingual administration was significantly greater than that following oral administration (14889 vs 3594 ng. min/ml, p less than 0.05).",Relative bioavailability of midazolam following sublingual versus oral administration in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411438/),[min·ng] / [ml],14889,14028,DB00683,Midazolam
,3411438,AUC0-4,"The mean AUC0-4 value following sublingual administration was significantly greater than that following oral administration (14889 vs 3594 ng. min/ml, p less than 0.05).",Relative bioavailability of midazolam following sublingual versus oral administration in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411438/),[min·ng] / [ml],3594,14029,DB00683,Midazolam
,7995003,CL,CL and Vc (mean +/- SE) were found to be directly proportional to birth weight (CL = 0.070 +/- 0.013 L/kg/hr; VC = 0.591 +/- 0.065 L/kg).,Population pharmacokinetics of midazolam in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995003/),[l] / [h·kg],0.070,14206,DB00683,Midazolam
,7995003,VC,CL and Vc (mean +/- SE) were found to be directly proportional to birth weight (CL = 0.070 +/- 0.013 L/kg/hr; VC = 0.591 +/- 0.065 L/kg).,Population pharmacokinetics of midazolam in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995003/),[l] / [kg],0.591,14207,DB00683,Midazolam
,7995003,Vp,"The Vp and Q (mean +/- SE; 0.42 +/- 0.11 L and 0.29 +/- 0.08 L/hr, respectively) were not influenced by any of the covariates studied.",Population pharmacokinetics of midazolam in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995003/),l,0.42,14208,DB00683,Midazolam
,7995003,Q,"The Vp and Q (mean +/- SE; 0.42 +/- 0.11 L and 0.29 +/- 0.08 L/hr, respectively) were not influenced by any of the covariates studied.",Population pharmacokinetics of midazolam in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995003/),[l] / [h],0.29,14209,DB00683,Midazolam
,11269571,Ki,"In vitro microsomal inhibition assays indicated that RG 12525 is a potent inhibitor of CYP3A4, with a Ki value of 0.5 microM.","Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269571/),μM,0.5,14463,DB00683,Midazolam
,7083724,total plasma clearance,"While no significant changes could be observed in the absorption and distribution process or the elimination half lives, total plasma clearance was higher during part A (616+/-157 ml/min, P=0.01) and C(463+/-82 ml/min, P=0.02), than in part B (317+/-110 ml/min, +/-SD).",Physiologic and temporal variation in hepatic elimination of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),[ml] / [min],616,14589,DB00683,Midazolam
,7083724,total plasma clearance,"While no significant changes could be observed in the absorption and distribution process or the elimination half lives, total plasma clearance was higher during part A (616+/-157 ml/min, P=0.01) and C(463+/-82 ml/min, P=0.02), than in part B (317+/-110 ml/min, +/-SD).",Physiologic and temporal variation in hepatic elimination of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),[ml] / [min],463,14590,DB00683,Midazolam
,7083724,total plasma clearance,"While no significant changes could be observed in the absorption and distribution process or the elimination half lives, total plasma clearance was higher during part A (616+/-157 ml/min, P=0.01) and C(463+/-82 ml/min, P=0.02), than in part B (317+/-110 ml/min, +/-SD).",Physiologic and temporal variation in hepatic elimination of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),[ml] / [min],317,14591,DB00683,Midazolam
,7083724,intrinsic (oral) clearance,"Since the intrinsic (oral) clearance was also higher during part A (1656+/-657 ml/min, P=0.003) and C(1310+/-579 ml/min, P=0.024) than during part B(710+/-241 ml/min), bioavailability did not change (range 37 to 44%).",Physiologic and temporal variation in hepatic elimination of midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),[ml] / [min],1656,14592,DB00683,Midazolam
,7083724,intrinsic (oral) clearance,"Since the intrinsic (oral) clearance was also higher during part A (1656+/-657 ml/min, P=0.003) and C(1310+/-579 ml/min, P=0.024) than during part B(710+/-241 ml/min), bioavailability did not change (range 37 to 44%).",Physiologic and temporal variation in hepatic elimination of midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),[ml] / [min],1310,14593,DB00683,Midazolam
,7083724,intrinsic (oral) clearance,"Since the intrinsic (oral) clearance was also higher during part A (1656+/-657 ml/min, P=0.003) and C(1310+/-579 ml/min, P=0.024) than during part B(710+/-241 ml/min), bioavailability did not change (range 37 to 44%).",Physiologic and temporal variation in hepatic elimination of midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),[ml] / [min],710,14594,DB00683,Midazolam
,7083724,bioavailability,"Since the intrinsic (oral) clearance was also higher during part A (1656+/-657 ml/min, P=0.003) and C(1310+/-579 ml/min, P=0.024) than during part B(710+/-241 ml/min), bioavailability did not change (range 37 to 44%).",Physiologic and temporal variation in hepatic elimination of midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083724/),%,37 to 44,14595,DB00683,Midazolam
,23363357,Maximum concentrations,"Maximum concentrations after IV administration (median, 1,394 ng/mL [range, 1,150 to 1,503 ng/mL]) and IM administration (411 ng/mL [217 to 675 ng/mL]) were measured at 3 minutes and at 5 to 30 minutes, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),[ng] / [ml],"1,394",15836,DB00683,Midazolam
,23363357,Maximum concentrations,"Maximum concentrations after IV administration (median, 1,394 ng/mL [range, 1,150 to 1,503 ng/mL]) and IM administration (411 ng/mL [217 to 675 ng/mL]) were measured at 3 minutes and at 5 to 30 minutes, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),[ng] / [ml],411,15837,DB00683,Midazolam
,23363357,Distribution half-life,Distribution half-life was 18.7 minutes (13 to 47 minutes) after IV administration and 41 minutes (30 to 80 minutes) after IM administration.,Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),min,18.7,15838,DB00683,Midazolam
,23363357,Distribution half-life,Distribution half-life was 18.7 minutes (13 to 47 minutes) after IV administration and 41 minutes (30 to 80 minutes) after IM administration.,Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),min,41,15839,DB00683,Midazolam
,23363357,Elimination half-life,"Elimination half-life was 98 minutes (67 to 373 minutes) and 234 minutes (103 to 320 minutes) after IV and IM administration, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),min,98,15840,DB00683,Midazolam
,23363357,Elimination half-life,"Elimination half-life was 98 minutes (67 to 373 minutes) and 234 minutes (103 to 320 minutes) after IV and IM administration, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),min,234,15841,DB00683,Midazolam
,23363357,Total clearance,"Total clearance after IV administration was 11.3 mL/min/kg (6.7 to 13.9 mL/min/kg), and steady-state volume of distribution was 525 mL/kg (446 to 798 mL/kg).",Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),[ml] / [kg·min],11.3,15842,DB00683,Midazolam
,23363357,steady-state volume of distribution,"Total clearance after IV administration was 11.3 mL/min/kg (6.7 to 13.9 mL/min/kg), and steady-state volume of distribution was 525 mL/kg (446 to 798 mL/kg).",Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),[ml] / [kg],525,15843,DB00683,Midazolam
,23363357,Bioavailability,Bioavailability of midazolam after IM administration was 92%.,Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363357/),%,92,15844,DB00683,Midazolam
,11259329,maximum inactivation rate constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),1/[min],0.0665,16036,DB00683,Midazolam
,11259329,apparent inactivation constant,"The maximum inactivation rate constant and the apparent inactivation constant of EM on MDZ metabolism were 0.0665 min(-1) and 81.8 microM, respectively.","Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259329/),μM,81.8,16037,DB00683,Midazolam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,29,19159,DB00683,Midazolam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,58.7,19160,DB00683,Midazolam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,55.4,19161,DB00683,Midazolam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,17.2,19162,DB00683,Midazolam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,24.6,19163,DB00683,Midazolam
,21474682,maximal inactivation rate constants (k(inact)),"Inactivation studies of mibefradil against the two isozymes showed that the maximal inactivation rate constants (k(inact)) were considerable in both isozymes (0.231-0.565 min(-1)), whereas the inhibitor concentration producing half the k(inact) (K(I, app)) of CYP3A2 (0.263-0.410 μM) was a good deal lower than that for CYP2C11 (6.82-11.4 μM).",Quantitative prediction of mechanism-based inhibition caused by mibefradil in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474682/),1/[min],0.231-0.565,19368,DB00683,Midazolam
,21474682,"half the k(inact) (K(I, app))","Inactivation studies of mibefradil against the two isozymes showed that the maximal inactivation rate constants (k(inact)) were considerable in both isozymes (0.231-0.565 min(-1)), whereas the inhibitor concentration producing half the k(inact) (K(I, app)) of CYP3A2 (0.263-0.410 μM) was a good deal lower than that for CYP2C11 (6.82-11.4 μM).",Quantitative prediction of mechanism-based inhibition caused by mibefradil in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474682/),μM,0.263-0.410,19369,DB00683,Midazolam
,21474682,"half the k(inact) (K(I, app))","Inactivation studies of mibefradil against the two isozymes showed that the maximal inactivation rate constants (k(inact)) were considerable in both isozymes (0.231-0.565 min(-1)), whereas the inhibitor concentration producing half the k(inact) (K(I, app)) of CYP3A2 (0.263-0.410 μM) was a good deal lower than that for CYP2C11 (6.82-11.4 μM).",Quantitative prediction of mechanism-based inhibition caused by mibefradil in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21474682/),μM,6.82-11.4,19370,DB00683,Midazolam
,31028057,IC50,"Compared with vehicle, indinavir (10 μM) inhibited midazolam 1'-hydroxylation by recombinant CYP3A4, human liver microsomes, and high-CYP3A activity cryopreserved human hepatocytes by ≥70%; the IC50 obtained with hepatocytes (2.7 μM) was within reported human unbound indinavir Cmax (≤5 μM).",Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028057/),μM,2.7,20008,DB00683,Midazolam
≤,31028057,Cmax,"Compared with vehicle, indinavir (10 μM) inhibited midazolam 1'-hydroxylation by recombinant CYP3A4, human liver microsomes, and high-CYP3A activity cryopreserved human hepatocytes by ≥70%; the IC50 obtained with hepatocytes (2.7 μM) was within reported human unbound indinavir Cmax (≤5 μM).",Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31028057/),μM,5,20009,DB00683,Midazolam
,19808952,area under the concentration-time curve ratios,Triiodothyronine administration significantly reduced the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0.36 to 0.25 (P < .05) and urinary ratios of 6 beta-hydroxycortisol/free cortisol from 6.92 to 5.88 (P < .05).,Effect of thyroid hormone on the activity of CYP3A enzyme in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808952/),,0.,21070,DB00683,Midazolam
,1504187,maximum quantity,The maximum quantity was 5.5 micrograms in the washed autologous red cell concentrate.,[The effect of blood conservation techniques on the plasma concentration and elimination of midazolam in patients undergoing hip joint surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1504187/),μg,5.5,21271,DB00683,Midazolam
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,121.8,21797,DB00683,Midazolam
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,254.5,21798,DB00683,Midazolam
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.28,21799,DB00683,Midazolam
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.17,21800,DB00683,Midazolam
,6120700,absolute bioavailability,The mean absolute bioavailability is 91% for the hydrochloride and 82% for the lactate.,[Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration/2nd comm.: Pharmacokinetical aspects (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120700/),%,91,21866,DB00683,Midazolam
,6120700,absolute bioavailability,The mean absolute bioavailability is 91% for the hydrochloride and 82% for the lactate.,[Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration/2nd comm.: Pharmacokinetical aspects (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120700/),%,82,21867,DB00683,Midazolam
,3358886,steady state plasma levels,2. Subsequently to an intravenous loading dose (0.07 mg kg-1) midazolam was infused for 6 h (0.035 mg kg-1 h-1) and steady state plasma levels between 54 to 114 micrograms l-1 were achieved.,Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),[μg] / [l],54 to 114,22717,DB00683,Midazolam
,3358886,t 1/2,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),h,2.5,22718,DB00683,Midazolam
,3358886,CL,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),[ml] / [min],548,22719,DB00683,Midazolam
,3358886,t 1/2,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),h,2.4,22720,DB00683,Midazolam
,3358886,CL,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),[ml] / [min],512,22721,DB00683,Midazolam
,30317077,run time,"The separation was carried out on a ZORBAX Eclipse Plus C18 Rapid Resolution High Definition column with a gradient elution, using water containing 0.1% formic acid (A) and acetonitrile (B) in a run time of only 3.0 min.","A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30317077/),min,3.0,22823,DB00683,Midazolam
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],283.7,23877,DB00683,Midazolam
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],295.7,23878,DB00683,Midazolam
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23879,DB00683,Midazolam
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23880,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],292.0,23881,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23882,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],424.9,23883,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23884,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],595.3,23885,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],760.6,23886,DB00683,Midazolam
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],788.7,23887,DB00683,Midazolam
,2869795,tmax,Absorption of midazolam proceeded very rapidly (median tmax = 0.4 h) and a rapid onset of sedative action was observed.,Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869795/),h,0.4,24105,DB00683,Midazolam
,2869795,tmax,Loprazolam absorption was relatively slow (median tmax = 3 h) and its absorption profile was often irregular.,Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869795/),h,3,24106,DB00683,Midazolam
,2869795,peak concentrations,"Median peak concentrations were 94 ng ml-1 and 3.1 ng ml-1 for midazolam and loprozolam, respectively.",Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869795/),[ng] / [ml],94,24107,DB00683,Midazolam
,2869795,peak concentrations,"Median peak concentrations were 94 ng ml-1 and 3.1 ng ml-1 for midazolam and loprozolam, respectively.",Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869795/),[ng] / [ml],3.1,24108,DB00683,Midazolam
,2869795,elimination half-life,The median elimination half-life of midazolam was 1.8 h and that of loprazolam 15 h.,Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869795/),h,1.8,24109,DB00683,Midazolam
,2869795,elimination half-life,The median elimination half-life of midazolam was 1.8 h and that of loprazolam 15 h.,Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869795/),h,15,24110,DB00683,Midazolam
,8061260,clearance,"The set of Scott et al with the lowest clearance (2.4 mL/kg/min) shows the best accuracy (MDAPE: 19.5%) and precision (P10: -40%, P90: 16%).",Predictive accuracy of alfentanil infusion in coronary artery surgery: a prebypass study in middle-aged and elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061260/),[ml] / [kg·min],2.4,24143,DB00683,Midazolam
,17619868,AUC(CSF)/AUC(serum) (0-120 min) concentration ratios,"The mean AUC(CSF)/AUC(serum) (0-120 min) concentration ratios were 0.18 and 0.09 after IV and IM, respectively.",Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17619868/),,0.18,24202,DB00683,Midazolam
,17619868,AUC(CSF)/AUC(serum) (0-120 min) concentration ratios,"The mean AUC(CSF)/AUC(serum) (0-120 min) concentration ratios were 0.18 and 0.09 after IV and IM, respectively.",Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17619868/),,0.09,24203,DB00683,Midazolam
,17470527,bioavailability,"The bioavailability of midazolam after oral administration was minimal in monkeys and rats, being only 2.1 and 1.1%, respectively.",Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470527/),%,2.1,24776,DB00683,Midazolam
,17470527,bioavailability,"The bioavailability of midazolam after oral administration was minimal in monkeys and rats, being only 2.1 and 1.1%, respectively.",Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470527/),%,1.1,24777,DB00683,Midazolam
,17470527,mucosal extraction ratio,"The values of mucosal extraction ratio were estimated to be 0.97, 0.93, and 0.89 during apical-to-basal transport in the upper, middle, and lower small intestine of monkeys, respectively, whereas the corresponding values for rats were close to zero, indicating that extensive metabolism of midazolam occurs, particularly in the upper region of the small intestine in monkeys, but not rats.",Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470527/),,0.97,24778,DB00683,Midazolam
,17470527,mucosal extraction ratio,"The values of mucosal extraction ratio were estimated to be 0.97, 0.93, and 0.89 during apical-to-basal transport in the upper, middle, and lower small intestine of monkeys, respectively, whereas the corresponding values for rats were close to zero, indicating that extensive metabolism of midazolam occurs, particularly in the upper region of the small intestine in monkeys, but not rats.",Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470527/),,0.93,24779,DB00683,Midazolam
,17470527,mucosal extraction ratio,"The values of mucosal extraction ratio were estimated to be 0.97, 0.93, and 0.89 during apical-to-basal transport in the upper, middle, and lower small intestine of monkeys, respectively, whereas the corresponding values for rats were close to zero, indicating that extensive metabolism of midazolam occurs, particularly in the upper region of the small intestine in monkeys, but not rats.",Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17470527/),,0.89,24780,DB00683,Midazolam
,9024169,area under the plasma triazolam concentration-time curve,The area under the plasma triazolam concentration-time curve in the rifampin phase was only 5.1% of that in the placebo phase (0.74 +/- 0.14 versus 14.8 +/- 1.0 ng.hr/ml [mean +/- SEM; p < 0.001]).,Triazolam is ineffective in patients taking rifampin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[h·ng] / [ml],0.74,24933,DB00683,Midazolam
,9024169,area under the plasma triazolam concentration-time curve,The area under the plasma triazolam concentration-time curve in the rifampin phase was only 5.1% of that in the placebo phase (0.74 +/- 0.14 versus 14.8 +/- 1.0 ng.hr/ml [mean +/- SEM; p < 0.001]).,Triazolam is ineffective in patients taking rifampin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[h·ng] / [ml],14.8,24934,DB00683,Midazolam
,9024169,maximum plasma concentration,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[ng] / [ml],2.9,24935,DB00683,Midazolam
,9024169,maximum plasma concentration,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[ng] / [ml],0.36,24936,DB00683,Midazolam
,9024169,elimination half-life,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),h,2.8,24937,DB00683,Midazolam
,9024169,elimination half-life,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),h,1.3,24938,DB00683,Midazolam
,7122996,limit of sensitivity,"Employing 3H-midazolam as the radioligand and a rabbit antiserum to a diazo conjugate of 5'-aminomidazolam and albumin, the method has a limit of sensitivity of 2 ng/ml of midazolam using a 20 microliters sample of plasma.",Midazolam: radioimmunoassay for pharmacokinetic studies in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122996/),[ng] / [ml],2,25136,DB00683,Midazolam
,2186650,time,The corresponding time was 125 minutes in those given midazolam.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,125,25278,DB00683,Midazolam
,2186650,elimination half-life,Pharmacokinetic analysis in 20 patients showed that the elimination half-life of propofol was prolonged (470 minutes) and clearance was reduced (1.14 litres/minute) compared with subjects who had not undergone cardiopulmonary bypass.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,470,25279,DB00683,Midazolam
,2186650,clearance,Pharmacokinetic analysis in 20 patients showed that the elimination half-life of propofol was prolonged (470 minutes) and clearance was reduced (1.14 litres/minute) compared with subjects who had not undergone cardiopulmonary bypass.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),[l] / [min],1.14,25280,DB00683,Midazolam
,2186650,redistribution half-life,"The rapid clinical recovery was reflected in a rapid redistribution half-life (13.4 minutes), but this was also longer than the redistribution time of 2-4 minutes in other patients.",Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,13.4,25281,DB00683,Midazolam
,2186650,red,"The rapid clinical recovery was reflected in a rapid redistribution half-life (13.4 minutes), but this was also longer than the redistribution time of 2-4 minutes in other patients.",Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,2-4,25282,DB00683,Midazolam
,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,∼100,27489,DB00683,Midazolam
<,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,25,27490,DB00683,Midazolam
,26114209,Bioavailability,"Bioavailability of midazolam was 4% in marmosets, presumably because of contribution of marmoset P450 3A4 expressed in small intestine and liver, with a high catalytic efficiency for midazolam 1'-hydroxylation as evident in the recombinant system.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,4,27491,DB00683,Midazolam
,30739353,bioavailability,"The results showed that the bioavailability of olerciamide A using hepatic, gastric and intestinal routes were 92.16%, 84.88% and 5.76%, respectively.","Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739353/),%,92.16,27840,DB00683,Midazolam
,30739353,bioavailability,"The results showed that the bioavailability of olerciamide A using hepatic, gastric and intestinal routes were 92.16%, 84.88% and 5.76%, respectively.","Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739353/),%,84.88,27841,DB00683,Midazolam
,30739353,bioavailability,"The results showed that the bioavailability of olerciamide A using hepatic, gastric and intestinal routes were 92.16%, 84.88% and 5.76%, respectively.","Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739353/),%,5.76,27842,DB00683,Midazolam
,2619028,peak plasma concentrations,Group 2: Rectal midazolam 0.35 mg/kg has a remarkably short onset of action with peak plasma concentrations (71 ng/ml) in the range of sedative levels in adults occurring in 7.5 min.,[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),[ng] / [ml],71,28058,DB00683,Midazolam
,2619028,peak levels,"Group 3 patients had peak levels of midazolam of 246 ng/ml after 12.5 min, falling to an average concentration of 120 ng/ml after 2 h.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),[ng] / [ml],246,28059,DB00683,Midazolam
,2619028,peak levels,"Group 3 patients had peak levels of midazolam of 246 ng/ml after 12.5 min, falling to an average concentration of 120 ng/ml after 2 h.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),ng,120,28060,DB00683,Midazolam
,2619028,bioavailability,"The bioavailability of rectal midazolam, comparing the area under the median curves, is 4.7% in group 2 and 16.1% in group 3.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),%,4.7,28061,DB00683,Midazolam
,2619028,bioavailability,"The bioavailability of rectal midazolam, comparing the area under the median curves, is 4.7% in group 2 and 16.1% in group 3.",[Pharmacokinetic studies following intravenous and rectal administration of midazolam in children]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619028/),%,16.1,28062,DB00683,Midazolam
,2350533,elimination half-life,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),h,4 to 4.5,28301,DB00683,Midazolam
,2350533,elimination half-life,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),h,less,28302,DB00683,Midazolam
,2350533,elimination half-life,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),h,3,28303,DB00683,Midazolam
,2350533,systemic clearance,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),[ml] / [min],376,28304,DB00683,Midazolam
,2350533,systemic clearance,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),[ml] / [min],551,28305,DB00683,Midazolam
,2350533,peak plasma drug concentration,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),[ng] / [ml],76,28306,DB00683,Midazolam
,2350533,peak plasma drug concentration,"In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1).",The pharmacokinetics of midazolam in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),[ng] / [ml],42,28307,DB00683,Midazolam
,2350533,systemic availability,"The systemic availability (45 vs 41%), the steady state volume of distribution (111 vs 108 l) and the time of peak plasma drug concentration after the p.o. dose (0.9 vs 0.9 h) were unchanged.",The pharmacokinetics of midazolam in patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),%,45,28308,DB00683,Midazolam
,2350533,systemic availability,"The systemic availability (45 vs 41%), the steady state volume of distribution (111 vs 108 l) and the time of peak plasma drug concentration after the p.o. dose (0.9 vs 0.9 h) were unchanged.",The pharmacokinetics of midazolam in patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),%,41,28309,DB00683,Midazolam
,2350533,steady state volume of distribution,"The systemic availability (45 vs 41%), the steady state volume of distribution (111 vs 108 l) and the time of peak plasma drug concentration after the p.o. dose (0.9 vs 0.9 h) were unchanged.",The pharmacokinetics of midazolam in patients with congestive heart failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),l,111,28310,DB00683,Midazolam
,2350533,steady state volume of distribution,"The systemic availability (45 vs 41%), the steady state volume of distribution (111 vs 108 l) and the time of peak plasma drug concentration after the p.o. dose (0.9 vs 0.9 h) were unchanged.",The pharmacokinetics of midazolam in patients with congestive heart failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),l,108,28311,DB00683,Midazolam
,2350533,time of peak plasma drug concentration,"The systemic availability (45 vs 41%), the steady state volume of distribution (111 vs 108 l) and the time of peak plasma drug concentration after the p.o. dose (0.9 vs 0.9 h) were unchanged.",The pharmacokinetics of midazolam in patients with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350533/),h,0.9,28312,DB00683,Midazolam
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],3.20,28337,DB00683,Midazolam
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],6.78,28338,DB00683,Midazolam
,15051745,EC(50),"An in vitro reporter gene assay also demonstrated the CYP3A isozyme induction potential of M100240 and MDL 100,173 with an EC(50) approximately 1.5 microM.","No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051745/),μM,1.5,29736,DB00683,Midazolam
,32304015,elimination half-life,Median maximum concentration was reached 2-6 h following single and repeat dosing of gilteritinib; mean elimination half-life was 113 h.,Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304015/),h,113,29795,DB00683,Midazolam
,6117393,t1/2 beta,Hepatic elimination is rapid: t1/2 beta is 2.4 +/- 0.8 hr (mean +/- S.D) and total body clearance is 283 +/- 43 ml/min (plasma) or 502 +/- 105 ml/min (blood).,Midazolam kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117393/),h,2.4,30396,DB00683,Midazolam
,6117393,total body clearance,Hepatic elimination is rapid: t1/2 beta is 2.4 +/- 0.8 hr (mean +/- S.D) and total body clearance is 283 +/- 43 ml/min (plasma) or 502 +/- 105 ml/min (blood).,Midazolam kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117393/),[ml] / [min],283,30397,DB00683,Midazolam
,6117393,total body clearance,Hepatic elimination is rapid: t1/2 beta is 2.4 +/- 0.8 hr (mean +/- S.D) and total body clearance is 283 +/- 43 ml/min (plasma) or 502 +/- 105 ml/min (blood).,Midazolam kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117393/),[ml] / [min],502,30398,DB00683,Midazolam
,6117393,bioavailability,"This substantial first-pass effect leads to bioavailability of only 44%, despite very rapid absorption (t1/2abs = 0.23 +/- 0.37 hr) after oral dosing.",Midazolam kinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117393/),%,44,30399,DB00683,Midazolam
,6117393,t1/2abs,"This substantial first-pass effect leads to bioavailability of only 44%, despite very rapid absorption (t1/2abs = 0.23 +/- 0.37 hr) after oral dosing.",Midazolam kinetics. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6117393/),h,0.23,30400,DB00683,Midazolam
,29653346,m/,"Precursor-to-product transitions were optimized to be m/z 450.1/260.1, m/z 464.1/98.1, and m/z 326.1/291.1 for crizotinib, crizotinib-lactam and midazolam (internal standard), respectively.",Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653346/),,450.1,30539,DB00683,Midazolam
,29653346,m/z,"Precursor-to-product transitions were optimized to be m/z 450.1/260.1, m/z 464.1/98.1, and m/z 326.1/291.1 for crizotinib, crizotinib-lactam and midazolam (internal standard), respectively.",Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653346/),,464.1,30540,DB00683,Midazolam
,29653346,m/z,"Precursor-to-product transitions were optimized to be m/z 450.1/260.1, m/z 464.1/98.1, and m/z 326.1/291.1 for crizotinib, crizotinib-lactam and midazolam (internal standard), respectively.",Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653346/),,98.1,30541,DB00683,Midazolam
,29653346,m/z,"Precursor-to-product transitions were optimized to be m/z 450.1/260.1, m/z 464.1/98.1, and m/z 326.1/291.1 for crizotinib, crizotinib-lactam and midazolam (internal standard), respectively.",Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653346/),,326.1,30542,DB00683,Midazolam
,29653346,m/z,"Precursor-to-product transitions were optimized to be m/z 450.1/260.1, m/z 464.1/98.1, and m/z 326.1/291.1 for crizotinib, crizotinib-lactam and midazolam (internal standard), respectively.",Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653346/),,291.1,30543,DB00683,Midazolam
more,29653346,extraction recovery,The extraction recovery was more than 87.12%.,Simple and sensitive LC-MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29653346/),%,87.12,30544,DB00683,Midazolam
,15509184,plasma elimination half-life,It has a long plasma elimination half-life (1 week) and accumulates about 10-fold in plasma during daily administration.,Bicalutamide: clinical pharmacokinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509184/),week,1,30607,DB00683,Midazolam
,18223475,Total body clearance,"Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[l] / [kg],33,30671,DB00683,Midazolam
,18223475,intrinsic hepatic clearance,"Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[ml] / [kg·min],19,30672,DB00683,Midazolam
,18223475,half-life,"Despite the high body clearance, the half-life of MDZ was in the range of 24 hours, approximately 10 times higher than after normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),h,24,30673,DB00683,Midazolam
,18223475,volume of distribution at steady state,"The volume of distribution at steady state was 33 L/kg, approximately 50 times higher than after normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),[l] / [kg],33,30674,DB00683,Midazolam
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,58,30675,DB00683,Midazolam
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,3,30676,DB00683,Midazolam
,18223475,free fraction,"The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses.",Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223475/),%,6,30677,DB00683,Midazolam
,17803735,half-life of elimination,"Estimates of the half-life of elimination of midazolam were 0.42, 1.45, 1.90, and 9.71 h for turkeys, chickens, bobwhite quail, and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,0.42,31058,DB00683,Midazolam
,17803735,half-life of elimination,"Estimates of the half-life of elimination of midazolam were 0.42, 1.45, 1.90, and 9.71 h for turkeys, chickens, bobwhite quail, and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,1.45,31059,DB00683,Midazolam
,17803735,half-life of elimination,"Estimates of the half-life of elimination of midazolam were 0.42, 1.45, 1.90, and 9.71 h for turkeys, chickens, bobwhite quail, and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,1.90,31060,DB00683,Midazolam
,17803735,half-life of elimination,"Estimates of the half-life of elimination of midazolam were 0.42, 1.45, 1.90, and 9.71 h for turkeys, chickens, bobwhite quail, and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,9.71,31061,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 1-hydroxymidazolam were 1.35, 1.86, 1.97, and 13.97 h for turkey, chicken, bobwhite quail and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,1.35,31062,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 1-hydroxymidazolam were 1.35, 1.86, 1.97, and 13.97 h for turkey, chicken, bobwhite quail and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,1.86,31063,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 1-hydroxymidazolam were 1.35, 1.86, 1.97, and 13.97 h for turkey, chicken, bobwhite quail and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,1.97,31064,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 1-hydroxymidazolam were 1.35, 1.86, 1.97, and 13.97 h for turkey, chicken, bobwhite quail and pheasant, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,13.97,31065,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 4-hydroxymidazolam were 0.76, 1.23, 2.85, and 13.82 h for chicken, turkey, pheasant, and bobwhite quail, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,0.76,31066,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 4-hydroxymidazolam were 0.76, 1.23, 2.85, and 13.82 h for chicken, turkey, pheasant, and bobwhite quail, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,1.23,31067,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 4-hydroxymidazolam were 0.76, 1.23, 2.85, and 13.82 h for chicken, turkey, pheasant, and bobwhite quail, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,2.85,31068,DB00683,Midazolam
,17803735,Elimination half-lives,"Elimination half-lives for 4-hydroxymidazolam were 0.76, 1.23, 2.85, and 13.82 h for chicken, turkey, pheasant, and bobwhite quail, respectively.","Plasma pharmacokinetics of midazolam in chickens, turkeys, pheasants and bobwhite quail. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803735/),h,13.82,31069,DB00683,Midazolam
,10381758,steady-state plasma concentrations,The continuous administration of dobutamine (steady-state plasma concentrations: 217 +/- 118 ng.,Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381758/),ng,217,32054,DB00683,Midazolam
,10381758,plasma levels,"In parallel, dobutamine plasma levels increased significantly (275 +/- 165 ng. ml-1; p <.05).",Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381758/),[ng] / [ml],275,32055,DB00683,Midazolam
,1855349,elimination half-life,"An almost significant circadian variation was found in elimination half-life, shortest at 2 PM (1.26 +/- 0.47 hours, mean +/- SD) and longest at 2 AM (1.57 +/- 0.44 hours) (p = 0.05).",The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855349/),h,1.26,33781,DB00683,Midazolam
,1855349,elimination half-life,"An almost significant circadian variation was found in elimination half-life, shortest at 2 PM (1.26 +/- 0.47 hours, mean +/- SD) and longest at 2 AM (1.57 +/- 0.44 hours) (p = 0.05).",The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855349/),h,1.57,33782,DB00683,Midazolam
,31802534,infusion rate,The mean propofol infusion rate was significantly higher in patients not monitored by BIS scores than in those who were (5.44 ± 2.12 vs 4.76 ± 1.84 mg/kg/h; P = 0.016).,Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31802534/),[mg] / [h·kg],5.44,34296,DB00683,Midazolam
,31802534,infusion rate,The mean propofol infusion rate was significantly higher in patients not monitored by BIS scores than in those who were (5.44 ± 2.12 vs 4.76 ± 1.84 mg/kg/h; P = 0.016).,Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31802534/),[mg] / [h·kg],4.76,34297,DB00683,Midazolam
,31256150,effectiveness,Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam.,"Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31256150/),%,65.5,34584,DB00683,Midazolam
,31256150,effectiveness,Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam.,"Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31256150/),%,37.1,34585,DB00683,Midazolam
,3176834,elimination half-life,"The elimination half-life of midazolam after i.m. administration (Group 2) was 6.6 +/- 1.2 h (mean +/- s.e. mean), which was significantly longer (P less than 0.05) than the 3.9 +/- 0.3 h observed after the combined i.m. and i.v. administration of midazolam (Group 1), and significantly longer than 2.9 h obtained from a calculated i.v. administration curve.",Prolonged elimination of midazolam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176834/),h,6.6,34699,DB00683,Midazolam
,3176834,elimination half-life,"The elimination half-life of midazolam after i.m. administration (Group 2) was 6.6 +/- 1.2 h (mean +/- s.e. mean), which was significantly longer (P less than 0.05) than the 3.9 +/- 0.3 h observed after the combined i.m. and i.v. administration of midazolam (Group 1), and significantly longer than 2.9 h obtained from a calculated i.v. administration curve.",Prolonged elimination of midazolam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176834/),h,3.9,34700,DB00683,Midazolam
,3176834,elimination half-life,"The elimination half-life of midazolam after i.m. administration (Group 2) was 6.6 +/- 1.2 h (mean +/- s.e. mean), which was significantly longer (P less than 0.05) than the 3.9 +/- 0.3 h observed after the combined i.m. and i.v. administration of midazolam (Group 1), and significantly longer than 2.9 h obtained from a calculated i.v. administration curve.",Prolonged elimination of midazolam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176834/),h,2.9,34701,DB00683,Midazolam
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35144,DB00683,Midazolam
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35145,DB00683,Midazolam
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],6.6,35146,DB00683,Midazolam
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35147,DB00683,Midazolam
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],4.2,35148,DB00683,Midazolam
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],6.6,35149,DB00683,Midazolam
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],7.9,35150,DB00683,Midazolam
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],7.9,35151,DB00683,Midazolam
,15916873,elimination half-life,"Plasma midazolam kinetics was well described by a bi-exponential model, with an elimination half-life of 6.4+/-1.8 h.",Cerebral and plasma kinetics of a high dose of midazolam and correlations with its respiratory effects in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15916873/),h,6.4,35203,DB00683,Midazolam
,20565452,bioavailability,Mean bioavailability of midazolam after nasal administration ranged from 76 +/- 12% to 92 +/- 15%.,Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),%,76,35516,DB00683,Midazolam
,20565452,bioavailability,Mean bioavailability of midazolam after nasal administration ranged from 76 +/- 12% to 92 +/- 15%.,Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),%,92,35517,DB00683,Midazolam
,20565452,C(max),"With formulations delivering 1 mg midazolam, mean C(max) values between 28.1 +/- 9.1 and 30.1 +/- 6.6 ng ml(-1) were reached after 9.4 +/- 3.2-11.3 +/- 4.4 min.",Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),[ng] / [ml],28.1,35518,DB00683,Midazolam
,20565452,C(max),"With formulations delivering 1 mg midazolam, mean C(max) values between 28.1 +/- 9.1 and 30.1 +/- 6.6 ng ml(-1) were reached after 9.4 +/- 3.2-11.3 +/- 4.4 min.",Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),[ng] / [ml],30.1,35519,DB00683,Midazolam
,20565452,C(max),"With formulations delivering 3 mg midazolam, mean C(max) values were between 68.9 +/- 19.8 and 80.6 +/- 15.2 ng ml(-1) after 7.2 +/- 0.7-13.0 +/- 4.3 min.",Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),[ng] / [ml],68.9,35520,DB00683,Midazolam
,20565452,C(max),"With formulations delivering 3 mg midazolam, mean C(max) values were between 68.9 +/- 19.8 and 80.6 +/- 15.2 ng ml(-1) after 7.2 +/- 0.7-13.0 +/- 4.3 min.",Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),[ng] / [ml],80.6,35521,DB00683,Midazolam
,20565452,maximum increase in reaction time,"The maximum increase in reaction time by the chitosan-containing formulation delivering 3 mg midazolam was greater compared with 1 mg midazolam i.v. (95 +/- 78 ms and 19 +/- 22 ms, mean difference 75.5 ms, 95% CI 15.5, 135.5, P < 0.01).",Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),ms,95,35522,DB00683,Midazolam
,20565452,maximum increase in reaction time,"The maximum increase in reaction time by the chitosan-containing formulation delivering 3 mg midazolam was greater compared with 1 mg midazolam i.v. (95 +/- 78 ms and 19 +/- 22 ms, mean difference 75.5 ms, 95% CI 15.5, 135.5, P < 0.01).",Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20565452/),ms,19,35523,DB00683,Midazolam
,7586951,half-life,"For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),min,5.0,35591,DB00683,Midazolam
,7586951,effect site concentration causing 50% of Emax,"For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),[ng] / [ml],13.7,35592,DB00683,Midazolam
,7586951,plasma concentration,"For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),ng,55,35593,DB00683,Midazolam
,7586951,half-life,"For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),min,3.9,35594,DB00683,Midazolam
,7586951,effect site concentration causing 50% of Emax,"For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml.",Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586951/),[ng] / [ml],20.6,35595,DB00683,Midazolam
,16542198,weight-normalized AUC(0-8),"The mean weight-normalized AUC(0-8) was 29.9 (95% confidence interval 15.5, 44.3) and 29.8 (18.6, 40.9) ng h(-1) ml(-1) kg(-1) for males and females, respectively.",Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542198/),[ng] / [h·kg·ml],29.9,35763,DB00683,Midazolam
,16542198,weight-normalized AUC(0-8),"The mean weight-normalized AUC(0-8) was 29.9 (95% confidence interval 15.5, 44.3) and 29.8 (18.6, 40.9) ng h(-1) ml(-1) kg(-1) for males and females, respectively.",Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542198/),[ng] / [h·kg·ml],29.8,35764,DB00683,Midazolam
,18256206,F(a),"When given alone, SQV absorption was extremely low both in situ (F(a) = 0.07%) and in vivo [C(max) = 0.068 microg/ml; area under the curve (AUC) = 6.8 microg x min/ml].","Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256206/),%,0.07,36752,DB00683,Midazolam
,18256206,C(max),"When given alone, SQV absorption was extremely low both in situ (F(a) = 0.07%) and in vivo [C(max) = 0.068 microg/ml; area under the curve (AUC) = 6.8 microg x min/ml].","Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256206/),[μg] / [ml],0.068,36753,DB00683,Midazolam
,18256206,area under the curve (AUC),"When given alone, SQV absorption was extremely low both in situ (F(a) = 0.07%) and in vivo [C(max) = 0.068 microg/ml; area under the curve (AUC) = 6.8 microg x min/ml].","Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256206/),[min·μg] / [ml],6.8,36754,DB00683,Midazolam
,25139487,AUC∞ ),"After oral administration, the dose-normalized erythromycin exposure (AUC∞ ) was 1335 h ng ml(-1) after 250 mg and 3-fold higher after the 1000 mg dose (4051 h ng ml(-1); P < 0.01), suggesting nonlinear pharmacokinetics of erythromycin.",Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25139487/),[h·ng] / [ml],1335,37012,DB00683,Midazolam
,25139487,AUC∞ ),"After oral administration, the dose-normalized erythromycin exposure (AUC∞ ) was 1335 h ng ml(-1) after 250 mg and 3-fold higher after the 1000 mg dose (4051 h ng ml(-1); P < 0.01), suggesting nonlinear pharmacokinetics of erythromycin.",Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25139487/),[h·ng] / [ml],4051,37013,DB00683,Midazolam
,25139487,AUC∞,The relationship between erythromycin exposure and CYP3A activity (Hill equation) revealed a 50% reduction of CYP3A activity by an erythromycin AUC∞ of 2106 h ng ml(-1).,Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25139487/),[h·ng] / [ml],2106,37014,DB00683,Midazolam
,31288895,AUC0-∞,"For midazolam, total quantum SMS (SMST) was 0.9582; total deviation was 0.0525; total variable probability was 4.18 %; total confidence of probability β was 97.17 % under significance level 0.05; AUC0-∞ were 334.3±334.1 ng•h•mL-1 (after administration of midazolam alone) and 206.9±172.2 ng•h•mL-1 (after co-administration of midazolam and flucloxacillin), respectively.",A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288895/),[h·ng] / [ml],334.3,37549,DB00683,Midazolam
,31288895,AUC0-∞,"For midazolam, total quantum SMS (SMST) was 0.9582; total deviation was 0.0525; total variable probability was 4.18 %; total confidence of probability β was 97.17 % under significance level 0.05; AUC0-∞ were 334.3±334.1 ng•h•mL-1 (after administration of midazolam alone) and 206.9±172.2 ng•h•mL-1 (after co-administration of midazolam and flucloxacillin), respectively.",A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288895/),[h·ng] / [ml],206.9,37550,DB00683,Midazolam
,31288895,AUC0-∞,"While, for 1'-hydroxy midazolam, SMST was 0.6920; total deviation was 0.3960; total variable probability was 30.80 %; total confidence of probability β was 94.10 % under significance level 0.05; AUC0-∞ were 1364±810.7 ng•h•mL-1 (after administration of midazolam alone) and 1637±632.6 ng•h•mL-1 (after co-administration of midazolam and flucloxacillin), respectively.",A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288895/),[h·ng] / [ml],1364,37551,DB00683,Midazolam
,31288895,AUC0-∞,"While, for 1'-hydroxy midazolam, SMST was 0.6920; total deviation was 0.3960; total variable probability was 30.80 %; total confidence of probability β was 94.10 % under significance level 0.05; AUC0-∞ were 1364±810.7 ng•h•mL-1 (after administration of midazolam alone) and 1637±632.6 ng•h•mL-1 (after co-administration of midazolam and flucloxacillin), respectively.",A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288895/),[h·ng] / [ml],1637,37552,DB00683,Midazolam
,9610952,EC50,"The EC50 values were 7.34 and 9.93 microg/ml for i.p. and p.o. caffeine, respectively.",Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610952/),[μg] / [ml],7.34,38290,DB00683,Midazolam
,9610952,EC50,"The EC50 values were 7.34 and 9.93 microg/ml for i.p. and p.o. caffeine, respectively.",Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610952/),[μg] / [ml],9.93,38291,DB00683,Midazolam
,1487833,apparent volume of distribution,"Mean (+/- SD) apparent volume of distribution was 3.0 +/- 0.9 l/kg, mean elimination half-life was 77 +/- 18 min, and clearance was 27 +/- 3 ml/kg/min.",Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487833/),[l] / [kg],3.0,38361,DB00683,Midazolam
,1487833,elimination half-life,"Mean (+/- SD) apparent volume of distribution was 3.0 +/- 0.9 l/kg, mean elimination half-life was 77 +/- 18 min, and clearance was 27 +/- 3 ml/kg/min.",Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487833/),min,77,38362,DB00683,Midazolam
,1487833,clearance,"Mean (+/- SD) apparent volume of distribution was 3.0 +/- 0.9 l/kg, mean elimination half-life was 77 +/- 18 min, and clearance was 27 +/- 3 ml/kg/min.",Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487833/),[ml] / [kg·min],27,38363,DB00683,Midazolam
,1487833,peak midazolam concentration,"A mean peak midazolam concentration of 549 +/- 121 ng/ml was reached within 15 min, and systemic availability was over 90% in each dog.",Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487833/),[ng] / [ml],549,38364,DB00683,Midazolam
over,1487833,systemic availability,"A mean peak midazolam concentration of 549 +/- 121 ng/ml was reached within 15 min, and systemic availability was over 90% in each dog.",Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487833/),%,90,38365,DB00683,Midazolam
,1487833,systemic availability,Oral administration to one dog resulted in peak midazolam concentrations within 10 min and a systemic availability of 69%.,Pharmacokinetics and preliminary observations of behavioral changes following administration of midazolam to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487833/),%,69,38366,DB00683,Midazolam
,31860112,AUC,"Regimen 6 involved 5 mg doses with a 48 h interval from Day 1-20, increasing to 5 mg once daily on Week 3, yielding AUC and Ctrough values of 37.2 mg·h/L and 1.3 mg/L, respectively.",Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31860112/),[h·mg] / [l],37.2,38699,DB00683,Midazolam
,31860112,Ctrough,"Regimen 6 involved 5 mg doses with a 48 h interval from Day 1-20, increasing to 5 mg once daily on Week 3, yielding AUC and Ctrough values of 37.2 mg·h/L and 1.3 mg/L, respectively.",Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31860112/),[mg] / [l],1.3,38700,DB00683,Midazolam
,19456308,C(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),[ng] / [ml],179.2,38753,DB00683,Midazolam
,19456308,C(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),[ng] / [ml],62.8,38754,DB00683,Midazolam
,19456308,T(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),min,28.8,38755,DB00683,Midazolam
,19456308,T(max),"The C(max) and T(max) values for i.n. DZP and MDZ were 179.2 ng/ml and 28.8 min vs 62.8 ng/ml and 21.6 min, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),min,21.6,38756,DB00683,Midazolam
,19456308,to,"Immediately following i.n. administration, subjects reported tolerability scores of 6.75 and 6.0, and identical pain scores, 3.2, for DZP and MDZ, respectively.",Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19456308/),,6,38757,DB00683,Midazolam
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39239,DB00683,Midazolam
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39240,DB00683,Midazolam
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39241,DB00683,Midazolam
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39242,DB00683,Midazolam
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39243,DB00683,Midazolam
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39244,DB00683,Midazolam
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],4.4,39245,DB00683,Midazolam
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),%,13,39246,DB00683,Midazolam
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],27.1,39247,DB00683,Midazolam
,28992870,time to peak midazolam concentration,"The median time to peak midazolam concentration was 10.1 min (interquartile range 9.7-10.8 min), and the median time to the procedure was 26 min (interquartile range 21-34 min).",Evaluating Clinical Effectiveness and Pharmacokinetic Profile of Atomized Intranasal Midazolam in Children Undergoing Laceration Repair. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28992870/),min,10.1,39253,DB00683,Midazolam
,28992870,time to the procedure,"The median time to peak midazolam concentration was 10.1 min (interquartile range 9.7-10.8 min), and the median time to the procedure was 26 min (interquartile range 21-34 min).",Evaluating Clinical Effectiveness and Pharmacokinetic Profile of Atomized Intranasal Midazolam in Children Undergoing Laceration Repair. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28992870/),min,26,39254,DB00683,Midazolam
,21204116,flow rate,The mobile phase was a gradient with 10 m m formic acid in Milli-Q water and methanol at a flow rate of 0.3 mL/min.,"A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204116/),[ml] / [min],0.3,39740,DB00683,Midazolam
,21204116,Total run time,Total run time was 10 min.,"A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204116/),min,10,39741,DB00683,Midazolam
,21204116,recoveries,Mean recoveries were between 94 and 109% for midazolam and its metabolites.,"A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204116/),%,94 and 109,39742,DB00683,Midazolam
,25588320,Dose-normalized AUC,"Dose-normalized AUC and Cmax were 37.1 ng ml(-1 ) h [95% CI 35.5, 40.6] and 39.1 ng ml(-1) [95% CI 30.4, 50.2] for the microdose and 39.0 ng ml(-1 ) h [95% CI 36.1, 42.1] and 37.1 ng ml(-1) [95% CI 26.9, 51.3] for the milligram dose.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[h·ng] / [ml],37.1,39998,DB00683,Midazolam
,25588320,Dose-normalized AUC,"Dose-normalized AUC and Cmax were 37.1 ng ml(-1 ) h [95% CI 35.5, 40.6] and 39.1 ng ml(-1) [95% CI 30.4, 50.2] for the microdose and 39.0 ng ml(-1 ) h [95% CI 36.1, 42.1] and 37.1 ng ml(-1) [95% CI 26.9, 51.3] for the milligram dose.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[h·ng] / [ml],39.0,39999,DB00683,Midazolam
,25588320,Cmax,"Dose-normalized AUC and Cmax were 37.1 ng ml(-1 ) h [95% CI 35.5, 40.6] and 39.1 ng ml(-1) [95% CI 30.4, 50.2] for the microdose and 39.0 ng ml(-1 ) h [95% CI 36.1, 42.1] and 37.1 ng ml(-1) [95% CI 26.9, 51.3] for the milligram dose.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[ng] / [ml],39.1,40000,DB00683,Midazolam
,25588320,Cmax,"Dose-normalized AUC and Cmax were 37.1 ng ml(-1 ) h [95% CI 35.5, 40.6] and 39.1 ng ml(-1) [95% CI 30.4, 50.2] for the microdose and 39.0 ng ml(-1 ) h [95% CI 36.1, 42.1] and 37.1 ng ml(-1) [95% CI 26.9, 51.3] for the milligram dose.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[ng] / [ml],37.1,40001,DB00683,Midazolam
,25588320,CLmet,"CLmet was 253 ml min(-1) [95% CI 201, 318] vs. 278 ml min(-1) [95% CI 248, 311] for intravenous doses and 1880 ml min(-1) [95% CI 1590, 2230] vs. 2050 ml min(-1) [95% CI 1720, 2450] for oral doses.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[ml] / [min],253,40002,DB00683,Midazolam
,25588320,CLmet,"CLmet was 253 ml min(-1) [95% CI 201, 318] vs. 278 ml min(-1) [95% CI 248, 311] for intravenous doses and 1880 ml min(-1) [95% CI 1590, 2230] vs. 2050 ml min(-1) [95% CI 1720, 2450] for oral doses.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[ml] / [min],278,40003,DB00683,Midazolam
,25588320,CLmet,"CLmet was 253 ml min(-1) [95% CI 201, 318] vs. 278 ml min(-1) [95% CI 248, 311] for intravenous doses and 1880 ml min(-1) [95% CI 1590, 2230] vs. 2050 ml min(-1) [95% CI 1720, 2450] for oral doses.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[ml] / [min],1880,40004,DB00683,Midazolam
,25588320,CLmet,"CLmet was 253 ml min(-1) [95% CI 201, 318] vs. 278 ml min(-1) [95% CI 248, 311] for intravenous doses and 1880 ml min(-1) [95% CI 1590, 2230] vs. 2050 ml min(-1) [95% CI 1720, 2450] for oral doses.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),[ml] / [min],2050,40005,DB00683,Midazolam
,25588320,Oral bioavailability,"Oral bioavailability of a midazolam microdose was 23.4% [95% CI 20.0, 27.3] vs. 20.9% [95% CI 17.1, 25.5] after the regular dose.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),%,23.4,40006,DB00683,Midazolam
,25588320,Oral bioavailability,"Oral bioavailability of a midazolam microdose was 23.4% [95% CI 20.0, 27.3] vs. 20.9% [95% CI 17.1, 25.5] after the regular dose.",Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588320/),%,20.9,40007,DB00683,Midazolam
,27780297,bioavailability,Nazolam bioavailability was 75%.,Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27780297/),%,75,40204,DB00683,Midazolam
,27780297,Maximal plasma concentrations,"Maximal plasma concentrations of 31 ng ml-1 (CV, 42.3%) were reached after 11 min (2.5 mg Nazolam), and of 66 ng ml-1 (coefficient of variability, 31.5%) after 14 min (5.0 mg Nazolam).",Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27780297/),[ng] / [ml],31,40205,DB00683,Midazolam
,27780297,Maximal plasma concentrations,"Maximal plasma concentrations of 31 ng ml-1 (CV, 42.3%) were reached after 11 min (2.5 mg Nazolam), and of 66 ng ml-1 (coefficient of variability, 31.5%) after 14 min (5.0 mg Nazolam).",Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27780297/),[ng] / [ml],66,40206,DB00683,Midazolam
,27780297,Sedation duration,"Sedation duration was 118 ± 95.6 min for 2.5 mg intravenous midazolam, 76 ± 80.4 min for 2.5 mg Nazolam, and 145 ± 104.9 min for 5.0 mg Nazolam.",Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27780297/),min,118,40207,DB00683,Midazolam
,27780297,Sedation duration,"Sedation duration was 118 ± 95.6 min for 2.5 mg intravenous midazolam, 76 ± 80.4 min for 2.5 mg Nazolam, and 145 ± 104.9 min for 5.0 mg Nazolam.",Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27780297/),min,76,40208,DB00683,Midazolam
,27780297,Sedation duration,"Sedation duration was 118 ± 95.6 min for 2.5 mg intravenous midazolam, 76 ± 80.4 min for 2.5 mg Nazolam, and 145 ± 104.9 min for 5.0 mg Nazolam.",Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27780297/),min,145,40209,DB00683,Midazolam
,11744613,K(i),"The K(i) values of KTZ for MDZ 1'-hydroxylation and 4-hydroxylation were 0.0237 and 0.111 microM, respectively, indicating that KTZ extensively inhibits hepatic CYP3A activity in dogs.","Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744613/),μM,0.0237,40339,DB00683,Midazolam
,11744613,K(i),"The K(i) values of KTZ for MDZ 1'-hydroxylation and 4-hydroxylation were 0.0237 and 0.111 microM, respectively, indicating that KTZ extensively inhibits hepatic CYP3A activity in dogs.","Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744613/),μM,0.111,40340,DB00683,Midazolam
,11420893,steady-state plasma concentrations,The steady-state plasma concentrations of midazolam ranged from 49-385 ng/mL.,Pharmacokinetics of midazolam in critically ill pediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420893/),[ng] / [ml],49-385,40980,DB00683,Midazolam
,11420893,total clearance,"The total clearance, apparent volume of distribution, and elimination half-life ranged from 0.1-3.1 L/kg/hr, 0.2-3.5 L/kg, and 0.3-10.9 hours, respectively.",Pharmacokinetics of midazolam in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420893/),[l] / [h·kg],0.1-3.1,40981,DB00683,Midazolam
,11420893,elimination half-life,"The total clearance, apparent volume of distribution, and elimination half-life ranged from 0.1-3.1 L/kg/hr, 0.2-3.5 L/kg, and 0.3-10.9 hours, respectively.",Pharmacokinetics of midazolam in critically ill pediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420893/),h,0.3-10.9,40982,DB00683,Midazolam
,15948934,V dss,The predicted V dss of theophylline was 0.4-0.6 l kg(-1) and showed only a modest change with age.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[l] / [kg],0.4-0.6,41088,DB00683,Midazolam
,15948934,t(1/2),"Predicted t(1/2) was 18 h in the neonate, dropping rapidly to 4.6-7.2 h from 6 months onwards, and the MPE was 24%.",Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,18,41089,DB00683,Midazolam
,15948934,t(1/2),"Predicted t(1/2) was 18 h in the neonate, dropping rapidly to 4.6-7.2 h from 6 months onwards, and the MPE was 24%.",Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,4.6-7.2,41090,DB00683,Midazolam
,15948934,V dss,V dss ranged between 1.0 and 1.7 l kg(-1) and showed only modest change with age.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[l] / [kg],1.0 and 1.7,41091,DB00683,Midazolam
,15948934,CL,CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[ml] / [h·kg],124,41092,DB00683,Midazolam
,15948934,CL,CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[ml] / [h·kg],664,41093,DB00683,Midazolam
,15948934,CL,CL was 124 ml h(-1) kg(-1) in the neonate and peaked at 664 ml h(-1) kg(-1) at 5 years before decreasing to 425 ml h(-1) kg(-1) in the adult.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),[ml] / [h·kg],425,41094,DB00683,Midazolam
,15948934,t(1/2),Predicted t(1/2) was 6.9 h in the neonate and attained 'adult' values of 2.5-3.5 h from 1 year onwards.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,6.9,41095,DB00683,Midazolam
,15948934,t(1/2),Predicted t(1/2) was 6.9 h in the neonate and attained 'adult' values of 2.5-3.5 h from 1 year onwards.,Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948934/),h,2.5-3.5,41096,DB00683,Midazolam
,29984832,relative bioavailability,"The novel formulation was subject to a higher estimated first-pass metabolism compared with the intravenous solution (8.6% vs. 5.0%) and a significantly lower relative bioavailability of 82.1% (p = 0.013), with no other significant differences.","A novel, palatable paediatric oral formulation of midazolam: pharmacokinetics, tolerability, efficacy and safety. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29984832/),%,82.1,41354,DB00683,Midazolam
,15993663,overall recoveries,"The overall recoveries were about 100% and 80% for midazolam and 1-hydroxymidazolam, respectively.",A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993663/),%,100,41360,DB00683,Midazolam
,15993663,overall recoveries,"The overall recoveries were about 100% and 80% for midazolam and 1-hydroxymidazolam, respectively.",A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993663/),%,80,41361,DB00683,Midazolam
,15993663,apparent total clearance,The validated method was successfully applied to quantify plasma concentration of midazolam and 1-hydroxymidazolam in authentic samples from a healthy volunteer following a single 15 mg oral dose of midazolam (apparent total clearance: 3.47 L h(-1)kg(-1) and AUC(0-alpha)IOH-MDZ/MDZ: 0.338).,A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993663/),[l] / [h],3.47,41362,DB00683,Midazolam
,15993663,AUC(0-alpha),The validated method was successfully applied to quantify plasma concentration of midazolam and 1-hydroxymidazolam in authentic samples from a healthy volunteer following a single 15 mg oral dose of midazolam (apparent total clearance: 3.47 L h(-1)kg(-1) and AUC(0-alpha)IOH-MDZ/MDZ: 0.338).,A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15993663/),,0.338,41363,DB00683,Midazolam
below,34365190,detection limits,The developed methods provided detection limits below 100 ng L-1 for all target analytes and high precision (below 4% RSD intraday).,"Quantitative analysis of human brain microdialysate for target site pharmacokinetics of major anesthetics ketamine, midazolam and propofol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34365190/),[ng] / [l],100,41389,DB00683,Midazolam
,18082981,intestinal extraction ratio (ER G),"The intestinal extraction ratio (ER G) of midazolam was determined to be 0.43 and decreased significantly to 0.12, 0.07, and 0.06 in the presence of 50, 100, and 200 microM DHA, respectively, in a concentration-dependent manner.",Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082981/),,0.43,41829,DB00683,Midazolam
,18082981,intestinal extraction ratio (ER G),"The intestinal extraction ratio (ER G) of midazolam was determined to be 0.43 and decreased significantly to 0.12, 0.07, and 0.06 in the presence of 50, 100, and 200 microM DHA, respectively, in a concentration-dependent manner.",Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082981/),,0.12,41830,DB00683,Midazolam
,18082981,intestinal extraction ratio (ER G),"The intestinal extraction ratio (ER G) of midazolam was determined to be 0.43 and decreased significantly to 0.12, 0.07, and 0.06 in the presence of 50, 100, and 200 microM DHA, respectively, in a concentration-dependent manner.",Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082981/),,0.07,41831,DB00683,Midazolam
,18082981,intestinal extraction ratio (ER G),"The intestinal extraction ratio (ER G) of midazolam was determined to be 0.43 and decreased significantly to 0.12, 0.07, and 0.06 in the presence of 50, 100, and 200 microM DHA, respectively, in a concentration-dependent manner.",Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082981/),,0.06,41832,DB00683,Midazolam
,18082981,Ki,"The results from an in vitro study using rat intestinal microsomes demonstrated that DHA competitively inhibited the intestinal CYP3A activity with Ki of 15.7 and 27.1 microM for the formations of 1'-OH midazolam and 4-OH midazolam, respectively.",Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082981/),μM,15.7,41833,DB00683,Midazolam
,18082981,Ki,"The results from an in vitro study using rat intestinal microsomes demonstrated that DHA competitively inhibited the intestinal CYP3A activity with Ki of 15.7 and 27.1 microM for the formations of 1'-OH midazolam and 4-OH midazolam, respectively.",Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082981/),μM,27.1,41834,DB00683,Midazolam
,22298759,total runtime,"Chromatographic separation is performed on a C(18) column using a mobile phase containing an acetonitrile-methanol-10 mM sodium heptanesulfonate buffer adjusted to pH 3, with glacial acetic acid (44:10:46, v:v) at a detection wavelength of 210 nm, with a total runtime of 10 min.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),min,10,42799,DB00683,Midazolam
,22298759,limits of detection,"The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),[ng] / [ml],17.8,42800,DB00683,Midazolam
,22298759,limits of detection,"The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),[ng] / [ml],10.3,42801,DB00683,Midazolam
,22298759,limits of detection,"The limits of detection are 17.8, 10.3, and 15.1 ng/mL for ketamine, xylazine, and midazolam, respectively.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),[ng] / [ml],15.1,42802,DB00683,Midazolam
,22298759,extraction recoveries,"The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),%,76.1,42803,DB00683,Midazolam
,22298759,extraction recoveries,"The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),%,91.0,42804,DB00683,Midazolam
,22298759,extraction recoveries,"The extraction recoveries are 76.1% for ketamine, 91.0% for midazolam, and 78.2% for xylazine.","Simultaneous HPLC-UV determination of ketamine, xylazine, and midazolam in canine plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22298759/),%,78.2,42805,DB00683,Midazolam
,18662297,C(max),"Median (range) MDZ C(max) of 481 (258-616), 253 (96-696) and 186 (64-394) ng ml(-1) were attained within a median (range) t(max) of 10 (5-15), 15 (5-60) and 10 (5-40) min, following IV, IM and buccal administration, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[ng] / [ml],481,43281,DB00683,Midazolam
,18662297,C(max),"Median (range) MDZ C(max) of 481 (258-616), 253 (96-696) and 186 (64-394) ng ml(-1) were attained within a median (range) t(max) of 10 (5-15), 15 (5-60) and 10 (5-40) min, following IV, IM and buccal administration, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[ng] / [ml],253,43282,DB00683,Midazolam
,18662297,C(max),"Median (range) MDZ C(max) of 481 (258-616), 253 (96-696) and 186 (64-394) ng ml(-1) were attained within a median (range) t(max) of 10 (5-15), 15 (5-60) and 10 (5-40) min, following IV, IM and buccal administration, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[ng] / [ml],186,43283,DB00683,Midazolam
,18662297,t(max),"Median (range) MDZ C(max) of 481 (258-616), 253 (96-696) and 186 (64-394) ng ml(-1) were attained within a median (range) t(max) of 10 (5-15), 15 (5-60) and 10 (5-40) min, following IV, IM and buccal administration, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),min,10,43284,DB00683,Midazolam
,18662297,t(max),"Median (range) MDZ C(max) of 481 (258-616), 253 (96-696) and 186 (64-394) ng ml(-1) were attained within a median (range) t(max) of 10 (5-15), 15 (5-60) and 10 (5-40) min, following IV, IM and buccal administration, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),min,15,43285,DB00683,Midazolam
,18662297,t(max),"Median (range) MDZ C(max) of 481 (258-616), 253 (96-696) and 186 (64-394) ng ml(-1) were attained within a median (range) t(max) of 10 (5-15), 15 (5-60) and 10 (5-40) min, following IV, IM and buccal administration, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),min,10,43286,DB00683,Midazolam
,18662297,"AUC(0,infinity)","Mean (95% confidence interval) of the pharmacokinetic parameters were: AUC(0,infinity) 596 (327, 865), 608 (353, 864) and 518 (294, 741) ng ml(-1) h; V(d) 0.85 l kg(-1); clearance 14.4 ml min(-1) kg(-1), elimination half-life 1.22 (0.65, 1.8) h, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[h·ng] / [ml],596,43287,DB00683,Midazolam
,18662297,"AUC(0,infinity)","Mean (95% confidence interval) of the pharmacokinetic parameters were: AUC(0,infinity) 596 (327, 865), 608 (353, 864) and 518 (294, 741) ng ml(-1) h; V(d) 0.85 l kg(-1); clearance 14.4 ml min(-1) kg(-1), elimination half-life 1.22 (0.65, 1.8) h, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[h·ng] / [ml],608,43288,DB00683,Midazolam
,18662297,"AUC(0,infinity)","Mean (95% confidence interval) of the pharmacokinetic parameters were: AUC(0,infinity) 596 (327, 865), 608 (353, 864) and 518 (294, 741) ng ml(-1) h; V(d) 0.85 l kg(-1); clearance 14.4 ml min(-1) kg(-1), elimination half-life 1.22 (0.65, 1.8) h, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[h·ng] / [ml],518,43289,DB00683,Midazolam
,18662297,V(d),"Mean (95% confidence interval) of the pharmacokinetic parameters were: AUC(0,infinity) 596 (327, 865), 608 (353, 864) and 518 (294, 741) ng ml(-1) h; V(d) 0.85 l kg(-1); clearance 14.4 ml min(-1) kg(-1), elimination half-life 1.22 (0.65, 1.8) h, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[l] / [kg],0.85,43290,DB00683,Midazolam
,18662297,clearance,"Mean (95% confidence interval) of the pharmacokinetic parameters were: AUC(0,infinity) 596 (327, 865), 608 (353, 864) and 518 (294, 741) ng ml(-1) h; V(d) 0.85 l kg(-1); clearance 14.4 ml min(-1) kg(-1), elimination half-life 1.22 (0.65, 1.8) h, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),[ml] / [kg·min],14.4,43291,DB00683,Midazolam
,18662297,elimination half-life,"Mean (95% confidence interval) of the pharmacokinetic parameters were: AUC(0,infinity) 596 (327, 865), 608 (353, 864) and 518 (294, 741) ng ml(-1) h; V(d) 0.85 l kg(-1); clearance 14.4 ml min(-1) kg(-1), elimination half-life 1.22 (0.65, 1.8) h, respectively.",Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18662297/),h,1.22,43292,DB00683,Midazolam
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,0.127,43675,DB00683,Midazolam
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,94.2,43676,DB00683,Midazolam
,15370956,apparent K(i),"2. Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370956/),μM,29.6,43677,DB00683,Midazolam
,12891222,AUC ratios,"At 26, 50, and 74 hours after grapefruit juice, the AUC ratios (mean AUC value at the indicated time divided by the mean control AUC on day 1) were 1.29, 1.29, and 1.06, respectively.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),,1.29,43850,DB00683,Midazolam
,12891222,AUC ratios,"At 26, 50, and 74 hours after grapefruit juice, the AUC ratios (mean AUC value at the indicated time divided by the mean control AUC on day 1) were 1.29, 1.29, and 1.06, respectively.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),,1.06,43851,DB00683,Midazolam
,12891222,recovery half-life,The relationship of time after grapefruit juice exposure versus AUC increase over control indicated a recovery half-life estimated at 23 hours.,Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),h,23,43852,DB00683,Midazolam
,12891222,50% inhibitory concentration,"6'7'-Dihydroxybergamottin inhibited midazolam alpha-hydroxylation in vitro, with a mean 50% inhibitory concentration of 4.7 micro mol/L; preincubation of microsomes with 6'7'-dihydroxybergamottin greatly reduced the 50% inhibitory concentration to 0.31 micro mol/L, consistent with mechanism-based inhibition.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),[μmol] / [l],4.7,43853,DB00683,Midazolam
,12891222,50% inhibitory concentration,"6'7'-Dihydroxybergamottin inhibited midazolam alpha-hydroxylation in vitro, with a mean 50% inhibitory concentration of 4.7 micro mol/L; preincubation of microsomes with 6'7'-dihydroxybergamottin greatly reduced the 50% inhibitory concentration to 0.31 micro mol/L, consistent with mechanism-based inhibition.",Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891222/),[μmol] / [l],0.31,43854,DB00683,Midazolam
>,22233204,IC(50),"In vitro studies demonstrated low potential for CYP inhibition (IC(50) estimates tofacitinib > 30 µm), CYP3A4 mRNA induction (observed at tofacitinib concentrations ≥ 25 µm) and no effect on enzymatic activity of CYP substrates.","Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22233204/),µm,30,43868,DB00683,Midazolam
,16628140,CL,"Midazolam CL were normally distributed in both groups, and ranged from 1.7 to 51.9 and 1.4 to 8.2 L/hour in the control and ketoconazole groups, respectively, corresponding to a 7-fold reduction in dispersion between the 2 groups.",Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628140/),[l] / [h],1.7 to 51.9,43995,DB00683,Midazolam
,16628140,CL,"Midazolam CL were normally distributed in both groups, and ranged from 1.7 to 51.9 and 1.4 to 8.2 L/hour in the control and ketoconazole groups, respectively, corresponding to a 7-fold reduction in dispersion between the 2 groups.",Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16628140/),[l] / [h],1.4 to 8.2,43996,DB00683,Midazolam
,25163980,Fg,"Using Enzyme-inhibition method, Fg of midazolam (1 mg/kg) was calculated as 0.71.",Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25163980/),,0.71,44947,DB00683,Midazolam
,25163980,Fg,"Additionally, total amount of raloxifene-6-glucuronide generated in enterocytes after oral administration of raloxifene was estimated using Metabolite-distribution method and Fg of raloxifene (0.98 μmol/kg) was calculated as 0.21.",Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25163980/),[μM] / [kg],0.98,44948,DB00683,Midazolam
,25163980,Fg,"Additionally, total amount of raloxifene-6-glucuronide generated in enterocytes after oral administration of raloxifene was estimated using Metabolite-distribution method and Fg of raloxifene (0.98 μmol/kg) was calculated as 0.21.",Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25163980/),[μM] / [kg],0.21,44949,DB00683,Midazolam
,16467135,volume of distribution,Midazolam volume of distribution (1.82; 1.57-2.11) and elimination half-life (1.19; 1.03-1.38) were also different on day 7 in comparison with day 1.,Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467135/),,1.82,45403,DB00683,Midazolam
,16467135,elimination half-life,Midazolam volume of distribution (1.82; 1.57-2.11) and elimination half-life (1.19; 1.03-1.38) were also different on day 7 in comparison with day 1.,Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467135/),,1.19,45404,DB00683,Midazolam
,18339815,F(H),"During the absorption phase, the F(H) of ITZ increased from 0.2 to 1.0, reflecting the time course of hepatic CYP3A inhibition.","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),,0.2,45475,DB00683,Midazolam
,18339815,F(H),"During the absorption phase, the F(H) of ITZ increased from 0.2 to 1.0, reflecting the time course of hepatic CYP3A inhibition.","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),,1.0,45476,DB00683,Midazolam
,18339815,Ki,"The in vivo Ki for OH-ITZ (38 +/- 3 nM) was estimated from C(IN,OH-ITZ) versus F(H) of ITZ, and is similar to values obtained from inhibition of midazolam hydroxylation in CYP3A4 supersomes (Drug Metab Dispos 32:1121-1131, 2004).","Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339815/),nM,38,45477,DB00683,Midazolam
,21937987,area under the curve (AUC),Plasma MDZ area under the curve (AUC) between 2 and 4 h after oral administration in the form of a solution strongly correlated with MDZ clearance.,Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937987/),h,2 and 4,45897,DB00683,Midazolam
,21937987,half-life,"Recovery of CYP3A activity occurred with a half-life of 24 h after voriconazole, whereas ritonavir inhibition was still strong 3 days after discontinuation.",Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937987/),h,24,45898,DB00683,Midazolam
,31358899,terminal half-lives,"Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively).",Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31358899/),h,32‒57,46656,DB00683,Midazolam
,31358899,terminal half-lives,"Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively).",Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31358899/),h,58‒307,46657,DB00683,Midazolam
,31358899,unbound fractions,"Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively).",Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31358899/),%,0.8,46658,DB00683,Midazolam
,31358899,unbound fractions,"Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively).",Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31358899/),%,2.9,46659,DB00683,Midazolam
,31358899,unbound fractions,"Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively).",Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31358899/),%,0.4,46660,DB00683,Midazolam
,31358899,unbound fractions,"Ginsenosides Rb1, Rd, and Rg1 and notoginsenoside R1 were the major circulating XueShuanTong compounds; their interaction-related pharmacokinetics comprised compound dose-dependent levels of systemic exposure and, for ginsenosides Rb1 and Rd, long terminal half-lives (32‒57 and 58‒307 h, respectively) and low unbound fractions in plasma (0.8%‒2.9% and 0.4%‒3.0%, respectively).",Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31358899/),%,3.0,46661,DB00683,Midazolam
,31494843,oral bioavailability,"The oral bioavailability of SPH3127 to rats and monkeys was about 11.5-24.5% and 3.3-11.3%, respectively, with the short peak time, Tmax, ranging from 0.25 to 1.3 h.","The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31494843/),%,11.5-24.5,47084,DB00683,Midazolam
,31494843,oral bioavailability,"The oral bioavailability of SPH3127 to rats and monkeys was about 11.5-24.5% and 3.3-11.3%, respectively, with the short peak time, Tmax, ranging from 0.25 to 1.3 h.","The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31494843/),%,3.3-11.3,47085,DB00683,Midazolam
,31494843,"peak time, Tmax","The oral bioavailability of SPH3127 to rats and monkeys was about 11.5-24.5% and 3.3-11.3%, respectively, with the short peak time, Tmax, ranging from 0.25 to 1.3 h.","The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31494843/),h,0.25 to 1.3,47086,DB00683,Midazolam
,31494843,plasma protein binding ratio,The plasma protein binding ratio of SPH3127 is low as 11.7-14.8% for all species.,"The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31494843/),%,11.7-14.8,47087,DB00683,Midazolam
,31494843,IC50,"The in vitro CYP inhibition study only found very weak action for CYP3A4 (midazolam 1'-hydroxylation) and CYP3A4 (midazolam 6β-hydroxylation) with IC50 of 56.8 µM and 41.1 µM, respectively.","The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31494843/),μM,56.8,47088,DB00683,Midazolam
,31494843,IC50,"The in vitro CYP inhibition study only found very weak action for CYP3A4 (midazolam 1'-hydroxylation) and CYP3A4 (midazolam 6β-hydroxylation) with IC50 of 56.8 µM and 41.1 µM, respectively.","The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31494843/),μM,41.1,47089,DB00683,Midazolam
,10430107,bioavailability,"Saquinavir increased the bioavailability of oral midazolam from 41% to 90% (P < .005), the peak midazolam plasma concentration more than twofold, and the area under plasma concentration-time curve more than fivefold (P < .001).",Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430107/),%,41,48043,DB00683,Midazolam
,10430107,bioavailability,"Saquinavir increased the bioavailability of oral midazolam from 41% to 90% (P < .005), the peak midazolam plasma concentration more than twofold, and the area under plasma concentration-time curve more than fivefold (P < .001).",Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430107/),%,90,48044,DB00683,Midazolam
,10430107,elimination half-life,Saquinavir decreased the clearance of intravenous midazolam by 56% (P < .001) and increased its elimination half-life from 4.1 to 9.5 hours (P < .01).,Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430107/),h,4.1,48045,DB00683,Midazolam
,10430107,elimination half-life,Saquinavir decreased the clearance of intravenous midazolam by 56% (P < .001) and increased its elimination half-life from 4.1 to 9.5 hours (P < .01).,Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430107/),h,9.5,48046,DB00683,Midazolam
,10460064,Michaelis-Menten constant,The mean (+/-SD) Michaelis-Menten constant for midazolam 1'-hydroxylation by human liver microsomes was 5.6 +/- 3.3 micromol/L.,Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],5.6,48761,DB00683,Midazolam
,10460064,inhibition constant,"The formation of 1'-hydroxymidazolam was competitively inhibited by propofol, and the mean inhibition constant was 56.7 +/- 16.6 micromol/L.",Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],56.7,48762,DB00683,Midazolam
,10460064,Michaelis-Menten constant,"The mean Michaelis-Menten constant and mean inhibition constant values for midazolam 1'-hydroxylation by recombinant CYP3A4 were 4.0 micromol/L and 61.0 micromol/L, respectively, consistent with the mean values obtained from human liver microsomes.",Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],4.0,48763,DB00683,Midazolam
,10460064,inhibition constant,"The mean Michaelis-Menten constant and mean inhibition constant values for midazolam 1'-hydroxylation by recombinant CYP3A4 were 4.0 micromol/L and 61.0 micromol/L, respectively, consistent with the mean values obtained from human liver microsomes.",Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],61.0,48764,DB00683,Midazolam
,34020149,maximum plasma midazolam concentration,"Mean maximum plasma midazolam concentration was 78.0 ng/mL, and mean time to peak concentration was 20.5 min, demonstrating that achieving maximum plasma midazolam concentration is not required for seizure cessation.","A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34020149/),[ng] / [ml],78.0,48844,DB00683,Midazolam
,34020149,time to peak concentration,"Mean maximum plasma midazolam concentration was 78.0 ng/mL, and mean time to peak concentration was 20.5 min, demonstrating that achieving maximum plasma midazolam concentration is not required for seizure cessation.","A Phase 3 open-label study of the efficacy, safety and pharmacokinetics of buccally administered midazolam hydrochloride for the treatment of status epilepticus in pediatric Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34020149/),min,20.5,48845,DB00683,Midazolam
,23489241,total clearance,"Median total clearance was 10.6 ml/min/kg (range 6.1-15.2 ml/min/kg) and 10.4 ml/min/kg (range 8.4-17.6 ml/min/kg), and median volume of distribution at steady state was 2094 ml/kg (range 2076-2413 ml/kg) and 2822 ml/kg (range 2270-7064 ml/kg) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),[ml] / [kg·min],10.6,49031,DB00683,Midazolam
,23489241,total clearance,"Median total clearance was 10.6 ml/min/kg (range 6.1-15.2 ml/min/kg) and 10.4 ml/min/kg (range 8.4-17.6 ml/min/kg), and median volume of distribution at steady state was 2094 ml/kg (range 2076-2413 ml/kg) and 2822 ml/kg (range 2270-7064 ml/kg) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),[ml] / [kg·min],10.4,49032,DB00683,Midazolam
,23489241,volume of distribution at steady state,"Median total clearance was 10.6 ml/min/kg (range 6.1-15.2 ml/min/kg) and 10.4 ml/min/kg (range 8.4-17.6 ml/min/kg), and median volume of distribution at steady state was 2094 ml/kg (range 2076-2413 ml/kg) and 2822 ml/kg (range 2270-7064 ml/kg) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),[ml] / [kg],2094,49033,DB00683,Midazolam
,23489241,volume of distribution at steady state,"Median total clearance was 10.6 ml/min/kg (range 6.1-15.2 ml/min/kg) and 10.4 ml/min/kg (range 8.4-17.6 ml/min/kg), and median volume of distribution at steady state was 2094 ml/kg (range 2076-2413 ml/kg) and 2822 ml/kg (range 2270-7064 ml/kg) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),[ml] / [kg],2822,49034,DB00683,Midazolam
,23489241,distribution half-life,"Median distribution half-life was 24 min (range 6-42 min) and 39 min (range 33.6-72 min) and median terminal half-life was 216 min (range 120-248 min) and 408 min (range 192-924 min) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),min,24,49035,DB00683,Midazolam
,23489241,distribution half-life,"Median distribution half-life was 24 min (range 6-42 min) and 39 min (range 33.6-72 min) and median terminal half-life was 216 min (range 120-248 min) and 408 min (range 192-924 min) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),min,39,49036,DB00683,Midazolam
,23489241,terminal half-life,"Median distribution half-life was 24 min (range 6-42 min) and 39 min (range 33.6-72 min) and median terminal half-life was 216 min (range 120-248 min) and 408 min (range 192-924 min) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),min,216,49037,DB00683,Midazolam
,23489241,terminal half-life,"Median distribution half-life was 24 min (range 6-42 min) and 39 min (range 33.6-72 min) and median terminal half-life was 216 min (range 120-248 min) and 408 min (range 192-924 min) after the 0.05 mg/kg and 0.1 mg/kg bwt doses, respectively.",Pharmacokinetics of midazolam after intravenous administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489241/),min,408,49038,DB00683,Midazolam
,7486273,plasma peak concentration,"The median plasma peak concentration was 1.74 mg.L-1 after 10 min for lidocaine, and 0.52 mg.L-1 after 7.5 min for bupivacaine respectively.",[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486273/),[mg] / [l],1.74,49113,DB00683,Midazolam
,7486273,plasma peak concentration,"The median plasma peak concentration was 1.74 mg.L-1 after 10 min for lidocaine, and 0.52 mg.L-1 after 7.5 min for bupivacaine respectively.",[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486273/),[mg] / [l],0.52,49114,DB00683,Midazolam
,2044333,',Infusion regimens for flumazenil were designed so that 'steady-state' concentrations of 10 and 20 micrograms/L were obtained.,Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],10,49679,DB00683,Midazolam
,2044333,steady-state' concentrations,Infusion regimens for flumazenil were designed so that 'steady-state' concentrations of 10 and 20 micrograms/L were obtained.,Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],10,49680,DB00683,Midazolam
,2044333,steady-state' concentrations,Infusion regimens for flumazenil were designed so that 'steady-state' concentrations of 10 and 20 micrograms/L were obtained.,Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],20,49681,DB00683,Midazolam
,2044333,plasma drug concentrations,"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],276,49682,DB00683,Midazolam
,2044333,EC50),"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],276,49683,DB00683,Midazolam
,2044333,EC50),"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],624,49684,DB00683,Midazolam
,2044333,EC50),"The mean (+/- SD) plasma drug concentrations of midazolam corresponding to half the maximum increase in TNW12-30 (EC50) were 276 +/- 64, 624 +/- 187 and 1086 +/- 379 micrograms/L in sessions A, B and C, respectively.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],1086,49685,DB00683,Midazolam
,2044333,half-lives,"The half-lives reflecting equilibration between plasma concentration and effect (t1/2ke0), estimated by a nonparametric method, were 2.2 +/- 1.2, 3.3 +/- 3.3 and 2.9 +/- 1.2 min for the 3 different sessions.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),min,2.2,49686,DB00683,Midazolam
,2044333,half-lives,"The half-lives reflecting equilibration between plasma concentration and effect (t1/2ke0), estimated by a nonparametric method, were 2.2 +/- 1.2, 3.3 +/- 3.3 and 2.9 +/- 1.2 min for the 3 different sessions.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),min,3.3,49687,DB00683,Midazolam
,2044333,half-lives,"The half-lives reflecting equilibration between plasma concentration and effect (t1/2ke0), estimated by a nonparametric method, were 2.2 +/- 1.2, 3.3 +/- 3.3 and 2.9 +/- 1.2 min for the 3 different sessions.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),min,2.9,49688,DB00683,Midazolam
,2044333,EC50,"The plasma concentration of flumazenil that doubled the EC50 of midazolam (Cf,2) was 6.5 +/- 1.0 micrograms/L.",Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044333/),[μg] / [l],6.5,49689,DB00683,Midazolam
,15685515,Blood flow,Blood flow through the 1.9-m 2 cellulose triacetate membrane filter was 180 mL/min.,Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[ml] / [min],180,49804,DB00683,Midazolam
,15685515,Total-body clearance,"Total-body clearance was 6.4 L/h, and volume of distribution was 376 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],6.4,49805,DB00683,Midazolam
,15685515,volume of distribution,"Total-body clearance was 6.4 L/h, and volume of distribution was 376 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),l,376,49806,DB00683,Midazolam
,15685515,Ultrafiltration clearance,"Ultrafiltration clearance was 0.31 L/h, equivalent to approximately 5% of total clearance.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],0.31,49807,DB00683,Midazolam
,15685515,plasma protein binding,"Average degree of plasma protein binding was 82.9% for lorazepam, with a sieving coefficient of 0.16 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,82.9,49808,DB00683,Midazolam
,15685515,sieving coefficient,"Average degree of plasma protein binding was 82.9% for lorazepam, with a sieving coefficient of 0.16 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.16,49809,DB00683,Midazolam
,15685515,degree of plasma protein binding,"For lorazepamglucuronide, degree of plasma protein binding was 39.5%, and sieving coefficient was 0.48 +/- 0.07.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,39.5,49810,DB00683,Midazolam
,15685515,sieving coefficient,"For lorazepamglucuronide, degree of plasma protein binding was 39.5%, and sieving coefficient was 0.48 +/- 0.07.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.48,49811,DB00683,Midazolam
,15685515,Total-body clearance,"Total-body clearance was 8.5 L/h, and volume of distribution was 157 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],8.5,49812,DB00683,Midazolam
,15685515,volume of distribution,"Total-body clearance was 8.5 L/h, and volume of distribution was 157 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),l,157,49813,DB00683,Midazolam
,15685515,Clearance by ultrafiltration,"Clearance by ultrafiltration was 0.055 L/h, equivalent to approximately 0.7% of total clearance.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],0.055,49814,DB00683,Midazolam
,15685515,degree of plasma protein binding,"Average degree of plasma protein binding was 95.8%, with a sieving coefficient of 0.04 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,95.8,49815,DB00683,Midazolam
,15685515,sieving coefficient,"Average degree of plasma protein binding was 95.8%, with a sieving coefficient of 0.04 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.04,49816,DB00683,Midazolam
,15685515,degree of plasma protein binding,"For the metabolite 1-hydroxymidazolamglucuronide, average degree of plasma protein binding was 43.4%, with a sieving coefficient of 0.45 +/- 0.06.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,43.4,49817,DB00683,Midazolam
,15685515,sieving coefficient,"For the metabolite 1-hydroxymidazolamglucuronide, average degree of plasma protein binding was 43.4%, with a sieving coefficient of 0.45 +/- 0.06.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.45,49818,DB00683,Midazolam
,18762932,AUC(0-infinity),"Midazolam AUC(0-infinity) slightly decreased from 124.0 +/- 62.5 ng/ml.h at baseline to 105.6 +/- 53.2 ng/ml.h after SJW (P < 0.05), representing a mean 11.3% decrease (95% CI: -22.8 to 0.21).",No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18762932/),[ng] / [h·ml],124.0,50831,DB00683,Midazolam
,18762932,AUC(0-infinity),"Midazolam AUC(0-infinity) slightly decreased from 124.0 +/- 62.5 ng/ml.h at baseline to 105.6 +/- 53.2 ng/ml.h after SJW (P < 0.05), representing a mean 11.3% decrease (95% CI: -22.8 to 0.21).",No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18762932/),[ng] / [h·ml],105.6,50832,DB00683,Midazolam
,3582373,Vdss,"Distribution volume (Vdss) was significantly increased in elderly subjects when compared to young subjects of the same sex (young vs. elderly males, Vdss = 1.22 +/- 0.31 l kg-1 and 2.47 +/- 0.98 l kg-1 respectively; and young vs. elderly females, Vdss = 0.91 +/- 0.29 l kg-1 and 1.70 +/- 0.78 l kg-1 respectively).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[l] / [kg],1.22,51324,DB00683,Midazolam
,3582373,Vdss,"Distribution volume (Vdss) was significantly increased in elderly subjects when compared to young subjects of the same sex (young vs. elderly males, Vdss = 1.22 +/- 0.31 l kg-1 and 2.47 +/- 0.98 l kg-1 respectively; and young vs. elderly females, Vdss = 0.91 +/- 0.29 l kg-1 and 1.70 +/- 0.78 l kg-1 respectively).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[l] / [kg],2.47,51325,DB00683,Midazolam
,3582373,Vdss,"Distribution volume (Vdss) was significantly increased in elderly subjects when compared to young subjects of the same sex (young vs. elderly males, Vdss = 1.22 +/- 0.31 l kg-1 and 2.47 +/- 0.98 l kg-1 respectively; and young vs. elderly females, Vdss = 0.91 +/- 0.29 l kg-1 and 1.70 +/- 0.78 l kg-1 respectively).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[l] / [kg],0.91,51326,DB00683,Midazolam
,3582373,Vdss,"Distribution volume (Vdss) was significantly increased in elderly subjects when compared to young subjects of the same sex (young vs. elderly males, Vdss = 1.22 +/- 0.31 l kg-1 and 2.47 +/- 0.98 l kg-1 respectively; and young vs. elderly females, Vdss = 0.91 +/- 0.29 l kg-1 and 1.70 +/- 0.78 l kg-1 respectively).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[l] / [kg],1.70,51327,DB00683,Midazolam
,3582373,Total body clearance,Total body clearance was significantly reduced in elderly males compared with young males (5.60 +/- 1.77 ml min-1 kg-1 vs. 8.10 +/- 3.58 ml min-1 kg-1).,Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[ml] / [kg·min],5.60,51328,DB00683,Midazolam
,3582373,Total body clearance,Total body clearance was significantly reduced in elderly males compared with young males (5.60 +/- 1.77 ml min-1 kg-1 vs. 8.10 +/- 3.58 ml min-1 kg-1).,Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[ml] / [kg·min],8.10,51329,DB00683,Midazolam
,3582373,clearance,No significant difference in clearance was found between young and elderly females (6.08 +/- 2.04 ml min-1 kg-1 vs. 9.14 +/- 3.36 ml min-1 kg-1).,Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[ml] / [kg·min],6.08,51330,DB00683,Midazolam
,3582373,clearance,No significant difference in clearance was found between young and elderly females (6.08 +/- 2.04 ml min-1 kg-1 vs. 9.14 +/- 3.36 ml min-1 kg-1).,Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),[ml] / [kg·min],9.14,51331,DB00683,Midazolam
,3582373,elimination half-life (T1/2E),"As a consequence, elimination half-life (T1/2E) was significantly prolonged in elderly compared to young males (8.52 +/- 5.4 h vs. 2.77 +/- 0.80 h).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),h,8.52,51332,DB00683,Midazolam
,3582373,elimination half-life (T1/2E),"As a consequence, elimination half-life (T1/2E) was significantly prolonged in elderly compared to young males (8.52 +/- 5.4 h vs. 2.77 +/- 0.80 h).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),h,2.77,51333,DB00683,Midazolam
,3582373,T1/2E,"In contrast, T1/2E was unchanged in elderly compared to young females (2.99 +/- 0.86 h vs. 2.86 +/- 1.04 h).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),h,2.99,51334,DB00683,Midazolam
,3582373,T1/2E,"In contrast, T1/2E was unchanged in elderly compared to young females (2.99 +/- 0.86 h vs. 2.86 +/- 1.04 h).",Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582373/),h,2.86,51335,DB00683,Midazolam
,28177137,clearance,"The population mean estimates for midazolam, 1-OH-M and 1-OH-MG clearance were 8.4 l h-1 (RSE 9%, IIV 49%), 45.4 l h-1 (RSE 12%, IIV 60.5%) and 5.1 l h-1 (RSE 11%, IIV 49.9%), respectively.","Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect? ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177137/),[l] / [h],5.1,51509,DB00683,Midazolam
,1560385,Emax,"The changes in EEG effect as a function of drug concentrations were described by a competitive interaction model, allowing the estimation of the pharmacodynamic parameters (means +/- S.E.) of the partial agonist, Emax = 15 +/- 5 microV/sec and EC50 = 19 +/- 5 ng/ml, and inverse agonist, Emax = -5.8 +/- 1.6 microV/sec and EC50 = 7.8 +/- 2.5 ng/ml.",In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1560385/),[μv] / [s],15,51851,DB00683,Midazolam
,1560385,EC50,"The changes in EEG effect as a function of drug concentrations were described by a competitive interaction model, allowing the estimation of the pharmacodynamic parameters (means +/- S.E.) of the partial agonist, Emax = 15 +/- 5 microV/sec and EC50 = 19 +/- 5 ng/ml, and inverse agonist, Emax = -5.8 +/- 1.6 microV/sec and EC50 = 7.8 +/- 2.5 ng/ml.",In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1560385/),[ng] / [ml],19,51852,DB00683,Midazolam
,1560385,Emax,"The changes in EEG effect as a function of drug concentrations were described by a competitive interaction model, allowing the estimation of the pharmacodynamic parameters (means +/- S.E.) of the partial agonist, Emax = 15 +/- 5 microV/sec and EC50 = 19 +/- 5 ng/ml, and inverse agonist, Emax = -5.8 +/- 1.6 microV/sec and EC50 = 7.8 +/- 2.5 ng/ml.",In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1560385/),[μv] / [s],-5.8,51853,DB00683,Midazolam
,1560385,EC50,"The changes in EEG effect as a function of drug concentrations were described by a competitive interaction model, allowing the estimation of the pharmacodynamic parameters (means +/- S.E.) of the partial agonist, Emax = 15 +/- 5 microV/sec and EC50 = 19 +/- 5 ng/ml, and inverse agonist, Emax = -5.8 +/- 1.6 microV/sec and EC50 = 7.8 +/- 2.5 ng/ml.",In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1560385/),[ng] / [ml],7.8,51854,DB00683,Midazolam
,11749829,Cmax,"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),[nM] / [l],191,52164,DB00683,Midazolam
,11749829,tmax,"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),h,1.01,52165,DB00683,Midazolam
,11749829,t(1/2),"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),h,3.2,52166,DB00683,Midazolam
,11749829,AUC(0-infinity),"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),[h·nM] / [l],681,52167,DB00683,Midazolam
,11749829,Cl(oral),"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),[l] / [h·kg],0.54,52168,DB00683,Midazolam
,11749829,Ke,"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),1/[h],0.2415,52169,DB00683,Midazolam
,11749829,Kalpha,"Pharmacokinetics parameters of midazolam were as follows: Cmax (191 +/- 17) nmol/L, tmax (1.01 +/- 0.14) h, t(1/2) (3.2 +/- 0.4) h, AUC(0-infinity) (681 +/- 43) nmol.h.L-1), Cl(oral) (0.54 +/- 0.04) L.h-1.kg-1, Ke (0.2415 +/- 0.0021) h-1, Kalpha (0.82 +/- 0.18) h-1.",Single plasma sampling to predict oral clearance of CYP3A probe midazolam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11749829/),1/[h],0.82,52170,DB00683,Midazolam
,20512335,AUC(0-24 h)),The effect of GJ on CYP3A4 activity was confirmed by an increase of ~50% of mean midazolam exposure (AUC(0-24 h)) from 122.1 to 182.0 ng h/mL (P = 0.034).,Marginal increase of sunitinib exposure by grapefruit juice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20512335/),[h·ng] / [ml],122.1,52227,DB00683,Midazolam
,20512335,AUC(0-24 h)),The effect of GJ on CYP3A4 activity was confirmed by an increase of ~50% of mean midazolam exposure (AUC(0-24 h)) from 122.1 to 182.0 ng h/mL (P = 0.034).,Marginal increase of sunitinib exposure by grapefruit juice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20512335/),[h·ng] / [ml],182.0,52228,DB00683,Midazolam
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,52,52850,DB00683,Midazolam
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,126,52851,DB00683,Midazolam
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,139,52852,DB00683,Midazolam
,2048708,initial midazolam,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52853,DB00683,Midazolam
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52854,DB00683,Midazolam
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],323,52855,DB00683,Midazolam
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],332,52856,DB00683,Midazolam
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],2.8,53268,DB00683,Midazolam
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],5.3,53269,DB00683,Midazolam
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],0.42,53270,DB00683,Midazolam
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,280,53271,DB00683,Midazolam
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,120,53272,DB00683,Midazolam
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,1030,53273,DB00683,Midazolam
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],4.2,53274,DB00683,Midazolam
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],8.8,53275,DB00683,Midazolam
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],1.2,53276,DB00683,Midazolam
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,62,53277,DB00683,Midazolam
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,34,53278,DB00683,Midazolam
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,211,53279,DB00683,Midazolam
,19203567,Apparent oral clearance,"Apparent oral clearance was 2,030 +/- 651 and 1,939 +/- 658 ml/min for the midazolam plus flumazenil and midazolam plus placebo groups.",Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203567/),[ml] / [min],"2,030",53874,DB00683,Midazolam
,19203567,Apparent oral clearance,"Apparent oral clearance was 2,030 +/- 651 and 1,939 +/- 658 ml/min for the midazolam plus flumazenil and midazolam plus placebo groups.",Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203567/),[ml] / [min],"1,939",53875,DB00683,Midazolam
> or =,8602660,train-of-four ratio,All patients were allowed to recover spontaneously to a train-of-four ratio > or = 0.70 after cisatracurium-induced neuromuscular block.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,0.70,54591,DB00683,Midazolam
,8602660,clearances,The clearances (5.28 +/- 1.23 vs.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,5.28,54592,DB00683,Midazolam
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,22.4,54593,DB00683,Midazolam
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,25.5,54594,DB00683,Midazolam
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],38,54595,DB00683,Midazolam
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],103,54596,DB00683,Midazolam
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],101,54597,DB00683,Midazolam
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],253,54598,DB00683,Midazolam
,2612542,"volume of distribution, Vss","The volume of distribution, Vss, was 1.29 l.kg-1, the elimination half-life 1.17 h and the serum clearance 9.11 ml.kg-1.min-1.",The pharmacokinetics of midazolam in paediatric patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),[l] / [kg],1.29,54848,DB00683,Midazolam
,2612542,elimination half-life,"The volume of distribution, Vss, was 1.29 l.kg-1, the elimination half-life 1.17 h and the serum clearance 9.11 ml.kg-1.min-1.",The pharmacokinetics of midazolam in paediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),h,1.17,54849,DB00683,Midazolam
,2612542,serum clearance,"The volume of distribution, Vss, was 1.29 l.kg-1, the elimination half-life 1.17 h and the serum clearance 9.11 ml.kg-1.min-1.",The pharmacokinetics of midazolam in paediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),[ml] / [kg·min],9.11,54850,DB00683,Midazolam
,2612542,Peak serum concentrations,"Peak serum concentrations for the intramuscular, rectal and oral routes were at 15 min, 30 min and 53 min respectively.",The pharmacokinetics of midazolam in paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),min,15,54851,DB00683,Midazolam
,2612542,Peak serum concentrations,"Peak serum concentrations for the intramuscular, rectal and oral routes were at 15 min, 30 min and 53 min respectively.",The pharmacokinetics of midazolam in paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),min,30,54852,DB00683,Midazolam
,2612542,Peak serum concentrations,"Peak serum concentrations for the intramuscular, rectal and oral routes were at 15 min, 30 min and 53 min respectively.",The pharmacokinetics of midazolam in paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),min,53,54853,DB00683,Midazolam
,2612542,Bioavailability,"Bioavailability was 87%, 18%, 27% respectively at a dose of 0.15 mg.",The pharmacokinetics of midazolam in paediatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),%,87,54854,DB00683,Midazolam
,2612542,Bioavailability,"Bioavailability was 87%, 18%, 27% respectively at a dose of 0.15 mg.",The pharmacokinetics of midazolam in paediatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),%,18,54855,DB00683,Midazolam
,2612542,Bioavailability,"Bioavailability was 87%, 18%, 27% respectively at a dose of 0.15 mg.",The pharmacokinetics of midazolam in paediatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),%,27,54856,DB00683,Midazolam
,2612542,bioavailability,The oral route bioavailability halved to 15% at the two higher doses.,The pharmacokinetics of midazolam in paediatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612542/),%,15,54857,DB00683,Midazolam
,2876073,Minimum plasma concentrations,"Minimum plasma concentrations of midazolam measured just before each injection were 258.8 +/- 108.4 ng ml-1 for the first protocol and 353.1 +/- 55.2 ng ml-1 for the second protocol; maximum midazolam concentrations, measured 5 min after the last administration, were 1103.1 +/- 237.9 ng ml-1 and 743.0 +/- 103.2 ng ml-1, respectively, suggesting that a continuous infusion of midazolam after a loading dose should be better than repeated injections at keeping the concentration close to the sedative level of 400 ng ml-1.",Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876073/),[ng] / [ml],258.8,54913,DB00683,Midazolam
,2876073,Minimum plasma concentrations,"Minimum plasma concentrations of midazolam measured just before each injection were 258.8 +/- 108.4 ng ml-1 for the first protocol and 353.1 +/- 55.2 ng ml-1 for the second protocol; maximum midazolam concentrations, measured 5 min after the last administration, were 1103.1 +/- 237.9 ng ml-1 and 743.0 +/- 103.2 ng ml-1, respectively, suggesting that a continuous infusion of midazolam after a loading dose should be better than repeated injections at keeping the concentration close to the sedative level of 400 ng ml-1.",Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876073/),[ng] / [ml],353.1,54914,DB00683,Midazolam
,2876073,maximum midazolam concentrations,"Minimum plasma concentrations of midazolam measured just before each injection were 258.8 +/- 108.4 ng ml-1 for the first protocol and 353.1 +/- 55.2 ng ml-1 for the second protocol; maximum midazolam concentrations, measured 5 min after the last administration, were 1103.1 +/- 237.9 ng ml-1 and 743.0 +/- 103.2 ng ml-1, respectively, suggesting that a continuous infusion of midazolam after a loading dose should be better than repeated injections at keeping the concentration close to the sedative level of 400 ng ml-1.",Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876073/),[ng] / [ml],1103.1,54915,DB00683,Midazolam
,2876073,maximum midazolam concentrations,"Minimum plasma concentrations of midazolam measured just before each injection were 258.8 +/- 108.4 ng ml-1 for the first protocol and 353.1 +/- 55.2 ng ml-1 for the second protocol; maximum midazolam concentrations, measured 5 min after the last administration, were 1103.1 +/- 237.9 ng ml-1 and 743.0 +/- 103.2 ng ml-1, respectively, suggesting that a continuous infusion of midazolam after a loading dose should be better than repeated injections at keeping the concentration close to the sedative level of 400 ng ml-1.",Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876073/),[ng] / [ml],743.0,54916,DB00683,Midazolam
,2876073,beta elimination half-life,"The estimated pharmacokinetic parameters were similar to those already published, except for the beta elimination half-life of midazolam (3.24 +/- 0.90 h for protocol 1 and 3.34 +/- 1.47 h for protocol 2) which was slightly longer than that reported for single dose studies.",Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876073/),h,3.24,54917,DB00683,Midazolam
,2876073,beta elimination half-life,"The estimated pharmacokinetic parameters were similar to those already published, except for the beta elimination half-life of midazolam (3.24 +/- 0.90 h for protocol 1 and 3.34 +/- 1.47 h for protocol 2) which was slightly longer than that reported for single dose studies.",Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876073/),h,3.34,54918,DB00683,Midazolam
,2810699,distribution half-life (T alpha 1/2),"The distribution half-life (T alpha 1/2) of midazolam, 1.24 minutes, was shorter than that of diazepam, 3.85 minutes.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),min,1.24,55579,DB00683,Midazolam
,2810699,distribution half-life (T alpha 1/2),"The distribution half-life (T alpha 1/2) of midazolam, 1.24 minutes, was shorter than that of diazepam, 3.85 minutes.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),min,3.85,55580,DB00683,Midazolam
,2810699,elimination half-life (T beta 1/2),"The elimination half-life (T beta 1/2) of midazolam, 5.44 hours, was similar to that of diazepam, 5.02 hours.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),h,5.44,55581,DB00683,Midazolam
,2810699,elimination half-life (T beta 1/2),"The elimination half-life (T beta 1/2) of midazolam, 5.44 hours, was similar to that of diazepam, 5.02 hours.",[Usefulness of midazolam in a modified NLA--study on plasma concentrations]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810699/),h,5.02,55582,DB00683,Midazolam
,17148773,Midazola,"Midazolam clearance (mean = 40 L/h, range = 10-111) was highly correlated with that of total and unbound gefitinib (R2 = .60 and R2 = .68, respectively) and with steady-state plasma trough concentrations of gefitinib (R2 = .58 and R2 = .60, respectively), and it accounted for approximately 40% of interindividual variability in gefitinib clearance in the pharmacokinetic model.",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),[l] / [h],40,58446,DB00683,Midazolam
above,17148773,steady-state plasma trough concentrations,"At a dose of 250 mg gefitinib, 11 of 13 patients achieved steady-state plasma trough concentrations above the IC50 for inhibition of mutant EGFR in vitro (0.015 microM), but only one achieved a steady-state plasma trough concentration above the IC50 for inhibition of wild-type EGFR (0.1 microM).",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),μM,0.015,58447,DB00683,Midazolam
,17148773,steady-state plasma trough concentration,"At a dose of 250 mg gefitinib, 11 of 13 patients achieved steady-state plasma trough concentrations above the IC50 for inhibition of mutant EGFR in vitro (0.015 microM), but only one achieved a steady-state plasma trough concentration above the IC50 for inhibition of wild-type EGFR (0.1 microM).",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),μM,0.1,58448,DB00683,Midazolam
,17148773,IC50,"At a dose of 250 mg gefitinib, 11 of 13 patients achieved steady-state plasma trough concentrations above the IC50 for inhibition of mutant EGFR in vitro (0.015 microM), but only one achieved a steady-state plasma trough concentration above the IC50 for inhibition of wild-type EGFR (0.1 microM).",CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17148773/),μM,0.1,58449,DB00683,Midazolam
,2702793,volumes of distribution,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[l] / [kg],1.2,58973,DB00683,Midazolam
,2702793,volumes of distribution,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[l] / [kg],2.3,58974,DB00683,Midazolam
,2702793,half-life,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),h,33,58975,DB00683,Midazolam
,2702793,half-life,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),h,2.8,58976,DB00683,Midazolam
,2702793,metabolic clearance,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ml] / [kg·min],0.5,58977,DB00683,Midazolam
,2702793,metabolic clearance,"Both diazepam and midazolam had large volumes of distribution (1.2 and 2.3 L/kg, respectively), but diazepam's half-life was considerably longer (33 versus 2.8 hours) and its metabolic clearance lower (0.5 versus 11.0 ml/min kg) than those of midazolam.","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ml] / [kg·min],11.0,58978,DB00683,Midazolam
,2702793,apparent EC50,The relationship of EEG change to plasma drug concentration indicated an apparent EC50 value of 269 ng/ml for diazepam as opposed to 35 ng/ml for midazolam.,"Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ng] / [ml],269,58979,DB00683,Midazolam
,2702793,apparent EC50,The relationship of EEG change to plasma drug concentration indicated an apparent EC50 value of 269 ng/ml for diazepam as opposed to 35 ng/ml for midazolam.,"Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),[ng] / [ml],35,58980,DB00683,Midazolam
,2702793,Emax,"However, Emax values were similar for both drugs (+19.4% and +21.3%, respectively).","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),%,19.4,58981,DB00683,Midazolam
,2702793,Emax,"However, Emax values were similar for both drugs (+19.4% and +21.3%, respectively).","Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702793/),%,21.3,58982,DB00683,Midazolam
,20864622,AUC ratio,"The mean simulated degree of interaction, measured by midazolam AUC ratio with and without ketoconazole (AUCR), was 10.28.",Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20864622/),,10.28,59097,DB00683,Midazolam
,34163139,flow rate,"The column was Acquity UPLC BEH C18 column and the mobile phase was acetonitrile-formic acid with gradient mode, and the flow rate was set at 0.4 mL/min.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),[ml] / [min],0.4,59672,DB00683,Midazolam
,34163139,m/,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,381.10,59673,DB00683,Midazolam
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,246.20,59674,DB00683,Midazolam
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,147.00,59675,DB00683,Midazolam
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,201.10,59676,DB00683,Midazolam
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,94.90,59677,DB00683,Midazolam
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,326.10,59678,DB00683,Midazolam
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,291.10,59679,DB00683,Midazolam
more,34163139,extraction recovery,"The extraction recovery was more than 79%, and the matrix effect was around 100%.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),%,79,59680,DB00683,Midazolam
,9013373,inhibitory binding affinities,"Dirithromycin and erythromycylamine were low affinity inhibitors of CYP3A (inhibitory binding affinities of 493 mumol/L and 701 mumol/L, respectively); conversely, terfenadine was a moderate affinity inhibitor (inhibitory binding affinity of 28 mumol/L).",Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013373/),[μM] / [l],493,60065,DB00683,Midazolam
,9013373,inhibitory binding affinities,"Dirithromycin and erythromycylamine were low affinity inhibitors of CYP3A (inhibitory binding affinities of 493 mumol/L and 701 mumol/L, respectively); conversely, terfenadine was a moderate affinity inhibitor (inhibitory binding affinity of 28 mumol/L).",Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013373/),[μM] / [l],701,60066,DB00683,Midazolam
,9013373,inhibitory binding affinity,"Dirithromycin and erythromycylamine were low affinity inhibitors of CYP3A (inhibitory binding affinities of 493 mumol/L and 701 mumol/L, respectively); conversely, terfenadine was a moderate affinity inhibitor (inhibitory binding affinity of 28 mumol/L).",Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013373/),[μM] / [l],28,60067,DB00683,Midazolam
,32578227,AUC0-∞,"The AUC0-∞ (1.08 [0.91-1.27]) and Cmax (0.95 [0.75-1.2]) of 1-hydroxymidazolam, the primary metabolite of midazolam, were also within the no-effect range.",The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32578227/),,1.08,61107,DB00683,Midazolam
,32578227,Cmax,"The AUC0-∞ (1.08 [0.91-1.27]) and Cmax (0.95 [0.75-1.2]) of 1-hydroxymidazolam, the primary metabolite of midazolam, were also within the no-effect range.",The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32578227/),,0.95,61108,DB00683,Midazolam
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],101,61552,DB00683,Midazolam
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],2 540,61553,DB00683,Midazolam
,23381882,plasma AUC0-24,"The mean plasma AUC0-24 (pg hour/mL) of saquinavir at phases 1, 2, and 3 was 101, 2 540, and 23 900 (P < .01), respectively.","Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23381882/),[h·pg] / [ml],23 900,61554,DB00683,Midazolam
less,11165818,half-life,"In freshly collected human serum in vitro at 37 degrees C, the half-life for the first-order rate constant for the ring-closing reaction was estimated to be less than 2 min for both alprazolam and midazolam.",Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),min,2,62331,DB00683,Midazolam
,11165818,maximum serum concentrations,Midazolam was absorbed rapidly reaching maximum serum concentrations of 54.3+/-5.0 ng/ml at 15+/-2 min.,Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),[ng] / [ml],54.3,62332,DB00683,Midazolam
,11165818,elimination half-life,The elimination half-life of midazolam was 2.2+/-0.3 h and the absolute availability was 73+/-7%.,Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),h,2.2,62333,DB00683,Midazolam
,11165818,absolute availability,The elimination half-life of midazolam was 2.2+/-0.3 h and the absolute availability was 73+/-7%.,Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165818/),%,73,62334,DB00683,Midazolam
,1880665,beta half-life,Mean beta half-life of midazolam was 47 +/- 26 minutes and mean clearance was 10.0 +/- 5.0 ml/min per kilogram of body weight.,Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880665/),min,47,62553,DB00683,Midazolam
,1880665,clearance,Mean beta half-life of midazolam was 47 +/- 26 minutes and mean clearance was 10.0 +/- 5.0 ml/min per kilogram of body weight.,Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880665/),[ml] / [kg·min],10.0,62554,DB00683,Midazolam
,1880665,peak midazolam serum concentration,Maximum level of sedation occurred at 5 minutes after initiation of the injection and corresponded to a mean peak midazolam serum concentration of 229 +/- 39 micrograms/L.,Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880665/),[μg] / [l],229,62555,DB00683,Midazolam
greater,1880665,peak midazolam concentration,We conclude that children metabolize and excrete midazolam more rapidly than adults do and that sedation adequate for endoscopy is safely achieved in the majority of children with a midazolam dose of 0.05 to 0.1 mg/kg and a mean peak midazolam concentration greater than 200 microgram/L.,Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880665/),[μg] / [l],200,62556,DB00683,Midazolam
,23527529,clearance,"Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),[l] / [h],24,62657,DB00683,Midazolam
,23527529,volume of distribution,"Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),l,469,62658,DB00683,Midazolam
,23527529,half-life,"Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),h,20,62659,DB00683,Midazolam
,23527529,KI,"IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,19,62660,DB00683,Midazolam
,23527529,KI,"IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,16,62661,DB00683,Midazolam
,23527529,KI,"IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,4.5,62662,DB00683,Midazolam
,23527529,IC50,IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein.,"The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,1.9,62663,DB00683,Midazolam
,7833228,"t1/2,z","Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),h,16,62961,DB00683,Midazolam
,7833228,CL,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[ml] / [min],1215,62962,DB00683,Midazolam
,7833228,CLR,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[ml] / [min],7,62963,DB00683,Midazolam
,7833228,Vss,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[1] / [kg],10.0,62964,DB00683,Midazolam
,9952152,total systemic clearance (Cl(T)),"Average parameter values (interpatient percent coefficient of variation) for infants with birth weights 1,000 g or less were total systemic clearance (Cl(T)) = 0.783 ml/min (83%), intercompartmental clearance (Cl(Q)) = 6.53 ml/min (116%), volume of distribution of the central compartment (V1) = 473 ml (70%), and volume of distribution of the peripheral compartment (V2) = 513 ml (146%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),[ml] / [min],0.783,63379,DB00683,Midazolam
,9952152,intercompartmental clearance (Cl(Q)),"Average parameter values (interpatient percent coefficient of variation) for infants with birth weights 1,000 g or less were total systemic clearance (Cl(T)) = 0.783 ml/min (83%), intercompartmental clearance (Cl(Q)) = 6.53 ml/min (116%), volume of distribution of the central compartment (V1) = 473 ml (70%), and volume of distribution of the peripheral compartment (V2) = 513 ml (146%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),[ml] / [min],6.53,63380,DB00683,Midazolam
,9952152,volume of distribution of the central compartment (V1),"Average parameter values (interpatient percent coefficient of variation) for infants with birth weights 1,000 g or less were total systemic clearance (Cl(T)) = 0.783 ml/min (83%), intercompartmental clearance (Cl(Q)) = 6.53 ml/min (116%), volume of distribution of the central compartment (V1) = 473 ml (70%), and volume of distribution of the peripheral compartment (V2) = 513 ml (146%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),ml,473,63381,DB00683,Midazolam
,9952152,volume of distribution of the peripheral compartment (V2),"Average parameter values (interpatient percent coefficient of variation) for infants with birth weights 1,000 g or less were total systemic clearance (Cl(T)) = 0.783 ml/min (83%), intercompartmental clearance (Cl(Q)) = 6.53 ml/min (116%), volume of distribution of the central compartment (V1) = 473 ml (70%), and volume of distribution of the peripheral compartment (V2) = 513 ml (146%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),ml,513,63382,DB00683,Midazolam
,9952152,Cl(T),"For infants with birth weights more than 1,000 g they were as follows: Cl(T) = 1.24 ml/min (78%), Cl(Q) = 9.82 ml/min (98%), V1 = 823 ml (43%), and V2 = 1,040 ml (193%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),[ml] / [min],1.24,63383,DB00683,Midazolam
,9952152,Cl(Q),"For infants with birth weights more than 1,000 g they were as follows: Cl(T) = 1.24 ml/min (78%), Cl(Q) = 9.82 ml/min (98%), V1 = 823 ml (43%), and V2 = 1,040 ml (193%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),[ml] / [min],9.82,63384,DB00683,Midazolam
,9952152,V1,"For infants with birth weights more than 1,000 g they were as follows: Cl(T) = 1.24 ml/min (78%), Cl(Q) = 9.82 ml/min (98%), V1 = 823 ml (43%), and V2 = 1,040 ml (193%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),ml,823,63385,DB00683,Midazolam
,9952152,V2,"For infants with birth weights more than 1,000 g they were as follows: Cl(T) = 1.24 ml/min (78%), Cl(Q) = 9.82 ml/min (98%), V1 = 823 ml (43%), and V2 = 1,040 ml (193%).",Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9952152/),ml,"1,040",63386,DB00683,Midazolam
,11966671,Apparent oral clearance,"Apparent oral clearance, apparent volume of distribution, plasma half-life and 1-OH-Midazolam/Midazolam AUC ratio were [median (range)]: 2.7 [0.67-15.5] ml kg(-1) min(-1), 1.4 [0.3-12.1] l kg(-1), 7.6 [1.2-15.1], h and 0.03 [0.01-0.96], respectively.",Pharmacokinetics and metabolism of oral midazolam in preterm infants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966671/),[ml] / [kg·min],2.7,63389,DB00683,Midazolam
,11966671,1-OH-Midazolam/Midazolam AUC ratio,"Apparent oral clearance, apparent volume of distribution, plasma half-life and 1-OH-Midazolam/Midazolam AUC ratio were [median (range)]: 2.7 [0.67-15.5] ml kg(-1) min(-1), 1.4 [0.3-12.1] l kg(-1), 7.6 [1.2-15.1], h and 0.03 [0.01-0.96], respectively.",Pharmacokinetics and metabolism of oral midazolam in preterm infants. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966671/),,0.03,63390,DB00683,Midazolam
,11966671,Absolute bioavailability,Absolute bioavailability was 0.49 [0.12-1.0].,Pharmacokinetics and metabolism of oral midazolam in preterm infants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966671/),,0.49,63391,DB00683,Midazolam
,22299599,clearance,"Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05).",Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22299599/),[l] / [h],63.3,64136,DB00683,Midazolam
,22299599,clearance,"Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05).",Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22299599/),[l] / [h],53.9,64137,DB00683,Midazolam
,2390433,Ks-,2. In vitro evaluation of the binding of cyclosporin A to rat microsomal cytochrome P-450 indicated a Ks-value of 0.4 microM.,Is cyclosporin A an inhibitor of drug metabolism? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,0.4,64894,DB00683,Midazolam
,2390433,IC50,"In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively.",Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,6,64895,DB00683,Midazolam
,2390433,IC50,"In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively.",Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,8,64896,DB00683,Midazolam
,2390433,IC50,"In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively.",Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,70,64897,DB00683,Midazolam
,2390433,IC50-,3. Comparative studies with human liver microsomes indicated IC50-values of approximately 300 microM for the formation of alpha-OH-midazolam and of 65 microM for the formation of 4-OH-midazolam.,Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,300,64898,DB00683,Midazolam
,2390433,IC50-,3. Comparative studies with human liver microsomes indicated IC50-values of approximately 300 microM for the formation of alpha-OH-midazolam and of 65 microM for the formation of 4-OH-midazolam.,Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,65,64899,DB00683,Midazolam
,2390433,t1/2,5. In these patients the hepatic elimination of midazolam was characterized by a mean t1/2 (+/- s.d.) of 2.3 +/- 1.2 h and a plasma clearance (CL) of 414 +/- 95 ml min-1.,Is cyclosporin A an inhibitor of drug metabolism? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),h,2.3,64900,DB00683,Midazolam
,2390433,plasma clearance (CL),5. In these patients the hepatic elimination of midazolam was characterized by a mean t1/2 (+/- s.d.) of 2.3 +/- 1.2 h and a plasma clearance (CL) of 414 +/- 95 ml min-1.,Is cyclosporin A an inhibitor of drug metabolism? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),[ml] / [min],414,64901,DB00683,Midazolam
,2390433,t1/2,"These values were not different from those of normal human subjects (t1/2 = 1.5 to 4 h, CL = 350 to 700 ml min-1).",Is cyclosporin A an inhibitor of drug metabolism? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),h,1.5 to 4,64902,DB00683,Midazolam
,2390433,CL,"These values were not different from those of normal human subjects (t1/2 = 1.5 to 4 h, CL = 350 to 700 ml min-1).",Is cyclosporin A an inhibitor of drug metabolism? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),[ml] / [min],350 to 700,64903,DB00683,Midazolam
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,22.48,65057,DB00683,Midazolam
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,18.34,65058,DB00683,Midazolam
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.62,65059,DB00683,Midazolam
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.68,65060,DB00683,Midazolam
,1820894,bioavailability,The bioavailability estimated by the AUC ratio (mean 0.52 +/- SDrel 16%) is compared to the deconvolution results obtained using only data points within 120 (0.46 +/- 22%) (p = 0.02) and 300 min (0.51 +/- 20%) (p = 0.6) after drug administration.,Absorption profiles of rectally administered midazolam estimated by deconvolution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820894/),%,0.52,65170,DB00683,Midazolam
,1820894,bioavailability,The bioavailability estimated by the AUC ratio (mean 0.52 +/- SDrel 16%) is compared to the deconvolution results obtained using only data points within 120 (0.46 +/- 22%) (p = 0.02) and 300 min (0.51 +/- 20%) (p = 0.6) after drug administration.,Absorption profiles of rectally administered midazolam estimated by deconvolution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820894/),%,0.46,65171,DB00683,Midazolam
,1820894,bioavailability,The bioavailability estimated by the AUC ratio (mean 0.52 +/- SDrel 16%) is compared to the deconvolution results obtained using only data points within 120 (0.46 +/- 22%) (p = 0.02) and 300 min (0.51 +/- 20%) (p = 0.6) after drug administration.,Absorption profiles of rectally administered midazolam estimated by deconvolution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820894/),%,0.51,65172,DB00683,Midazolam
,26363369,flow rate,"The analytes and the internal standard (midazolam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1mm×50mm, 1.7μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4mL/min.","Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363369/),[ml] / [min],0.4,65242,DB00683,Midazolam
,26363369,m/,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 245.1→113.1 for ribavirin, m/z 530.3→243.1 for sofosbuvir, m/z 261.5→113.1 for GS-331007 and m/z 326.2→291.1 for midazolam (IS) using a positive electrospray ionization interface.","Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363369/),,261.5,65243,DB00683,Midazolam
,26363369,Total time,Total time for each chromatograph was 3.0min.,"Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363369/),min,3.0,65244,DB00683,Midazolam
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],5.3,65594,DB00683,Midazolam
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],14.6,65595,DB00683,Midazolam
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.1,65596,DB00683,Midazolam
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,58,65597,DB00683,Midazolam
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,35,65598,DB00683,Midazolam
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,630,65599,DB00683,Midazolam
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],4.9,65600,DB00683,Midazolam
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],13.2,65601,DB00683,Midazolam
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.5,65602,DB00683,Midazolam
,32710209,bioavailability,"In contrast, the predicted bioavailability of posaconazole, a poorly soluble drug, decreased from 12% pre-RYGBS to 5% post-RYGBS.",PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710209/),%,12,65654,DB00683,Midazolam
,32710209,bioavailability,"In contrast, the predicted bioavailability of posaconazole, a poorly soluble drug, decreased from 12% pre-RYGBS to 5% post-RYGBS.",PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710209/),%,5,65655,DB00683,Midazolam
,10193676,oral bioavailability,"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%.",Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193676/),%,30,66836,DB00683,Midazolam
,24588344,recoveries,Mean recoveries of MGCD0103 in rat plasma were in the range of 89.7-96.1%.,Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588344/),%,89.7-96.1,67391,DB00683,Midazolam
,24588344,bioavailability,The bioavailability of MGCD0103 was 29.3% in rats.,Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588344/),%,29.3,67392,DB00683,Midazolam
,9378843,total clearance,"The mean (SD) for total clearance, distributional clearance, volume of distribution in the central compartment, volume of distribution in the peripheral compartment, absorption rate constant, bioavailability, and half-life were 0.57 (0.26) L/hr/kg, 0.31 (0.29) L/hr/kg, 0.27 (0.14) L/kg, 0.67 (0.11) L/kg, 2.46 (1.72) hr-1, 50% (13%), and 3.1 (0.84) hours, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378843/),[l] / [h·kg],0.57,68074,DB00683,Midazolam
,9378843,half-life,"The mean (SD) for total clearance, distributional clearance, volume of distribution in the central compartment, volume of distribution in the peripheral compartment, absorption rate constant, bioavailability, and half-life were 0.57 (0.26) L/hr/kg, 0.31 (0.29) L/hr/kg, 0.27 (0.14) L/kg, 0.67 (0.11) L/kg, 2.46 (1.72) hr-1, 50% (13%), and 3.1 (0.84) hours, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378843/),h,3.1,68075,DB00683,Midazolam
,9378843,maximal effect,"The mean (SD) for the concentration at which the effect is half maximal (EC50) and the maximal effect or the maximal change in effect measure from baseline (Emax) were 63.1 (21.2) ng/mL and 52.8 (21.1) correct substitutions, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378843/),[ng] / [ml],63.1,68076,DB00683,Midazolam
,9378843,maximal change in effect measure from baseline (Emax),"The mean (SD) for the concentration at which the effect is half maximal (EC50) and the maximal effect or the maximal change in effect measure from baseline (Emax) were 63.1 (21.2) ng/mL and 52.8 (21.1) correct substitutions, respectively.",Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378843/),,52.8,68077,DB00683,Midazolam
<,10877118,inter-response times,Midazolam increased shorter-response (inter-response times < 45 s) rates and decreased reinforcement rates in a time-related manner.,"Post-injection delays in experimental chambers, but not in home cages, produce both sensitization and tolerance of operant behaviour to midazolam: relation to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877118/),s,45,68311,DB00683,Midazolam
,25501671,AUCinf ratio,"Following brivaracetam 150 mg/day, the Day 13/Day 1 AUCinf ratio (90% confidence interval) was 1.09 (0.97, 1.21) and 1.04 (0.93, 1.17) for midazolam and 1'-hydroxymidazolam, respectively.","Effect of brivaracetam on CYP3A activity, measured by oral midazolam. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25501671/),,1.09,70449,DB00683,Midazolam
,25501671,AUCinf ratio,"Following brivaracetam 150 mg/day, the Day 13/Day 1 AUCinf ratio (90% confidence interval) was 1.09 (0.97, 1.21) and 1.04 (0.93, 1.17) for midazolam and 1'-hydroxymidazolam, respectively.","Effect of brivaracetam on CYP3A activity, measured by oral midazolam. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25501671/),,1.04,70450,DB00683,Midazolam
,25501671,AUCinf ratios,"For the Day 20/Day 1 comparison, the corresponding AUCinf ratios were 1.10 (0.98, 1.23) and 1.07 (0.97, 1.18).","Effect of brivaracetam on CYP3A activity, measured by oral midazolam. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25501671/),,1,70451,DB00683,Midazolam
,12883399,Volume,"Volume (mean +/- standard error) expanded monoexponentially from the onset of extracorporeal membrane oxygenation to a maximum value, 0.8 l +/- 0.5 and 4.1 +/- 0.5 l/kg, respectively.",Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883399/),l,0.8,70780,DB00683,Midazolam
,12883399,Volume,"Volume (mean +/- standard error) expanded monoexponentially from the onset of extracorporeal membrane oxygenation to a maximum value, 0.8 l +/- 0.5 and 4.1 +/- 0.5 l/kg, respectively.",Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883399/),[l] / [kg],4.1,70781,DB00683,Midazolam
,12883399,plasma half-life,"Consequently, plasma half-life was substantially prolonged (median [range]) from onset to steady-state: 6.8 (2.2-39.8) and 33.3 (7.4-178) h, respectively.",Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883399/),h,6.8,70782,DB00683,Midazolam
,12883399,plasma half-life,"Consequently, plasma half-life was substantially prolonged (median [range]) from onset to steady-state: 6.8 (2.2-39.8) and 33.3 (7.4-178) h, respectively.",Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883399/),h,33.3,70783,DB00683,Midazolam
,12883399,Total body clearance,Total body clearance was determined as (mean +/- standard error) 1.4 +/- 0.15 ml.,Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883399/),ml,1.4,70784,DB00683,Midazolam
,12883399,metabolic ratio,The median metabolic ratio was 0.17 (0.03-0.9).,Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883399/),,0.17,70785,DB00683,Midazolam
,8723850,time to peak plasma concentration (Cmax),The mean (+/-sd) time to peak plasma concentration (Cmax) was shorter for im midazolam (17.5 +/- 6.5 min) relative to diazepam (33.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,17.5,70819,DB00683,Midazolam
,8723850,time to peak plasma concentration (Cmax),The mean (+/-sd) time to peak plasma concentration (Cmax) was shorter for im midazolam (17.5 +/- 6.5 min) relative to diazepam (33.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,33.8,70820,DB00683,Midazolam
,8723850,time to peak absorption rate,The mean (+sd) time to peak absorption rate was also shorter for midazolam (9 +/- 2 vs 13.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,9,70821,DB00683,Midazolam
,8723850,time to peak absorption rate,The mean (+sd) time to peak absorption rate was also shorter for midazolam (9 +/- 2 vs 13.8 +/- 7.5 min).,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),min,13.8,70822,DB00683,Midazolam
,8723850,peak rate of absorption,The peak rate of absorption was identical (0.18 mg.,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),mg,0.18,70823,DB00683,Midazolam
,8723850,bioavailability,min-1) and bioavailability was 1.0 for both drugs.,Comparative absorption kinetics of intramuscular midazolam and diazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723850/),,1.0,70824,DB00683,Midazolam
,17112809,AUC,"The median AUC of IV midazolam was 0.05 mg.h/L (range, 0.02-0.14 mg.h/L) in women and 0.06 mg.h/L (range, 0.02-0.14 mg.h/L) in men.",Sex differences in CYP3A activity using intravenous and oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112809/),[h·mg] / [l],0.05,71048,DB00683,Midazolam
,17112809,AUC,"The median AUC of IV midazolam was 0.05 mg.h/L (range, 0.02-0.14 mg.h/L) in women and 0.06 mg.h/L (range, 0.02-0.14 mg.h/L) in men.",Sex differences in CYP3A activity using intravenous and oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112809/),[h·mg] / [l],0.06,71049,DB00683,Midazolam
,17112809,AUC,"The median AUC of oral midazolam was 0.11 mg.h/L (range, 0.02-0.60 mg.h/L) in women and 0.12 mg.h/L (range, 0.04-0.45 mg.h/L) in men.",Sex differences in CYP3A activity using intravenous and oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112809/),[h·mg] / [l],0.11,71050,DB00683,Midazolam
,17112809,AUC,"The median AUC of oral midazolam was 0.11 mg.h/L (range, 0.02-0.60 mg.h/L) in women and 0.12 mg.h/L (range, 0.04-0.45 mg.h/L) in men.",Sex differences in CYP3A activity using intravenous and oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112809/),[h·mg] / [l],0.12,71051,DB00683,Midazolam
,3580236,Plasma clearance,"Plasma clearance (483 ml min-1), apparent volume of distribution (1.94 litre kg-1) and terminal half-life (3.1 h) were in agreement with other reports.",Pharmacokinetics of midazolam in total i.v. anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580236/),[ml] / [min],483,71313,DB00683,Midazolam
,3580236,apparent volume of distribution,"Plasma clearance (483 ml min-1), apparent volume of distribution (1.94 litre kg-1) and terminal half-life (3.1 h) were in agreement with other reports.",Pharmacokinetics of midazolam in total i.v. anaesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580236/),[l] / [kg],1.94,71314,DB00683,Midazolam
,3580236,terminal half-life,"Plasma clearance (483 ml min-1), apparent volume of distribution (1.94 litre kg-1) and terminal half-life (3.1 h) were in agreement with other reports.",Pharmacokinetics of midazolam in total i.v. anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580236/),h,3.1,71315,DB00683,Midazolam
,12494801,duration of continuous in,The mean duration of continuous infusion was 11 +/- 6 days.,[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12494801/),,11,71317,DB00683,Midazolam
over,12494801,Peak plasma levels,"Peak plasma levels were over 150 ng ml-1 during the first 3 days, but normalized after that, only by drug adjustment based on scoring and clinical observation.",[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12494801/),[ng] / [ml],150,71318,DB00683,Midazolam
,12494801,Sieving coefficient (S),The Sieving coefficient (S) was 0.11 +/- 0.10 and 0.44 +/- 0.15 for midazolam and conjugated OH-midazolam respectively.,[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12494801/),,0.11,71319,DB00683,Midazolam
,12494801,Sieving coefficient (S),The Sieving coefficient (S) was 0.11 +/- 0.10 and 0.44 +/- 0.15 for midazolam and conjugated OH-midazolam respectively.,[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12494801/),,0.44,71320,DB00683,Midazolam
,12494801,clearance,A significant clearance (9.6 +/- 1.9 ml min-1) was observed for the conjugated products.,[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12494801/),[ml] / [min],9.6,71321,DB00683,Midazolam
,12494801,T 1/2 beta,T 1/2 beta was 11 h and was correlated with the mean time of recovery.,[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12494801/),h,11,71322,DB00683,Midazolam
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.4,71665,DB00683,Midazolam
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],2.6,71666,DB00683,Midazolam
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.7,71667,DB00683,Midazolam
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],5.5,71668,DB00683,Midazolam
,10759364,maximum (Cmax),"In series 2, after intranasal midazolam administration of 0.4 mg/kg, plasma concentrations attained a maximum (Cmax) of 0.13 +/- 0.04 mg/l at 5 min (median Tmax) and remained higher than 0.04 mg/l until 60 min.",Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759364/),[mg] / [l],0.13,71892,DB00683,Midazolam
higher,10759364,Tmax,"In series 2, after intranasal midazolam administration of 0.4 mg/kg, plasma concentrations attained a maximum (Cmax) of 0.13 +/- 0.04 mg/l at 5 min (median Tmax) and remained higher than 0.04 mg/l until 60 min.",Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759364/),[mg] / [l],0.04,71893,DB00683,Midazolam
,10759364,bioavailability factor (F),The bioavailability factor (F) in this study was F = 0.64 +/- 0.17 by the intranasal route.,Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759364/),,0.64,71894,DB00683,Midazolam
,10759364,terminal half-life (T1/2 lambda z),The terminal half-life (T1/2 lambda z) = 145 +/- 138 min was comparable with the i.v. administration half-life (158 +/- 127 min).,Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759364/),min,145,71895,DB00683,Midazolam
,10759364,half-life,The terminal half-life (T1/2 lambda z) = 145 +/- 138 min was comparable with the i.v. administration half-life (158 +/- 127 min).,Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10759364/),min,158,71896,DB00683,Midazolam
greater,15060510,hepatic extraction ratio,The hepatic extraction ratio of propofol was greater than 0.8 and remained constant throughout surgery.,"Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060510/),,0.8,71947,DB00683,Midazolam
,16432274,C(max),"MDZ exposure was very similar in the presence and absence of R667 (C(max) = 50.8 vs 46.2 ng/mL; AUC(0-last) = 215 vs 216 ng.h/mL; AUC(0-last) ratio = 0.26 vs 0.26, respectively).","Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432274/),[ng] / [ml],50.8,73126,DB00683,Midazolam
,16432274,C(max),"MDZ exposure was very similar in the presence and absence of R667 (C(max) = 50.8 vs 46.2 ng/mL; AUC(0-last) = 215 vs 216 ng.h/mL; AUC(0-last) ratio = 0.26 vs 0.26, respectively).","Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432274/),[ng] / [ml],46.2,73127,DB00683,Midazolam
,16432274,AUC(0-last),"MDZ exposure was very similar in the presence and absence of R667 (C(max) = 50.8 vs 46.2 ng/mL; AUC(0-last) = 215 vs 216 ng.h/mL; AUC(0-last) ratio = 0.26 vs 0.26, respectively).","Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432274/),[h·ng] / [ml],215,73128,DB00683,Midazolam
,16432274,AUC(0-last),"MDZ exposure was very similar in the presence and absence of R667 (C(max) = 50.8 vs 46.2 ng/mL; AUC(0-last) = 215 vs 216 ng.h/mL; AUC(0-last) ratio = 0.26 vs 0.26, respectively).","Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432274/),[h·ng] / [ml],216,73129,DB00683,Midazolam
,16432274,AUC(0-last) ratio,"MDZ exposure was very similar in the presence and absence of R667 (C(max) = 50.8 vs 46.2 ng/mL; AUC(0-last) = 215 vs 216 ng.h/mL; AUC(0-last) ratio = 0.26 vs 0.26, respectively).","Effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432274/),,0,73130,DB00683,Midazolam
,11887131,Peak heart rate,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),[beats] / [min],91,73469,DB00683,Midazolam
,11887131,Peak heart rate,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),[beats] / [min],107,73470,DB00683,Midazolam
,11887131,peak systolic blood pressure,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),hg·mm,131,73471,DB00683,Midazolam
,11887131,peak systolic blood pressure,"Peak heart rate (91 beats/min for remifentanil vs 107 beats/min for meperidine, P <.01) and peak systolic blood pressure (131 mm Hg for remifentanil vs. 142 mm Hg for meperidine, P <.05) were significantly lower for the remifentanil group.",Remifentanil for use during conscious sedation in outpatient oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11887131/),hg·mm,142,73472,DB00683,Midazolam
,32386327,total recovery,Excretion was mainly in urine; the total recovery in urine and feces was 77-94%.,Proof of Concept: First Pediatric [14 C]microtracer Study to Create Metabolite Profiles of Midazolam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32386327/),%,77-94,74181,DB00683,Midazolam
,12630977,Clearance (CL),"Clearance (CL) and steady state volume of distribution (Vss) of midazolam (mean +/- SD, 95% confidence level) in cancer (424 +/- 155, 61.3 ml min(-1); 1.21 +/- 0.46, 0.18 l kg(-1)) and noncancer (407 +/- 135, 57.1 ml min(-1); 1.15 +/- 0.33, 0.155 l kg(-1)) patients, respectively, were not different and comparable with published data.",Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12630977/),[ml] / [min],424,74242,DB00683,Midazolam
,12630977,Clearance (CL),"Clearance (CL) and steady state volume of distribution (Vss) of midazolam (mean +/- SD, 95% confidence level) in cancer (424 +/- 155, 61.3 ml min(-1); 1.21 +/- 0.46, 0.18 l kg(-1)) and noncancer (407 +/- 135, 57.1 ml min(-1); 1.15 +/- 0.33, 0.155 l kg(-1)) patients, respectively, were not different and comparable with published data.",Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12630977/),[ml] / [min],407,74243,DB00683,Midazolam
,12630977,steady state volume of distribution (Vss),"Clearance (CL) and steady state volume of distribution (Vss) of midazolam (mean +/- SD, 95% confidence level) in cancer (424 +/- 155, 61.3 ml min(-1); 1.21 +/- 0.46, 0.18 l kg(-1)) and noncancer (407 +/- 135, 57.1 ml min(-1); 1.15 +/- 0.33, 0.155 l kg(-1)) patients, respectively, were not different and comparable with published data.",Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12630977/),[ml] / [min],57.1,74244,DB00683,Midazolam
,12630977,steady state volume of distribution (Vss),"Clearance (CL) and steady state volume of distribution (Vss) of midazolam (mean +/- SD, 95% confidence level) in cancer (424 +/- 155, 61.3 ml min(-1); 1.21 +/- 0.46, 0.18 l kg(-1)) and noncancer (407 +/- 135, 57.1 ml min(-1); 1.15 +/- 0.33, 0.155 l kg(-1)) patients, respectively, were not different and comparable with published data.",Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12630977/),[l] / [kg],1.15,74245,DB00683,Midazolam
,15198070,time to seizure termination,The mean time to seizure termination was 8.8 +/- 1.6 min.,Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,8.8,74668,DB00683,Midazolam
,15198070,apparent volumes of distribution (Vd),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[l] / [kg],1.4,74669,DB00683,Midazolam
,15198070,apparent volumes of distribution (Vd),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[l] / [kg],1.7,74670,DB00683,Midazolam
,15198070,area under the time-concentration curves (AUC),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[min·ng] / [ml],"15,990",74671,DB00683,Midazolam
,15198070,area under the time-concentration curves (AUC),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[min·ng] / [ml],"15,120",74672,DB00683,Midazolam
,15198070,times to maximal plasma concentration (Tmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,1.66,74673,DB00683,Midazolam
,15198070,times to maximal plasma concentration (Tmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),min,2.91,74674,DB00683,Midazolam
,15198070,maximal plasma concentrations (Cmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[ng] / [ml],535.1,74675,DB00683,Midazolam
,15198070,maximal plasma concentrations (Cmax),"The following parameter estimates were determined from the model-fit for seizure terminated and not-terminated animals respectively: apparent volumes of distribution (Vd) were 1.4 and 1.7 l/kg; area under the time-concentration curves (AUC), 15,990 and 15,120 ng.min/ml; times to maximal plasma concentration (Tmax), 1.66 and 2.91 min and maximal plasma concentrations (Cmax) 535.1 and 436.6 ng/ml.",Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198070/),[ng] / [ml],436.6,74676,DB00683,Midazolam
,21680781,area under the curve (AUC(0-12 h)),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),[h·ng] / [ml],160.88,75115,DB00683,Midazolam
,21680781,area under the curve (AUC(0-12 h)),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),[h·ng] / [ml],188.07,75116,DB00683,Midazolam
,21680781,AUC(0-∞),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),[h·ng] / [ml],165.46,75117,DB00683,Midazolam
,21680781,AUC(0-∞),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),[h·ng] / [ml],211.84,75118,DB00683,Midazolam
,21680781,t(1/2),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),h,2.06,75119,DB00683,Midazolam
,21680781,t(1/2),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),h,2.75,75120,DB00683,Midazolam
,21680781,t(max),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),h,0.48,75121,DB00683,Midazolam
,21680781,t(max),"The results showed that coadministration of quercetin in CYP3A5*1/*1 and CYP3A5*1/*3 individuals significantly decreased the area under the curve (AUC(0-12 h)) of midazolam (160.88 ± 45.58 ng·h/mL vs 188.07 ± 65.75 ng·h/mL, P < .05), significantly decreased the AUC(0-∞) of midazolam (165.46 ± 47.15 ng·h/mL vs 211.84 ± 75.80 ng·h/mL, P < .01), shortened t(1/2) (2.06 ± 0.51 h vs 2.75 ± 0.89 h, P < .01), and decreased t(max) significantly (0.48 ± 0.36 h vs 1.06 ± 0.69 h, P < .01), respectively.",Effect of quercetin on CYP3A activity in Chinese healthy participants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680781/),h,1.06,75122,DB00683,Midazolam
,18242899,efflux ratio,"Over a range from 0.03 to 0.3%, pluronic F68 increased apical-to-basolateral permeability (AP-BL) and decreased basolateral-to-apical permeability (BL-AP) of the P-gp substrate CEL in Caco-2 cell monolayer with the efflux ratio values of 2.8+/-0.3 (0.03%), 2.6+/-0.3 (0.1%), 2.3+/-0.2 (0.3%), respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),,2.8,75380,DB00683,Midazolam
,18242899,efflux ratio,"Over a range from 0.03 to 0.3%, pluronic F68 increased apical-to-basolateral permeability (AP-BL) and decreased basolateral-to-apical permeability (BL-AP) of the P-gp substrate CEL in Caco-2 cell monolayer with the efflux ratio values of 2.8+/-0.3 (0.03%), 2.6+/-0.3 (0.1%), 2.3+/-0.2 (0.3%), respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),,2.6,75381,DB00683,Midazolam
,18242899,efflux ratio,"Over a range from 0.03 to 0.3%, pluronic F68 increased apical-to-basolateral permeability (AP-BL) and decreased basolateral-to-apical permeability (BL-AP) of the P-gp substrate CEL in Caco-2 cell monolayer with the efflux ratio values of 2.8+/-0.3 (0.03%), 2.6+/-0.3 (0.1%), 2.3+/-0.2 (0.3%), respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),,2.3,75382,DB00683,Midazolam
,18242899,IC(50),"Furthermore, CYP3A4-catalyzed formation of 1'-hydroxymidazolam was inhibited by pluronic F68 with IC(50) and K(i) values of 0.11 and 0.16 mg/ml, respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),[mg] / [ml],0.11,75383,DB00683,Midazolam
,18242899,K(i),"Furthermore, CYP3A4-catalyzed formation of 1'-hydroxymidazolam was inhibited by pluronic F68 with IC(50) and K(i) values of 0.11 and 0.16 mg/ml, respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),[mg] / [ml],0.16,75384,DB00683,Midazolam
more,26556257,bioavailability (F),Studies have demonstrated that a mean bioavailability (F) of more than 73% can be achieved with IN-administered midazolam.,The Use of Intranasal Midazolam in a Special Care Dentistry Department: Technique and Cases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556257/),%,73,76927,DB00683,Midazolam
,11994056,peak plasma concentration,The mean (+/-s.d.) peak plasma concentration of midazolam of 71 (+/-25 ng ml-1) was reached after 14 (+/-5 min).,Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),[ng] / [ml],71,77430,DB00683,Midazolam
,11994056,bioavailability,Mean bioavailability following intranasal administration was 0.83+/-0.19.,Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),,0.83,77431,DB00683,Midazolam
,11994056,volume of distribution at steady state,"After intravenous and intranasal administration, the pharmacokinetic estimates of midazolam were: mean volume of distribution at steady state 1.11+/-0.25 l kg-1, mean systemic clearance 16.1+/-4.1 ml min-1 kg-1 and harmonic mean initial and terminal half lives 8.4+/-2.4 and 79+/-30 min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),[l] / [kg],1.11,77432,DB00683,Midazolam
,11994056,systemic clearance,"After intravenous and intranasal administration, the pharmacokinetic estimates of midazolam were: mean volume of distribution at steady state 1.11+/-0.25 l kg-1, mean systemic clearance 16.1+/-4.1 ml min-1 kg-1 and harmonic mean initial and terminal half lives 8.4+/-2.4 and 79+/-30 min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),[ml] / [kg·min],16.1,77433,DB00683,Midazolam
,11994056,initial,"After intravenous and intranasal administration, the pharmacokinetic estimates of midazolam were: mean volume of distribution at steady state 1.11+/-0.25 l kg-1, mean systemic clearance 16.1+/-4.1 ml min-1 kg-1 and harmonic mean initial and terminal half lives 8.4+/-2.4 and 79+/-30 min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),min,8.4,77434,DB00683,Midazolam
,11994056,terminal half lives,"After intravenous and intranasal administration, the pharmacokinetic estimates of midazolam were: mean volume of distribution at steady state 1.11+/-0.25 l kg-1, mean systemic clearance 16.1+/-4.1 ml min-1 kg-1 and harmonic mean initial and terminal half lives 8.4+/-2.4 and 79+/-30 min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),min,8.4,77435,DB00683,Midazolam
,11994056,terminal half lives,"After intravenous and intranasal administration, the pharmacokinetic estimates of midazolam were: mean volume of distribution at steady state 1.11+/-0.25 l kg-1, mean systemic clearance 16.1+/-4.1 ml min-1 kg-1 and harmonic mean initial and terminal half lives 8.4+/-2.4 and 79+/-30 min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994056/),min,79,77436,DB00683,Midazolam
,9728893,oral clearance,The oral clearance of midazolam was found to be significantly greater in female subjects (1.9 +/- 1.0 versus 1.0 +/- 0.3 L/hr/kg; p < 0.05) than in male subjects but not systemic clearance (0.35 +/- 0.1 versus 0.44 +/- 0.1 L/hr/kg).,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),[l] / [h·kg],1.9,78040,DB00683,Midazolam
,9728893,oral clearance,The oral clearance of midazolam was found to be significantly greater in female subjects (1.9 +/- 1.0 versus 1.0 +/- 0.3 L/hr/kg; p < 0.05) than in male subjects but not systemic clearance (0.35 +/- 0.1 versus 0.44 +/- 0.1 L/hr/kg).,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),[l] / [h·kg],1.0,78041,DB00683,Midazolam
,9728893,systemic clearance,The oral clearance of midazolam was found to be significantly greater in female subjects (1.9 +/- 1.0 versus 1.0 +/- 0.3 L/hr/kg; p < 0.05) than in male subjects but not systemic clearance (0.35 +/- 0.1 versus 0.44 +/- 0.1 L/hr/kg).,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),[l] / [h·kg],0.35,78042,DB00683,Midazolam
,9728893,systemic clearance,The oral clearance of midazolam was found to be significantly greater in female subjects (1.9 +/- 1.0 versus 1.0 +/- 0.3 L/hr/kg; p < 0.05) than in male subjects but not systemic clearance (0.35 +/- 0.1 versus 0.44 +/- 0.1 L/hr/kg).,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),[l] / [h·kg],0.44,78043,DB00683,Midazolam
,9728893,systemic clearance,A significant (p < 0.05) reduction in the systemic clearance of midazolam from 28 +/- 9 L/hr to 10 +/- 3 L/hr occurred after clarithromycin administration.,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),[l] / [h],28,78044,DB00683,Midazolam
,9728893,systemic clearance,A significant (p < 0.05) reduction in the systemic clearance of midazolam from 28 +/- 9 L/hr to 10 +/- 3 L/hr occurred after clarithromycin administration.,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),[l] / [h],10,78045,DB00683,Midazolam
,9728893,Oral midazolam,Oral midazolam availability was significantly increased from 0.31 +/- 0.1 to 0.75 +/- 0.2 after clarithromycin dosing.,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.31,78046,DB00683,Midazolam
,9728893,Oral midazolam,Oral midazolam availability was significantly increased from 0.31 +/- 0.1 to 0.75 +/- 0.2 after clarithromycin dosing.,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.75,78047,DB00683,Midazolam
,9728893,availability,Oral midazolam availability was significantly increased from 0.31 +/- 0.1 to 0.75 +/- 0.2 after clarithromycin dosing.,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.31,78048,DB00683,Midazolam
,9728893,availability,Oral midazolam availability was significantly increased from 0.31 +/- 0.1 to 0.75 +/- 0.2 after clarithromycin dosing.,The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.75,78049,DB00683,Midazolam
,9728893,intestinal,"Likewise, intestinal and oral availability were significantly increased from 0.42 +/- 0.2 to 0.83 +/- 0.2 and from 0.74 +/- 0.1 to 0.90 +/- 0.04, respectively.",The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.42,78050,DB00683,Midazolam
,9728893,oral availability,"Likewise, intestinal and oral availability were significantly increased from 0.42 +/- 0.2 to 0.83 +/- 0.2 and from 0.74 +/- 0.1 to 0.90 +/- 0.04, respectively.",The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.83,78051,DB00683,Midazolam
,9728893,oral availability,"Likewise, intestinal and oral availability were significantly increased from 0.42 +/- 0.2 to 0.83 +/- 0.2 and from 0.74 +/- 0.1 to 0.90 +/- 0.04, respectively.",The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.74,78052,DB00683,Midazolam
,9728893,oral availability,"Likewise, intestinal and oral availability were significantly increased from 0.42 +/- 0.2 to 0.83 +/- 0.2 and from 0.74 +/- 0.1 to 0.90 +/- 0.04, respectively.",The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728893/),,0.90,78053,DB00683,Midazolam
,18294328,Apparent oral clearance,Apparent oral clearance of midazolam was significantly increased after St John's wort administration from 65.3 +/- 8.4 l h(-1) (day -14) to 86.8 +/- 17.3 l h(-1) (day 0).,The recovery time-course of CYP3A after induction by St John's wort administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294328/),[l] / [h],65.3,78128,DB00683,Midazolam
,18294328,Apparent oral clearance,Apparent oral clearance of midazolam was significantly increased after St John's wort administration from 65.3 +/- 8.4 l h(-1) (day -14) to 86.8 +/- 17.3 l h(-1) (day 0).,The recovery time-course of CYP3A after induction by St John's wort administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294328/),[l] / [h],86.8,78129,DB00683,Midazolam
,18294328,half-life,The changes in apparent oral clearance after St John's wort discontinuation indicated that CYP3A activity recovers from enzyme induction with an estimated half-life of 46.2 h.,The recovery time-course of CYP3A after induction by St John's wort administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294328/),h,46.2,78130,DB00683,Midazolam
,8749262,analytical recoveries,"Mean analytical recoveries were 87% and 86% at a concentration of 300 ng/ml for midazolam and 1-hydroxymidazolam, respectively, and the quantification limit was 2 ng/ml for a plasma volume of 1 ml.",Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749262/),%,87,79836,DB00683,Midazolam
,8749262,analytical recoveries,"Mean analytical recoveries were 87% and 86% at a concentration of 300 ng/ml for midazolam and 1-hydroxymidazolam, respectively, and the quantification limit was 2 ng/ml for a plasma volume of 1 ml.",Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749262/),%,86,79837,DB00683,Midazolam
,8749262,flow-rate,"The separation of midazolam, 1-hydroxymidazolam and flurazepam (internal standard) was achieved on a Spherisorb 5 CN column using methanol-2(r)propanol (75:25, v/v) containing 0.015% perchloric acid at a flow-rate of 1.5 ml/min.",Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749262/),[ml] / [min],1.5,79838,DB00683,Midazolam
,9849746,oral bioavailability,Concomitant intake of rifampicin (600 mg/die) induced especially the presystemic (prehepatic) metabolism of verapamil so that oral bioavailability approached zero and PD effects almost diminished.,Effect of age on pharmacokinetics and pharmacodynamics in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9849746/),,zero,80042,DB00683,Midazolam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.33,80465,DB00683,Midazolam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.14,80466,DB00683,Midazolam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.64,80467,DB00683,Midazolam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.23,80468,DB00683,Midazolam
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,2.2,80742,DB00683,Midazolam
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80743,DB00683,Midazolam
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.3,80744,DB00683,Midazolam
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80745,DB00683,Midazolam
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.8,80746,DB00683,Midazolam
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],1440,80747,DB00683,Midazolam
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],499,80748,DB00683,Midazolam
,9349062,clearance,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],425,80749,DB00683,Midazolam
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,34.9,80750,DB00683,Midazolam
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,21.9,80751,DB00683,Midazolam
>,20434409,recovery,Sample preparation either from human plasma (100 microL) or liver microsomal incubations involved a simple protein precipitation using acetonitrile (900 microL) with an average recovery of >90% for all compounds.,"Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434409/),%,90,80754,DB00683,Midazolam
,20434409,flow rate,The flow rate was 0.25 mL/min and total run time was 5.5 min.,"Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434409/),[ml] / [min],0.25,80755,DB00683,Midazolam
,20434409,total run time,The flow rate was 0.25 mL/min and total run time was 5.5 min.,"Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20434409/),min,5.5,80756,DB00683,Midazolam
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00683,Midazolam
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00683,Midazolam
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00683,Midazolam
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00683,Midazolam
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00683,Midazolam
,24922600,flow rate,The flow rate was set at 0.4 mL/min.,Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24922600/),[ml] / [min],0.4,80877,DB00683,Midazolam
,24922600,recoveries,Mean recoveries of solasodine in rat plasma were in the range of 87.6-94.1%.,Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24922600/),%,87.6-94.1,80878,DB00683,Midazolam
,24922600,Matrix effects,Matrix effects for solasodine were between 94.9% and 102.3%.,Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24922600/),%,94.9,80879,DB00683,Midazolam
,24922600,Matrix effects,Matrix effects for solasodine were between 94.9% and 102.3%.,Development and validation a liquid chromatography mass spectrometry for determination of solasodine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24922600/),%,102.3,80880,DB00683,Midazolam
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.95,81454,DB00683,Midazolam
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.01,81455,DB00683,Midazolam
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.97,81456,DB00683,Midazolam
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81457,DB00683,Midazolam
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.36,81458,DB00683,Midazolam
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.90,81459,DB00683,Midazolam
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.79,81460,DB00683,Midazolam
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81461,DB00683,Midazolam
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.66,81462,DB00683,Midazolam
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.90,81463,DB00683,Midazolam
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,266,81576,DB00683,Midazolam
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,168,81577,DB00683,Midazolam
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1201,81578,DB00683,Midazolam
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1687,81579,DB00683,Midazolam
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],726,81580,DB00683,Midazolam
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1331,81581,DB00683,Midazolam
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2046,81582,DB00683,Midazolam
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2665,81583,DB00683,Midazolam
,17971810,half-lives,"The half-lives of CYP3A4 and CYP1A2 were estimated to be 70 and 105 h, respectively.","Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971810/),h,70,81949,DB00683,Midazolam
,17971810,half-lives,"The half-lives of CYP3A4 and CYP1A2 were estimated to be 70 and 105 h, respectively.","Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971810/),h,105,81950,DB00683,Midazolam
,9764959,maximum plasma concentration,The maximum plasma concentration was 55.9 ng ml(-1) (range 35.6-77.9 ng ml(-1)) at 30 min (range 15-90 min) following buccal administration.,Midazolam pharmacokinetics following intravenous and buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764959/),[ng] / [ml],55.9,82214,DB00683,Midazolam
,9764959,AUC,AUC was calculated to be 15016 ng ml(-1) min (s.d. 3778 ng ml(-1) min) following i.v. and 11191 ng ml(-1) min (s.d. 1777 ng ml(-1) min) following buccal midazolam.,Midazolam pharmacokinetics following intravenous and buccal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764959/),[min·ng] / [ml],15016,82215,DB00683,Midazolam
,9764959,AUC,AUC was calculated to be 15016 ng ml(-1) min (s.d. 3778 ng ml(-1) min) following i.v. and 11191 ng ml(-1) min (s.d. 1777 ng ml(-1) min) following buccal midazolam.,Midazolam pharmacokinetics following intravenous and buccal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764959/),[min·ng] / [ml],11191,82216,DB00683,Midazolam
,9764959,bioavailability,This gave a mean midazolam bioavailability of 74.5%.,Midazolam pharmacokinetics following intravenous and buccal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764959/),%,74.5,82217,DB00683,Midazolam
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,151.2,83339,DB00683,Midazolam
,25965875,m/,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,110.0,83340,DB00683,Midazolam
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,302.3,83341,DB00683,Midazolam
,25965875,m/z,"The MRM transitions of m/z 151.2→110.0 and m/z 302.3→199.2 were used to quantify for AAP and DHC, respectively.",Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),,199.2,83342,DB00683,Midazolam
,25965875,analysis time of,The analysis time of per sample was 1.0min.,Simultaneous determination of acetaminophen and dihydrocodeine in human plasma by UPLC-MS/MS: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25965875/),min,1.0,83343,DB00683,Midazolam
,1869600,t1/2a,The plasma levels versus time corresponded to a biexponential process with a very rapid distribution phase (t1/2a = 5.7 +/- 2.4 min) and an elimination phase (t1/2 beta = 66 +/- 37 min).,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),min,5.7,83746,DB00683,Midazolam
,1869600,t1/2 beta,The plasma levels versus time corresponded to a biexponential process with a very rapid distribution phase (t1/2a = 5.7 +/- 2.4 min) and an elimination phase (t1/2 beta = 66 +/- 37 min).,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),min,66,83747,DB00683,Midazolam
,1869600,Vc,Mean values for distribution volumes in the central compartment and extrapolated values were Vc = 0.12 +/- 0.04 l/kg and V beta = 1.28 +/- 0.92 l/kg.,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),[l] / [kg],0.12,83748,DB00683,Midazolam
,1869600,V beta,Mean values for distribution volumes in the central compartment and extrapolated values were Vc = 0.12 +/- 0.04 l/kg and V beta = 1.28 +/- 0.92 l/kg.,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),[l] / [kg],1.28,83749,DB00683,Midazolam
,1869600,induction time,"The induction time, estimated from the start of hypnosis (eye closure), was from 60 to 120 s with i.v. injection.",Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),s,60 to 120,83750,DB00683,Midazolam
,31873765,half-life,The half-life range of remimazolam was from 34.1 ± 8.1 to 59.8 ± 20.5 min in the SAD study.,"Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873765/),min,34.1,84920,DB00683,Midazolam
,31873765,half-life,The half-life range of remimazolam was from 34.1 ± 8.1 to 59.8 ± 20.5 min in the SAD study.,"Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873765/),min,59.8,84921,DB00683,Midazolam
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB00683,Midazolam
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB00683,Midazolam
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB00683,Midazolam
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB00683,Midazolam
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB00683,Midazolam
,21868471,clearance of midazolam (CYP3A),"Noncompartmental analysis showed that the clearance of midazolam (CYP3A) in CA hypothermia was reduced from sham normothermia rats (681.6 ± 190.0 versus 1268.8 ± 348.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],681.6,85784,DB00683,Midazolam
,21868471,clearance of midazolam (CYP3A),"Noncompartmental analysis showed that the clearance of midazolam (CYP3A) in CA hypothermia was reduced from sham normothermia rats (681.6 ± 190.0 versus 1268.8 ± 348.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],1268.8,85785,DB00683,Midazolam
,21868471,clearance,"The clearance of chlorzoxazone (CYP2E) in CA hypothermia was also reduced from sham normothermia rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],229.6,85786,DB00683,Midazolam
,21868471,clearance,"The clearance of chlorzoxazone (CYP2E) in CA hypothermia was also reduced from sham normothermia rats (229.6 ± 75.6 versus 561.89 ± 215.9 ml · h(-1) · kg(-1), p < 0.05).",Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21868471/),[ml] / [h·kg],561.89,85787,DB00683,Midazolam
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00683,Midazolam
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00683,Midazolam
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00683,Midazolam
,18613930,plasma concentration,Arousal to light touch or voice appears to occur at a mean plasma concentration of 0.5 mg.l(-1) in both children and adults.,Ketamine anesthesia in children--exploring infusion regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),,0.5,86795,DB00683,Midazolam
,18613930,steady-state target concentration,h(-1) from 1 to 2 h resulted in a steady-state target concentration of 3 mg.,Ketamine anesthesia in children--exploring infusion regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),mg,3,86796,DB00683,Midazolam
,18613930,half-time,"The context sensitive half-time in children was shorter than in adults after 1.5 h, rising from 30 min at 1 h to 55 min at 5 h after an infusion of 3 mg.",Ketamine anesthesia in children--exploring infusion regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),h,1.5,86797,DB00683,Midazolam
,18613930,half-time,"The context sensitive half-time in children was shorter than in adults after 1.5 h, rising from 30 min at 1 h to 55 min at 5 h after an infusion of 3 mg.",Ketamine anesthesia in children--exploring infusion regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),min,30,86798,DB00683,Midazolam
,18613930,half-time,"The context sensitive half-time in children was shorter than in adults after 1.5 h, rising from 30 min at 1 h to 55 min at 5 h after an infusion of 3 mg.",Ketamine anesthesia in children--exploring infusion regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),min,55,86799,DB00683,Midazolam
,18613930,steady-state concentrations,Children require higher infusion rates than adults to maintain steady-state concentrations of 3 mg.l(-1) and have shorter context sensitive half-times than adults after prolonged infusion.,Ketamine anesthesia in children--exploring infusion regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613930/),[mg] / [l],3,86800,DB00683,Midazolam
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.90,86872,DB00683,Midazolam
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.24,86873,DB00683,Midazolam
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.19,86874,DB00683,Midazolam
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],2.84,86875,DB00683,Midazolam
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],1.99,86876,DB00683,Midazolam
,1982140,blood flow,"Hepatosplanchnic blood flow was highest in the alphaxolone/alphadolone anaesthetized animals (71.7 mL min-1 kg-1), with the urethane anaesthetized animals demonstrating a significantly (P less than 0.05) lower (33.4 mL min-1 kg-1) blood flow.",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [kg·min],71.7,86877,DB00683,Midazolam
,1982140,blood flow,"Hepatosplanchnic blood flow was highest in the alphaxolone/alphadolone anaesthetized animals (71.7 mL min-1 kg-1), with the urethane anaesthetized animals demonstrating a significantly (P less than 0.05) lower (33.4 mL min-1 kg-1) blood flow.",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [kg·min],33.4,86878,DB00683,Midazolam
,29803320,duration of examination,The average duration of examination were 2.9 ± 1.4 min for EGD and 6.6 ± 2.7 min for colonoscopy.,Plasma concentration based response surface model predict better than effect-site concentration based model for wake-up time during gastrointestinal endoscopy sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803320/),min,2.9,86879,DB00683,Midazolam
,29803320,duration of examination,The average duration of examination were 2.9 ± 1.4 min for EGD and 6.6 ± 2.7 min for colonoscopy.,Plasma concentration based response surface model predict better than effect-site concentration based model for wake-up time during gastrointestinal endoscopy sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803320/),min,6.6,86880,DB00683,Midazolam
,8880291,AUC,"For example, the AUC was increased from 248.84-888.75 hng/ml (factor of 3.57, p < 0.0001) and the mean duration of sleep increased from 135.4 min to 281.3 min (p < 0.05).",Interaction between midazolam and clarithromycin: comparison with azithromycin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880291/),[hng] / [ml],248.84-888.75,87110,DB00683,Midazolam
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],21.4,87213,DB00683,Midazolam
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],88.1,87214,DB00683,Midazolam
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],34.4,87215,DB00683,Midazolam
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],41.4,87216,DB00683,Midazolam
,1309878,Emax,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),[μv] / [s],80,87944,DB00683,Midazolam
,1309878,EC50,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),[ng] / [ml],35,87945,DB00683,Midazolam
,1309878,N,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),,1.1,87946,DB00683,Midazolam
,1309878,EC50,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),[ng] / [ml],24,87947,DB00683,Midazolam
,1309878,N,"An agonist-antagonist interaction model was used to quantify the interaction, yielding the pharmacodynamic parameters of midazolam [(mean +/- S.E.): Emax = 80 +/- 5 microV/sec, EC50 = 35 +/- 3 ng/ml and N = 1.1 +/- 0.2] and flumazenil: EC50 = 24 +/- 2 ng/ml and N = 1.6 +/- 0.1.",In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1309878/),,1.6,87948,DB00683,Midazolam
,23772874,CLu,"In patients with severe liver cirrhosis unbound midazolam clearance was only 14% of controls (CP C: CLu = 843 ± 346 l h(-1), MELD ≥ 15: CLu = 805 ± 474 l h(-1), controls: CLu = 5815 ± 2649 l h(-1), P < 0.01).",CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23772874/),[l] / [h],843,88276,DB00683,Midazolam
,23772874,CLu,"In patients with severe liver cirrhosis unbound midazolam clearance was only 14% of controls (CP C: CLu = 843 ± 346 l h(-1), MELD ≥ 15: CLu = 805 ± 474 l h(-1), controls: CLu = 5815 ± 2649 l h(-1), P < 0.01).",CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23772874/),[l] / [h],805,88277,DB00683,Midazolam
,23772874,CLu,"In patients with severe liver cirrhosis unbound midazolam clearance was only 14% of controls (CP C: CLu = 843 ± 346 l h(-1), MELD ≥ 15: CLu = 805 ± 474 l h(-1), controls: CLu = 5815 ± 2649 l h(-1), P < 0.01).",CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23772874/),[l] / [h],5815,88278,DB00683,Midazolam
,1611810,effective concentrations,"The median effective concentrations of midazolam and alpha-hydroxymidazolam were (mean +/- SE) 77 +/- 15 and 98 +/- 17 ng/ml, respectively, for the EEG effect measure.",Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611810/),[ng] / [ml],77,88376,DB00683,Midazolam
,1611810,effective concentrations,"The median effective concentrations of midazolam and alpha-hydroxymidazolam were (mean +/- SE) 77 +/- 15 and 98 +/- 17 ng/ml, respectively, for the EEG effect measure.",Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611810/),[ng] / [ml],98,88377,DB00683,Midazolam
,1611810,peak saccadic velocity,For peak saccadic velocity the values were 40 +/- 7 ng/ml for midazolam and 49 +/- 10 ng/ml for alpha-hydroxymidazolam.,Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611810/),[ng] / [ml],40,88378,DB00683,Midazolam
,1611810,peak saccadic velocity,For peak saccadic velocity the values were 40 +/- 7 ng/ml for midazolam and 49 +/- 10 ng/ml for alpha-hydroxymidazolam.,Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611810/),[ng] / [ml],49,88379,DB00683,Midazolam
,2109476,biological half-life,"Due to its biological half-life of 150-180 min and interindividual differences in drug susceptibility, prolonged recovery periods have been observed that can safely and reliably be antagonised by flumazenil, if necessary.",Anaesthesia techniques for midazolam and flumazenil--an overview. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109476/),min,150-180,88516,DB00683,Midazolam
,16928785,EC(50),"In monkey hepatocytes, rifampin markedly induced DF 4'-hydroxylase activity, with values for EC(50) of 0.2 to 0.4 microM and E(max) of 2- to 5-fold over control.","Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928785/),μM,0.2 to 0.4,88587,DB00683,Midazolam
,16928785,EC(50),"Under similar treatment conditions, rifampin was previously shown to induce midazolam (MDZ) 1'-hydroxylation in rhesus monkey hepatocytes (EC(50) and E(max) values approximately 0.2 microM and approximately 2- to 3-fold, respectively), and markedly affected the in vivo pharmacokinetics of MDZ (>10-fold decreases in the i.pv.","Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928785/),μM,0.2,88588,DB00683,Midazolam
,30169515,absolute oral bioavailability (F),"The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, ≥ 90%) for clonazepam.",In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169515/),%,44,89279,DB00683,Midazolam
,30169515,absolute oral bioavailability (F),"The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, ≥ 90%) for clonazepam.",In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169515/),%,93,89280,DB00683,Midazolam
≥,30169515,absolute oral bioavailability (F),"The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, ≥ 90%) for clonazepam.",In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169515/),%,90,89281,DB00683,Midazolam
,16719544,AUCinfinity,"Gefitinib geometric mean AUCinfinity and peak plasma drug concentration were higher in poor CYP2D6 metabolisers compared with extensive metabolisers (AUCinfinity 3060 vs 1430 ng . h/mL, p < 0.05, ANOVA), although the range of values was wide with considerable overlap between the groups.",Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719544/),[h·ng] / [ml],3060,89609,DB00683,Midazolam
,16719544,AUCinfinity,"Gefitinib geometric mean AUCinfinity and peak plasma drug concentration were higher in poor CYP2D6 metabolisers compared with extensive metabolisers (AUCinfinity 3060 vs 1430 ng . h/mL, p < 0.05, ANOVA), although the range of values was wide with considerable overlap between the groups.",Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719544/),[h·ng] / [ml],1430,89610,DB00683,Midazolam
,17085083,flow-rate,"The mobile phase for separation consisted of 10mM ammonium acetate and methanol (50:50, v/v) and was delivered at a flow-rate of 0.2ml/min.",A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),[ml] / [min],0.2,89781,DB00683,Midazolam
less,17085083,total time for,The total time for chromatographic separation was less than 16min.,A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),min,16,89782,DB00683,Midazolam
,17085083,recoveries,Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ.,A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),%,93.6,89783,DB00683,Midazolam
,17085083,recoveries,Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ.,A developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: application of human pharmacokinetic study for measurement of CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085083/),%,86.6,89784,DB00683,Midazolam
,19889885,maximum inactivation rate constant (k(inact)),"The in vitro maximum inactivation rate constant (k(inact)) and concentration of inhibitor that gave half-maximal k(inact) (K(I)) were estimated to be 10.1 h(-1) and 2050 ng/ml, respectively.","Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889885/),1/[h],10.1,90345,DB00683,Midazolam
,19889885,half-maximal k(inact) (K(I)),"The in vitro maximum inactivation rate constant (k(inact)) and concentration of inhibitor that gave half-maximal k(inact) (K(I)) were estimated to be 10.1 h(-1) and 2050 ng/ml, respectively.","Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889885/),[ng] / [ml],2050,90346,DB00683,Midazolam
,19889885,inactivation rate,"A pharmacokinetic model developed for this study, which described the time course of concentrations of both FK1706 and midazolam and incorporated CYP3A4/5 inactivation in the liver and intestine, successfully predicted the change in the pharmacokinetics of midazolam using in vitro k(inact) and K(I) values (1.66- to 2.81-fold increases in AUC predicted) and estimated the in vivo inactivation rate to be 0.00404 to 0.0318 h(-1) x ml/ng.","Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. ",KI-Q13,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889885/),[ml] / [h·ng],0.00404 to 0.0318,90347,DB00683,Midazolam
,7628179,bioavailability,"After oral administration, pretreatment with grapefruit juice led to a 56% increase in peak plasma concentration (Cmax), a 79% increase in time to reach Cmax (tmax), and a 52% increase in the area under the plasma concentration-time curve (AUC) of midazolam, which was associated with an increase in the bioavailability from 24% +/- 3% (water) to 35% +/- 3% (Grapefruit juice; mean +/- SEM, p < 0.01) After oral administration of midazolam, pretreatment with grapefruit juice was associated with a 105% increase in tmax and with a 30% increase in the AUC of alpha-hydroxymidazolam.",Interaction between grapefruit juice and midazolam in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628179/),%,24,90808,DB00683,Midazolam
,7628179,bioavailability,"After oral administration, pretreatment with grapefruit juice led to a 56% increase in peak plasma concentration (Cmax), a 79% increase in time to reach Cmax (tmax), and a 52% increase in the area under the plasma concentration-time curve (AUC) of midazolam, which was associated with an increase in the bioavailability from 24% +/- 3% (water) to 35% +/- 3% (Grapefruit juice; mean +/- SEM, p < 0.01) After oral administration of midazolam, pretreatment with grapefruit juice was associated with a 105% increase in tmax and with a 30% increase in the AUC of alpha-hydroxymidazolam.",Interaction between grapefruit juice and midazolam in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628179/),%,35,90809,DB00683,Midazolam
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],8.2,91245,DB00683,Midazolam
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],9.5,91246,DB00683,Midazolam
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,23.4,91247,DB00683,Midazolam
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,12.2,91248,DB00683,Midazolam
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],109.2,91249,DB00683,Midazolam
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],166.7,91250,DB00683,Midazolam
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],37.7,91251,DB00683,Midazolam
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],39.0,91252,DB00683,Midazolam
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],215.9,91253,DB00683,Midazolam
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],97.5,91254,DB00683,Midazolam
,16238904,absolute oral bioavailability,"The absolute oral bioavailability of telithromycin is approximately 57%, which is unaffected by food intake.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),%,57,91339,DB00683,Midazolam
,16238904,steady-state concentration,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),[μg] / [ml],2,91340,DB00683,Midazolam
,16238904,elimination half-life,"At the recommended 800 mg once-daily oral dosing regimen, telithromycin reaches a steady-state concentration of approximately 2 microg/mL in plasma and has an elimination half-life of approximately 10 hours.",Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16238904/),h,10,91341,DB00683,Midazolam
,7995324,area under the plasma midazolam concentration-time curve,Roxithromycin administration significantly increased the area under the plasma midazolam concentration-time curve from 8.3 to 12.2 micrograms.,A pharmacokinetic interaction between roxithromycin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995324/),μg,8.3,91844,DB00683,Midazolam
,7995324,area under the plasma midazolam concentration-time curve,Roxithromycin administration significantly increased the area under the plasma midazolam concentration-time curve from 8.3 to 12.2 micrograms.,A pharmacokinetic interaction between roxithromycin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995324/),μg,12.2,91845,DB00683,Midazolam
,7995324,elimination half-lives,ml-1.min and the elimination half-lives from 1.7 to 2.2 h.,A pharmacokinetic interaction between roxithromycin and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995324/),h,1.7 to 2.2,91846,DB00683,Midazolam
,12798199,recovery,The recovery in human plasma for the different analytes varied between 85 and 11%.,"Simultaneous determination of levomepromazine, midazolam and their major metabolites in human plasma by reversed-phase liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798199/),%,85 and 11,92580,DB00683,Midazolam
,12798199,half-life,The first results of pharmacokinetic analysis of midazolam indicated that half-life varied between 1.1 and 1.9 h.,"Simultaneous determination of levomepromazine, midazolam and their major metabolites in human plasma by reversed-phase liquid chromatography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798199/),h,1.1 and 1.9,92581,DB00683,Midazolam
,12798199,apparent volume of distribution,Pharmacokinetic analysis using a one-compartment model of levomepromazine revealed that the apparent volume of distribution was 4.1+/-2.4 l per kg lean body mass and the metabolic clearance was 309+/-225 l per hour per 70 kg.,"Simultaneous determination of levomepromazine, midazolam and their major metabolites in human plasma by reversed-phase liquid chromatography. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798199/),[l] / [kg],4.1,92582,DB00683,Midazolam
,12798199,metabolic clearance,Pharmacokinetic analysis using a one-compartment model of levomepromazine revealed that the apparent volume of distribution was 4.1+/-2.4 l per kg lean body mass and the metabolic clearance was 309+/-225 l per hour per 70 kg.,"Simultaneous determination of levomepromazine, midazolam and their major metabolites in human plasma by reversed-phase liquid chromatography. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798199/),[l] / [70·h·kg],309,92583,DB00683,Midazolam
,34073662,half-life,The half-life of urinary endogenous 1β-OH-DCA/ToDCA was estimated as four days.,Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34073662/),d,four,93135,DB00683,Midazolam
,15523087,exposure,"In addition, the presence of a UGT1A1 variant with a (TA)7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng x h/mL, 95% confidence interval [CI] = 339 to 531 ng x h/mL in patients who are homozygous for wild-type UGT1A1; 631 ng x h/mL, 95% CI = 499 to 762 ng .",Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523087/),[h·ng] / [ml],435,93629,DB00683,Midazolam
,15523087,exposure,"In addition, the presence of a UGT1A1 variant with a (TA)7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng x h/mL, 95% confidence interval [CI] = 339 to 531 ng x h/mL in patients who are homozygous for wild-type UGT1A1; 631 ng x h/mL, 95% CI = 499 to 762 ng .",Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15523087/),[h·ng] / [ml],631,93630,DB00683,Midazolam
,9806224,t(1/2),The t(1/2) of the dexamethasone pretreatment group (14.4+/-0.7 min) was significantly shorter than that of the prednisolone group (20.9+/-1.5 min).,Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806224/),min,14.4,93713,DB00683,Midazolam
,9806224,t(1/2),The t(1/2) of the dexamethasone pretreatment group (14.4+/-0.7 min) was significantly shorter than that of the prednisolone group (20.9+/-1.5 min).,Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806224/),min,20.9,93714,DB00683,Midazolam
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],76-324,94436,DB00683,Midazolam
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],63-229,94437,DB00683,Midazolam
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],22,94438,DB00683,Midazolam
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],31,94439,DB00683,Midazolam
,9447861,peak concentrations,"Mean peak concentrations occurred 20-30 min later and ranged from 61-174 ng/ml, related to the dose administered.",Oral transmucosal etomidate in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447861/),[ng] / [ml],61-174,95276,DB00683,Midazolam
,12496752,AUC ratio,"The AUC ratio (flumazenil plus midazolam/midazolam) was 0.99, with a 90% confidence interval of 0.98 to 1.00.",Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496752/),,0.,96363,DB00683,Midazolam
,30837282,bioavailability,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),%,114,97385,DB00683,Midazolam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],71.5,97386,DB00683,Midazolam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],388,97387,DB00683,Midazolam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],355,97388,DB00683,Midazolam
,30837282,times to peak plasma concentration,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),min,5,97389,DB00683,Midazolam
,30837282,times to peak plasma concentration,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),min,8,97390,DB00683,Midazolam
,30837282,first-order absorption rate constants,Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 ± 0.0080 minutes-1 for diazepam and 0.122 ± 0.022 minutes-1 for the intermediate.,Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),1/[min],0.0689,97391,DB00683,Midazolam
,30837282,first-order absorption rate constants,Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 ± 0.0080 minutes-1 for diazepam and 0.122 ± 0.022 minutes-1 for the intermediate.,Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),1/[min],0.122,97392,DB00683,Midazolam
,19792991,half-life,Midazolam's half-life increased from 4.7 to 14.9 hours.,Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19792991/),h,4.7,97579,DB00683,Midazolam
,19792991,half-life,Midazolam's half-life increased from 4.7 to 14.9 hours.,Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19792991/),h,14.9,97580,DB00683,Midazolam
,19792991,AUC(0-infinity):,The 1'-hydroxymidazolam AUC(0-infinity):midazolam AUC(0-infinity) ratio was only 1% during coadministration of midazolam with saquinavir-ritonavir compared with 33% for midazolam alone.,Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19792991/),%,1,97581,DB00683,Midazolam
,19792991,AUC(0-infinity):,The 1'-hydroxymidazolam AUC(0-infinity):midazolam AUC(0-infinity) ratio was only 1% during coadministration of midazolam with saquinavir-ritonavir compared with 33% for midazolam alone.,Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19792991/),%,33,97582,DB00683,Midazolam
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],182,97918,DB00683,Midazolam
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],48,97919,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.58,98193,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,2.1,98194,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.4,98195,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.1,98196,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.4,98197,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.5,98198,DB00683,Midazolam
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.7,98199,DB00683,Midazolam
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.3,98200,DB00683,Midazolam
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,3.1,98201,DB00683,Midazolam
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.8,98202,DB00683,Midazolam
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.2,98203,DB00683,Midazolam
,16678547,area under the plasma concentration-time curve from 0 to 4 hours,"In humans UDCA significantly decreased the extent of digoxin absorption from 0.77 to 0.70 and the oral d3-digoxin area under the plasma concentration-time curve from 0 to 4 hours from 6.4 +/- 1.7 ng.h.mL(-1) to 5.3 +/- 1.5 ng.h.mL(-1) (P = .01 and P = .05, respectively).",Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678547/),[h·ng] / [ml],6.4,99396,DB00683,Midazolam
,16678547,area under the plasma concentration-time curve from 0 to 4 hours,"In humans UDCA significantly decreased the extent of digoxin absorption from 0.77 to 0.70 and the oral d3-digoxin area under the plasma concentration-time curve from 0 to 4 hours from 6.4 +/- 1.7 ng.h.mL(-1) to 5.3 +/- 1.5 ng.h.mL(-1) (P = .01 and P = .05, respectively).",Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678547/),[h·ng] / [ml],5.3,99397,DB00683,Midazolam
,11675907,50% of effective concentration,"The 50% of effective concentration values of SS 5, estimated by logistic regression analysis, varied greatly (mean, 251 ng/ml).",Midazolam for continuous sedation in Japanese patients in the critical care setting: phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11675907/),[ng] / [ml],251,99823,DB00683,Midazolam
,8646820,systemic,No gender-related differences were noted in either the systemic (370 +/- 114 ml/min [mean +/- SD]) or oral (1413 +/- 807 ml/min) clearance values of midazolam.,Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646820/),[ml] / [min],370,100372,DB00683,Midazolam
,8646820,systemic,No gender-related differences were noted in either the systemic (370 +/- 114 ml/min [mean +/- SD]) or oral (1413 +/- 807 ml/min) clearance values of midazolam.,Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646820/),[ml] / [min],1413,100373,DB00683,Midazolam
,8646820,extraction ratio,Pharmacokinetic estimation of the intestinal component indicated an extraction ratio (0.43 +/- 0.24) that was similar to that of the liver (0.44 +/- 0.14).,Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646820/),,0.43,100374,DB00683,Midazolam
,8646820,extraction ratio,Pharmacokinetic estimation of the intestinal component indicated an extraction ratio (0.43 +/- 0.24) that was similar to that of the liver (0.44 +/- 0.14).,Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646820/),,0.44,100375,DB00683,Midazolam
,8646820,intrinsic clearance (V(max)/Km),"1'-Hydroxymidazolam was extensively but variably formed in vitro by both hepatic and intestinal microsomes and, although the intrinsic clearance (V(max)/Km) was higher in the liver preparations (540 +/- 747 versus 135 +/- 92 microliters/min/mg protein), this difference was not statistically significant.",Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646820/),[μl] / [mg·min],540,100376,DB00683,Midazolam
,8646820,intrinsic clearance (V(max)/Km),"1'-Hydroxymidazolam was extensively but variably formed in vitro by both hepatic and intestinal microsomes and, although the intrinsic clearance (V(max)/Km) was higher in the liver preparations (540 +/- 747 versus 135 +/- 92 microliters/min/mg protein), this difference was not statistically significant.",Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646820/),[μl] / [mg·min],135,100377,DB00683,Midazolam
>,25582505,extraction efficiency,"The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%.","Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582505/),%,90.5,101195,DB00683,Midazolam
,8832431,detection limit,The detection limit was 10 ng/ml for all the compounds using an ultraviolet detector operated at 230 nm.,Determination of midazolam and its metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832431/),[ng] / [ml],10,101235,DB00683,Midazolam
,20027108,apparent terminal half-life (t1/2),"The apparent terminal half-life (t1/2) for midazolam was similar in the presence/absence of rolofylline (4.31 and 4.27 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,4.31,101412,DB00683,Midazolam
,20027108,apparent terminal half-life (t1/2),"The apparent terminal half-life (t1/2) for midazolam was similar in the presence/absence of rolofylline (4.31 and 4.27 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,4.27,101413,DB00683,Midazolam
,20027108,t1/2,"The t1/2 for 1'-hydroxymidazolam was slightly higher in the presence relative to absence of rolofylline (4.24 and 3.17 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,4.24,101414,DB00683,Midazolam
,20027108,t1/2,"The t1/2 for 1'-hydroxymidazolam was slightly higher in the presence relative to absence of rolofylline (4.24 and 3.17 hours, respectively).",The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027108/),h,3.17,101415,DB00683,Midazolam
,22122233,plasma C(max),AZD7325 reached a plasma C(max) of 0.2 µm after 10 mg daily dosing to steady-state.,"A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122233/),µm,0.2,102647,DB00683,Midazolam
,22122233,CL/F,The mean CL/F of midazolam increased from 62 l h(-1) (midazolam alone) to 76 l h(-1) when co-administered with AZD7325.,"A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122233/),[l] / [h],62,102648,DB00683,Midazolam
,22122233,CL/F,The mean CL/F of midazolam increased from 62 l h(-1) (midazolam alone) to 76 l h(-1) when co-administered with AZD7325.,"A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122233/),[l] / [h],76,102649,DB00683,Midazolam
,3221325,stable [MID],"Based on the pharmacokinetic parameters determined for Group 1, dogs in Group 2 (n = 4) received Mid as a continuous infusion of 21 micrograms kg-1 min-1 for 5 hr accompanied by an initial loading dose (3 mg/kg infused over 20 min) designed to produce a stable [MID] of 1000 ng/ml in plasma.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),[ng] / [ml],1000,103116,DB00683,Midazolam
,3221325,"t1/2,z","Group 2: t1/2,z = 98 +/- 5 vs. 95 +/- 10 min (mean +/- SEM); V = 3.94 +/- 0.27 vs.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),min,98,103117,DB00683,Midazolam
,3221325,"t1/2,z","Group 2: t1/2,z = 98 +/- 5 vs. 95 +/- 10 min (mean +/- SEM); V = 3.94 +/- 0.27 vs.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),min,95,103118,DB00683,Midazolam
,3221325,V,"Group 2: t1/2,z = 98 +/- 5 vs. 95 +/- 10 min (mean +/- SEM); V = 3.94 +/- 0.27 vs.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),,3.94,103119,DB00683,Midazolam
,3221325,Cl,2.98 +/- 25 L/kg; Cl = 28.5 +/- 3.1 vs.,Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),,28.5,103120,DB00683,Midazolam
,3221325,[MID],"When administered as a continuous intravenous infusion (Group 2), [MID] remained stable at 949 +/- 53 ng/ml for more than 5 hr.",Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221325/),[ng] / [ml],949,103121,DB00683,Midazolam
,2253674,plasma clearance,The plasma clearance was 6.85 ml.min-1 and the elimination half-life was 6.52 h.,Pharmacokinetics of midazolam in critically ill neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253674/),[ml] / [min],6.85,103517,DB00683,Midazolam
,2253674,elimination half-life,The plasma clearance was 6.85 ml.min-1 and the elimination half-life was 6.52 h.,Pharmacokinetics of midazolam in critically ill neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253674/),h,6.52,103518,DB00683,Midazolam
,2225714,half-time of blood:brain,The half-time of blood:brain equilibration was significantly longer for midazolam than diazepam (4.8 minutes versus 1.6 minutes).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),min,4.8,103698,DB00683,Midazolam
,2225714,half-time of blood:brain,The half-time of blood:brain equilibration was significantly longer for midazolam than diazepam (4.8 minutes versus 1.6 minutes).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),min,1.6,103699,DB00683,Midazolam
,2225714,intrinsic steady-state potency,Midazolam was found to have an intrinsic steady-state potency that was approximately five times greater than that of diazepam (152 ng/ml versus 958 ng/ml).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),[ng] / [ml],152,103700,DB00683,Midazolam
,2225714,intrinsic steady-state potency,Midazolam was found to have an intrinsic steady-state potency that was approximately five times greater than that of diazepam (152 ng/ml versus 958 ng/ml).,Electroencephalographic effects of benzodiazepines. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225714/),[ng] / [ml],958,103701,DB00683,Midazolam
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,6.7,104991,DB00683,Midazolam
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,0.13,104992,DB00683,Midazolam
,16684712,bioavailability (F),The bioavailability (F) of midazolam in cynomolgus monkeys (0.02) was markedly lower than that in humans (0.24-0.46) and the reason for this difference in F between the two species was investigated.,Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,0.02,105148,DB00683,Midazolam
,16684712,bioavailability (F),The bioavailability (F) of midazolam in cynomolgus monkeys (0.02) was markedly lower than that in humans (0.24-0.46) and the reason for this difference in F between the two species was investigated.,Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,0.24-0.46,105149,DB00683,Midazolam
,16684712,hepatic availability (F(h)),"Based on the area under the plasma concentration-time curve after intravenous and intraportal infusion to cynomolgus monkeys, the hepatic availability (F(h)) was estimated as 0.66.",Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,0.66,105150,DB00683,Midazolam
,16684712,fraction of dose absorbed (F(a)),The fraction of dose absorbed (F(a)) estimated from the single-pass intestinal perfusion method was 1.0 in cynomolgus monkeys.,Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,1.0,105151,DB00683,Midazolam
,16684712,intestinal availability (F(g),The intestinal availability (F(g) = F/F(a)/F(h)) was calculated as 0.03 in cynomolgus monkeys.,Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,0.03,105152,DB00683,Midazolam
,16684712,F(a),"Since the F(a) of midazolam has been reported to be almost 1.0 in humans, F(h) and F(g) were calculated as 0.33-0.76 and 0.46-1.00 when the reference values for hepatic blood flow (1026-1530 ml h(-1) kg(-1)) were used.",Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,1.0,105153,DB00683,Midazolam
,16684712,F(h),"Since the F(a) of midazolam has been reported to be almost 1.0 in humans, F(h) and F(g) were calculated as 0.33-0.76 and 0.46-1.00 when the reference values for hepatic blood flow (1026-1530 ml h(-1) kg(-1)) were used.",Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,0.33-0.76,105154,DB00683,Midazolam
,16684712,F(g),"Since the F(a) of midazolam has been reported to be almost 1.0 in humans, F(h) and F(g) were calculated as 0.33-0.76 and 0.46-1.00 when the reference values for hepatic blood flow (1026-1530 ml h(-1) kg(-1)) were used.",Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),,0.46-1.00,105155,DB00683,Midazolam
,16684712,hepatic blood flow,"Since the F(a) of midazolam has been reported to be almost 1.0 in humans, F(h) and F(g) were calculated as 0.33-0.76 and 0.46-1.00 when the reference values for hepatic blood flow (1026-1530 ml h(-1) kg(-1)) were used.",Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16684712/),[ml] / [h·kg],1026-1530,105156,DB00683,Midazolam
,3567042,V1,"Computerized non-linear least squares curve-fitting of the two-compartment open model to the oral and intravenous data simultaneously yielded the following estimates: V1, 0.33 1 kg-1, VdSS, 1.08 1 kg-1, t1/2,lambda, 0.10 h, t1/2,Z, 1.89 h, ka 1.17 h-1 and bioavailability, 49%.","Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567042/),[1] / [kg],0.33,106287,DB00683,Midazolam
,3567042,VdSS,"Computerized non-linear least squares curve-fitting of the two-compartment open model to the oral and intravenous data simultaneously yielded the following estimates: V1, 0.33 1 kg-1, VdSS, 1.08 1 kg-1, t1/2,lambda, 0.10 h, t1/2,Z, 1.89 h, ka 1.17 h-1 and bioavailability, 49%.","Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567042/),[1] / [kg],1.08,106288,DB00683,Midazolam
,3567042,"t1/2,lambda","Computerized non-linear least squares curve-fitting of the two-compartment open model to the oral and intravenous data simultaneously yielded the following estimates: V1, 0.33 1 kg-1, VdSS, 1.08 1 kg-1, t1/2,lambda, 0.10 h, t1/2,Z, 1.89 h, ka 1.17 h-1 and bioavailability, 49%.","Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567042/),h,0.10,106289,DB00683,Midazolam
,3567042,Z,"Computerized non-linear least squares curve-fitting of the two-compartment open model to the oral and intravenous data simultaneously yielded the following estimates: V1, 0.33 1 kg-1, VdSS, 1.08 1 kg-1, t1/2,lambda, 0.10 h, t1/2,Z, 1.89 h, ka 1.17 h-1 and bioavailability, 49%.","Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567042/),h,1.89,106290,DB00683,Midazolam
,3567042,ka,"Computerized non-linear least squares curve-fitting of the two-compartment open model to the oral and intravenous data simultaneously yielded the following estimates: V1, 0.33 1 kg-1, VdSS, 1.08 1 kg-1, t1/2,lambda, 0.10 h, t1/2,Z, 1.89 h, ka 1.17 h-1 and bioavailability, 49%.","Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567042/),1/[h],1.17,106291,DB00683,Midazolam
,3567042,bioavailability,"Computerized non-linear least squares curve-fitting of the two-compartment open model to the oral and intravenous data simultaneously yielded the following estimates: V1, 0.33 1 kg-1, VdSS, 1.08 1 kg-1, t1/2,lambda, 0.10 h, t1/2,Z, 1.89 h, ka 1.17 h-1 and bioavailability, 49%.","Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567042/),%,49,106292,DB00683,Midazolam
,25141974,clearance,"In the three-compartment model in which oral absorption was characterized by a transit absorption model, population mean clearance (relative standard error %) was similar [0.36 (4 %) L/min], while oral bioavailability was 60 % (13 %) in morbidly obese patients versus 28 % (7 %) in healthy volunteers (P < 0.001).",Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141974/),[l] / [min],0.36,106490,DB00683,Midazolam
,25141974,oral bioavailability,"In the three-compartment model in which oral absorption was characterized by a transit absorption model, population mean clearance (relative standard error %) was similar [0.36 (4 %) L/min], while oral bioavailability was 60 % (13 %) in morbidly obese patients versus 28 % (7 %) in healthy volunteers (P < 0.001).",Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141974/),%,60,106491,DB00683,Midazolam
,25141974,oral bioavailability,"In the three-compartment model in which oral absorption was characterized by a transit absorption model, population mean clearance (relative standard error %) was similar [0.36 (4 %) L/min], while oral bioavailability was 60 % (13 %) in morbidly obese patients versus 28 % (7 %) in healthy volunteers (P < 0.001).",Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141974/),%,28,106492,DB00683,Midazolam
,25141974,absorption rate (transit rate constant),"Central and peripheral volumes of distribution increased substantially with body weight (both P < 0.001) and absorption rate (transit rate constant) was lower in morbidly obese patients [0.057 (5 %) vs. 0.130 (14 %) min(-1), P < 0.001].",Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141974/),1/[min],0.057,106493,DB00683,Midazolam
,25141974,absorption rate (transit rate constant),"Central and peripheral volumes of distribution increased substantially with body weight (both P < 0.001) and absorption rate (transit rate constant) was lower in morbidly obese patients [0.057 (5 %) vs. 0.130 (14 %) min(-1), P < 0.001].",Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141974/),1/[min],0.130,106494,DB00683,Midazolam
,23385102,plasma levels,"Plasma levels of fentanyl were higher in patients with clinical coma (3.7±4.7 vs. 2.0±1.8 ng/mL, p=0.0001) as were midazolam plasma levels (1050±2232 vs. 168±249 ng/mL, p=0.0001).","Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385102/),[ng] / [ml],1050,106990,DB00683,Midazolam
,23385102,plasma levels,"Plasma levels of fentanyl were higher in patients with clinical coma (3.7±4.7 vs. 2.0±1.8 ng/mL, p=0.0001) as were midazolam plasma levels (1050±2232 vs. 168±249 ng/mL, p=0.0001).","Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385102/),[ng] / [ml],168,106991,DB00683,Midazolam
,8745970,Cmax,The Cmax was 859 +/- 503 ng.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),ng,859,108253,DB00683,Midazolam
,8745970,Tmax,mL-1 after a Tmax to 47 +/- 17 min.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,47,108254,DB00683,Midazolam
,8745970,elimination half-life,The mean elimination half-life was 87 +/- 19 min (mean +/- SD).,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,87,108255,DB00683,Midazolam
,8745970,total clearance,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),[ml] / [min],"4,521",108256,DB00683,Midazolam
,8745970,volume of distribution,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),l,568,108257,DB00683,Midazolam
,34383278,elimination half-life,"However, repeated administration of esaxerenone did not affect the elimination half-life of midazolam (2.86 versus 2.63 h with and without esaxerenone).",Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34383278/),h,2.86,110498,DB00683,Midazolam
,34383278,elimination half-life,"However, repeated administration of esaxerenone did not affect the elimination half-life of midazolam (2.86 versus 2.63 h with and without esaxerenone).",Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34383278/),h,2.63,110499,DB00683,Midazolam
,16243813,clearance,"The mean clearance of midazolam was 24.4 +/- 9.12 L/h, and phenotypic CYP3A activity varied about 4-fold in this population (range, 10.8-44.3 L/h).",Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243813/),[l] / [h],24.4,110917,DB00683,Midazolam
,32879877,recovery,"The mean recovery and the matrix effects were found to be 64.4-86.8% and 94.1-109.4%, respectively.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,64.4-86.8,111256,DB00683,Midazolam
,32879877,matrix effects,"The mean recovery and the matrix effects were found to be 64.4-86.8% and 94.1-109.4%, respectively.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,94.1-109.4,111257,DB00683,Midazolam
,32879877,half-life,The pharmacokinetic results showed that six Uncaria alkaloids metabolized rapidly in mice with a half-life between 0.6 h and 4.4 h.,Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),h,0.6,111258,DB00683,Midazolam
,32879877,half-life,The pharmacokinetic results showed that six Uncaria alkaloids metabolized rapidly in mice with a half-life between 0.6 h and 4.4 h.,Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),h,4.4,111259,DB00683,Midazolam
,32879877,bioavailability,"The bioavailability of corynoxeine, isocorynoxeine, rhynchophylline, isorhynchophylline, hirsutine, and hirsuteine was 27.3%, 32.7%, 49.4%, 29.5%, 68.9%, and 51.0%, respectively, which showed satisfactory oral absorption of each alkaloid.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,27.3,111260,DB00683,Midazolam
,32879877,bioavailability,"The bioavailability of corynoxeine, isocorynoxeine, rhynchophylline, isorhynchophylline, hirsutine, and hirsuteine was 27.3%, 32.7%, 49.4%, 29.5%, 68.9%, and 51.0%, respectively, which showed satisfactory oral absorption of each alkaloid.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,32.7,111261,DB00683,Midazolam
,32879877,bioavailability,"The bioavailability of corynoxeine, isocorynoxeine, rhynchophylline, isorhynchophylline, hirsutine, and hirsuteine was 27.3%, 32.7%, 49.4%, 29.5%, 68.9%, and 51.0%, respectively, which showed satisfactory oral absorption of each alkaloid.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,49.4,111262,DB00683,Midazolam
,32879877,bioavailability,"The bioavailability of corynoxeine, isocorynoxeine, rhynchophylline, isorhynchophylline, hirsutine, and hirsuteine was 27.3%, 32.7%, 49.4%, 29.5%, 68.9%, and 51.0%, respectively, which showed satisfactory oral absorption of each alkaloid.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,29.5,111263,DB00683,Midazolam
,32879877,bioavailability,"The bioavailability of corynoxeine, isocorynoxeine, rhynchophylline, isorhynchophylline, hirsutine, and hirsuteine was 27.3%, 32.7%, 49.4%, 29.5%, 68.9%, and 51.0%, respectively, which showed satisfactory oral absorption of each alkaloid.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,68.9,111264,DB00683,Midazolam
,32879877,bioavailability,"The bioavailability of corynoxeine, isocorynoxeine, rhynchophylline, isorhynchophylline, hirsutine, and hirsuteine was 27.3%, 32.7%, 49.4%, 29.5%, 68.9%, and 51.0%, respectively, which showed satisfactory oral absorption of each alkaloid.",Simultaneous Determination of Six Uncaria Alkaloids in Mouse Blood by UPLC-MS/MS and Its Application in Pharmacokinetics and Bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879877/),%,51.0,111265,DB00683,Midazolam
,2922980,sedation score,During infusion the sedation score decreased from 3.8 after ICU arrival to 2.2 at 8 a.m. of the first postoperative day.,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),,3.8,111355,DB00683,Midazolam
,2922980,sedation score,During infusion the sedation score decreased from 3.8 after ICU arrival to 2.2 at 8 a.m. of the first postoperative day.,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),,2.2,111356,DB00683,Midazolam
,2922980,T1/2 beta,T1/2 beta of MDZ after cessation was 125 min (range 90-320) and its total body clearance was 10.5 ml/kg/min (s.d. = 3.1).,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),min,125,111357,DB00683,Midazolam
,2922980,total body clearance,T1/2 beta of MDZ after cessation was 125 min (range 90-320) and its total body clearance was 10.5 ml/kg/min (s.d. = 3.1).,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),[ml] / [kg·min],10.5,111358,DB00683,Midazolam
,10073327,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 7.36 +/- 2.73, 6.34 +/- 3.59, and 6.23 +/- 2.04 ml/kg/min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Menstrual cycle variability in midazolam pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073327/),[ml] / [kg·min],7.36,111359,DB00683,Midazolam
,10073327,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 7.36 +/- 2.73, 6.34 +/- 3.59, and 6.23 +/- 2.04 ml/kg/min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Menstrual cycle variability in midazolam pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073327/),[ml] / [kg·min],6.34,111360,DB00683,Midazolam
,10073327,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 7.36 +/- 2.73, 6.34 +/- 3.59, and 6.23 +/- 2.04 ml/kg/min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Menstrual cycle variability in midazolam pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073327/),[ml] / [kg·min],6.23,111361,DB00683,Midazolam
,7199323,half-life of elimination,"The half-life of elimination of midazolam and the glucuronides of the metabolites 1-hydroxymethyl-midazolam, 4-hydroxy-midazolam and 1-hydroxymethyl-4-hydroxy-midazolam are identical, 53 min in dogs and 90 min in man.",Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199323/),min,53,111653,DB00683,Midazolam
,7199323,half-life of elimination,"The half-life of elimination of midazolam and the glucuronides of the metabolites 1-hydroxymethyl-midazolam, 4-hydroxy-midazolam and 1-hydroxymethyl-4-hydroxy-midazolam are identical, 53 min in dogs and 90 min in man.",Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high-performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199323/),min,90,111654,DB00683,Midazolam
,24637575,Ki,"Results showed a time-dependent inhibition of MDZ metabolism by erlotinib, with a Ki of 7.5 µmol/l and an inactivation rate constant of 0.009/min.","Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24637575/),[μM] / [l],7.5,111778,DB00683,Midazolam
,24637575,inactivation rate constant,"Results showed a time-dependent inhibition of MDZ metabolism by erlotinib, with a Ki of 7.5 µmol/l and an inactivation rate constant of 0.009/min.","Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24637575/),1/[min],0.009,111779,DB00683,Midazolam
,25464106,flow rate,"Separation of analytes was performed with a Hypersil C18 column and a mobile phase with acetonitrile and 0.1% formic acid (60/40, v/v) under isocratic conditions at a flow rate of 280μl/min.","Simultaneous detection of ketamine, lorazepam, midazolam and sufentanil in human serum with liquid chromatography-tandem mass spectrometry for monitoring of analgosedation in critically ill patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25464106/),[μl] / [min],280,112299,DB00683,Midazolam
,9384466,volume of distribution,"The volume of distribution and clearance of Ro 48-8684 were larger than of midazolam (337+/-114 vs 50+/-121 and 2.4+/-0.5 vs 0.47+/-0.11 l min(-1), resp).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384466/),[l] / [min],337,112525,DB00683,Midazolam
,9384466,clearance,"The volume of distribution and clearance of Ro 48-8684 were larger than of midazolam (337+/-114 vs 50+/-121 and 2.4+/-0.5 vs 0.47+/-0.11 l min(-1), resp).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384466/),[l] / [min],50,112526,DB00683,Midazolam
,9384466,clearance,"The volume of distribution and clearance of Ro 48-8684 were larger than of midazolam (337+/-114 vs 50+/-121 and 2.4+/-0.5 vs 0.47+/-0.11 l min(-1), resp).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384466/),[l] / [min],2.4,112527,DB00683,Midazolam
,9384466,clearance,"The volume of distribution and clearance of Ro 48-8684 were larger than of midazolam (337+/-114 vs 50+/-121 and 2.4+/-0.5 vs 0.47+/-0.11 l min(-1), resp).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384466/),[l] / [min],0.47,112528,DB00683,Midazolam
,3694534,systemic serum clearance,"After i.v. administration, both drugs had high systemic serum clearance, averaging 24 ml/min/kg.",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ml] / [kg·min],24,112552,DB00683,Midazolam
,3694534,Area under the serum concentration curve (AUC),"Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01).",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ng] / [h·ml],769,112553,DB00683,Midazolam
,3694534,Area under the serum concentration curve (AUC),"Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01).",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ng] / [h·ml],737,112554,DB00683,Midazolam
,3694534,AUC,"Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01).",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ng] / [h·ml],1035,112555,DB00683,Midazolam
,3694534,AUC,"Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01).",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ng] / [h·ml],778,112556,DB00683,Midazolam
,3694534,AU,"Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01).",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ng] / [h·ml],1035,112557,DB00683,Midazolam
,3694534,AU,"Area under the serum concentration curve (AUC) for systemic vs. portal sites was nearly identical for midazolam (769 vs. 737 ng/ml x hr); for flurazepam, systemic AUC exceeded portal AUC (1035 vs. 778 ng/ml x hr, P less than .01).",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),[ng] / [h·ml],778,112558,DB00683,Midazolam
,3694534,systemic/portal AUC ratio,"After p.o. dosage, the systemic/portal AUC ratio averaged 0.15 for midazolam and 0.11 for flurazepam; for both drugs, portal AUC after p.o. dosage did not differ significantly from systemic AUC after i.v. administration.",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),,0.15,112559,DB00683,Midazolam
,3694534,systemic/portal AUC ratio,"After p.o. dosage, the systemic/portal AUC ratio averaged 0.15 for midazolam and 0.11 for flurazepam; for both drugs, portal AUC after p.o. dosage did not differ significantly from systemic AUC after i.v. administration.",Hepatic vs. gastrointestinal presystemic extraction of oral midazolam and flurazepam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694534/),,0.11,112560,DB00683,Midazolam
,34417912,IC50,"In vitro, entrectinib is a CYP3A4/5 inhibitor (IC50 2 μM) and a weak CYP3A4 inducer.","In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417912/),μM,2,114198,DB00683,Midazolam
,34417912,IC50,Entrectinib inhibited P-glycoprotein (IC50 1.33 μM) but is a poor substrate.,"In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417912/),μM,1.33,114199,DB00683,Midazolam
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.90,115460,DB00683,Midazolam
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.52,115461,DB00683,Midazolam
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,0.84,115462,DB00683,Midazolam
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.01,115463,DB00683,Midazolam
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.02,115464,DB00683,Midazolam
,33822485,AUC ratios,"The AUC ratios following multiple doses of ivosidenib and a single dose of CYP2B6 (bupropion), CYP2C8 (repaglinide), CYP2C9 (warfarin), P-gp (digoxin), OATP1B1/1B3 (rosuvastatin), and OAT3 (methotrexate) substrates were 0.90, 0.52, 0.84, 1.01, 1.02, and 1.27, respectively.",PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33822485/),,1.27,115465,DB00683,Midazolam
,21057365,clearance,"Midazolam clearance was significantly lower in children with multiple organ failure (defined as Pediatric Logistic Organ Dysfunction ≥ 10, n = 11) compared with children without multiple organ failure (Pediatric Logistic Organ Dysfunction <10, n = 10) (median 0.14 [interquartile range, 0.11-0.23] vs. 0.28 [interquartile range, 0.14-0.43]) L/kg/h, p = .035).",The effect of critical illness and inflammation on midazolam therapy in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21057365/),[l] / [h·kg],0.14,115773,DB00683,Midazolam
,21057365,clearance,"Midazolam clearance was significantly lower in children with multiple organ failure (defined as Pediatric Logistic Organ Dysfunction ≥ 10, n = 11) compared with children without multiple organ failure (Pediatric Logistic Organ Dysfunction <10, n = 10) (median 0.14 [interquartile range, 0.11-0.23] vs. 0.28 [interquartile range, 0.14-0.43]) L/kg/h, p = .035).",The effect of critical illness and inflammation on midazolam therapy in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21057365/),[l] / [h·kg],0.28,115774,DB00683,Midazolam
,31442620,AUC,"After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),,62,116459,DB00683,Midazolam
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],18,116460,DB00683,Midazolam
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],1.,116461,DB00683,Midazolam
,19702545,AUC up to infinity,"There were no differences in PK profiles after i.v. administration of CyA between RIR and control rats; however, AUC up to infinity (1.81+/-0.18 microg.h/ml) in RIR rats after i.d. administration was significantly lower than in control rats (5.01+/-1.78 microg.h/ml).",Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702545/),[h·μg] / [ml],1.81,116886,DB00683,Midazolam
,19702545,AUC up to infinity,"There were no differences in PK profiles after i.v. administration of CyA between RIR and control rats; however, AUC up to infinity (1.81+/-0.18 microg.h/ml) in RIR rats after i.d. administration was significantly lower than in control rats (5.01+/-1.78 microg.h/ml).",Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702545/),[h·μg] / [ml],5.01,116887,DB00683,Midazolam
,9034939,distribution half-life,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),min,8.38,116900,DB00683,Midazolam
,9034939,distribution half-life,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),min,1.49,116901,DB00683,Midazolam
,9034939,elimination half-life,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),h,2.49,116902,DB00683,Midazolam
,9034939,elimination half-life,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),h,1.48,116903,DB00683,Midazolam
,9034939,clearance,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),[ml] / [kg·min],4.93,116904,DB00683,Midazolam
,9034939,clearance,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),[ml] / [kg·min],5.90,116905,DB00683,Midazolam
,9034939,steady state volume of distribution,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),[l] / [kg],0.863,116906,DB00683,Midazolam
,9034939,steady state volume of distribution,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),[l] / [kg],0.530,116907,DB00683,Midazolam
,9034939,percentage of unbound drug in plasma,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),,4.89,116908,DB00683,Midazolam
,9034939,percentage of unbound drug in plasma,"No significant differences were found between the Vietnamese and Caucasian groups with regard to distribution half-life of midazolam (8.38 +/- 13.1 vs 1.49 +/- 0.63 min, respectively), elimination half-life (2.49 +/- 1.80 vs 1.48 +/- 0.66 h, respectively), clearance (4.93 +/- 1.31 vs 5.90 +/- 2.12 mL/min per kg, respectively), steady state volume of distribution (0.863 +/- 0.497 vs 0.530 +/- 0.132 L/kg, respectively) or percentage of unbound drug in plasma (4.89 +/- 0.74 vs 4.11 +/- 1.08, respectively).",Pharmacokinetics of midazolam in Vietnamese subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034939/),,4.11,116909,DB00683,Midazolam
,30672747,midazolam,The estimated midazolam clearance was 0.61 L/min/70kg.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),[l] / [70kg·min],0.61,117232,DB00683,Midazolam
,30672747,clearance,The estimated midazolam clearance was 0.61 L/min/70kg.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),[l] / [70kg·min],0.61,117233,DB00683,Midazolam
,30672747,Time to reach 50% complete mature midaz,Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),years,1.0,117234,DB00683,Midazolam
,30672747,Time to reach 50% complete mature midaz,Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),years,0.97,117235,DB00683,Midazolam
,25470746,95% inhibitory concentration,"Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type virus (95% inhibitory concentration 19 nM, 50% human serum).","Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25470746/),nM,19,117326,DB00683,Midazolam
,25470746,apparent terminal half-life,The maximum plasma concentration (Cmax) of doravirine was achieved within 1-5 h with an apparent terminal half-life of 12-21 h.,"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25470746/),h,12-21,117327,DB00683,Midazolam
,25470746,accumulation ratios,"Consistent with single-dose pharmacokinetics, steady state was achieved after approximately 7 days of once daily administration, with accumulation ratios (day 10/day 1) of 1.1-1.5 in the area under the plasma concentration-time curve during the dosing interval (AUC0-24 h), Cmax and trough plasma concentration (C24 h).","Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25470746/),,1.1-1.5,117328,DB00683,Midazolam
>,25470746,C24 h,All dose levels produced C24 h>19 nM.,"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25470746/),nM,19,117329,DB00683,Midazolam
,9051210,flow-rate,"The mobile phase used was a mixture of acetonitrile at 0.02 M and sodium acetate at pH 3.0 (80:20, v/v) and a flow-rate of 1.2 mL/min.",A routine HPLC method for monitoring midazolam in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051210/),[ml] / [min],1.2,117615,DB00683,Midazolam
,9051210,recoveries,"The recoveries from serum sample spiked with 50, 100, 500 ng/mL were 85.46, 85.38 and 85.57%, respectively.",A routine HPLC method for monitoring midazolam in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051210/),%,85.46,117616,DB00683,Midazolam
,9051210,recoveries,"The recoveries from serum sample spiked with 50, 100, 500 ng/mL were 85.46, 85.38 and 85.57%, respectively.",A routine HPLC method for monitoring midazolam in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051210/),%,85.38,117617,DB00683,Midazolam
,9051210,recoveries,"The recoveries from serum sample spiked with 50, 100, 500 ng/mL were 85.46, 85.38 and 85.57%, respectively.",A routine HPLC method for monitoring midazolam in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9051210/),%,85.57,117618,DB00683,Midazolam
,8471371,elimination half-life,"Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),min,107,118266,DB00683,Midazolam
,8471371,total body clearance,"Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ml] / [kg·min],15.4,118267,DB00683,Midazolam
,8471371,apparent volume of distribution at steady state,"Midazolam data were consistent with a three-compartment model with a mean (SD) elimination half-life of 107 (30) min, total body clearance of 15.4 (3.2) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.9 (0.6) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[l] / [kg],1.9,118268,DB00683,Midazolam
,8471371,terminal elimination half-life,"Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),min,35.3,118269,DB00683,Midazolam
,8471371,total plasma clearance,"Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ml] / [kg·min],20.6,118270,DB00683,Midazolam
,8471371,apparent volume of distribution at steady state,"Flumazenil data were best interpreted by a monoexponential function, with a mean terminal elimination half-life of 35.3 (13.8) min, a total plasma clearance of 20.6 (6.9) ml min-1 kg-1 and apparent volume of distribution at steady state of 1.0 (0.2) litre kg-1.",Pharmacokinetics of flumazenil and midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[l] / [kg],1.0,118271,DB00683,Midazolam
,8471371,plasma concentrations,"At the time of self identification, 4.5 (1.4) min after flumazenil administration, the mean plasma concentrations of midazolam and flumazenil were 163.1 (43.7) and 29.9 (16.1) ng ml-1, respectively.",Pharmacokinetics of flumazenil and midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ng] / [ml],163.1,118272,DB00683,Midazolam
,8471371,plasma concentrations,"At the time of self identification, 4.5 (1.4) min after flumazenil administration, the mean plasma concentrations of midazolam and flumazenil were 163.1 (43.7) and 29.9 (16.1) ng ml-1, respectively.",Pharmacokinetics of flumazenil and midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471371/),[ng] / [ml],29.9,118273,DB00683,Midazolam
,29203151,clearance,"Parameter estimations for a subject of 34kg indicated values of midazolam clearance of 34.7l·h-1, a central volume of distribution of 27.9l and a peripheral volume of distribution of 413l.","Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29203151/),[l] / [h],34.7,118684,DB00683,Midazolam
,29203151,central volume of distribution,"Parameter estimations for a subject of 34kg indicated values of midazolam clearance of 34.7l·h-1, a central volume of distribution of 27.9l and a peripheral volume of distribution of 413l.","Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29203151/),l,27.9,118685,DB00683,Midazolam
,29203151,peripheral volume of distribution,"Parameter estimations for a subject of 34kg indicated values of midazolam clearance of 34.7l·h-1, a central volume of distribution of 27.9l and a peripheral volume of distribution of 413l.","Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29203151/),l,413,118686,DB00683,Midazolam
,21191377,half-life,The midazolam AUC(0-∞) returned to baseline with a half-life of ~8 days.,Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191377/),d,8,118747,DB00683,Midazolam
,10520618,successful dose,The mean +/- SD successful dose was 0.4 +/- 0.2 microg x kg(-1) x min(-1).,Conscious sedation with remifentanil and midazolam during brief painful procedures in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520618/),[μg] / [kg·min],0.4,118960,DB00683,Midazolam
,10520618,time to reach discharge criteria,The mean +/- SD time to reach discharge criteria was 9.5 +/- 4.3 minutes.,Conscious sedation with remifentanil and midazolam during brief painful procedures in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10520618/),min,9.5,118961,DB00683,Midazolam
,7669465,T1/T0,"Mivacurium chloride was infused at a rate of 15 micrograms kg-1 min-1 for 10 min, 7.5 micrograms kg-1 min-1 for a further 10 min, and then at a rate adjusted to maintain T1/T0 at 5%.","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),%,5,119905,DB00683,Midazolam
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.4,119906,DB00683,Midazolam
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.1,119907,DB00683,Midazolam
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],3.8,119908,DB00683,Midazolam
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],759,120029,DB00683,Midazolam
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],567,120030,DB00683,Midazolam
,20012430,half maximal inactivation (K (I)),"In HLMs, the concentration required for half maximal inactivation (K (I)) was 122 microM and the maximal rate of inactivation (k (inact)) was 0.094 min(-1).",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),μM,122,120069,DB00683,Midazolam
,20012430,maximal rate of inactivation (k (inact)),"In HLMs, the concentration required for half maximal inactivation (K (I)) was 122 microM and the maximal rate of inactivation (k (inact)) was 0.094 min(-1).",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),1/[min],0.094,120070,DB00683,Midazolam
,20012430,K (I),"In comparison, K (I) and k (inact) values with rCYP3A4 were 50 microM and 0.229 min(-1), respectively.",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),μM,50,120071,DB00683,Midazolam
,20012430,k (inact),"In comparison, K (I) and k (inact) values with rCYP3A4 were 50 microM and 0.229 min(-1), respectively.",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),1/[min],0.229,120072,DB00683,Midazolam
,10391668,clearance,"Pharmacokinetic parameters were similar in both groups (clearance, 399+/-91 and 388+/-97 mL/min; steady-state volume of distribution, 85+/-22 and 104 +/-11 L in young and elderly subjects, respectively).",The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391668/),[ml] / [min],399,120869,DB00683,Midazolam
,10391668,clearance,"Pharmacokinetic parameters were similar in both groups (clearance, 399+/-91 and 388+/-97 mL/min; steady-state volume of distribution, 85+/-22 and 104 +/-11 L in young and elderly subjects, respectively).",The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391668/),[ml] / [min],388,120870,DB00683,Midazolam
,10391668,steady-state volume of distribution,"Pharmacokinetic parameters were similar in both groups (clearance, 399+/-91 and 388+/-97 mL/min; steady-state volume of distribution, 85+/-22 and 104 +/-11 L in young and elderly subjects, respectively).",The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391668/),l,85,120871,DB00683,Midazolam
,10391668,steady-state volume of distribution,"Pharmacokinetic parameters were similar in both groups (clearance, 399+/-91 and 388+/-97 mL/min; steady-state volume of distribution, 85+/-22 and 104 +/-11 L in young and elderly subjects, respectively).",The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391668/),l,104,120872,DB00683,Midazolam
,10391668,half-maximum concentration (EC50,"Pharmacodynamic data showed a large difference in half-maximum concentration (EC50; young subjects, 522+/-236 ng/mL; elderly subjects, 223+/-56 ng/mL; P < .05), a steep concentration-response curve, and distinct hysteresis.",The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391668/),[ng] / [ml],522,120873,DB00683,Midazolam
,10391668,half-maximum concentration (EC50,"Pharmacodynamic data showed a large difference in half-maximum concentration (EC50; young subjects, 522+/-236 ng/mL; elderly subjects, 223+/-56 ng/mL; P < .05), a steep concentration-response curve, and distinct hysteresis.",The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391668/),[ng] / [ml],223,120874,DB00683,Midazolam
,8126758,t1/2-alpha,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,1.8,120970,DB00683,Midazolam
,8126758,t1/2-beta,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,27.8,120971,DB00683,Midazolam
,8126758,t1/2-alpha,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,1.35,120972,DB00683,Midazolam
,8126758,t1/2-beta,"Serum concentrations were best described using a two-compartment open model and indicated a t1/2-alpha of 1.8 min and t1/2-beta of 27.8 min after i.v. bolus, and t1/2-alpha of 1.35 min and t1/2-beta of 31.6 min after i.v. infusion.",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),min,31.6,120973,DB00683,Midazolam
,8126758,coefficient,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],429,120974,DB00683,Midazolam
,8126758,coefficient,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],888,120975,DB00683,Midazolam
,8126758,B,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],429,120976,DB00683,Midazolam
,8126758,B,"The calculated pharmacokinetic coefficient B was significantly smaller after i.v. infusion (429 +/- 244 ng/ml) than after i.v. bolus (888 +/- 130 ng/ml, P = 0.004).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [ml],888,120977,DB00683,Midazolam
,8126758,AUC,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [h·ml],"29,800",120978,DB00683,Midazolam
,8126758,AUC,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ng] / [h·ml],"42,500",120979,DB00683,Midazolam
,8126758,ClB,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ml] / [kg·min],17.4,120980,DB00683,Midazolam
,8126758,ClB,"Furthermore, AUC was significantly smaller after i.v. infusion (29,800 +/- 6120 ng/h/ml) than after i.v. bolus (42,500 +/- 8460 ng/h/ml, P < 0.05), resulting in a larger ClB after i.v. infusion (17.4 +/- 4.00 ml/min/kg than after i.v. bolus (12.1 +/- 2.24 ml/min/kg, P < 0.05).",Pharmacokinetics of midazolam administered concurrently with ketamine after intravenous bolus or infusion in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126758/),[ml] / [kg·min],12.1,120981,DB00683,Midazolam
,26324195,flow rate,Chromatographic separation was carried out on an Acquity UPLC BEH C18 column using a gradient mobile phase system composed of acetonitrile and 1% formic acid in water at a flow rate of 0.40 mL/min.,Determination of Sertraline in Human Plasma by UPLC-MS/MS and its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26324195/),[ml] / [min],0.40,121065,DB00683,Midazolam
>,19373887,IC(50),"CP-100,356 was devoid of inhibition (IC(50) >50 microM) against major human P450 enzymes including P4503A4.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,50,121222,DB00683,Midazolam
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,0.5,121223,DB00683,Midazolam
,19373887,IC(50),"In human MDR1-transfected MDCKII cells, CP-100,356 inhibited acetoxymethyl calcein (calcein-AM) uptake (IC(50) approximately 0.5 +/- 0.07 microM) and digoxin transport (IC(50) approximately 1.2 +/- 0.1 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.2,121224,DB00683,Midazolam
,19373887,IC(50),"Inhibition of prazosin transport (IC(50) approximately 1.5 +/- 0.3 microM) in human BCRP-transfected MDCKII cells by CP-100,356 confirmed the dual MDR1/BCRP inhibitory properties.","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,1.5,121225,DB00683,Midazolam
,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,66,121226,DB00683,Midazolam
>,19373887,IC(50),"CP-100,356 was a weak inhibitor of OATP1B1 (IC(50) approximately 66 +/- 1.1 microM) and was devoid of MRP2 inhibition (IC(50) >15 microM).","N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a ""chemical knock-out equivalent"" to assess the impact of efflux transporters on oral drug absorption in the rat. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19373887/),μM,15,121227,DB00683,Midazolam
,1990898,peak plasma concentration,Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min.,Plasma concentrations of midazolam in children following intranasal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990898/),[ng] / [ml],72.2,121885,DB00683,Midazolam
,3203485,elimination half-life (t1/2),In young healthy volunteers elimination half-life (t1/2) is about 2.4 hours.,No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203485/),h,2.4,122021,DB00683,Midazolam
,3203485,t1/2,"A recent study showed a prolonged t1/2 from 8 to 22 hours in 6.5% of surgical patients, and a genetic polymorphism of midazolam's metabolism has been suggested.",No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203485/),h,8 to 22,122022,DB00683,Midazolam
,3203485,area under plasma-level curve of midazolam (AUC-midazolam/dose,Data for the dose-corrected area under plasma-level curve of midazolam (AUC-midazolam/dose: 1.23 +/- 961 x 10(5) h/ml; mean +/- SD) and for the metabolic plasma ratio (AUC of alpha-OH-midazolam/AUC-midazolam: 0.52 +/- 0.28) demonstrated a log-normal distribution.,No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203485/),[h] / [ml],1.23,122023,DB00683,Midazolam
,3203485,metabolic plasma ratio (AUC of alpha-OH-midazolam/AUC-midazolam,Data for the dose-corrected area under plasma-level curve of midazolam (AUC-midazolam/dose: 1.23 +/- 961 x 10(5) h/ml; mean +/- SD) and for the metabolic plasma ratio (AUC of alpha-OH-midazolam/AUC-midazolam: 0.52 +/- 0.28) demonstrated a log-normal distribution.,No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203485/),,0.52,122024,DB00683,Midazolam
,3203485,t1/2,"Likewise, the percentage of the unbound fraction of midazolam in plasma (5.0 +/- 2.4%), urinary excretion of alpha-OH-midazolam (55.9 +/- 22.7% of dose) and the values for t1/2 (2.9 +/- 1.1 hours) did indicate a unimodal distribution.",No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203485/),h,2.9,122025,DB00683,Midazolam
,3203485,t1/2,"Only in 3 patients could a prolonged t1/2 of midazolam from 7.5 to 10.2 hours be detected, but plasma levels and urinary excretion of alpha-OH-midazolam in those individuals were found to be normal.",No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203485/),h,7.5 to 10.2,122026,DB00683,Midazolam
,20020418,K(m),"Using non-linear regression, we determined a K(m) value of 577 nM, indicating relatively low threshold enzyme saturation consistent with previous in vivo observation.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),nM,577,122411,DB00683,Midazolam
,20020418,T(1/2),"The metabolic stability was determined at a concentration of 100 nm (<<K(m)) and the observed T(1/2) was 90 min with a CL(i) of 0.008 mL/min indicating moderately low clearance in dog liver microsomes, also consistent with previous in vivo data.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),min,90,122412,DB00683,Midazolam
,20020418,CL(i),"The metabolic stability was determined at a concentration of 100 nm (<<K(m)) and the observed T(1/2) was 90 min with a CL(i) of 0.008 mL/min indicating moderately low clearance in dog liver microsomes, also consistent with previous in vivo data.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),[ml] / [min],0.008,122413,DB00683,Midazolam
,28301096,IC50,In vitro experiments assessing the potential of tenapanor to affect various CYPs indicated that it could inhibit CYP3A4/5 (IC50 0.4-0.7 μM).,Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301096/),μM,0.4-0.7,122756,DB00683,Midazolam
,16651648,Fractional survival,Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01).,Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651648/),%,1.3,122794,DB00683,Midazolam
,16651648,Fractional survival,Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01).,Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651648/),%,100,122795,DB00683,Midazolam
,30472551,Elimination half-life,Elimination half-life was 0.999 ± 0.241 h in seven patients.,"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472551/),h,0.999,122998,DB00683,Midazolam
,30472551,Total body clearance,Total body clearance ranged from 423 to 1220 mL/h/kg in older children but was notably higher in a 10-month-old infant (2010 mL/h/kg).,"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472551/),[ml] / [h·kg],423 to 1220,122999,DB00683,Midazolam
,30472551,Total body clearance,Total body clearance ranged from 423 to 1220 mL/h/kg in older children but was notably higher in a 10-month-old infant (2010 mL/h/kg).,"Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472551/),[ml] / [h·kg],2010,123000,DB00683,Midazolam
,23858609,time to stop seizures,"Intranasal midazolam was proved to be effective (complete remission;65%), rapidly (an average time to stop seizures; 5.7 min) and safe with no adverse effects including respiratory depression with this dosage (an average of 0.26 mg/kg).",[Study of an efficacy and a pharmacokinetics of intranasal midazolam for status epilepticus on childhood epilepsy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23858609/),min,5.7,123614,DB00683,Midazolam
,29287157,peak plasma midazolam concentration,"The mean peak plasma midazolam concentration for the H2 formulation was 187.0 and 106.3 ng/mL when the midazolam dose administered was 0.6 and 0.3 mg/kg, respectively.",Pharmacokinetic evaluation of novel midazolam gel formulations following buccal administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287157/),[ng] / [ml],187.0,124092,DB00683,Midazolam
,29287157,peak plasma midazolam concentration,"The mean peak plasma midazolam concentration for the H2 formulation was 187.0 and 106.3 ng/mL when the midazolam dose administered was 0.6 and 0.3 mg/kg, respectively.",Pharmacokinetic evaluation of novel midazolam gel formulations following buccal administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29287157/),[ng] / [ml],106.3,124093,DB00683,Midazolam
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.24,124543,DB00683,Midazolam
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,12.54,124544,DB00683,Midazolam
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,0.81,124545,DB00683,Midazolam
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,1.49,124546,DB00683,Midazolam
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,3.90,124547,DB00683,Midazolam
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.35,124548,DB00683,Midazolam
,19041719,IC(50),"Among the tested nonionic surfactants, polysorbate 20 was the most potent inhibitor of midazolam 1'-hydroxylation with an IC(50) of 2.06 and 0.39mgml(-1) in the liver and intestinal microsomes, respectively.",Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041719/),1/[mgml],2.06,126343,DB00683,Midazolam
,19041719,IC(50),"Among the tested nonionic surfactants, polysorbate 20 was the most potent inhibitor of midazolam 1'-hydroxylation with an IC(50) of 2.06 and 0.39mgml(-1) in the liver and intestinal microsomes, respectively.",Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041719/),1/[mgml],0.39,126344,DB00683,Midazolam
,10086837,half-life,Serum KCZ concentrations showed an apparent nonlinear pattern of decline with a short half-life (1.38 h).,Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086837/),h,1.38,127287,DB00683,Midazolam
,16997909,Cmax,"Cmax increased from 23 ng/ml (95% CI 19-29 ng/ml) to 55 ng/ml (95% CI 46-66 ng/ml), p < 0.0001.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[ng] / [ml],23,127959,DB00683,Midazolam
,16997909,Cmax,"Cmax increased from 23 ng/ml (95% CI 19-29 ng/ml) to 55 ng/ml (95% CI 46-66 ng/ml), p < 0.0001.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[ng] / [ml],55,127960,DB00683,Midazolam
,16997909,AUCs,"AUCs [median (range)] were 0.20 mg . min/ml (0.05-0.81 mg . min/ml) and 1.94 mg . min/ml (0.25-25.4 mg . min/ml) at baseline and inhibition phase, with CV% of 41 and 61%, respectively.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[mg·min] / [ml],0.20,127961,DB00683,Midazolam
,16997909,AUCs,"AUCs [median (range)] were 0.20 mg . min/ml (0.05-0.81 mg . min/ml) and 1.94 mg . min/ml (0.25-25.4 mg . min/ml) at baseline and inhibition phase, with CV% of 41 and 61%, respectively.",Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997909/),[mg·min] / [ml],1.94,127962,DB00683,Midazolam
greater,21382685,recoveries,"Alfentanil and midazolam were extracted from plasma using a mixed-mode cation exchange solid phase extraction method, with recoveries of both compounds greater than 80% at 3 different concentrations (1, 10 and 100ng/ml).",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),%,80,128197,DB00683,Midazolam
,21382685,flow rate,"Compounds were analyzed on a C(18) column with a water and methanol mobile phase gradient with acetic acid as an additive, at a flow rate of 0.3ml/min.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),[ml] / [min],0.3,128198,DB00683,Midazolam
,21382685,signal to noise ratio,"The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),,80,128199,DB00683,Midazolam
,21382685,signal to noise ratio,"The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),,40,128200,DB00683,Midazolam
,16782766,EC50,"In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1'-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.5,128314,DB00683,Midazolam
,16782766,EC50,"In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1'-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.2,128315,DB00683,Midazolam
,16782766,KI,"Compound A (N-[2(R)-hydroxy-1(S)-indanyl-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)-methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide), a known potent and mechanism-based inhibitor of CYP3A4, strongly inhibited the formation of 1'-hydroxy MDZ by recombinant CYP3A64 in a concentration- and time-dependent manner (KI = 0.25 microM; k(inact) = 0.4 min(-1)).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.25,128316,DB00683,Midazolam
,16782766,k(inact),"Compound A (N-[2(R)-hydroxy-1(S)-indanyl-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)-methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide), a known potent and mechanism-based inhibitor of CYP3A4, strongly inhibited the formation of 1'-hydroxy MDZ by recombinant CYP3A64 in a concentration- and time-dependent manner (KI = 0.25 microM; k(inact) = 0.4 min(-1)).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),1/[min],0.4,128317,DB00683,Midazolam
,16782766,hepatic availability (Fh,"In rhesus monkeys, MDZ exhibited a relatively high metabolic clearance (primarily via 1'-hydroxylation followed by glucuronidation) and a low hepatic availability (Fh = 16%).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),%,16,128318,DB00683,Midazolam
,6116606,time to reach peak plasma midazolam concentration,"The time to reach peak plasma midazolam concentration after the 10-mg solution dose (0.37 +/- 0.45 h) did not differ significantly ('t' = 2.04, df = 10, p greater than 0.05) from the time to reach peak plasma midazolam level after the 10-mg tablet dose (0.74 +/- 0.45 h).",The pharmacokinetics of midazolam in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116606/),h,0.37,129197,DB00683,Midazolam
,6116606,time to reach peak plasma midazolam level,"The time to reach peak plasma midazolam concentration after the 10-mg solution dose (0.37 +/- 0.45 h) did not differ significantly ('t' = 2.04, df = 10, p greater than 0.05) from the time to reach peak plasma midazolam level after the 10-mg tablet dose (0.74 +/- 0.45 h).",The pharmacokinetics of midazolam in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116606/),h,0.74,129198,DB00683,Midazolam
,6116606,"terminal half-life, (t 1/2)","The terminal half-life, (t 1/2), of midazolam in plasma was 1.77 +/- 0.83 h and there was no significant difference between the mean terminal half-life values obtained for the three midazolam formulations.",The pharmacokinetics of midazolam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116606/),h,1.77,129199,DB00683,Midazolam
,6116606,total clearance (Cl),"The mean total clearance (Cl), of midazolam after 5-mg intravenous administration was 0.383 +/- 0.0941 . kg-1 . h-1.",The pharmacokinetics of midazolam in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116606/),1/[h·kg],0.383,129200,DB00683,Midazolam
,6116606,"first pass effect, F","The first pass effect, F, determined experimentally (0.36 +/- 0.09) indicated the substantial first pass metabolism of midazolam.",The pharmacokinetics of midazolam in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116606/),,0.36,129201,DB00683,Midazolam
,30916851,Partial metabolic clearance,Partial metabolic clearance of midazolam in patients with haematological diseases was highly variable (36.9 ± 52.7 L/h).,Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916851/),[l] / [h],36.9,129308,DB00683,Midazolam
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.343,129709,DB00683,Midazolam
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.343,129710,DB00683,Midazolam
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.269,129711,DB00683,Midazolam
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.267,129712,DB00683,Midazolam
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.534,129713,DB00683,Midazolam
,12496753,bioavailability,"There were no significant differences in bioavailability (0.343 +/- 0.100 versus 0.343 +/- 0.094), ER(H) (0.269 +/- 0.064 versus 0.267 +/- 0.077), and ER(G) (0.534 +/- 0.135 versus 0.531 +/- 0.124) between the traditional and semisimultaneous methods.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.531,129714,DB00683,Midazolam
,12496753,bioavailability,"As expected, ketoconazole markedly increased the mean bioavailability to 0.838 (2.4-fold), the mean ER(H) was decreased 3.7-fold, and the mean ER(G) was decreased 5.7-fold.",Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496753/),,0.838,129715,DB00683,Midazolam
,20435936,constant C(T),"During session B, in addition to this midazolam infusion scheme, a target-controlled infusion of propofol (constant C(T): 0.6 or 1.0 microg x mL(-1)) was given from 15 minutes before the start until 6 hours after termination of the midazolam infusion.",Propofol reduces the distribution and clearance of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[μg] / [ml],0.6,130087,DB00683,Midazolam
,20435936,constant C(T),"During session B, in addition to this midazolam infusion scheme, a target-controlled infusion of propofol (constant C(T): 0.6 or 1.0 microg x mL(-1)) was given from 15 minutes before the start until 6 hours after termination of the midazolam infusion.",Propofol reduces the distribution and clearance of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[μg] / [ml],1.0,130088,DB00683,Midazolam
,20435936,C(blood),"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[μg] / [ml],1.2,130089,DB00683,Midazolam
,20435936,central volume of distribution,"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),l,5.37 to 2.98,130090,DB00683,Midazolam
,20435936,elimination clearance,"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[l] / [min],0.39 to 0.31,130091,DB00683,Midazolam
,20435936,distribution clearance,"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[l] / [min],2.77 to 2.11,130092,DB00683,Midazolam
,31666152,time to maximal concentration (Tmax),"Intranasal administration can provide a time to maximal concentration (Tmax) of drugs (e.g., naloxone and midazolam) of 30 min or less.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,30,131501,DB00683,Midazolam
,31666152,Tmax,"Tmax was long for both dosages (High dose 75.0 ± 49.4 min, Low dose 61.9 ± 37.1 min), compared to other intranasally administered drugs and some previous studies with IN SCOP.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,75.0,131502,DB00683,Midazolam
,31666152,Tmax,"Tmax was long for both dosages (High dose 75.0 ± 49.4 min, Low dose 61.9 ± 37.1 min), compared to other intranasally administered drugs and some previous studies with IN SCOP.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,61.9,131503,DB00683,Midazolam
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,34.2,131865,DB00683,Midazolam
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,30.0,131866,DB00683,Midazolam
,7488483,clearance,"In the healthy patients, clearance of 51W89 was greater in males, but it decreased with increasing age by approximately 1.5 ml min-1 yr-1.",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),[ml] / [min·yr],1.5,131867,DB00683,Midazolam
,27604990,AUC ratio,"Based on simulations, the midazolam AUC ratio ranged from 0.06 to 0.16 and was comparable to the observed ratio of 0.14.","Application of a ""Fit for Purpose"" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604990/),,0.06 to 0.16,131876,DB00683,Midazolam
,1545554,temperature coefficient,The median temperature coefficient for man on nonpulsatile cardiopulmonary bypass is 2.8.,The effect of temperature on cerebral metabolism and blood flow in adults during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545554/),,2.8,132760,DB00683,Midazolam
,11370704,half-life,"Although the MI complex was undetectable after 1 day's treatment with erythromycin, its content increased with duration of erythromycin treatment, and the complex disappeared after the end of erythromycin treatment with a half-life of 12.3 h.","In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11370704/),h,12.3,132890,DB00683,Midazolam
,31401049,times to sternal,"The times to sternal, mean 32.3 and 24.6 minutes, for groups KMF and KM, respectively, were not different between the groups.",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,32.3,133019,DB00683,Midazolam
,31401049,times to sternal,"The times to sternal, mean 32.3 and 24.6 minutes, for groups KMF and KM, respectively, were not different between the groups.",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,24.6,133020,DB00683,Midazolam
,31401049,time to standing,"The time to standing, 73 and 36 minutes in groups KMF and KM, respectively, was significantly different (p = 0.002).",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,73,133021,DB00683,Midazolam
,31401049,time to standing,"The time to standing, 73 and 36 minutes in groups KMF and KM, respectively, was significantly different (p = 0.002).",Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,36,133022,DB00683,Midazolam
,31401049,duration,The duration of elevated HR compared with baseline was longer in KMF (110 minutes) than in KM (25 minutes) (p < 0.05).,Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,110,133023,DB00683,Midazolam
,31401049,duration,The duration of elevated HR compared with baseline was longer in KMF (110 minutes) than in KM (25 minutes) (p < 0.05).,Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401049/),min,25,133024,DB00683,Midazolam
,28544992,AUC0-∞,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),mg,70,133399,DB00683,Midazolam
,28544992,AUC0-∞,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),mg,54,133400,DB00683,Midazolam
,28544992,AUC0-∞,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),[h·ng] / [ml],157,133401,DB00683,Midazolam
,28544992,AUC0-∞,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),,110,133402,DB00683,Midazolam
,28544992,Cmax,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),mg,27.1,133403,DB00683,Midazolam
,28544992,Cmax,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),mg,22.5,133404,DB00683,Midazolam
,28544992,Cmax,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),mg,55.8,133405,DB00683,Midazolam
,28544992,Cmax,"Midazolam exposure and plasma concentrations were higher in geriatric versus non-geriatric adults (geometric mean AUC0-∞ [ng*h/mL] 2.5mg: 70 vs 54, respectively; 5.0mg: 157 vs 110; Cmax [ng/mL] 2.5mg: 27.1 vs 22.5; 5.0mg: 55.8 vs 46.1).","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),mg,46.1,133406,DB00683,Midazolam
,28544992,Tmax,"USL261 was rapidly absorbed, with no differences in median Tmax (14.5-17.3min); mean t1/2 was longer in geriatric subjects.","Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28544992/),min,14.5-17.3,133407,DB00683,Midazolam
,8110554,Free plasma concentration,Free plasma concentration of midazolam increased from 2.0 (SD 1.5) ng ml-1 to 2.2 (1.9) ng ml-1 after introduction of the propofol infusion (P = 0.32).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],2.0,133827,DB00683,Midazolam
,8110554,Free plasma concentration,Free plasma concentration of midazolam increased from 2.0 (SD 1.5) ng ml-1 to 2.2 (1.9) ng ml-1 after introduction of the propofol infusion (P = 0.32).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],2.2,133828,DB00683,Midazolam
,8110554,plasma concentration,Free propofol plasma concentration was unchanged at 18.5 (5.3) ng ml-1 before and 18.7 (7.8) ng ml-1 after introduction of the midazolam infusion (P = 0.94).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],18.5,133829,DB00683,Midazolam
,8110554,plasma concentration,Free propofol plasma concentration was unchanged at 18.5 (5.3) ng ml-1 before and 18.7 (7.8) ng ml-1 after introduction of the midazolam infusion (P = 0.94).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],18.7,133830,DB00683,Midazolam
better,25638029,recoveries,The recoveries were better than 80.4% and matrix effects ranged from 96.9% to 105.1%.,Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25638029/),%,80.4,133898,DB00683,Midazolam
longer,25638029,t1/2,"The pharmacokinetics of four different dosages (iv 5, 10mg/kg and ig 15, 30mg/kg) revealed that XL184 was eliminated slowly, the t1/2 was longer than 10h and the absolute bioavailability was 25.6±8.3%.",Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25638029/),h,10,133899,DB00683,Midazolam
,25638029,absolute bioavailability,"The pharmacokinetics of four different dosages (iv 5, 10mg/kg and ig 15, 30mg/kg) revealed that XL184 was eliminated slowly, the t1/2 was longer than 10h and the absolute bioavailability was 25.6±8.3%.",Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25638029/),%,25.6,133900,DB00683,Midazolam
,23192725,body clearance (CL),"Pharmacokinetic parameter estimates for midazolam for the hypothermic group are a body clearance (CL) of 12.6 l/h, an apparent volume of the central compartment (V1) of 19.1 l, an apparent volume of the peripheral compartment (V2) of 108 l and an intercompartmental clearance (Q) of 18.4 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),[l] / [h],12.6,134049,DB00683,Midazolam
,23192725,apparent volume of the central compartment (V1),"Pharmacokinetic parameter estimates for midazolam for the hypothermic group are a body clearance (CL) of 12.6 l/h, an apparent volume of the central compartment (V1) of 19.1 l, an apparent volume of the peripheral compartment (V2) of 108 l and an intercompartmental clearance (Q) of 18.4 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),l,19.1,134050,DB00683,Midazolam
,23192725,apparent volume of the peripheral compartment (V2),"Pharmacokinetic parameter estimates for midazolam for the hypothermic group are a body clearance (CL) of 12.6 l/h, an apparent volume of the central compartment (V1) of 19.1 l, an apparent volume of the peripheral compartment (V2) of 108 l and an intercompartmental clearance (Q) of 18.4 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),l,108,134051,DB00683,Midazolam
,23192725,intercompartmental clearance (Q),"Pharmacokinetic parameter estimates for midazolam for the hypothermic group are a body clearance (CL) of 12.6 l/h, an apparent volume of the central compartment (V1) of 19.1 l, an apparent volume of the peripheral compartment (V2) of 108 l and an intercompartmental clearance (Q) of 18.4 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),[l] / [h],18.4,134052,DB00683,Midazolam
,23192725,CL,"Estimated parameters for the control group are CL of 14.2 l/h, a V1 of 15.7 l, a V2 of 171 l and Q of 25.6 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),[l] / [h],14.2,134053,DB00683,Midazolam
,23192725,V1,"Estimated parameters for the control group are CL of 14.2 l/h, a V1 of 15.7 l, a V2 of 171 l and Q of 25.6 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),l,15.7,134054,DB00683,Midazolam
,23192725,V2,"Estimated parameters for the control group are CL of 14.2 l/h, a V1 of 15.7 l, a V2 of 171 l and Q of 25.6 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),l,171,134055,DB00683,Midazolam
,23192725,Q,"Estimated parameters for the control group are CL of 14.2 l/h, a V1 of 15.7 l, a V2 of 171 l and Q of 25.6 l/h.",Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192725/),[l] / [h],25.6,134056,DB00683,Midazolam
,11753268,Total body clearance,"Total body clearance, apparent volume of distribution, and plasma half-life of midazolam were (median [range]): 1.8 (0.7-6.7) ml/kg per min, 1.1 (0.4-4.2) L/kg, and 6.3 (2.6-17.7) h, respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),[ml] / [kg·min],1.8,134244,DB00683,Midazolam
,11753268,apparent volume of distribution,"Total body clearance, apparent volume of distribution, and plasma half-life of midazolam were (median [range]): 1.8 (0.7-6.7) ml/kg per min, 1.1 (0.4-4.2) L/kg, and 6.3 (2.6-17.7) h, respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),[l] / [kg],1.1,134245,DB00683,Midazolam
,11753268,plasma half-life,"Total body clearance, apparent volume of distribution, and plasma half-life of midazolam were (median [range]): 1.8 (0.7-6.7) ml/kg per min, 1.1 (0.4-4.2) L/kg, and 6.3 (2.6-17.7) h, respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),h,6.3,134246,DB00683,Midazolam
,11753268,maximal concentration of drug in plasma (C(max)),"In 19 of 24 preterm infants, 1-OH-midazolam concentrations could be detected: 1-OH-midazolam (1-OH-M) maximal concentration of drug in plasma (C(max)), time to reach C(max) (T(max)), and 1-OH-M/M area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)) ratio were [median (range)]: 8.2 (<0.5-68.2) ng/ml, 6 (1-12) h, and 0.09 (<0.001-1), respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),[ng] / [ml],8.2,134247,DB00683,Midazolam
,11753268,time to reach C(max) (T(max)),"In 19 of 24 preterm infants, 1-OH-midazolam concentrations could be detected: 1-OH-midazolam (1-OH-M) maximal concentration of drug in plasma (C(max)), time to reach C(max) (T(max)), and 1-OH-M/M area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)) ratio were [median (range)]: 8.2 (<0.5-68.2) ng/ml, 6 (1-12) h, and 0.09 (<0.001-1), respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),h,6,134248,DB00683,Midazolam
,11753268,area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)),"In 19 of 24 preterm infants, 1-OH-midazolam concentrations could be detected: 1-OH-midazolam (1-OH-M) maximal concentration of drug in plasma (C(max)), time to reach C(max) (T(max)), and 1-OH-M/M area under the concentration-time curve from time zero to the last sampling time point (AUC(0-t)) ratio were [median (range)]: 8.2 (<0.5-68.2) ng/ml, 6 (1-12) h, and 0.09 (<0.001-1), respectively.",Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753268/),,0.09,134249,DB00683,Midazolam
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],18.5,134403,DB00683,Midazolam
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],20.8,134404,DB00683,Midazolam
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,20,134405,DB00683,Midazolam
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,25,134406,DB00683,Midazolam
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,14,134407,DB00683,Midazolam
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,10.5,134408,DB00683,Midazolam
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,5,134409,DB00683,Midazolam
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,3,134410,DB00683,Midazolam
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],165,134411,DB00683,Midazolam
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],411,134412,DB00683,Midazolam
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,39.0,134661,DB00683,Midazolam
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,18.3,134662,DB00683,Midazolam
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,12.3,134663,DB00683,Midazolam
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,68.0,134664,DB00683,Midazolam
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,52.6,134665,DB00683,Midazolam
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,13.5,134666,DB00683,Midazolam
,28978489,total run time,The analytes were separated by gradient elution using a C18 analytical column with a total run time of 5min.,"Development and validation of a sensitive assay for analysis of midazolam, free and conjugated 1-hydroxymidazolam and 4-hydroxymidazolam in pediatric plasma: Application to Pediatric Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28978489/),min,5,134759,DB00683,Midazolam
,32616542,area under the curve ratios (AUCRs),"When the clinical impacts of esaxerenone on the inhibition and induction of CYP3A were estimated separately by using a mechanistic static model, the predicted area under the curve ratios (AUCRs) of midazolam, a typical CYP3A substrate, were 1.80 and 0.31, respectively, suggesting that the DDI potential of esaxerenone cannot be neglected.",Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32616542/),,1.80,135112,DB00683,Midazolam
,32616542,area under the curve ratios (AUCRs),"When the clinical impacts of esaxerenone on the inhibition and induction of CYP3A were estimated separately by using a mechanistic static model, the predicted area under the curve ratios (AUCRs) of midazolam, a typical CYP3A substrate, were 1.80 and 0.31, respectively, suggesting that the DDI potential of esaxerenone cannot be neglected.",Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32616542/),,0.31,135113,DB00683,Midazolam
,32616542,AUCR,"The predicted AUCR of midazolam was approximately 1.2, which is close to that in a clinical study, despite the difficulty of predicting DDIs for compounds with both inhibition and induction effects.",Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32616542/),,1.2,135114,DB00683,Midazolam
,9630828,apparent volume of distribution,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[l] / [kg],1.3,135230,DB00683,Midazolam
,9630828,apparent volume of distribution,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[l] / [kg],1.1,135231,DB00683,Midazolam
,9630828,halflife,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),h,3.3,135232,DB00683,Midazolam
,9630828,halflife,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),h,3.7,135233,DB00683,Midazolam
,9630828,total body clearance,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ml] / [min],451,135234,DB00683,Midazolam
,9630828,total body clearance,"There were no significant age-dependent differences in disposition of midazolam between young and elderly patients (apparent volume of distribution, 1.3 +/- 0.2 versus 1.1 +/- 0.4 L/kg; halflife, 3.3 +/- 1.5 hours versus 3.7 +/- 2.2 hours; total body clearance, 451 +/- 186 ml/min versus 343 +/- 137 ml/min).",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ml] / [min],343,135235,DB00683,Midazolam
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,573,135236,DB00683,Midazolam
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,261,135237,DB00683,Midazolam
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,37.7,135238,DB00683,Midazolam
,9630828,AUEC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,14.4,135239,DB00683,Midazolam
,9630828,AUECRT/AUC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,6.3,135240,DB00683,Midazolam
,9630828,AUECRT/AUC,"However, higher values of area under the effect curve (AUEC) and AUEC divided by area under the serum concentration-time curve (AUC) (sensitivity index) were observed among the elderly as follows: AUEC for reaction time (AUECRT) (573 versus 261; p = 0.042), AUEC for visual analog scale (AUECVAS) (37.7 versus 14.4; p = 0.011), AUECRT/AUC (6.3 versus 1.8; p = 0.007), and AUECVAS/AUC (0.40 versus 0.11; p = 0.009) compared with the young group.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),,1.8,135241,DB00683,Midazolam
,9630828,concentration at half-maximal effect,"Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ng] / [ml],20.5,135242,DB00683,Midazolam
,9630828,concentration at half-maximal effect,"Likewise, mean concentration at half-maximal effect for sedation was lower (p = 0.025) among older patients (20.5 +/- 2.2 ng/ml) than among younger (29.7 +/- 6.6 ng/ml) patients.",Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630828/),[ng] / [ml],29.7,135243,DB00683,Midazolam
,10470750,maximum dose,The maximum dose allowed for each drug was 60 mg/hr for midazolam and 4 mg/hr for lorazepam.,Continuous infusion of lorazepam versus medazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470750/),,60,135664,DB00683,Midazolam
,10470750,maximum dose,The maximum dose allowed for each drug was 60 mg/hr for midazolam and 4 mg/hr for lorazepam.,Continuous infusion of lorazepam versus medazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470750/),,4,135665,DB00683,Midazolam
,31587004,oral bioavailability,"Subsequently, pharmacokinetic study showed that the oral bioavailability of WZ35 is 10.56%.",Cytochrome P450-Mediated Metabolic Characterization of a Mono-Carbonyl Curcumin Analog WZ35. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587004/),%,10.56,135697,DB00683,Midazolam
,9435179,k(eo),"Rate constants for k(eo), k(vo) and terminal half-life were (mean +/- S.E.M.) 0.32 +/- 0.062, 0.093 +/- 0.013 and 0.0217 +/- 0.0008 min-1, respectively, indicating the existence of significant arteriovenous concentration differences.",Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435179/),1/[min],0.32,136011,DB00683,Midazolam
,9435179,k(vo),"Rate constants for k(eo), k(vo) and terminal half-life were (mean +/- S.E.M.) 0.32 +/- 0.062, 0.093 +/- 0.013 and 0.0217 +/- 0.0008 min-1, respectively, indicating the existence of significant arteriovenous concentration differences.",Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435179/),1/[min],0.093,136012,DB00683,Midazolam
,9435179,terminal half-life,"Rate constants for k(eo), k(vo) and terminal half-life were (mean +/- S.E.M.) 0.32 +/- 0.062, 0.093 +/- 0.013 and 0.0217 +/- 0.0008 min-1, respectively, indicating the existence of significant arteriovenous concentration differences.",Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435179/),1/[min],0.0217,136013,DB00683,Midazolam
,9435179,EC50,"Pharmacodynamic estimates as determined on basis of the arterial concentrations and the traditional-effect compartment model were EC50 = 104 +/- 1 ng/ml, Emax = 151 +/- 4 microV/sec and gamma = 0.83 +/- 0.06.",Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435179/),[ng] / [ml],104,136014,DB00683,Midazolam
,9435179,Emax,"Pharmacodynamic estimates as determined on basis of the arterial concentrations and the traditional-effect compartment model were EC50 = 104 +/- 1 ng/ml, Emax = 151 +/- 4 microV/sec and gamma = 0.83 +/- 0.06.",Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435179/),[μv] / [s],151,136015,DB00683,Midazolam
,9435179,gamma,"Pharmacodynamic estimates as determined on basis of the arterial concentrations and the traditional-effect compartment model were EC50 = 104 +/- 1 ng/ml, Emax = 151 +/- 4 microV/sec and gamma = 0.83 +/- 0.06.",Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435179/),,0.83,136016,DB00683,Midazolam
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136808,DB00683,Midazolam
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136809,DB00683,Midazolam
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136810,DB00683,Midazolam
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136811,DB00683,Midazolam
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136812,DB00683,Midazolam
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136813,DB00683,Midazolam
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],312,136814,DB00683,Midazolam
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136815,DB00683,Midazolam
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],3536,136816,DB00683,Midazolam
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,9.4,136817,DB00683,Midazolam
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,12.4,136818,DB00683,Midazolam
,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,80,137185,DB00683,Midazolam
less,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,10,137186,DB00683,Midazolam
,29117990,area under the curve ratio,The simulated midazolam area under the curve ratio of 0.54 and an accompanying observed 1.9-fold increase in the CYP3A4 activity of biomarker 4β-hydroxycholesterol indicated a weak-to-moderate CYP3A4 induction by midostaurin and its metabolites at steady state in patients with advSM.,Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117990/),,0.54,137187,DB00683,Midazolam
,16019953,extraction ratio,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,93,137207,DB00683,Midazolam
,16019953,extraction ratio,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,77,137208,DB00683,Midazolam
,16019953,bioavailability,"When ketoconazole was given orally to the animals, in conjunction with midazolam, the extraction ratio in the liver decreased from 93% to 77% in the control rats, and the bioavailability of midazolam increased to 23%.",Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019953/),%,23,137209,DB00683,Midazolam
,11140564,infusion rate,The initial propofol infusion rate was 200 mg/h (20 ml/h) for 21 of the 23 implant surgery treatments.,A sedation technique for implant and periodontal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140564/),[mg] / [h],200,137733,DB00683,Midazolam
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137989,DB00683,Midazolam
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137990,DB00683,Midazolam
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137991,DB00683,Midazolam
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137992,DB00683,Midazolam
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137993,DB00683,Midazolam
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137994,DB00683,Midazolam
,21042038,IC₅₀,"A Lineweaver-Burk plot showed that GA was a mixed inhibitor of CYP3A, with an IC₅₀ of 7.25 μmol/l, a K(m) of 4.3 μmol/l and a K(i) of 6.4 μmol/l by non-linear regression analysis.",In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21042038/),[μM] / [l],7.25,139222,DB00683,Midazolam
,21042038,K(m),"A Lineweaver-Burk plot showed that GA was a mixed inhibitor of CYP3A, with an IC₅₀ of 7.25 μmol/l, a K(m) of 4.3 μmol/l and a K(i) of 6.4 μmol/l by non-linear regression analysis.",In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21042038/),[μM] / [l],4.3,139223,DB00683,Midazolam
,21042038,K(i),"A Lineweaver-Burk plot showed that GA was a mixed inhibitor of CYP3A, with an IC₅₀ of 7.25 μmol/l, a K(m) of 4.3 μmol/l and a K(i) of 6.4 μmol/l by non-linear regression analysis.",In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21042038/),[μM] / [l],6.4,139224,DB00683,Midazolam
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB00683,Midazolam
,18482233,absorption half-life,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),h,4.6,140032,DB00683,Midazolam
,18482233,hydrolysis half-life,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),h,0.028,140033,DB00683,Midazolam
,18482233,clearance,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),[l] / [70·h·kg],12,140034,DB00683,Midazolam
,18482233,intercompartmental clearance,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),[l] / [70·h·kg],116,140035,DB00683,Midazolam
,18482233,central,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),70·l,7.9,140036,DB00683,Midazolam
,18482233,peripheral volume of distribution,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),70·l,7.9,140037,DB00683,Midazolam
,18482233,peripheral volume of distribution,"Parameter estimates were: absorption half-life from the rectum 4.6 h, propacetamol hydrolysis half-life 0.028 h, clearance 12 l.h(-1).70 kg(-1), intercompartmental clearance 116 l.h(-1).70 kg(-1), central and peripheral volume of distribution 7.9 and 44 l.70 kg(-1), respectively.",Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18482233/),1/[kg],44,140038,DB00683,Midazolam
greater,2306422,half-life (t1/2),It has recently been shown by several investigators that the half-life (t1/2) of midazolam is prolonged (greater than 7 h) in a small proportion of the population.,Increased volume of distribution prolongs midazolam half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306422/),h,7,141425,DB00683,Midazolam
,8720318,"area under the concentration-time curve, AUC (C)","The parameters are summarized as follows: area under the concentration-time curve, AUC (C) 173.8 h.ng.ml-1 vs.",Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720318/),[h·ng] / [ml],173.8,141635,DB00683,Midazolam
,8720318,concentration maxima (C),(E) 662.7 h.ng.ml-1*+ and (A) 220.0 h.ng.ml-1; concentration maxima (C) 67.2 ng.,Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720318/),ng,67.2,141636,DB00683,Midazolam
,8720318,elimination half-life (C),ml-1; elimination half-life (C) 2.21 h vs.,Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8720318/),h,2.21,141637,DB00683,Midazolam
,28954786,response rate,"Across all doses, in patients with EGFR T790M, the response rate was 30.7% (n = 27/88; 95% CI, 19.5%-44.5%), and median progression-free survival was 6.8 months (95% CI, 5.5-10.1 months).","A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28954786/),%,30.7,142656,DB00683,Midazolam
,28954786,progression-free survival,"Across all doses, in patients with EGFR T790M, the response rate was 30.7% (n = 27/88; 95% CI, 19.5%-44.5%), and median progression-free survival was 6.8 months (95% CI, 5.5-10.1 months).","A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28954786/),month,6.8,142657,DB00683,Midazolam
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],4.6,142800,DB00683,Midazolam
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],4.8,142801,DB00683,Midazolam
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],3.9,142802,DB00683,Midazolam
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],7.8,142803,DB00683,Midazolam
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],7.7,142804,DB00683,Midazolam
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],6.0,142805,DB00683,Midazolam
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],11.8,142806,DB00683,Midazolam
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],13.3,142807,DB00683,Midazolam
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],12.6,142808,DB00683,Midazolam
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],35.2,142809,DB00683,Midazolam
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],36.4,142810,DB00683,Midazolam
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],29.4,142811,DB00683,Midazolam
,7270857,halflife,The fast distribution phase (alpha-phase) lasted about 30 to 45 min with a mean halflife of about 8-9 min.,[Pharmacokinetics of midazolam in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),min,8-9,144518,DB00683,Midazolam
,7270857,half-life,The half-life of the slow redistribution and elimination phase (beta-phase) amounted to a mean of about 150 min.,[Pharmacokinetics of midazolam in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),min,150,144519,DB00683,Midazolam
,7270857,apparent volume of distribution of the cental compartment (V1),"The apparent volume of distribution of the cental compartment (V1) was calculated as 24.11 and the volume of distribution at steady state as 84.21 (Vd, ss).",[Pharmacokinetics of midazolam in man (author's transl)]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),,24.11,144520,DB00683,Midazolam
,7270857,volume of distribution at steady state,"The apparent volume of distribution of the cental compartment (V1) was calculated as 24.11 and the volume of distribution at steady state as 84.21 (Vd, ss).",[Pharmacokinetics of midazolam in man (author's transl)]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),,84.21,144521,DB00683,Midazolam
,7270857,"Vd, ss","The apparent volume of distribution of the cental compartment (V1) was calculated as 24.11 and the volume of distribution at steady state as 84.21 (Vd, ss).",[Pharmacokinetics of midazolam in man (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),,84.21,144522,DB00683,Midazolam
,7270857,volume of distribution in the beta-phase (Vd beta),The volume of distribution in the beta-phase (Vd beta) ranged from 71.5 to 129.51 with a mean of 104.21.,[Pharmacokinetics of midazolam in man (author's transl)]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),,104.21,144523,DB00683,Midazolam
,7270857,total plasma clearance,The total plasma clearance varied from 380 to 527 ml/min with a mean of 472 ml/min.,[Pharmacokinetics of midazolam in man (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7270857/),[ml] / [min],472,144524,DB00683,Midazolam
,17410605,recoveries,"The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid.",Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410605/),%,90.6,145516,DB00683,Midazolam
,17410605,recoveries,"The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid.",Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410605/),%,86.7,145517,DB00683,Midazolam
,17410605,recoveries,"The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid.",Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410605/),%,79.0,145518,DB00683,Midazolam
,17410605,recoveries,"The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid.",Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410605/),%,95.3,145519,DB00683,Midazolam
,17410605,recoveries,"The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid.",Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410605/),%,96.6,145520,DB00683,Midazolam
,17410605,recoveries,"The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid.",Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410605/),%,86.8,145521,DB00683,Midazolam
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.39,146728,DB00683,Midazolam
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,6.46,146729,DB00683,Midazolam
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.64,146730,DB00683,Midazolam
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],1.12,146731,DB00683,Midazolam
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.07,146732,DB00683,Midazolam
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,6.46,146733,DB00683,Midazolam
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],1.12,146734,DB00683,Midazolam
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,5.89,146735,DB00683,Midazolam
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.07,146736,DB00683,Midazolam
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,7.93,146737,DB00683,Midazolam
,14744949,unbound fraction,"The in vitro unbound fraction was 0.84 for S-verapamil, 0.68 for R-verapamil, and 0.84 for (+/-)-norverapamil.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.84,146738,DB00683,Midazolam
,14744949,unbound fraction,"The in vitro unbound fraction was 0.84 for S-verapamil, 0.68 for R-verapamil, and 0.84 for (+/-)-norverapamil.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.68,146739,DB00683,Midazolam
,14744949,fm,A mechanism-based pharmacokinetic model predicted that the oral area under the curve (AUC) of a CYP3A substrate that is eliminated completely (fm=1) by the hepatic CYP3A increased 1.6- to 2.2-fold after repeated oral administration of verapamil.,Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,1,146740,DB00683,Midazolam
,14744949,fm,"For midazolam (fm=0.9), a drug that undergoes extensive intestinal wall metabolism, the predicted increase in oral AUC was 3.2- to 4.5-fold.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.9,146741,DB00683,Midazolam
,20481651,volume of distribution,"Following the start of ECMO, the volume of distribution of midazolam increased from 4.29 to 14.6 L/3 kg, with an elimination half-life of 1.85 hours.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),[l] / [3·kg],4,147355,DB00683,Midazolam
,20481651,volume of distribution,"Following the start of ECMO, the volume of distribution of midazolam increased from 4.29 to 14.6 L/3 kg, with an elimination half-life of 1.85 hours.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),[l] / [3·kg],14,147356,DB00683,Midazolam
,20481651,elimination half-life,"Following the start of ECMO, the volume of distribution of midazolam increased from 4.29 to 14.6 L/3 kg, with an elimination half-life of 1.85 hours.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),h,1.85,147357,DB00683,Midazolam
,20481651,clearance,"The median midazolam and 1-hydroxymidazolam clearance values increased 3-fold within the first 5 days (up to 1.38 and 5.31 L/h/3 kg, respectively), whereas hydroxymidazolam glucuronide clearance remained constant at 0.18 L/h/3 kg.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),[l] / [3·h·kg],1.38,147358,DB00683,Midazolam
,20481651,clearance,"The median midazolam and 1-hydroxymidazolam clearance values increased 3-fold within the first 5 days (up to 1.38 and 5.31 L/h/3 kg, respectively), whereas hydroxymidazolam glucuronide clearance remained constant at 0.18 L/h/3 kg.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),[l] / [3·h·kg],5.31,147359,DB00683,Midazolam
,20481651,g,"The median midazolam and 1-hydroxymidazolam clearance values increased 3-fold within the first 5 days (up to 1.38 and 5.31 L/h/3 kg, respectively), whereas hydroxymidazolam glucuronide clearance remained constant at 0.18 L/h/3 kg.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),[l] / [3·h·kg],0.18,147360,DB00683,Midazolam
,20481651,clearance,"The median midazolam and 1-hydroxymidazolam clearance values increased 3-fold within the first 5 days (up to 1.38 and 5.31 L/h/3 kg, respectively), whereas hydroxymidazolam glucuronide clearance remained constant at 0.18 L/h/3 kg.",Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20481651/),[l] / [3·h·kg],0.18,147361,DB00683,Midazolam
,21497708,AUC(0-∞),"Differences in the mean AUC(0-∞) were 12.7 (4.4) and 14.2 (6.6) ng/mL/h in pomegranate juice and control groups, respectively (geometric mean ratio: 1.02 [95% CI, 0.95-1.09]; P = 0.40).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [h·ml],12.7,147494,DB00683,Midazolam
,21497708,AUC(0-∞),"Differences in the mean AUC(0-∞) were 12.7 (4.4) and 14.2 (6.6) ng/mL/h in pomegranate juice and control groups, respectively (geometric mean ratio: 1.02 [95% CI, 0.95-1.09]; P = 0.40).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [h·ml],14.2,147495,DB00683,Midazolam
,21497708,C(max),"Differences in C(max) for midazolam did not reach the level of statistical significance (5.1 [1.7] vs 5.0 [2.0] ng/mL, geometric mean ratio: 0.95 [95% CI, 0.79-1.11]; P = 0.68).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [ml],5.1,147496,DB00683,Midazolam
,21497708,C(max),"Differences in C(max) for midazolam did not reach the level of statistical significance (5.1 [1.7] vs 5.0 [2.0] ng/mL, geometric mean ratio: 0.95 [95% CI, 0.79-1.11]; P = 0.68).","Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21497708/),[ng] / [ml],5.0,147497,DB00683,Midazolam
,17635500,clearances,36.0 l h(-1)) and p.o. (119 vs. 124 l h(-1)) clearances of midazolam.,Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],36.0,147933,DB00683,Midazolam
,17635500,clearances,36.0 l h(-1)) and p.o. (119 vs. 124 l h(-1)) clearances of midazolam.,Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],119,147934,DB00683,Midazolam
,17635500,clearances,36.0 l h(-1)) and p.o. (119 vs. 124 l h(-1)) clearances of midazolam.,Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],124,147935,DB00683,Midazolam
,17635500,intestinal availability,"Midazolam hepatic availability was significantly (P = 0.006) greater in men [0.79, 95% confidence interval (CI) 0.75, 0.84] than in women (0.66, 95% CI 0.59, 0.73), but midazolam intestinal availability (0.39 vs. 0.55) was not different.",Interaction between midazolam and clarithromycin in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),,0.39,147936,DB00683,Midazolam
,17635500,intestinal availability,"Midazolam hepatic availability was significantly (P = 0.006) greater in men [0.79, 95% confidence interval (CI) 0.75, 0.84] than in women (0.66, 95% CI 0.59, 0.73), but midazolam intestinal availability (0.39 vs. 0.55) was not different.",Interaction between midazolam and clarithromycin in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),,0.55,147937,DB00683,Midazolam
,17635500,systemic,"Following clarithromycin dosing, a significant decrease in systemic (33.2 l h(-1) to 11.5 l h(-1)) and oral (121 l h(-1) to 17.4 l h(-1)) midazolam clearance occurred.",Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],33.2,147938,DB00683,Midazolam
,17635500,systemic,"Following clarithromycin dosing, a significant decrease in systemic (33.2 l h(-1) to 11.5 l h(-1)) and oral (121 l h(-1) to 17.4 l h(-1)) midazolam clearance occurred.",Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],11.5,147939,DB00683,Midazolam
,17635500,systemic,"Following clarithromycin dosing, a significant decrease in systemic (33.2 l h(-1) to 11.5 l h(-1)) and oral (121 l h(-1) to 17.4 l h(-1)) midazolam clearance occurred.",Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],121,147940,DB00683,Midazolam
,17635500,systemic,"Following clarithromycin dosing, a significant decrease in systemic (33.2 l h(-1) to 11.5 l h(-1)) and oral (121 l h(-1) to 17.4 l h(-1)) midazolam clearance occurred.",Interaction between midazolam and clarithromycin in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635500/),[l] / [h],17.4,147941,DB00683,Midazolam
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,3.9,149435,DB00683,Midazolam
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,1.2,149436,DB00683,Midazolam
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,107,149437,DB00683,Midazolam
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,31,149438,DB00683,Midazolam
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],20,149439,DB00683,Midazolam
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],18,149440,DB00683,Midazolam
,11549100,elimination half-life,The elimination half-life of midazolam ranged from 7.6 to 22.8 hours.,Midazolam disposition in patients undergoing continuous venovenous hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549100/),h,7.6 to 22.8,149545,DB00683,Midazolam
,11549100,clearance of ultrafiltration,The clearance of ultrafiltration was between 0.13 and 4.7 ml/min and reached approximately 11% of the total clearance.,Midazolam disposition in patients undergoing continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549100/),[ml] / [min],0.13 and 4.7,149546,DB00683,Midazolam
,11549100,sieving coefficient,"The range of sieving coefficient was from 0.006 to 0.26, with an average fraction removal of 0.2%.",Midazolam disposition in patients undergoing continuous venovenous hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549100/),,0.006 to 0.26,149547,DB00683,Midazolam
,11549100,fraction removal,"The range of sieving coefficient was from 0.006 to 0.26, with an average fraction removal of 0.2%.",Midazolam disposition in patients undergoing continuous venovenous hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549100/),%,0.2,149548,DB00683,Midazolam
,11549100,clearance of ultrafiltration,"1-Hydroxy-midazolam glucuronide was removed by continuous hemodialysis (sieving 0.36 to 0.63), with a clearance of ultrafiltration ranging from 7.8 to 12.0 ml/min.",Midazolam disposition in patients undergoing continuous venovenous hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549100/),[ml] / [min],7.8 to 12.0,149549,DB00683,Midazolam
,20466872,t(max),"The midazolam doses studied exhibited a median t(max) of 0.5 hours with a geometric mean terminal elimination half-life value of 4.1 hours (range, 2.9-4.5 hours).",Human safety and pharmacokinetic study of intramuscular midazolam administered by autoinjector. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20466872/),h,0.5,149923,DB00683,Midazolam
,20466872,terminal elimination half-life,"The midazolam doses studied exhibited a median t(max) of 0.5 hours with a geometric mean terminal elimination half-life value of 4.1 hours (range, 2.9-4.5 hours).",Human safety and pharmacokinetic study of intramuscular midazolam administered by autoinjector. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20466872/),h,4.1,149924,DB00683,Midazolam
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,5.59,150101,DB00683,Midazolam
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,1.34,150102,DB00683,Midazolam
,29038231,AUCR,"The AUCR static model estimations for clofazimine with the substrates midazolam, repaglinide, and desipramine were 5.59, 1.34, and 1.69, respectively.",Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29038231/),,1.69,150103,DB00683,Midazolam
,31626965,clearance,"For a typical subject, scaled to the adult body weight of 70 kg, population pharmacokinetic values were estimated at 8.52 L/h for clearance (when maturation function was 1), 25.5 L/h for intercompartmental clearance, and 5.71 L and 39.8 L for the volume of the central and peripheral compartment, respectively.",Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31626965/),[l] / [h],8.52,150342,DB00683,Midazolam
,31626965,intercompartmental clearance,"For a typical subject, scaled to the adult body weight of 70 kg, population pharmacokinetic values were estimated at 8.52 L/h for clearance (when maturation function was 1), 25.5 L/h for intercompartmental clearance, and 5.71 L and 39.8 L for the volume of the central and peripheral compartment, respectively.",Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31626965/),[l] / [h],25.5,150343,DB00683,Midazolam
,31626965,volume of the central,"For a typical subject, scaled to the adult body weight of 70 kg, population pharmacokinetic values were estimated at 8.52 L/h for clearance (when maturation function was 1), 25.5 L/h for intercompartmental clearance, and 5.71 L and 39.8 L for the volume of the central and peripheral compartment, respectively.",Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31626965/),l,5.71,150344,DB00683,Midazolam
,31626965,volume of the central,"For a typical subject, scaled to the adult body weight of 70 kg, population pharmacokinetic values were estimated at 8.52 L/h for clearance (when maturation function was 1), 25.5 L/h for intercompartmental clearance, and 5.71 L and 39.8 L for the volume of the central and peripheral compartment, respectively.",Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31626965/),l,39.8,150345,DB00683,Midazolam
,31105561,Ki,In vitro incubations in porcine hepatic microsomes revealed a potent inhibition of the midazolam (CYP3A) biotransformation by T-2 toxin (T-2) (Ki = 27.0 ± 3.97 μM) and zearalenone (ZEA) (Ki = 1.1 ± 0.22 μM).,Impact of Subacute Exposure to T-2 Toxin and Zearalenone on the Pharmacokinetics of Midazolam as CYP3A Probe Drug in a Porcine Animal Model: A Pilot Study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31105561/),μM,27.0,150346,DB00683,Midazolam
,31105561,Ki,In vitro incubations in porcine hepatic microsomes revealed a potent inhibition of the midazolam (CYP3A) biotransformation by T-2 toxin (T-2) (Ki = 27.0 ± 3.97 μM) and zearalenone (ZEA) (Ki = 1.1 ± 0.22 μM).,Impact of Subacute Exposure to T-2 Toxin and Zearalenone on the Pharmacokinetics of Midazolam as CYP3A Probe Drug in a Porcine Animal Model: A Pilot Study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31105561/),μM,1.1,150347,DB00683,Midazolam
,24607696,recoveries,Mean recoveries of bicuculline in plasma were in the range of 80.5-91.8%.,Determination of bicuculline in rat plasma by liquid chromatography mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607696/),%,80.5-91.8,150481,DB00683,Midazolam
,17122576,total clearance,"For midazolam, total clearance was 0.157 l/min, central volume was 3.8 l, peripheral volume was 30.2 l, and intercompartmental clearance was 0.30 l/min.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),[l] / [min],0.157,150656,DB00683,Midazolam
,17122576,central volume,"For midazolam, total clearance was 0.157 l/min, central volume was 3.8 l, peripheral volume was 30.2 l, and intercompartmental clearance was 0.30 l/min.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),l,3.8,150657,DB00683,Midazolam
,17122576,peripheral volume,"For midazolam, total clearance was 0.157 l/min, central volume was 3.8 l, peripheral volume was 30.2 l, and intercompartmental clearance was 0.30 l/min.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),l,30.2,150658,DB00683,Midazolam
,17122576,intercompartmental clearance,"For midazolam, total clearance was 0.157 l/min, central volume was 3.8 l, peripheral volume was 30.2 l, and intercompartmental clearance was 0.30 l/min.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),[l] / [min],0.30,150659,DB00683,Midazolam
,17122576,volume of distribution,"Assuming 60% conversion of midazolam to 1-OH-midazolam, the volume of distribution for 1-OH-midazolam and 1-OH-midazolamglucuronide was 6.7 and 1.7 l, and clearance was 0.21 and 0.047 l/min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),l,6.7,150660,DB00683,Midazolam
,17122576,volume of distribution,"Assuming 60% conversion of midazolam to 1-OH-midazolam, the volume of distribution for 1-OH-midazolam and 1-OH-midazolamglucuronide was 6.7 and 1.7 l, and clearance was 0.21 and 0.047 l/min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),l,1.7,150661,DB00683,Midazolam
,17122576,clearance,"Assuming 60% conversion of midazolam to 1-OH-midazolam, the volume of distribution for 1-OH-midazolam and 1-OH-midazolamglucuronide was 6.7 and 1.7 l, and clearance was 0.21 and 0.047 l/min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),[l] / [min],0.21,150662,DB00683,Midazolam
,17122576,clearance,"Assuming 60% conversion of midazolam to 1-OH-midazolam, the volume of distribution for 1-OH-midazolam and 1-OH-midazolamglucuronide was 6.7 and 1.7 l, and clearance was 0.21 and 0.047 l/min, respectively.",Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),[l] / [min],0.047,150663,DB00683,Midazolam
,17122576,concentration at half maximum effect,The midazolam concentration at half maximum effect was 0.58 mum with a high interindividual variability of 89%.,Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17122576/),mum,0.58,150664,DB00683,Midazolam
,10579473,Total bioavailability,Total bioavailability increased from 25% to 80% (P < .001).,Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579473/),%,25,150793,DB00683,Midazolam
,10579473,Total bioavailability,Total bioavailability increased from 25% to 80% (P < .001).,Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579473/),%,80,150794,DB00683,Midazolam
,21753749,Systemic,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],269,152160,DB00683,Midazolam
,21753749,Systemic,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],354,152161,DB00683,Midazolam
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],354,152162,DB00683,Midazolam
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],31,152163,DB00683,Midazolam
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],479,152164,DB00683,Midazolam
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],688,152165,DB00683,Midazolam
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.1,152189,DB00683,Midazolam
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.8,152190,DB00683,Midazolam
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],507.8,152191,DB00683,Midazolam
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],392.2,152192,DB00683,Midazolam
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],285.4,152193,DB00683,Midazolam
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],435.6,152194,DB00683,Midazolam
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],338.8,152195,DB00683,Midazolam
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],462.7,152196,DB00683,Midazolam
,31051051,CL,"Typical midazolam CL and F estimates were 32.9 L/h and 0.31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14.2 and 85.3.","Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051051/),[l] / [h],32.9,152473,DB00683,Midazolam
,31051051,F,"Typical midazolam CL and F estimates were 32.9 L/h and 0.31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14.2 and 85.3.","Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051051/),,0.31,152474,DB00683,Midazolam
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],195.0,154011,DB00683,Midazolam
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],174.8,154012,DB00683,Midazolam
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.1,154013,DB00683,Midazolam
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.7,154014,DB00683,Midazolam
,11312475,CPB time,"CPB time was 116 +/- 10 minutes, and ischemic time was 81 +/- 6 minutes.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),min,116,154299,DB00683,Midazolam
,11312475,ischemic time,"CPB time was 116 +/- 10 minutes, and ischemic time was 81 +/- 6 minutes.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),min,81,154300,DB00683,Midazolam
,11312475,pump flow,"Mean pump flow was 4.49 +/- 0.03 L/min, and mean arterial pressure was 70.1 +/- 1 mmHg during the study period.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),[l] / [min],4.49,154301,DB00683,Midazolam
>,24186263,AUC ratio,The static model predicted in vivo interaction with predicted AUC ratio values of >1.1 for all CYP (except CYP3A4).,"Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24186263/),,1.1,154701,DB00683,Midazolam
,1422570,clearance,"In the 4-month-old rats the values of the clearance, volume of distribution and elimination half-life were 104 +/- 13 ml min-1 kg-1 (mean +/- s.e. mean), 3.4 +/- 0.7 l kg-1 and 30 +/- 3 min, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),[ml] / [kg·min],104,154729,DB00683,Midazolam
,1422570,volume of distribution,"In the 4-month-old rats the values of the clearance, volume of distribution and elimination half-life were 104 +/- 13 ml min-1 kg-1 (mean +/- s.e. mean), 3.4 +/- 0.7 l kg-1 and 30 +/- 3 min, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),[l] / [kg],3.4,154730,DB00683,Midazolam
,1422570,elimination half-life,"In the 4-month-old rats the values of the clearance, volume of distribution and elimination half-life were 104 +/- 13 ml min-1 kg-1 (mean +/- s.e. mean), 3.4 +/- 0.7 l kg-1 and 30 +/- 3 min, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),min,30,154731,DB00683,Midazolam
,1422570,relative maximum effect,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/- 6 micrograms l-1 and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),%,106,154732,DB00683,Midazolam
,1422570,midazola,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/- 6 micrograms l-1 and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),%,106,154733,DB00683,Midazolam
,1422570,midazola,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/- 6 micrograms l-1 and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),[μg] / [l],50,154734,DB00683,Midazolam
,1422570,concentration at half maximum effect,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/- 6 micrograms l-1 and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),[μg] / [l],50,154735,DB00683,Midazolam
,1422570,Hill factor,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/- 6 micrograms l-1 and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),,1.6,154736,DB00683,Midazolam
,1422570,relative maximum effect,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/-6 lg 1' and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),%,106,154737,DB00683,Midazolam
,1422570,midazola,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/-6 lg 1' and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),%,106,154738,DB00683,Midazolam
,1422570,concentration at half maximum effect,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/-6 lg 1' and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),1'·lg,50,154739,DB00683,Midazolam
,1422570,Hill factor,"In the 4-month-old rats the values of the parameters relative maximum effect, midazolam concentration at half maximum effect and Hill factor were 106 +/- 10%, 50 +/-6 lg 1' and 1.6 +/- 0.3, respectively.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),,1.6,154740,DB00683,Midazolam
,1422570,concentration at half maximum effect,"However, when diseased animals were excluded from the evaluation, a tendency towards a decrease in the midazolam concentration at half maximum effect to 25 +/- 14 pg 1-1 was observed in the 36-month-old rats.5.",Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1422570/),pg,25,154741,DB00683,Midazolam
,7965755,clearance,The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 +/- 0.24 versus 0.59 +/- 0.25 liter/min).,Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965755/),[l] / [min],0.60,154888,DB00683,Midazolam
,7965755,clearance,The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 +/- 0.24 versus 0.59 +/- 0.25 liter/min).,Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965755/),[l] / [min],0.59,154889,DB00683,Midazolam
,21437702,AUC,Thirty-four patients with advanced ovarian and primary peritoneal cancer were administered docetaxel at 75 mg/m(2) as a 1-h infusion in combination with carboplatin IV over 30 min at a target AUC of 5 mg/ml min.,Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21437702/),[mg] / [min·ml],5,154962,DB00683,Midazolam
,16416302,k (inact),All five macrolides inactivated testosterone 6beta-hydroxylation by HLM and recombinant CYP3A4 with k (inact) values in the range of 0.023 to 0.058 min(-1).,Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416302/),1/[min],0.023 to 0.058,155592,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],116.95,156601,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],201.23,156602,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],8.01,156603,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],18.87,156604,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],485.16,156605,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],843.88,156606,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],2.67,156607,DB00683,Midazolam
,31852530,steady-state plasma concentrations (Css),"Postmenopausal status increased steady-state plasma concentrations (Css) of tamoxifen (116.95 vs 201.23 ng/mL), endoxifen (8.01 vs 18.87 ng/mL), N-desmethyltamoxifen (485.16 vs 843.88 ng/mL) and 4-hydroxytamoxifen (2.67 vs 4.11 ng/mL).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),[ng] / [ml],4.11,156608,DB00683,Midazolam
,31852530,Css,"The final regression models included hormonal status as the only predictor for Css of tamoxifen [β-coef ± SE, p-value (75.03 ± 17.71, p = 0.0001)] and 4-hydroxytamoxifen (1.7822 ± 0.4385, p = 0.0002), while endoxifen Css included hormonal status (8.578 ± 3.402, p = 0.02) and race (11.945 ± 2.836, p = 0.007).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),,8.578,156609,DB00683,Midazolam
,31852530,Css,"The final regression models included hormonal status as the only predictor for Css of tamoxifen [β-coef ± SE, p-value (75.03 ± 17.71, p = 0.0001)] and 4-hydroxytamoxifen (1.7822 ± 0.4385, p = 0.0002), while endoxifen Css included hormonal status (8.578 ± 3.402, p = 0.02) and race (11.945 ± 2.836, p = 0.007).",Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31852530/),,11.945,156610,DB00683,Midazolam
,23765407,MR effect ratio,"The effect was more pronounced in null-responders, who demonstrated a mean MR effect ratio of 0.46 (90 % CI 0.39-0.53) compared to volunteers.",Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23765407/),,0.46,156703,DB00683,Midazolam
,23765407,area under the concentration-time curve (AUCinf),"The mean area under the concentration-time curve (AUCinf) for midazolam in healthy volunteers, naïve patients, and null-responders was 32.3 [coefficient of variation (CV%) 41], 36.5 (CV% 33.5), and 55.3 (CV% 36.9) ng.h/mL, respectively.",Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23765407/),[h·ng] / [ml],32.3,156704,DB00683,Midazolam
,23765407,area under the concentration-time curve (AUCinf),"The mean area under the concentration-time curve (AUCinf) for midazolam in healthy volunteers, naïve patients, and null-responders was 32.3 [coefficient of variation (CV%) 41], 36.5 (CV% 33.5), and 55.3 (CV% 36.9) ng.h/mL, respectively.",Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23765407/),[h·ng] / [ml],36.5,156705,DB00683,Midazolam
,23765407,area under the concentration-time curve (AUCinf),"The mean area under the concentration-time curve (AUCinf) for midazolam in healthy volunteers, naïve patients, and null-responders was 32.3 [coefficient of variation (CV%) 41], 36.5 (CV% 33.5), and 55.3 (CV% 36.9) ng.h/mL, respectively.",Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23765407/),[h·ng] / [ml],55.3,156706,DB00683,Midazolam
,2097906,peak absorption,"The mean peak absorption was reached at 10 minutes by the SM route (80.4 ng/ml) and at 20 minutes (92.0 ng/ml) by the IM route, with considerable individual variability.",Absorption and elimination of midazolam by submucosal and intramuscular routes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097906/),[ng] / [ml],80.4,157911,DB00683,Midazolam
,2097906,peak absorption,"The mean peak absorption was reached at 10 minutes by the SM route (80.4 ng/ml) and at 20 minutes (92.0 ng/ml) by the IM route, with considerable individual variability.",Absorption and elimination of midazolam by submucosal and intramuscular routes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097906/),[ng] / [ml],92.0,157912,DB00683,Midazolam
,32959922,Tmax,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,1.5,158149,DB00683,Midazolam
,32959922,Tmax,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,1,158150,DB00683,Midazolam
,32959922,terminal elimination half-life,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,10.6,158151,DB00683,Midazolam
,32959922,terminal elimination half-life,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,10.8,158152,DB00683,Midazolam
,28577272,bioavailability,ADV6209 had a bioavailability of 39.6%.,A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577272/),%,39.6,158205,DB00683,Midazolam
,28577272,oral elimination half-life,The oral elimination half-life with ADV6209 was slightly shorter than with the reference i.v. form (2.66 h versus 2.99 h).,A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577272/),h,2.66,158206,DB00683,Midazolam
,28577272,oral elimination half-life,The oral elimination half-life with ADV6209 was slightly shorter than with the reference i.v. form (2.66 h versus 2.99 h).,A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577272/),h,2.99,158207,DB00683,Midazolam
,32558923,turnover half-life,"Based on the recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours.","Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558923/),h,53,159396,DB00683,Midazolam
,33340279,IC50,PC945 only inhibited CYP3A4/5 substrate metabolism (IC50 : 1.33 µM [testosterone] and 0.085 µM [midazolam]).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),μM,1.33,159670,DB00683,Midazolam
,33340279,IC50,PC945 only inhibited CYP3A4/5 substrate metabolism (IC50 : 1.33 µM [testosterone] and 0.085 µM [midazolam]).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),μM,0.085,159671,DB00683,Midazolam
,33340279,Cmax,Geometric mean Cmax was 322 pg/mL (healthy subjects) and 335 pg/mL (subjects with mild asthma) 4-5 hours (median tmax ) after a single inhalation (5 mg).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),[pg] / [ml],322,159672,DB00683,Midazolam
,33340279,Cmax,Geometric mean Cmax was 322 pg/mL (healthy subjects) and 335 pg/mL (subjects with mild asthma) 4-5 hours (median tmax ) after a single inhalation (5 mg).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),[pg] / [ml],335,159673,DB00683,Midazolam
,33340279,tmax,Geometric mean Cmax was 322 pg/mL (healthy subjects) and 335 pg/mL (subjects with mild asthma) 4-5 hours (median tmax ) after a single inhalation (5 mg).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),h,4-5,159674,DB00683,Midazolam
,33340279,Cmax,"Following repeat, once daily inhalation (5 mg), Day 7 Cmax was 951 pg/mL (0.0016 µM) 45 minutes after dosing.","Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),[pg] / [ml],951,159675,DB00683,Midazolam
,6734699,elimination half-life,"After intravenous dosing, the mean (+/- SD) elimination half-life (2.14 +/- 1.24 h) showed a statistically significant trend to increase with age in the subjects older than 60 years.",Pharmacokinetics of midazolam in the aged. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),h,2.14,160585,DB00683,Midazolam
,6734699,clearance,"While the mean (+/- SD) clearance value (0.30 +/- 0.19 l kg-1h-1) tended to fall with age in the elderly subjects, this trend was not statistically significant.",Pharmacokinetics of midazolam in the aged. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),[l] / [kg],0.30,160586,DB00683,Midazolam
,6734699,Apparent volume of distribution,"Apparent volume of distribution did not appear to be related to advancing age beyond 60 years, and this parameter (mean +/- SD) did not differ to a statistically significant extent between the aged subjects (0.77 +/- 0.47 l kg-1) and the young subjects studied previously (1.09 +/- 0.58 l kg-1).",Pharmacokinetics of midazolam in the aged. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),[l] / [kg],0.77,160587,DB00683,Midazolam
,6734699,Apparent volume of distribution,"Apparent volume of distribution did not appear to be related to advancing age beyond 60 years, and this parameter (mean +/- SD) did not differ to a statistically significant extent between the aged subjects (0.77 +/- 0.47 l kg-1) and the young subjects studied previously (1.09 +/- 0.58 l kg-1).",Pharmacokinetics of midazolam in the aged. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),[l] / [kg],1.09,160588,DB00683,Midazolam
,6734699,F,"Bioavailability appeared incomplete (F = 0.59 +/- 0.15, mean +/- SD), possibly due to saturable elimination of the drug at the higher plasma levels which were obtained after intravenous midazolam.",Pharmacokinetics of midazolam in the aged. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),,0.59,160589,DB00683,Midazolam
,6734699,Oral bioavailability,"Oral bioavailability, relative to intravenous, was 0.34 +/- 0.17, (mean +/- SD), with an appreciable but variable lag time (0.74 +/- 0.40 h, mean +/- SD).",Pharmacokinetics of midazolam in the aged. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),,0.34,160590,DB00683,Midazolam
,6734699,lag time,"Oral bioavailability, relative to intravenous, was 0.34 +/- 0.17, (mean +/- SD), with an appreciable but variable lag time (0.74 +/- 0.40 h, mean +/- SD).",Pharmacokinetics of midazolam in the aged. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734699/),h,0.74,160591,DB00683,Midazolam
,32403162,clearance,"For midazolam, in a one-compartment model, bodyweight was a significant predictor for clearance (0.98 L/hour) and volume of distribution (8.7 L) (values for a typical individual of 5 kg).",The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403162/),[l] / [h],0.98,161016,DB00683,Midazolam
,32403162,volume of distribution,"For midazolam, in a one-compartment model, bodyweight was a significant predictor for clearance (0.98 L/hour) and volume of distribution (8.7 L) (values for a typical individual of 5 kg).",The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403162/),l,8.7,161017,DB00683,Midazolam
,32403162,oral bioavailability,The typical oral bioavailability in the population was 66% (range 25-85%).,The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403162/),%,66,161018,DB00683,Midazolam
lower,32403162,oral bioavailability,"The oral bioavailability of midazolam, largely reflective of intestinal and hepatic CYP3A activity, was on average lower than the reported 49-92% for preterm neonates, and higher than the reported 21% for children> 1 year of age and 30% for adults.",The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403162/),%,49-92,161019,DB00683,Midazolam
,32403162,oral bioavailability,"The oral bioavailability of midazolam, largely reflective of intestinal and hepatic CYP3A activity, was on average lower than the reported 49-92% for preterm neonates, and higher than the reported 21% for children> 1 year of age and 30% for adults.",The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403162/),%,21,161020,DB00683,Midazolam
,32403162,oral bioavailability,"The oral bioavailability of midazolam, largely reflective of intestinal and hepatic CYP3A activity, was on average lower than the reported 49-92% for preterm neonates, and higher than the reported 21% for children> 1 year of age and 30% for adults.",The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403162/),%,30,161021,DB00683,Midazolam
,10519446,AUC0-infinity,"In patients taking glucocorticoid, the AUC0-infinity and CL of MDZ was decreased to 63.9% (16.3 +/- 10.5 vs 25.5 +/- 20.7 microg x min/mL) and increased to 127.5% (16.7 +/- 10.7 vs 13.1 +/- 8.3 mL/min/kg) of that in the control group, respectively.",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[min·μg] / [ml],16.3,161565,DB00683,Midazolam
,10519446,AUC0-infinity,"In patients taking glucocorticoid, the AUC0-infinity and CL of MDZ was decreased to 63.9% (16.3 +/- 10.5 vs 25.5 +/- 20.7 microg x min/mL) and increased to 127.5% (16.7 +/- 10.7 vs 13.1 +/- 8.3 mL/min/kg) of that in the control group, respectively.",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[min·μg] / [ml],25.5,161566,DB00683,Midazolam
,10519446,CL,"In patients taking glucocorticoid, the AUC0-infinity and CL of MDZ was decreased to 63.9% (16.3 +/- 10.5 vs 25.5 +/- 20.7 microg x min/mL) and increased to 127.5% (16.7 +/- 10.7 vs 13.1 +/- 8.3 mL/min/kg) of that in the control group, respectively.",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[min·μg] / [ml],25.5,161567,DB00683,Midazolam
,10519446,CL,"In patients taking glucocorticoid, the AUC0-infinity and CL of MDZ was decreased to 63.9% (16.3 +/- 10.5 vs 25.5 +/- 20.7 microg x min/mL) and increased to 127.5% (16.7 +/- 10.7 vs 13.1 +/- 8.3 mL/min/kg) of that in the control group, respectively.",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[ml] / [kg·min],16.7,161568,DB00683,Midazolam
,10519446,CL,"In patients taking glucocorticoid, the AUC0-infinity and CL of MDZ was decreased to 63.9% (16.3 +/- 10.5 vs 25.5 +/- 20.7 microg x min/mL) and increased to 127.5% (16.7 +/- 10.7 vs 13.1 +/- 8.3 mL/min/kg) of that in the control group, respectively.",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[ml] / [kg·min],13.1,161569,DB00683,Midazolam
,10519446,AUC0-infinity,"In patients taking glucocorticoid, the AUC0-infinity of 1'-hydroxymidazolam (1'-OH MDZ) was 66.7% of that in the control group (7.6 +/- 2.6 vs 11.4 +/- 9.7 microg x min/mL), and the terminal t1/2 of 1'-OH MDZ was significantly (p < 0.01) decreased (1.8 +/- 0.5 vs 3.0 +/- 0.8 hr).",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[min·μg] / [ml],7.6,161570,DB00683,Midazolam
,10519446,AUC0-infinity,"In patients taking glucocorticoid, the AUC0-infinity of 1'-hydroxymidazolam (1'-OH MDZ) was 66.7% of that in the control group (7.6 +/- 2.6 vs 11.4 +/- 9.7 microg x min/mL), and the terminal t1/2 of 1'-OH MDZ was significantly (p < 0.01) decreased (1.8 +/- 0.5 vs 3.0 +/- 0.8 hr).",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),[min·μg] / [ml],11.4,161571,DB00683,Midazolam
,10519446,terminal t1/2,"In patients taking glucocorticoid, the AUC0-infinity of 1'-hydroxymidazolam (1'-OH MDZ) was 66.7% of that in the control group (7.6 +/- 2.6 vs 11.4 +/- 9.7 microg x min/mL), and the terminal t1/2 of 1'-OH MDZ was significantly (p < 0.01) decreased (1.8 +/- 0.5 vs 3.0 +/- 0.8 hr).",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),h,1.8,161572,DB00683,Midazolam
,10519446,terminal t1/2,"In patients taking glucocorticoid, the AUC0-infinity of 1'-hydroxymidazolam (1'-OH MDZ) was 66.7% of that in the control group (7.6 +/- 2.6 vs 11.4 +/- 9.7 microg x min/mL), and the terminal t1/2 of 1'-OH MDZ was significantly (p < 0.01) decreased (1.8 +/- 0.5 vs 3.0 +/- 0.8 hr).",Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),h,3.0,161573,DB00683,Midazolam
,10519446,Accumulative urinary excretion,Accumulative urinary excretion of 1'-OH MDZ glucuronide was increased to 157.6%.,Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519446/),%,157.6,161574,DB00683,Midazolam
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,33-36,161929,DB00683,Midazolam
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,26-30,161930,DB00683,Midazolam
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,100.1,161931,DB00683,Midazolam
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161932,DB00683,Midazolam
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,114.5,161933,DB00683,Midazolam
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161934,DB00683,Midazolam
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,108.8,161935,DB00683,Midazolam
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,164.8,161936,DB00683,Midazolam
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.20,161937,DB00683,Midazolam
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.26,161938,DB00683,Midazolam
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],1.40,161939,DB00683,Midazolam
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],0.93,161940,DB00683,Midazolam
,1577053,plasma clearance,"Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h.",Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577053/),[ml] / [min],3.9,162451,DB00683,Midazolam
,1577053,elimination half-life,"Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h.",Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577053/),h,12.0,162452,DB00683,Midazolam
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00683,Midazolam
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00683,Midazolam
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00683,Midazolam
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00683,Midazolam
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00683,Midazolam
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00683,Midazolam
,20233179,apparent oral clearance,"Clotrimazole decreased the apparent oral clearance of midazolam from 57 +/- 13 l h(-1)[95% confidence interval 48, 66] to 36 +/- 9.8 l h(-1) (95% confidence interval 29, 43) (P= 0.003).",Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233179/),[l] / [h],57,163774,DB00683,Midazolam
,20233179,apparent oral clearance,"Clotrimazole decreased the apparent oral clearance of midazolam from 57 +/- 13 l h(-1)[95% confidence interval 48, 66] to 36 +/- 9.8 l h(-1) (95% confidence interval 29, 43) (P= 0.003).",Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233179/),[l] / [h],36,163775,DB00683,Midazolam
,12433824,"area under plasma concentration curve (AUC, 0-8 h)","The average area under plasma concentration curve (AUC, 0-8 h) of midazolam was 9237 +/- 1050 ng-min/ml (mean +/- S.E.M.) in homozygous CYP3A5*3 (n = 14) subjects and 7934 +/- 768 ng-min/ml in heterozygous CYP3A5*1/*3 (n = 12) subjects, respectively.",Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433824/),[ng-min] / [ml],9237,165945,DB00683,Midazolam
,12433824,"area under plasma concentration curve (AUC, 0-8 h)","The average area under plasma concentration curve (AUC, 0-8 h) of midazolam was 9237 +/- 1050 ng-min/ml (mean +/- S.E.M.) in homozygous CYP3A5*3 (n = 14) subjects and 7934 +/- 768 ng-min/ml in heterozygous CYP3A5*1/*3 (n = 12) subjects, respectively.",Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433824/),[ng-min] / [ml],7934,165946,DB00683,Midazolam
,12433824,AUC (0-8 h),The average AUC (0-8 h) of 1'-hydroxymidazolam was 3748 +/- 427 ng-min/ml in homozygous CYP3A5*3 subjects and 3920 +/- 402 ng-min/ml in heterozygous CYP3A5*1/*3 subjects.,Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433824/),[ng-min] / [ml],3748,165947,DB00683,Midazolam
,12433824,AUC (0-8 h),The average AUC (0-8 h) of 1'-hydroxymidazolam was 3748 +/- 427 ng-min/ml in homozygous CYP3A5*3 subjects and 3920 +/- 402 ng-min/ml in heterozygous CYP3A5*1/*3 subjects.,Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433824/),[ng-min] / [ml],3920,165948,DB00683,Midazolam
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],32,166423,DB00683,Midazolam
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],43,166424,DB00683,Midazolam
,14749695,area under the concentration-time curve,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),μg,127,166425,DB00683,Midazolam
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],137,166426,DB00683,Midazolam
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],146,166427,DB00683,Midazolam
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),%,108,166428,DB00683,Midazolam
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.23,166429,DB00683,Midazolam
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166430,DB00683,Midazolam
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.72,166431,DB00683,Midazolam
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166432,DB00683,Midazolam
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166433,DB00683,Midazolam
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166434,DB00683,Midazolam
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],6.6,166435,DB00683,Midazolam
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],4.9,166436,DB00683,Midazolam
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.81,166437,DB00683,Midazolam
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.72,166438,DB00683,Midazolam
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1289,166439,DB00683,Midazolam
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1281,166440,DB00683,Midazolam
,3505731,elimination half-life,The effects of an ultra-rapidly eliminated hypnotic (midazolam 7.5-15.0 mg; mean elimination half-life approximately 2 h) and a rapidly eliminated hypnotic (brotizolam 0.125-0.25 mg; mean elimination half-life approximately 5 h) were studied on transient insomnia induced by sleeping in a reclining seat.,Transient insomnia and rapidly eliminated hypnotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3505731/),h,2,167325,DB00683,Midazolam
,3505731,elimination half-life,The effects of an ultra-rapidly eliminated hypnotic (midazolam 7.5-15.0 mg; mean elimination half-life approximately 2 h) and a rapidly eliminated hypnotic (brotizolam 0.125-0.25 mg; mean elimination half-life approximately 5 h) were studied on transient insomnia induced by sleeping in a reclining seat.,Transient insomnia and rapidly eliminated hypnotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3505731/),h,5,167326,DB00683,Midazolam
,3505731,elimination half-lives,"Low doses of ultra-rapidly eliminated drugs are indicated for sleep-onset insomnia and for short periods of sleep, while rapidly eliminated hypnotics with elimination half-lives of approximately 5 h have the potential to sustain sleep free of residual effects.",Transient insomnia and rapidly eliminated hypnotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3505731/),h,5,167327,DB00683,Midazolam
,12449497,constant plasma concentrations,Ethanol was administered as a constant rate infusion resulting in constant plasma concentrations of 0.5 g/l.,"Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[g] / [l],0.5,167442,DB00683,Midazolam
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],76,167443,DB00683,Midazolam
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],12,167444,DB00683,Midazolam
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],512,167445,DB00683,Midazolam
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],113,167446,DB00683,Midazolam
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],44,167447,DB00683,Midazolam
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],175,167448,DB00683,Midazolam
,19371318,K(m),"The pathway exhibited atypical kinetics and a substrate inhibitory cooperative binding model was applied to determine K(m) (46 microM, 64 microM), V(max) (445 pmol min(-1) mg(-1), 427 pmol min(-1) mg(-1)) and K(i) (58 microM, 79 microM) in HLM and rUGT1A4, respectively.",In vitro and in vivo glucuronidation of midazolam in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371318/),μM,46,167690,DB00683,Midazolam
,19371318,K(m),"The pathway exhibited atypical kinetics and a substrate inhibitory cooperative binding model was applied to determine K(m) (46 microM, 64 microM), V(max) (445 pmol min(-1) mg(-1), 427 pmol min(-1) mg(-1)) and K(i) (58 microM, 79 microM) in HLM and rUGT1A4, respectively.",In vitro and in vivo glucuronidation of midazolam in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371318/),μM,64,167691,DB00683,Midazolam
,19371318,V(max),"The pathway exhibited atypical kinetics and a substrate inhibitory cooperative binding model was applied to determine K(m) (46 microM, 64 microM), V(max) (445 pmol min(-1) mg(-1), 427 pmol min(-1) mg(-1)) and K(i) (58 microM, 79 microM) in HLM and rUGT1A4, respectively.",In vitro and in vivo glucuronidation of midazolam in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371318/),[pM] / [mg·min],445,167692,DB00683,Midazolam
,19371318,V(max),"The pathway exhibited atypical kinetics and a substrate inhibitory cooperative binding model was applied to determine K(m) (46 microM, 64 microM), V(max) (445 pmol min(-1) mg(-1), 427 pmol min(-1) mg(-1)) and K(i) (58 microM, 79 microM) in HLM and rUGT1A4, respectively.",In vitro and in vivo glucuronidation of midazolam in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371318/),[pM] / [mg·min],427,167693,DB00683,Midazolam
,19371318,K(i),"The pathway exhibited atypical kinetics and a substrate inhibitory cooperative binding model was applied to determine K(m) (46 microM, 64 microM), V(max) (445 pmol min(-1) mg(-1), 427 pmol min(-1) mg(-1)) and K(i) (58 microM, 79 microM) in HLM and rUGT1A4, respectively.",In vitro and in vivo glucuronidation of midazolam in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371318/),μM,58,167694,DB00683,Midazolam
,19371318,K(i),"The pathway exhibited atypical kinetics and a substrate inhibitory cooperative binding model was applied to determine K(m) (46 microM, 64 microM), V(max) (445 pmol min(-1) mg(-1), 427 pmol min(-1) mg(-1)) and K(i) (58 microM, 79 microM) in HLM and rUGT1A4, respectively.",In vitro and in vivo glucuronidation of midazolam in humans. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371318/),μM,79,167695,DB00683,Midazolam
,8477017,plasma clearance,Mean plasma clearance of ketamine was 0.94 +/- 0.22 L/kg/h.,Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477017/),[l] / [h·kg],0.94,167769,DB00683,Midazolam
,8477017,elimination half-life,"The elimination half-life was 3.1 +/- 1.6 hours, but in some children late samples indicated an even longer elimination half-life.",Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477017/),h,3.1,167770,DB00683,Midazolam
,8477017,elimination half-life,The elimination half-life of norketamine was estimated to be 6.0 +/- 1.8 hours.,Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8477017/),h,6.0,167771,DB00683,Midazolam
,28444958,clearance,"Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test).",Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444958/),[l] / [h],3.15,168505,DB00683,Midazolam
,28444958,clearance,"Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test).",Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444958/),[l] / [h],3.93,168506,DB00683,Midazolam
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],4.6,168775,DB00683,Midazolam
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.7,168776,DB00683,Midazolam
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.3,168777,DB00683,Midazolam
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],2.7,168778,DB00683,Midazolam
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],9.5,168779,DB00683,Midazolam
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],13,168780,DB00683,Midazolam
,9384465,volume of distribution (V(SS)),"The volume of distribution (V(SS)) and plasma clearance of Ro 48-6791 were on average markedly larger than those of midazolam (171 +/- 65 vs 41 +/- 10 l and 2.2 +/- 0.9 vs 0.42 +/- 0.11 l min(-1), respectively).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384465/),l,171,169042,DB00683,Midazolam
,9384465,plasma clearance,"The volume of distribution (V(SS)) and plasma clearance of Ro 48-6791 were on average markedly larger than those of midazolam (171 +/- 65 vs 41 +/- 10 l and 2.2 +/- 0.9 vs 0.42 +/- 0.11 l min(-1), respectively).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384465/),l,41,169043,DB00683,Midazolam
,9384465,plasma clearance,"The volume of distribution (V(SS)) and plasma clearance of Ro 48-6791 were on average markedly larger than those of midazolam (171 +/- 65 vs 41 +/- 10 l and 2.2 +/- 0.9 vs 0.42 +/- 0.11 l min(-1), respectively).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384465/),[l] / [min],2.2,169044,DB00683,Midazolam
,9384465,plasma clearance,"The volume of distribution (V(SS)) and plasma clearance of Ro 48-6791 were on average markedly larger than those of midazolam (171 +/- 65 vs 41 +/- 10 l and 2.2 +/- 0.9 vs 0.42 +/- 0.11 l min(-1), respectively).","Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384465/),[l] / [min],0.42,169045,DB00683,Midazolam
,28441044,apparent volume of distribution,"RESULTS Following IV administration, midazolam was rapidly and extensively distributed and rapidly eliminated; mean ± SD apparent volume of distribution, elimination half-life, clearance, and area under the concentration-time curve were 838 ± 330 mL/kg, 0.79 ± 0.44 hours, 1,272 ± 310 mL/h/kg, and 423 ± 143 h·ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),[ml] / [kg],838,169960,DB00683,Midazolam
,28441044,elimination half-life,"RESULTS Following IV administration, midazolam was rapidly and extensively distributed and rapidly eliminated; mean ± SD apparent volume of distribution, elimination half-life, clearance, and area under the concentration-time curve were 838 ± 330 mL/kg, 0.79 ± 0.44 hours, 1,272 ± 310 mL/h/kg, and 423 ± 143 h·ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),h,0.79,169961,DB00683,Midazolam
,28441044,area under the concentration-time curve,"RESULTS Following IV administration, midazolam was rapidly and extensively distributed and rapidly eliminated; mean ± SD apparent volume of distribution, elimination half-life, clearance, and area under the concentration-time curve were 838 ± 330 mL/kg, 0.79 ± 0.44 hours, 1,272 ± 310 mL/h/kg, and 423 ± 143 h·ng/mL, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),[h·ng] / [ml],423,169962,DB00683,Midazolam
,28441044,maximum plasma concentration,"Following IM administration, midazolam was rapidly absorbed and bioavailability was high; mean ± SD maximum plasma concentration, time to maximum plasma concentration, area under the concentration-time curve, and bioavailability were 820 ± 268 ng/mL, 0.46 ± 0.26 hours, 1,396 ± 463 h·ng/mL, and 352 ± 148%, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),[ng] / [ml],820,169963,DB00683,Midazolam
,28441044,time to maximum plasma concentration,"Following IM administration, midazolam was rapidly absorbed and bioavailability was high; mean ± SD maximum plasma concentration, time to maximum plasma concentration, area under the concentration-time curve, and bioavailability were 820 ± 268 ng/mL, 0.46 ± 0.26 hours, 1,396 ± 463 h·ng/mL, and 352 ± 148%, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),h,0.46,169964,DB00683,Midazolam
,28441044,time to maximum plasma concentration,"Following IM administration, midazolam was rapidly absorbed and bioavailability was high; mean ± SD maximum plasma concentration, time to maximum plasma concentration, area under the concentration-time curve, and bioavailability were 820 ± 268 ng/mL, 0.46 ± 0.26 hours, 1,396 ± 463 h·ng/mL, and 352 ± 148%, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),[h·ng] / [ml],"1,396",169965,DB00683,Midazolam
,28441044,area under the concentration-time curve,"Following IM administration, midazolam was rapidly absorbed and bioavailability was high; mean ± SD maximum plasma concentration, time to maximum plasma concentration, area under the concentration-time curve, and bioavailability were 820 ± 268 ng/mL, 0.46 ± 0.26 hours, 1,396 ± 463 h·ng/mL, and 352 ± 148%, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),[h·ng] / [ml],"1,396",169966,DB00683,Midazolam
,28441044,bioavailability,"Following IM administration, midazolam was rapidly absorbed and bioavailability was high; mean ± SD maximum plasma concentration, time to maximum plasma concentration, area under the concentration-time curve, and bioavailability were 820 ± 268 ng/mL, 0.46 ± 0.26 hours, 1,396 ± 463 h·ng/mL, and 352 ± 148%, respectively.",Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28441044/),%,352,169967,DB00683,Midazolam
,12496748,CL,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),,2,170285,DB00683,Midazolam
,12496748,CL,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[l] / [min],2.1,170286,DB00683,Midazolam
,12496748,volume of central compartment,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),l,22.2,170287,DB00683,Midazolam
,12496748,CL (distribution),"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[l] / [min],1.5,170288,DB00683,Midazolam
,12496748,volume of peripheral compartment,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),l,168,170289,DB00683,Midazolam
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.13,170290,DB00683,Midazolam
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.31,170291,DB00683,Midazolam
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.56,170292,DB00683,Midazolam
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.79,170293,DB00683,Midazolam
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],1.78,170294,DB00683,Midazolam
<,20444025,IC(50),"Using a panel of individually expressed canine cytochromes P450 cloned from beagle liver, this report demonstrates that medetomidine is an extremely potent CYP2B11 inhibitor (IC(50) < 10 nm) and that ketamine and midazolam are CYP2B11 substrates with high intrinsic clearances.",Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444025/),nm,10,170559,DB00683,Midazolam
,10412885,absolute bioavailability,The absolute bioavailability was close to 100%.,Pharmacokinetics of midazolam: comparison of sublingual and intravenous routes in rabbit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10412885/),%,100,170910,DB00683,Midazolam
,3605671,elimination half-life,"The elimination half-life varied from 0.79 to 2.83 hr, which is shorter than in adult patients.",Midazolam as an induction agent in children: a pharmacokinetic and clinical study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605671/),h,0.79 to 2.83,171083,DB00683,Midazolam
,8320806,elimination half-life,The elimination half-life of midazolam was about 3 times longer in hepatectomy group (24.2 hours) than in the group without liver injury (8.4 hours).,[Pharmacokinetics of midazolam in patients with liver damage for hepatectomy]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8320806/),h,24.2,171273,DB00683,Midazolam
,8320806,elimination half-life,The elimination half-life of midazolam was about 3 times longer in hepatectomy group (24.2 hours) than in the group without liver injury (8.4 hours).,[Pharmacokinetics of midazolam in patients with liver damage for hepatectomy]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8320806/),h,8.4,171274,DB00683,Midazolam
,19372331,constant C(t),"During Session B, in addition to this propofol infusion scheme, a target-controlled infusion of midazolam (constant C(t): 125 ng/mL) was given from 15 min before the start until 6 h after termination of the propofol infusion.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[ng] / [ml],125,173648,DB00683,Midazolam
,19372331,C(blood),"In the presence of midazolam (C(blood): 224.8 +/- 41.6 ng/mL), the blood propofol concentration increased by 25.1% +/- 13.3% compared with when propofol was given as single drug.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[ng] / [ml],224.8,173649,DB00683,Midazolam
,19372331,C(blood),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[ng] / [ml],225,173650,DB00683,Midazolam
,19372331,Cl(1),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[l] / [min],1.94 to 1.61,173651,DB00683,Midazolam
,19372331,Cl(2),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[l] / [min],2.86 to 1.52,173652,DB00683,Midazolam
,19372331,Cl(3),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[l] / [min],0.95 to 0.73,173653,DB00683,Midazolam
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,1.4,173884,DB00683,Midazolam
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,53,173885,DB00683,Midazolam
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,34.3,173886,DB00683,Midazolam
,11434513,urinary recovery,Median urinary recovery of the i.v. midazolam dose varied between 1.4% and 53% and was significantly lower in samples collected while patients were receiving fluvoxamine (34.3% versus 23.1%; P= 0.0004).,Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11434513/),%,23.1,173887,DB00683,Midazolam
,7582388,concentration peak time,Azithromycin treatment increased the median (range) concentration peak time of midazolam from 1.0 (0.5-2) h to 1.25 (0.5-5) h and decreased plasma concentrations of midazolam during initial 3 hours after the intake of midazolam (p < 0.05).,Azithromycin does not increase plasma concentrations of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582388/),h,1.0,174403,DB00683,Midazolam
,7582388,concentration peak time,Azithromycin treatment increased the median (range) concentration peak time of midazolam from 1.0 (0.5-2) h to 1.25 (0.5-5) h and decreased plasma concentrations of midazolam during initial 3 hours after the intake of midazolam (p < 0.05).,Azithromycin does not increase plasma concentrations of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582388/),h,1.25,174404,DB00683,Midazolam
,7582388,peak concentration,Mean +/- SE mean peak concentration of midazolam was decreased from 86 +/- 17 ng ml-1 to 57 +/- 9 ng ml-1 (p < 0.05).,Azithromycin does not increase plasma concentrations of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582388/),[ng] / [ml],86,174405,DB00683,Midazolam
,7582388,peak concentration,Mean +/- SE mean peak concentration of midazolam was decreased from 86 +/- 17 ng ml-1 to 57 +/- 9 ng ml-1 (p < 0.05).,Azithromycin does not increase plasma concentrations of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582388/),[ng] / [ml],57,174406,DB00683,Midazolam
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],25.6,174693,DB00683,Midazolam
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],17,174694,DB00683,Midazolam
,26114223,apparent oral MDZ clearance,"In mixed model analysis, decreasing CYP3A4 activity, measured by apparent oral MDZ clearance (924 ± 443 ml min(-1) at day 7 vs.",Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[ml] / [min],924,174695,DB00683,Midazolam
,24250625,t½,"The mean (± SD) value of pharmacokinetic parameters of Midazolam in continuous infusion and intermittent bolus doses methods were as follows: (t½ = 17.88 ± 14.65 h, Cl = 21.80 ± 14.95 L/h) vs. (t½ = 19.74 ± 12.45 h, Cl = 29.43 ± 19.45 L/h).",Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250625/),h,17.88,175145,DB00683,Midazolam
,24250625,Cl,"The mean (± SD) value of pharmacokinetic parameters of Midazolam in continuous infusion and intermittent bolus doses methods were as follows: (t½ = 17.88 ± 14.65 h, Cl = 21.80 ± 14.95 L/h) vs. (t½ = 19.74 ± 12.45 h, Cl = 29.43 ± 19.45 L/h).",Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250625/),[l] / [h],21.80,175146,DB00683,Midazolam
,24250625,t½,"The mean (± SD) value of pharmacokinetic parameters of Midazolam in continuous infusion and intermittent bolus doses methods were as follows: (t½ = 17.88 ± 14.65 h, Cl = 21.80 ± 14.95 L/h) vs. (t½ = 19.74 ± 12.45 h, Cl = 29.43 ± 19.45 L/h).",Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250625/),h,19.74,175147,DB00683,Midazolam
,24250625,Cl,"The mean (± SD) value of pharmacokinetic parameters of Midazolam in continuous infusion and intermittent bolus doses methods were as follows: (t½ = 17.88 ± 14.65 h, Cl = 21.80 ± 14.95 L/h) vs. (t½ = 19.74 ± 12.45 h, Cl = 29.43 ± 19.45 L/h).",Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250625/),[l] / [h],29.43,175148,DB00683,Midazolam
,24250625,Volume of distribution (Vd),Volume of distribution (Vd) was measured in continuous infusion group which was 612.58 ± 582.93 L.,Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250625/),l,612.58,175149,DB00683,Midazolam
,16952487,half-life [t((1/2))],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,45.1,175305,DB00683,Midazolam
,16952487,clearance [CL],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],1.38,175306,DB00683,Midazolam
,16952487,volume of distribution [V],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,90.1,175307,DB00683,Midazolam
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,35.7,175308,DB00683,Midazolam
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],1.3,175309,DB00683,Midazolam
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,123,175310,DB00683,Midazolam
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,4.87,175311,DB00683,Midazolam
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],21.2,175312,DB00683,Midazolam
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,145,175313,DB00683,Midazolam
,16952487,oral bioavailability [F],"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),,0.23,175314,DB00683,Midazolam
,16952487,t((1/2)),"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),h,3.31,175315,DB00683,Midazolam
,16952487,CL,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],20.4,175316,DB00683,Midazolam
,16952487,V,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,75,175317,DB00683,Midazolam
,16952487,F,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),,0.22,175318,DB00683,Midazolam
<,16952487,F,"Good concordance between microdose and therapeutic dose pharmacokinetics was observed for diazepam (half-life [t((1/2))] of 45.1 hours, clearance [CL] of 1.38 L/h, and volume of distribution [V] of 90.1 L for 100 microg and t((1/2)) of 35.7 hours, CL of 1.3 L/h, and V of 123 L for 10 mg), midazolam (t((1/2)) of 4.87 hours, CL of 21.2 L/h, V of 145 L, and oral bioavailability [F] of 0.23 for 100 microg and t((1/2)) of 3.31 hours, CL of 20.4 L/h, V of 75 L, and F of 0.22 for 7.5 mg), and development compound ZK253 (F = <1% for both 100 microg and 50 mg).",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),%,1,175319,DB00683,Midazolam
,16952487,clearance,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],0.17,175320,DB00683,Midazolam
,16952487,clearance,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),[l] / [h],0.26,175321,DB00683,Midazolam
,16952487,distribution,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,67,175322,DB00683,Midazolam
,16952487,distribution,"For warfarin, clearance was reasonably well predicted (0.17 L/h for 100 microg and 0.26 L/h for 5 mg), but the discrepancy observed in distribution (67 L for 100 microg and 17.9 L for 5 mg) was probably a result of high-affinity, low-capacity tissue binding.",Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952487/),l,17.9,175323,DB00683,Midazolam
,27530285,first order rate constant of absorption,The absorption rate constant was poorly characterised by the data and an estimate of the first order rate constant of absorption when fixed to 10 h-1 provided a stable model and lowest objective function.,Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530285/),1/[h],10,175627,DB00683,Midazolam
,27530285,half-life,This represents extremely rapid absorption with a half-life of 5 min.,Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530285/),min,5,175628,DB00683,Midazolam
,27530285,clearance,"The final model had a clearance of 41.9 l h-1 and volume of distribution of the central compartment of, 73.6 l.",Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530285/),[l] / [h],41.9,175629,DB00683,Midazolam
,27530285,volume of distribution of the central compartment,"The final model had a clearance of 41.9 l h-1 and volume of distribution of the central compartment of, 73.6 l.",Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530285/),l,73.6,175630,DB00683,Midazolam
,27530285,initial (alpha) half-life,Median and interquartile range of initial (alpha) half-life was 0.32 h (0.26-0.37 h) and second (beta) half-life was 3.0 h (2.5-3.6 h).,Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530285/),h,0.32,175631,DB00683,Midazolam
,27530285,second (beta) half-life,Median and interquartile range of initial (alpha) half-life was 0.32 h (0.26-0.37 h) and second (beta) half-life was 3.0 h (2.5-3.6 h).,Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27530285/),h,3.0,175632,DB00683,Midazolam
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.3,175652,DB00683,Midazolam
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,2.0,175653,DB00683,Midazolam
,19774504,IC(50),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.1,175654,DB00683,Midazolam
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,3.8,175655,DB00683,Midazolam
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,1.5,175656,DB00683,Midazolam
,19774504,K(i),"In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively.","Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774504/),%,1.9,175657,DB00683,Midazolam
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],117,175692,DB00683,Midazolam
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],286,175693,DB00683,Midazolam
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],705,175694,DB00683,Midazolam
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],53,175695,DB00683,Midazolam
,31983556,volumes of distribution,"Typical values (% interindividual variability where estimated) for the volumes of distribution for midazolam (three compartments) and hydroxymidazolam (two compartments) were 117 (14), 286 (10), 705 (14), 53 (36) and 334 mL kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg],334,175696,DB00683,Midazolam
,31983556,clearance,"Midazolam clearance to 1-hydroxymidazolam, midazolam fast and slow intercompartmental clearances, 1-hydroxymidazolam clearance and 1-hydroxymidazolam intercompartment clearance were 18.3, 63.5 (15), 22.1 (8), 1.7 (67) and 3.8 mL minute-1 kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg·min],18.3,175697,DB00683,Midazolam
,31983556,intercompartment clearance,"Midazolam clearance to 1-hydroxymidazolam, midazolam fast and slow intercompartmental clearances, 1-hydroxymidazolam clearance and 1-hydroxymidazolam intercompartment clearance were 18.3, 63.5 (15), 22.1 (8), 1.7 (67) and 3.8 mL minute-1 kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg·min],1.7,175698,DB00683,Midazolam
,31983556,intercompartment clearance,"Midazolam clearance to 1-hydroxymidazolam, midazolam fast and slow intercompartmental clearances, 1-hydroxymidazolam clearance and 1-hydroxymidazolam intercompartment clearance were 18.3, 63.5 (15), 22.1 (8), 1.7 (67) and 3.8 mL minute-1 kg-1, respectively.",Pharmacokinetics of midazolam in sevoflurane-anesthetized cats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31983556/),[ml] / [kg·min],3.8,175699,DB00683,Midazolam
,1959542,Serum midazolam concentrations,Serum midazolam concentrations between 100-400 micrograms/l were sufficient for sedation.,Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959542/),,100-400,175836,DB00683,Midazolam
,12631050,CBF,"In group 1, baseline CBF was 55 +/- 7 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],55,176357,DB00683,Midazolam
,12631050,CBF,Indomethacin decreased CBF to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176358,DB00683,Midazolam
,12631050,CBF,"In group 2, baseline CBF was 54 +/- 10 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],54,176359,DB00683,Midazolam
,12631050,CBF,Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176360,DB00683,Midazolam
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],3.9,176361,DB00683,Midazolam
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],1.4,176362,DB00683,Midazolam
,11740342,MRT,"Following IV or oral midazolam administration, the average MRT was found to be approximately 3.5 h, suggesting that the optimal single sampling time to predict AUC was between 3 and 4 h.",In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11740342/),h,3.5,176577,DB00683,Midazolam
,20959500,clearance,"In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).",Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959500/),[l] / [h],21.7,177346,DB00683,Midazolam
,20959500,clearance,"In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).",Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959500/),[l] / [h],32.3,177347,DB00683,Midazolam
,11762564,absolute bioavailability,The absolute bioavailability of midazolam averaged 36% with a very broad range (9%-71%).,The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762564/),%,36,177813,DB00683,Midazolam
,20704661,CL,"Mature CL was 523 (CV 32%, 95%CI 469, 597) ml·min(-1) ·70 kg(-1) .",A maturation model for midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),[ml] / [70·kg·min],523,178522,DB00683,Midazolam
,20704661,maturation half-time,"The maturation half-time was 73.6 (95%CI 59.4, 80.0) weeks PMA and the Hill coefficient 3 (95%CI 2.2, 4.1).",A maturation model for midazolam clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),weeks,73.6,178523,DB00683,Midazolam
,20704661,Hill coefficient,"The maturation half-time was 73.6 (95%CI 59.4, 80.0) weeks PMA and the Hill coefficient 3 (95%CI 2.2, 4.1).",A maturation model for midazolam clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),,3,178524,DB00683,Midazolam
,20704661,sedation target concentration,"If a midazolam sedation target concentration of 0.1 mg·l(-1) , similar to that given to adults, is assumed, then we might anticipate steady-state infusion rates of 0.014 mg·kg(-1) ·h(-1) in neonates, 0.05 mg·kg(-1) ·h(-1) in a 1-year-old, 0.06 mg·kg(-1) ·h(-1) in a 5-year-old and 0.05 mg·kg(-1) ·h(-1) in a 12-year-old child.",A maturation model for midazolam clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),[mg] / [l],0.1,178525,DB00683,Midazolam
,20704661,steady-state infusion rates,"If a midazolam sedation target concentration of 0.1 mg·l(-1) , similar to that given to adults, is assumed, then we might anticipate steady-state infusion rates of 0.014 mg·kg(-1) ·h(-1) in neonates, 0.05 mg·kg(-1) ·h(-1) in a 1-year-old, 0.06 mg·kg(-1) ·h(-1) in a 5-year-old and 0.05 mg·kg(-1) ·h(-1) in a 12-year-old child.",A maturation model for midazolam clearance. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),[mg] / [h·kg],0.014,178526,DB00683,Midazolam
,20704661,steady-state infusion rates,"If a midazolam sedation target concentration of 0.1 mg·l(-1) , similar to that given to adults, is assumed, then we might anticipate steady-state infusion rates of 0.014 mg·kg(-1) ·h(-1) in neonates, 0.05 mg·kg(-1) ·h(-1) in a 1-year-old, 0.06 mg·kg(-1) ·h(-1) in a 5-year-old and 0.05 mg·kg(-1) ·h(-1) in a 12-year-old child.",A maturation model for midazolam clearance. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),[mg] / [h·kg],0.05,178527,DB00683,Midazolam
,20704661,steady-state infusion rates,"If a midazolam sedation target concentration of 0.1 mg·l(-1) , similar to that given to adults, is assumed, then we might anticipate steady-state infusion rates of 0.014 mg·kg(-1) ·h(-1) in neonates, 0.05 mg·kg(-1) ·h(-1) in a 1-year-old, 0.06 mg·kg(-1) ·h(-1) in a 5-year-old and 0.05 mg·kg(-1) ·h(-1) in a 12-year-old child.",A maturation model for midazolam clearance. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704661/),[mg] / [h·kg],0.06,178528,DB00683,Midazolam
,33607532,tmax,"Intranasal administration leads to rapid (tmax 9.0-21.5 min), consistent, and extensive absorption of MDZ, with fast distribution to the central nervous system (CNS), as demonstrated by the onset of sedation within 10 min after administration and the occurrence of peak psychomotor impairment at approximately 17-120 min after administration.",Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33607532/),min,9.0-21.5,179256,DB00683,Midazolam
,33607532,t½,Rapid plasma clearance of MDZ and its active metabolite 1-OH-MDZ (t½ 3.6-8.1 h) results in a return to baseline alertness and psychomotor functionality by approximately 240 min post dose.,Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33607532/),h,3.6-8.1,179257,DB00683,Midazolam
,30926700,Recovery time,Recovery time for the 2 mg/kg (median 90 minutes) was significantly longer than that for the 1 mg/kg (median 50 minutes).,Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),min,90,179424,DB00683,Midazolam
,30926700,Recovery time,Recovery time for the 2 mg/kg (median 90 minutes) was significantly longer than that for the 1 mg/kg (median 50 minutes).,Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),min,50,179425,DB00683,Midazolam
,30926700,elimination half-life,"The median (range) elimination half-life, total clearance and volume of distribution were 58.2 (42.3-70.7) minutes, 11.6 (10.3-14.5) ml/minute/kg and 0.8 (0.7-0.9) l/kg for the 1 mg/kg and 59.8 (47.5-68.0) minutes, 14.7 (12.1-16.0) ml/minute/kg and 0.9 (0.9-1.2) l/kg for the 2 mg/kg, respectively.",Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),min,58.2,179426,DB00683,Midazolam
,30926700,total clearance,"The median (range) elimination half-life, total clearance and volume of distribution were 58.2 (42.3-70.7) minutes, 11.6 (10.3-14.5) ml/minute/kg and 0.8 (0.7-0.9) l/kg for the 1 mg/kg and 59.8 (47.5-68.0) minutes, 14.7 (12.1-16.0) ml/minute/kg and 0.9 (0.9-1.2) l/kg for the 2 mg/kg, respectively.",Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),[ml] / [kg·min],11.6,179427,DB00683,Midazolam
,30926700,total clearance,"The median (range) elimination half-life, total clearance and volume of distribution were 58.2 (42.3-70.7) minutes, 11.6 (10.3-14.5) ml/minute/kg and 0.8 (0.7-0.9) l/kg for the 1 mg/kg and 59.8 (47.5-68.0) minutes, 14.7 (12.1-16.0) ml/minute/kg and 0.9 (0.9-1.2) l/kg for the 2 mg/kg, respectively.",Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),min,59.8,179428,DB00683,Midazolam
,30926700,volume of distribution,"The median (range) elimination half-life, total clearance and volume of distribution were 58.2 (42.3-70.7) minutes, 11.6 (10.3-14.5) ml/minute/kg and 0.8 (0.7-0.9) l/kg for the 1 mg/kg and 59.8 (47.5-68.0) minutes, 14.7 (12.1-16.0) ml/minute/kg and 0.9 (0.9-1.2) l/kg for the 2 mg/kg, respectively.",Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),[l] / [kg],0.8,179429,DB00683,Midazolam
,30926700,volume of distribution,"The median (range) elimination half-life, total clearance and volume of distribution were 58.2 (42.3-70.7) minutes, 11.6 (10.3-14.5) ml/minute/kg and 0.8 (0.7-0.9) l/kg for the 1 mg/kg and 59.8 (47.5-68.0) minutes, 14.7 (12.1-16.0) ml/minute/kg and 0.9 (0.9-1.2) l/kg for the 2 mg/kg, respectively.",Clinical pharmacokinetics and pharmacodynamics of intravenous alfaxalone in young Thoroughbred horses premedicated with medetomidine and midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30926700/),[l] / [kg],0.9,179430,DB00683,Midazolam
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180275,DB00683,Midazolam
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180276,DB00683,Midazolam
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.52,180277,DB00683,Midazolam
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180278,DB00683,Midazolam
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180279,DB00683,Midazolam
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.28,180280,DB00683,Midazolam
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180281,DB00683,Midazolam
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180282,DB00683,Midazolam
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180283,DB00683,Midazolam
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,34.7,180284,DB00683,Midazolam
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,10.9,180285,DB00683,Midazolam
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180286,DB00683,Midazolam
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.99,180287,DB00683,Midazolam
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180288,DB00683,Midazolam
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.69,180289,DB00683,Midazolam
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180290,DB00683,Midazolam
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180291,DB00683,Midazolam
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.16,180292,DB00683,Midazolam
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,1.0,180293,DB00683,Midazolam
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.85,180294,DB00683,Midazolam
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,339,180295,DB00683,Midazolam
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180296,DB00683,Midazolam
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,6.7,180297,DB00683,Midazolam
,2323155,EC50,The plasma drug concentration corresponding to half the maximum increase in TNW12-30 (EC50) was 290 +/- 98 micrograms/L.(ABSTRACT TRUNCATED AT 250 WORDS),Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323155/),[μg] / [l],290,182237,DB00683,Midazolam
,27548392,ED50,"1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD.","Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27548392/),[mg] / [kg],2.3,182675,DB00683,Midazolam
,3395535,Total plasma clearance,Total plasma clearance was 637 +/- 223 ml min-1 (mean +/- SD) in control patients and 402 +/- 170 ml min-1 in cirrhotic patients (P less than 0.05).,Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395535/),[ml] / [min],637,182951,DB00683,Midazolam
,3395535,Total plasma clearance,Total plasma clearance was 637 +/- 223 ml min-1 (mean +/- SD) in control patients and 402 +/- 170 ml min-1 in cirrhotic patients (P less than 0.05).,Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395535/),[ml] / [min],402,182952,DB00683,Midazolam
,3395535,Elimination half-life,Elimination half-life was 135 +/- 40 min in controls and 168 +/- 30 min in cirrhosis (P less than 0.05).,Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395535/),min,135,182953,DB00683,Midazolam
,3395535,Elimination half-life,Elimination half-life was 135 +/- 40 min in controls and 168 +/- 30 min in cirrhosis (P less than 0.05).,Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395535/),min,168,182954,DB00683,Midazolam
,3395535,free fraction,"No saturation occurred, but the free fraction was 4.9 +/- 1.7% in cirrhotic patients, compared with 1.9 +/- 0.6% in controls (P less than 0.01).",Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395535/),%,4.9,182955,DB00683,Midazolam
,3395535,free fraction,"No saturation occurred, but the free fraction was 4.9 +/- 1.7% in cirrhotic patients, compared with 1.9 +/- 0.6% in controls (P less than 0.01).",Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395535/),%,1.9,182956,DB00683,Midazolam
,1770572,time to clear response to verbal commands,The time to clear response to verbal commands after cessation of the continuous infusion was 168 +/- 109 min.,[Continuous infusion of ketamine and midazolam for prolonged sedation in the intensive care unit]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770572/),min,168,183288,DB00683,Midazolam
,1770572,plasma half-life,"The plasma concentrations of ketamine and midazolam decreased rapidly, and plasma half-life of ketamine was about 1 hour and for midazolam less than 2 hours.",[Continuous infusion of ketamine and midazolam for prolonged sedation in the intensive care unit]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770572/),h,1,183289,DB00683,Midazolam
,33673881,terminal half-life,"FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively.",A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),min,26.3,183456,DB00683,Midazolam
,33673881,plasma clearance,"FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively.",A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),[ml] / [kg·min],18.74,183457,DB00683,Midazolam
,33673881,volume of distribution,"FLU terminal half-life, plasma clearance and volume of distribution were 26.3 min [95%CI: 23.3 to 29.3], 18.74 mL/min/kg [16.47 to 21.00] and 0.63 L/kg [0.55 to 0.71], respectively.",A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),[l] / [kg],0.63,183458,DB00683,Midazolam
,33673881,ReRR,ReRR was 25 times faster in rabbits treated with FLU (23 [8 to 44] s) compared with SAL (576 [130 to 1141] s; 95%CI [425 to 914 s]).,A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),s,23,183459,DB00683,Midazolam
,33673881,ReRR,ReRR was 25 times faster in rabbits treated with FLU (23 [8 to 44] s) compared with SAL (576 [130 to 1141] s; 95%CI [425 to 914 s]).,A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673881/),s,576,183460,DB00683,Midazolam
,21425376,inhibition constant (K(i) ),"Danshen extract (50-2000 µg/mL) competitively inhibited human and rat liver microsomal CYP3A activity with inhibition constant (K(i) ) values of 51 and 65 µg/mL, respectively.",Effects of Salvia miltiorrhiza extract on the liver CYP3A activity in humans and rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425376/),[μg] / [ml],51,183610,DB00683,Midazolam
,21425376,inhibition constant (K(i) ),"Danshen extract (50-2000 µg/mL) competitively inhibited human and rat liver microsomal CYP3A activity with inhibition constant (K(i) ) values of 51 and 65 µg/mL, respectively.",Effects of Salvia miltiorrhiza extract on the liver CYP3A activity in humans and rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425376/),[μg] / [ml],65,183611,DB00683,Midazolam
,31237691,Peak BECs,"Peak BECs were 34 and 87 mg/dl for 0.5 and 1.0 g/kg doses, respectively, and occurred at 66 and 87 minutes following gavage.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [dl],34,183696,DB00683,Midazolam
,31237691,Peak BECs,"Peak BECs were 34 and 87 mg/dl for 0.5 and 1.0 g/kg doses, respectively, and occurred at 66 and 87 minutes following gavage.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [dl],87,183697,DB00683,Midazolam
,31237691,ED50,"All GABAA and NMDA ligands tested resulted in responding on the EtOH-appropriate lever with the potency ranking of MK-801 (ED50 : 0.017 mg/kg) > midazolam (ED50 : 1.6 mg/kg) > pentobarbital (ED50 : 3.7 mg/kg) > EtOH (ED50 : 700 mg/kg, or 0.7 g/kg) in these subjects.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [kg],0.017,183698,DB00683,Midazolam
,3382589,Maximum plasma concentrations,2. Maximum plasma concentrations of 92-156 ng ml-1 (mean 118 ng ml-1) were recorded from 20 to 50 min (mean 31 min) after rectal application.,Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382589/),[ng] / [ml],92-156,183858,DB00683,Midazolam
,3382589,Maximum plasma concentrations,2. Maximum plasma concentrations of 92-156 ng ml-1 (mean 118 ng ml-1) were recorded from 20 to 50 min (mean 31 min) after rectal application.,Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382589/),[ng] / [ml],118,183859,DB00683,Midazolam
,3382589,rectal bioavailability,The rectal bioavailability was 40-65% (mean 52%) and the terminal half-life was 114-305 min (mean 161 min).,Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382589/),%,40-65,183860,DB00683,Midazolam
,3382589,rectal bioavailability,The rectal bioavailability was 40-65% (mean 52%) and the terminal half-life was 114-305 min (mean 161 min).,Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382589/),%,52,183861,DB00683,Midazolam
,3382589,terminal half-life,The rectal bioavailability was 40-65% (mean 52%) and the terminal half-life was 114-305 min (mean 161 min).,Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382589/),min,161,183862,DB00683,Midazolam
,22453191,Maximal plasma concentrations,"Maximal plasma concentrations of 63 and 110 ng/ml were reached at 8.4 and 7.6 min after 3 and 6 mg i.n. midazolam, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),[ng] / [ml],63,183917,DB00683,Midazolam
,22453191,Maximal plasma concentrations,"Maximal plasma concentrations of 63 and 110 ng/ml were reached at 8.4 and 7.6 min after 3 and 6 mg i.n. midazolam, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),[ng] / [ml],110,183918,DB00683,Midazolam
,22453191,times to onset,"After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18-25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,1.2,183919,DB00683,Midazolam
,22453191,times to onset,"After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18-25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,5.5,183920,DB00683,Midazolam
,22453191,times to onset,"After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18-25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,6.9,183921,DB00683,Midazolam
,22453191,times to loss of response,"After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18-25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,3.0,183922,DB00683,Midazolam
,22453191,times to loss of response,"After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18-25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,8.0,183923,DB00683,Midazolam
,22453191,times to loss of response,"After 5 mg i.v. and 6 and 3 mg i.n. midazolam, the times to onset of significant EEG effects in the β2 band (18-25 Hz) were 1.2, 5.5, and 6.9 min, respectively, and the times to loss of response to auditory stimuli were 3.0, 8.0, and 15.0 min, respectively.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,15.0,183924,DB00683,Midazolam
,22453191,half-lives,"A sigmoid maximum-effect (E(max)) model indicated disequilibrium between plasma and effect-site concentrations, with equilibration half-lives of 2.1-4.8 min.",Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22453191/),min,2.1-4.8,183925,DB00683,Midazolam
,31601999,total clearance,Mean estimated total clearance of fentanyl and mean metabolic clearance of midazolam (as a marker of CYP3A activity) were 75.5 and 36.3 L/h.,Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31601999/),[l] / [h],75.5,184567,DB00683,Midazolam
,31601999,metabolic clearance,Mean estimated total clearance of fentanyl and mean metabolic clearance of midazolam (as a marker of CYP3A activity) were 75.5 and 36.3 L/h.,Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31601999/),[l] / [h],36.3,184568,DB00683,Midazolam
,29663428,clearance,"An estimate (interindividual variability) of midazolam clearance was 32.5 L/hr (52.9%), covariate of central volume was 67 L (39.1%), and oral bioavailability was 0.33 (45.5%).",Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29663428/),[l] / [h],32.5,184581,DB00683,Midazolam
,29663428,central volume,"An estimate (interindividual variability) of midazolam clearance was 32.5 L/hr (52.9%), covariate of central volume was 67 L (39.1%), and oral bioavailability was 0.33 (45.5%).",Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29663428/),l,67,184582,DB00683,Midazolam
,29663428,oral bioavailability,"An estimate (interindividual variability) of midazolam clearance was 32.5 L/hr (52.9%), covariate of central volume was 67 L (39.1%), and oral bioavailability was 0.33 (45.5%).",Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29663428/),,0.33,184583,DB00683,Midazolam
,33638195,clearance rates,"The median pharmacokinetic clearance rates were 0.10 L/kg/h (Q25 0.01-Q75 0.34) in patients with the allelic variant (TT+TC) and 0.03 L/kg/h (Q25 0.002-Q75 0.13) in patients with the normal genotype (CC), p = 0.042.",The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638195/),[l] / [h·kg],0.10,184863,DB00683,Midazolam
,33638195,clearance rates,"The median pharmacokinetic clearance rates were 0.10 L/kg/h (Q25 0.01-Q75 0.34) in patients with the allelic variant (TT+TC) and 0.03 L/kg/h (Q25 0.002-Q75 0.13) in patients with the normal genotype (CC), p = 0.042.",The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638195/),[l] / [h·kg],0.03,184864,DB00683,Midazolam
,33638195,clearance,"Our results show that compared with carriers of the normal allele, patients with the CYP3A5*3 allelic variant (rs776746) had increased plasma midazolam levels at 3 h after infusion discontinuation (320.3 ng/ml) and greater clearance (0.10 L/kg/h) of the drug.",The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33638195/),[l] / [h·kg],0.10,184865,DB00683,Midazolam
,9403781,clearance,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[min·ml] / [kg],53,184989,DB00683,Midazolam
,9403781,volume of distribution,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[l] / [kg],1.19,184990,DB00683,Midazolam
,9403781,terminal half-life,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),min,24.5,184991,DB00683,Midazolam
,9403781,E0,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),μv,57,184992,DB00683,Midazolam
,9403781,Emax,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),μv,95,184993,DB00683,Midazolam
,9403781,EC50,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[ng] / [ml],202,184994,DB00683,Midazolam
,9403781,Hill factor,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),,1.53,184995,DB00683,Midazolam
,12392582,t(max),"After s.c. infusion t(max) and C(max) were 0.51 +/- 0.18 h and 127.8 +/- 29.3 ng ml-1 (mean +/- s.d.), respectively.",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),h,0.51,186281,DB00683,Midazolam
,12392582,C(max),"After s.c. infusion t(max) and C(max) were 0.51 +/- 0.18 h and 127.8 +/- 29.3 ng ml-1 (mean +/- s.d.), respectively.",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),[ng] / [ml],127.8,186282,DB00683,Midazolam
,12392582,absolute bioavailability,"The mean (+/- s.d.) absolute bioavailability of subcutaneous midazolam was 0.96 (+/- 0.14) (CI 0.84, 1.03).",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),,0.96,186283,DB00683,Midazolam
,12392582,t1/2,"Mean (+/- s.d.) t1/2 was similar after s.c. (3.2 (+/- 1.0) h) and i.v. infusion (2.9 (+/- 0.7) h), although a statistically significant difference was reached (P < 0.05).",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),h,3.2,186284,DB00683,Midazolam
,12392582,t1/2,"Mean (+/- s.d.) t1/2 was similar after s.c. (3.2 (+/- 1.0) h) and i.v. infusion (2.9 (+/- 0.7) h), although a statistically significant difference was reached (P < 0.05).",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),h,2.9,186285,DB00683,Midazolam
,12392582,CL,"Mean CL and V of i.v. midazolam were 4.4 +/- 1.0 ml min-1 kg-1 and 1.1 +/- 0.2 l kg-1 (mean +/- s.d.), respectively.",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),[ml] / [kg·min],4.4,186286,DB00683,Midazolam
,12392582,V,"Mean CL and V of i.v. midazolam were 4.4 +/- 1.0 ml min-1 kg-1 and 1.1 +/- 0.2 l kg-1 (mean +/- s.d.), respectively.",Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392582/),[l] / [kg],1.1,186287,DB00683,Midazolam
,12814973,K'app,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),μM,12.6,186513,DB00683,Midazolam
,12814973,K'app,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),μM,41.4,186514,DB00683,Midazolam
,12814973,K'app,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),μM,623,186515,DB00683,Midazolam
,12814973,kinact,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),1/[min],0.0240,186516,DB00683,Midazolam
,12814973,kinact,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),1/[min],0.0423,186517,DB00683,Midazolam
,12814973,kinact,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),μM,623,186518,DB00683,Midazolam
,12814973,kinact,"The kinetic parameters for enzyme inactivation (K'app and kinact) involved in midazolam alpha-hydroxylation were 12.6 microM and 0.0240 min-1, respectively, for erythromycin, 41.4 microM and 0.0423 min-1, respectively, for clarithromycin, and 623 microM and 0.0158 min-1, respectively, for azithromycin.",Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814973/),1/[min],0.0158,186519,DB00683,Midazolam
,10069275,Total sufen,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186592,DB00683,Midazolam
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186593,DB00683,Midazolam
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μ,610,186594,DB00683,Midazolam
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,14.4,186595,DB00683,Midazolam
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,11.2,186596,DB00683,Midazolam
,10069275,Plasma,Plasma sufentanil concentrations at extubation were similar in both groups (0.5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],0.5,186597,DB00683,Midazolam
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],17,186598,DB00683,Midazolam
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],23,186599,DB00683,Midazolam
,21350850,area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[h·mg] / [l],38.1,186875,DB00683,Midazolam
,21350850,maximum plasma concentration (C(max)),"On day 28, area under the plasma concentration-time curve from time 0 to 12 h (AUC(0-12)) and maximum plasma concentration (C(max)) for sorafenib were 38.1 mg h/l and 4.9 mg/l, respectively.",Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21350850/),[mg] / [l],4.9,186876,DB00683,Midazolam
≤,22321528,t(max),Midazolam displayed rapid sublingual absorption (mean t(max) ≤30min from the liquid formulations and 60 min from the solid formulation) with high absolute bioavailability (>68%) from all evaluated formulations.,The effect of hydroxypropyl-beta-cyclodextrin and sucrose on the sublingual absorption of midazolam in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22321528/),min,30,187201,DB00683,Midazolam
,22321528,t(max),Midazolam displayed rapid sublingual absorption (mean t(max) ≤30min from the liquid formulations and 60 min from the solid formulation) with high absolute bioavailability (>68%) from all evaluated formulations.,The effect of hydroxypropyl-beta-cyclodextrin and sucrose on the sublingual absorption of midazolam in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22321528/),min,60,187202,DB00683,Midazolam
>,22321528,absolute bioavailability,Midazolam displayed rapid sublingual absorption (mean t(max) ≤30min from the liquid formulations and 60 min from the solid formulation) with high absolute bioavailability (>68%) from all evaluated formulations.,The effect of hydroxypropyl-beta-cyclodextrin and sucrose on the sublingual absorption of midazolam in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22321528/),%,68,187203,DB00683,Midazolam
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],8.5,187223,DB00683,Midazolam
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],13.5,187224,DB00683,Midazolam
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,0.58,187225,DB00683,Midazolam
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,1.09,187226,DB00683,Midazolam
,23129213,inactivation constant (K(I)),"Crizotinib inactivation constant (K(I)) and maximum inactivation rate constant (k(inact)) for TDI were estimated as, respectively, 0.37 µM and 6.9 h(-1) in HLM and 0.89 µM and 0.78 h(-1) in HSP.",Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23129213/),μM,0.37,189990,DB00683,Midazolam
,23129213,inactivation constant (K(I)),"Crizotinib inactivation constant (K(I)) and maximum inactivation rate constant (k(inact)) for TDI were estimated as, respectively, 0.37 µM and 6.9 h(-1) in HLM and 0.89 µM and 0.78 h(-1) in HSP.",Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23129213/),μM,0.89,189991,DB00683,Midazolam
,23129213,maximum inactivation rate constant (k(inact)),"Crizotinib inactivation constant (K(I)) and maximum inactivation rate constant (k(inact)) for TDI were estimated as, respectively, 0.37 µM and 6.9 h(-1) in HLM and 0.89 µM and 0.78 h(-1) in HSP.",Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23129213/),1/[h],6.9,189992,DB00683,Midazolam
,23129213,maximum inactivation rate constant (k(inact)),"Crizotinib inactivation constant (K(I)) and maximum inactivation rate constant (k(inact)) for TDI were estimated as, respectively, 0.37 µM and 6.9 h(-1) in HLM and 0.89 µM and 0.78 h(-1) in HSP.",Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23129213/),1/[h],0.78,189993,DB00683,Midazolam
,6742481,elimination half-life (t1/2),Midazolam elimination half-life (t1/2) after iv dosage was significantly prolonged in elderly (aged 60-74 yr) versus young (24-33 yr) males (5.6 vs.,"Effect of age, gender, and obesity on midazolam kinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),,5.6,190679,DB00683,Midazolam
,6742481,total clearance,"2.1 hours, P less than 0.01) and total clearance was significantly reduced (4.4 vs.","Effect of age, gender, and obesity on midazolam kinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),,4.4,190680,DB00683,Midazolam
,6742481,total volume of distribution,However total volume of distribution calculated by the area method (Vd) (1.6 vs. 1.3 1/kg) and protein binding (3.5 vs.,"Effect of age, gender, and obesity on midazolam kinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),[1] / [kg],1.6,190681,DB00683,Midazolam
,6742481,total volume of distribution,However total volume of distribution calculated by the area method (Vd) (1.6 vs. 1.3 1/kg) and protein binding (3.5 vs.,"Effect of age, gender, and obesity on midazolam kinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),[1] / [kg],1.3,190682,DB00683,Midazolam
,6742481,protein binding,However total volume of distribution calculated by the area method (Vd) (1.6 vs. 1.3 1/kg) and protein binding (3.5 vs.,"Effect of age, gender, and obesity on midazolam kinetics. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),,3.5,190683,DB00683,Midazolam
,6742481,t1/2,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),h,4.0,190684,DB00683,Midazolam
,6742481,t1/2,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),h,2.6,190685,DB00683,Midazolam
,6742481,clearance,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),[ml] / [kg·min],7.5,190686,DB00683,Midazolam
,6742481,clearance,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),[ml] / [kg·min],9.4,190687,DB00683,Midazolam
,6742481,Vd,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),[1] / [kg],2.1,190688,DB00683,Midazolam
,6742481,Vd,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),[1] / [kg],2.0,190689,DB00683,Midazolam
,6742481,protein binding,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),%,3.7,190690,DB00683,Midazolam
,6742481,oral bioavailability,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),%,38,190691,DB00683,Midazolam
,6742481,oral bioavailability,"Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%).","Effect of age, gender, and obesity on midazolam kinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),%,36,190692,DB00683,Midazolam
,6742481,Vd,"In obese volunteers (mean weight 117 kg; 173% of ideal weight) versus control subjects of normal weight (66 kg, 95% of ideal weight) matched for age, sex, and smoking habits, midazolam Vd was increased significantly (311 vs. 114 1, P less than 0.001).","Effect of age, gender, and obesity on midazolam kinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),1,311,190693,DB00683,Midazolam
,6742481,Vd,"In obese volunteers (mean weight 117 kg; 173% of ideal weight) versus control subjects of normal weight (66 kg, 95% of ideal weight) matched for age, sex, and smoking habits, midazolam Vd was increased significantly (311 vs. 114 1, P less than 0.001).","Effect of age, gender, and obesity on midazolam kinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6742481/),1,114,190694,DB00683,Midazolam
,10945319,systemic clearance,"A lower systemic clearance (265+/-54 versus 310+/-56 mL/min; P = .04), but not oral clearance, was observed in African Americans.",CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945319/),[ml] / [min],265,191051,DB00683,Midazolam
,10945319,systemic clearance,"A lower systemic clearance (265+/-54 versus 310+/-56 mL/min; P = .04), but not oral clearance, was observed in African Americans.",CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945319/),[ml] / [min],310,191052,DB00683,Midazolam
,10945319,systemic clearance,"Hepatic CYP3A activity and the systemic clearance of midazolam were about 30% lower in G/G homozygotes than in A/A homozygotes (252+/-53 versus 310+/-54 mL/min; P = .02), and a gene-dose effect was present (P = .01).",CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945319/),[ml] / [min],310,191053,DB00683,Midazolam
,3161005,half-life,"After both oral and parenteral administration, midazolam has a fast absorption rate and is rapidly excreted, with a half-life of only about 2 hours.","Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161005/),h,2,191122,DB00683,Midazolam
,20739919,half maximal inhibitory concentration (IC(50)),The in vivo half maximal inhibitory concentration (IC(50)) for ITZ ranged from 5 to 132 nmol/l in the six subjects.,Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20739919/),[nM] / [l],5 to 132,191471,DB00683,Midazolam
,3134933,total plasma clearance,The total plasma clearance ranged between 93 and 431 ml min-1 (mean 249 ml min-1).,Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[ml] / [min],249,191911,DB00683,Midazolam
,3134933,apparent volume of distribution at steady-state,The apparent volume of distribution at steady-state ranged between 0.27 and 0.64 litre kg-1 (mean 0.44 litre kg-1).,Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[l] / [kg],0.44,191912,DB00683,Midazolam
,3134933,apparent volume of distribution (Vd beta),"The apparent volume of distribution (Vd beta) was 0.58 litre kg-1, resulting in a terminal half-life of 112 min.",Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[l] / [kg],0.58,191913,DB00683,Midazolam
,3134933,terminal half-life,"The apparent volume of distribution (Vd beta) was 0.58 litre kg-1, resulting in a terminal half-life of 112 min.",Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),min,112,191914,DB00683,Midazolam
,9757150,midazolam clearance,Mean +/- SD midazolam clearance was 0.00816 +/- 0.00252 L/min/kg during the midfollicular phase and 0.00818 +/- 0.00224 during the midluteal phase (P = .96).,Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757150/),[l] / [kg·min],0.00816,192118,DB00683,Midazolam
,9757150,midazolam clearance,Mean +/- SD midazolam clearance was 0.00816 +/- 0.00252 L/min/kg during the midfollicular phase and 0.00818 +/- 0.00224 during the midluteal phase (P = .96).,Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757150/),[l] / [kg·min],0.00818,192119,DB00683,Midazolam
,9757150,midazolam,"When the menstrual cycle phases were combined, mean midazolam clearance in women was 0.00817 +/- 0.00235 L/min/kg.",Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757150/),[l] / [kg·min],0.00817,192120,DB00683,Midazolam
,9757150,clearance,"When the menstrual cycle phases were combined, mean midazolam clearance in women was 0.00817 +/- 0.00235 L/min/kg.",Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757150/),[l] / [kg·min],0.00817,192121,DB00683,Midazolam
,9757150,midazolam,Mean male midazolam clearance was 0.00766 +/ 0.00167 L/min/kg.,Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757150/),[l] / [kg·min],0.00766,192122,DB00683,Midazolam
,9757150,clearance,Mean male midazolam clearance was 0.00766 +/ 0.00167 L/min/kg.,Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757150/),[l] / [kg·min],0.00766,192123,DB00683,Midazolam
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,70,192332,DB00683,Midazolam
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,22,192333,DB00683,Midazolam
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,9,192334,DB00683,Midazolam
,15371986,IV clearance,Rifampin decreased bioavailability and oral and IV methadone plasma concentrations and increased IV clearance (4.42 +/- 1.00 mL.,"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,4.42,192335,DB00683,Midazolam
,15371986,oral clearance,"kg -1. min -1, P <.05) and oral clearance (8.50 +/- 3.68 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,8.50,192336,DB00683,Midazolam
,15371986,area under the curve (AUC) ratios,"kg -1. min -1, P <.05), EDDP/methadone area under the curve (AUC) ratios, EDDP formation clearances, and hepatic extraction (0.27 +/- 0.06 versus 0.09 +/- 0.04, P <.05).","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.27,192337,DB00683,Midazolam
,15371986,formation clearances,"kg -1. min -1, P <.05), EDDP/methadone area under the curve (AUC) ratios, EDDP formation clearances, and hepatic extraction (0.27 +/- 0.06 versus 0.09 +/- 0.04, P <.05).","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.09,192338,DB00683,Midazolam
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.17,192339,DB00683,Midazolam
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.14,192340,DB00683,Midazolam
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.27,192341,DB00683,Midazolam
,15371986,IV,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,1.29,192342,DB00683,Midazolam
,15371986,clearance,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,1.29,192343,DB00683,Midazolam
,15371986,oral clearance,kg -1. min -1 ) or oral clearance (2.05 +/- 1.52 mL.,"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,2.05,192344,DB00683,Midazolam
,32725383,Vss ratio,"Changes in exposure (area under the curve) up to 5.1-fold were observed; however, ratios of Vss changes have a range of 0.70-1.26, with one outlier displaying a Vss ratio of 0.57.",Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32725383/),,0.57,192758,DB00683,Midazolam
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB00683,Midazolam
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB00683,Midazolam
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],7.6,193012,DB00683,Midazolam
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],139.0,193013,DB00683,Midazolam
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],12,193014,DB00683,Midazolam
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],409.6,193015,DB00683,Midazolam
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],35.0,193016,DB00683,Midazolam
,21220434,exposure,Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l).,Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],267,193017,DB00683,Midazolam
,21220434,exposure,Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l).,Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],268,193018,DB00683,Midazolam
,21220434,exposure,Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l).,Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],1344,193019,DB00683,Midazolam
,11948536,serum Cmax,"Mean serum Cmax were 92.3 +/- 42.5 (mean +/- SD), 274.3 +/- 150.8, 377.1 +/- 211.3, and 2552.4 +/- 1305.3 ng/mL for pH 2.8, 3.2, 3.9 solutions and iv infusion, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),[ng] / [ml],92.3,193362,DB00683,Midazolam
,11948536,serum Cmax,"Mean serum Cmax were 92.3 +/- 42.5 (mean +/- SD), 274.3 +/- 150.8, 377.1 +/- 211.3, and 2552.4 +/- 1305.3 ng/mL for pH 2.8, 3.2, 3.9 solutions and iv infusion, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),[ng] / [ml],274.3,193363,DB00683,Midazolam
,11948536,serum Cmax,"Mean serum Cmax were 92.3 +/- 42.5 (mean +/- SD), 274.3 +/- 150.8, 377.1 +/- 211.3, and 2552.4 +/- 1305.3 ng/mL for pH 2.8, 3.2, 3.9 solutions and iv infusion, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),[ng] / [ml],377.1,193364,DB00683,Midazolam
,11948536,serum Cmax,"Mean serum Cmax were 92.3 +/- 42.5 (mean +/- SD), 274.3 +/- 150.8, 377.1 +/- 211.3, and 2552.4 +/- 1305.3 ng/mL for pH 2.8, 3.2, 3.9 solutions and iv infusion, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),[ng] / [ml],2552.4,193365,DB00683,Midazolam
,11948536,t(max),Mean t(max) for all buccal solutions and iv infusion was 15 min.,Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),min,15,193366,DB00683,Midazolam
,11948536,Bioavailability,"Bioavailability for the pH 2.8, 3.2, and 3.9 solutions were 6.2, 18.7, and 22.6%, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),%,6.2,193367,DB00683,Midazolam
,11948536,Bioavailability,"Bioavailability for the pH 2.8, 3.2, and 3.9 solutions were 6.2, 18.7, and 22.6%, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),%,18.7,193368,DB00683,Midazolam
,11948536,Bioavailability,"Bioavailability for the pH 2.8, 3.2, and 3.9 solutions were 6.2, 18.7, and 22.6%, respectively.",Oral mucosal absorption of midazolam in dogs is strongly pH dependent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948536/),%,22.6,193369,DB00683,Midazolam
,21209240,kdeg,"In addition, the authors believe that a hepatic CYP3A kdeg of 0.03 h(-1) should be considered for future Simcyp studies.",Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go? ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209240/),1/[h],0.03,193945,DB00683,Midazolam
,6138080,elimination half-life,"The following average values were found: elimination half-life, 2.3 h; total clearance, 323 ml/min, and apparent volume of distribution at steady-state (VSS), 50.21.",Pharmacokinetics and bioavailability of midazolam in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138080/),h,2.3,194168,DB00683,Midazolam
,6138080,total clearance,"The following average values were found: elimination half-life, 2.3 h; total clearance, 323 ml/min, and apparent volume of distribution at steady-state (VSS), 50.21.",Pharmacokinetics and bioavailability of midazolam in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138080/),[ml] / [min],323,194169,DB00683,Midazolam
,6138080,apparent volume of distribution at steady-state (VSS),"The following average values were found: elimination half-life, 2.3 h; total clearance, 323 ml/min, and apparent volume of distribution at steady-state (VSS), 50.21.",Pharmacokinetics and bioavailability of midazolam in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138080/),,50.21,194170,DB00683,Midazolam
,6138080,bioavailability,"The bioavailability after the ingestion of 10, 20 and 40 mg midazolam in the form of tablets ranged from 31 to 72%, due to the high liver extraction quota of midazolam.",Pharmacokinetics and bioavailability of midazolam in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138080/),%,31 to 72,194171,DB00683,Midazolam
,30062590,intrinsic gut wall clearance,"The whole-organ intrinsic clearance in the gut wall and liver were found to increase with body weight, with a 105 (95% confidence interval (CI): 5-405) times lower intrinsic gut wall clearance than the intrinsic hepatic clearance (i.e. 5.08 L/h (relative standard error (RSE) 10%) versus 527 L/h (RSE 7%) for a 16 kg individual, respectively).",Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30062590/),[l] / [h],5.08,194180,DB00683,Midazolam
,30062590,intrinsic gut wall clearance,"The whole-organ intrinsic clearance in the gut wall and liver were found to increase with body weight, with a 105 (95% confidence interval (CI): 5-405) times lower intrinsic gut wall clearance than the intrinsic hepatic clearance (i.e. 5.08 L/h (relative standard error (RSE) 10%) versus 527 L/h (RSE 7%) for a 16 kg individual, respectively).",Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30062590/),[l] / [h],527,194181,DB00683,Midazolam
,30062590,total bioavailability,The resulting total bioavailability was found to be age-independent with a median of 20.8% in children (95%CI: 3.8-50.0%).,Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30062590/),%,20.8,194182,DB00683,Midazolam
,18635703,maximum,"Org 28611 is, therefore, not suitable for providing sedation for outpatient surgical procedures and doses above the maximum tolerated dose of 3 microg/kg (either administered as a slow infusion or a bolus dose) can cause untoward psychotropic effects.",Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18635703/),,3,194839,DB00683,Midazolam
,1364836,clearance,"The values (mean +/- s.e. mean, n = 20) of clearance, volume of distribution at steady-state and terminal half-life were 67 +/- 2 ml min-1 kg-1, 1.61 +/- 0.071 kg-1 and 27 +/- 1 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),[ml] / [kg·min],67,195235,DB00683,Midazolam
,1364836,volume of distribution at steady-state,"The values (mean +/- s.e. mean, n = 20) of clearance, volume of distribution at steady-state and terminal half-life were 67 +/- 2 ml min-1 kg-1, 1.61 +/- 0.071 kg-1 and 27 +/- 1 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),1/[kg],1.61,195236,DB00683,Midazolam
,1364836,terminal half-life,"The values (mean +/- s.e. mean, n = 20) of clearance, volume of distribution at steady-state and terminal half-life were 67 +/- 2 ml min-1 kg-1, 1.61 +/- 0.071 kg-1 and 27 +/- 1 min, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),min,27,195237,DB00683,Midazolam
,1364836,systemic availability,Following oral administration midazolam was rapidly absorbed with a systemic availability of 45 +/- 9%.,Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),%,45,195238,DB00683,Midazolam
,1364836,Eo,"The averaged pharmacodynamic parameters of midazolam obtained after combining the results of all rates and routes of administration were (mean + s.e.mean, n = 27): Eo = 61 + 3puV s 1, Emax = 85 + 3 Vs 1, EC50 = 40 + 3 ngmlP-1 and N = 0.84 + 0.04.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),1·puv·s,61,195239,DB00683,Midazolam
,1364836,Emax,"The averaged pharmacodynamic parameters of midazolam obtained after combining the results of all rates and routes of administration were (mean + s.e.mean, n = 27): Eo = 61 + 3puV s 1, Emax = 85 + 3 Vs 1, EC50 = 40 + 3 ngmlP-1 and N = 0.84 + 0.04.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),1·vs,85,195240,DB00683,Midazolam
,1364836,EC50,"The averaged pharmacodynamic parameters of midazolam obtained after combining the results of all rates and routes of administration were (mean + s.e.mean, n = 27): Eo = 61 + 3puV s 1, Emax = 85 + 3 Vs 1, EC50 = 40 + 3 ngmlP-1 and N = 0.84 + 0.04.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),1/[ngmlp],40,195241,DB00683,Midazolam
,1364836,N,"The averaged pharmacodynamic parameters of midazolam obtained after combining the results of all rates and routes of administration were (mean + s.e.mean, n = 27): Eo = 61 + 3puV s 1, Emax = 85 + 3 Vs 1, EC50 = 40 + 3 ngmlP-1 and N = 0.84 + 0.04.",Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364836/),,0.84,195242,DB00683,Midazolam
,28370390,eCLmet,"Midazolam eCLmet was 516 ml min-1 (420-640) following 100 mg 4 h-1 voriconazole, 152 ml min-1 (139-166) for 400 mg 6 h-1 , 192 ml min-1 (167-220) for 400 mg 4 h-1 , and 202 ml min-1 (189-217) for 400 mg 2 h-1 .",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),[ml] / [min],516,196004,DB00683,Midazolam
,28370390,eCLmet,"Midazolam eCLmet was 516 ml min-1 (420-640) following 100 mg 4 h-1 voriconazole, 152 ml min-1 (139-166) for 400 mg 6 h-1 , 192 ml min-1 (167-220) for 400 mg 4 h-1 , and 202 ml min-1 (189-217) for 400 mg 2 h-1 .",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),[ml] / [min],152,196005,DB00683,Midazolam
,28370390,eCLmet,"Midazolam eCLmet was 516 ml min-1 (420-640) following 100 mg 4 h-1 voriconazole, 152 ml min-1 (139-166) for 400 mg 6 h-1 , 192 ml min-1 (167-220) for 400 mg 4 h-1 , and 202 ml min-1 (189-217) for 400 mg 2 h-1 .",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),[ml] / [min],192,196006,DB00683,Midazolam
,28370390,eCLmet,"Midazolam eCLmet was 516 ml min-1 (420-640) following 100 mg 4 h-1 voriconazole, 152 ml min-1 (139-166) for 400 mg 6 h-1 , 192 ml min-1 (167-220) for 400 mg 4 h-1 , and 202 ml min-1 (189-217) for 400 mg 2 h-1 .",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),[ml] / [min],202,196007,DB00683,Midazolam
,28370390,Concentration giving 50%,"Concentration giving 50% CYP inhibition of voriconazole N-oxide was 146 ± 23 μmol l-1 for CYP3A4, and 40.2 ± 4.2 μmol l-1 for CYP2C19.",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),[μM] / [l],146,196008,DB00683,Midazolam
,28370390,Concentration giving 50%,"Concentration giving 50% CYP inhibition of voriconazole N-oxide was 146 ± 23 μmol l-1 for CYP3A4, and 40.2 ± 4.2 μmol l-1 for CYP2C19.",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),[μM] / [l],40.2,196009,DB00683,Midazolam
,28370390,infusion rate,"To avoid reduced exposure, the infusion rate should be 2 h.",Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28370390/),,2,196010,DB00683,Midazolam
,8518376,plasma midazolam,"The plasma midazolam level for induction was 196 +/- 139 ng/mL in the CACI group and 300 +/- 128 ng/mL in the MCI group, and the fentanyl level was similar in both groups, 6.7 +/- 1.9 ng/mL in CACI and 6.3 +/- 4.6 ng/mL in the MCI group.",Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8518376/),[ng] / [ml],196,196314,DB00683,Midazolam
,8518376,plasma midazolam,"The plasma midazolam level for induction was 196 +/- 139 ng/mL in the CACI group and 300 +/- 128 ng/mL in the MCI group, and the fentanyl level was similar in both groups, 6.7 +/- 1.9 ng/mL in CACI and 6.3 +/- 4.6 ng/mL in the MCI group.",Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8518376/),[ng] / [ml],300,196315,DB00683,Midazolam
,8518376,duration,"In the MCI group, the average duration of anesthesia was 246.5 +/- 35.0 minutes, with a mean total fentanyl dose of 30.27 +/- 11.14 micrograms/kg.",Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8518376/),min,246,196316,DB00683,Midazolam
more,17452028,extraction efficiency,The extraction efficiency was more than 79.5% for each of the six analytes.,"Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452028/),%,79.5,196786,DB00683,Midazolam
,12923616,duration of sedation,The mean duration of sedation was 12+/-7 days.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),d,12,198213,DB00683,Midazolam
,12923616,initial half-life t(1/2alpha),The initial half-life t(1/2alpha) was 1.33+/-1.15 h.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,1.33,198214,DB00683,Midazolam
,12923616,elimination half-life (t(1/2beta),The observed prolonged elimination half-life (t(1/2beta)=25.5+/-9.4 h) was related to the large volume of distribution (Vdbeta=22.6+/-9.4 l/kg).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,25.5,198215,DB00683,Midazolam
,12923616,volume of distribution (Vdbeta,The observed prolonged elimination half-life (t(1/2beta)=25.5+/-9.4 h) was related to the large volume of distribution (Vdbeta=22.6+/-9.4 l/kg).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),[l] / [kg],22.6,198216,DB00683,Midazolam
,12923616,total clearance,The mean total clearance was 13.4+/-7.0 ml/kg per minute.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),[ml] / [kg·min],13.4,198217,DB00683,Midazolam
,12923616,tcp(0/2,The mean time required to obtain a 50% decrease in plasma concentration was short (tcp(0/2=)4.7+/-3.7 h).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,4.7,198218,DB00683,Midazolam
,22078155,C(max),"The mean C(max) of 78 (40) ng/mL was reached 44 minutes after IN administration, whereas the mean C(max) was 51 (5) ng/mL after IV administration.","Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],78,198585,DB00683,Midazolam
,22078155,C(max),"The mean C(max) of 78 (40) ng/mL was reached 44 minutes after IN administration, whereas the mean C(max) was 51 (5) ng/mL after IV administration.","Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],51,198586,DB00683,Midazolam
,22078155,C(t,The mean estimated C(t=5 min) was 31.4 (28.1) ng/mL after IN administration.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],5,198587,DB00683,Midazolam
,22078155,C(t,The mean estimated C(t=5 min) was 31.4 (28.1) ng/mL after IN administration.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),[ng] / [ml],31.4,198588,DB00683,Midazolam
,22078155,elimination t(½),The elimination t(½) was 1.9 (0.41) hours for IN midazolam and 2.3 (0.19) hours for IV midazolam.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),h,1.9,198589,DB00683,Midazolam
,22078155,elimination t(½),The elimination t(½) was 1.9 (0.41) hours for IN midazolam and 2.3 (0.19) hours for IV midazolam.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),h,2.3,198590,DB00683,Midazolam
,22078155,bioavailability,The bioavailability of IN midazolam was 82%.,"Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22078155/),%,82,198591,DB00683,Midazolam
,26044579,clearance,"In the model for midazolam and metabolites, total body weight was not of influence on clearance (0.66 l min(-1) (RSE 8.3%)), while peripheral volume of distribution of midazolam (154 l (11.2%)), increased substantially with total body weight (P < 0.001).",Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26044579/),[l] / [min],0.66,198798,DB00683,Midazolam
,26044579,peripheral volume of distribution,"In the model for midazolam and metabolites, total body weight was not of influence on clearance (0.66 l min(-1) (RSE 8.3%)), while peripheral volume of distribution of midazolam (154 l (11.2%)), increased substantially with total body weight (P < 0.001).",Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26044579/),l,154,198799,DB00683,Midazolam
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],4.48,199576,DB00683,Midazolam
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],3.49,199577,DB00683,Midazolam
,29112329,AUCinf,"Administration of midazolam alone or concomitantly with PF-04171327 resulted in equivalent pharmacokinetic profiles (AUCinf , 21.17 vs 20.28 ng·h/mL, respectively), indicating that PF-04171327 had no net effect on CYP3A activity in vivo.","In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112329/),[h·ng] / [ml],21.17,200547,DB00683,Midazolam
,29112329,AUCinf,"Administration of midazolam alone or concomitantly with PF-04171327 resulted in equivalent pharmacokinetic profiles (AUCinf , 21.17 vs 20.28 ng·h/mL, respectively), indicating that PF-04171327 had no net effect on CYP3A activity in vivo.","In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112329/),[h·ng] / [ml],20.28,200548,DB00683,Midazolam
,9065257,total clearance,The total clearance of Ro 48-6791 was found to be 1410 +/- 380 vs.,[RO 48-6791--a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065257/),,1410,201282,DB00683,Midazolam
,9065257,central volume of distribution,399 +/- 91 ml min-1 for midazolam (mean +/- SD; P < 0.005) and the central volume of distribution to be 20.5 +/- 7.1 vs.,[RO 48-6791--a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065257/),,20.5,201283,DB00683,Midazolam
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],90.37,202305,DB00683,Midazolam
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],33.32,202306,DB00683,Midazolam
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],16.93,202307,DB00683,Midazolam
,27006091,peak concentrations of unbound plasma concentration,"The peak concentrations of unbound plasma concentration of MET, α-hydroxy metoprolol (HM), O-desmethyl metoprolol (ODM) and N-desisopropyl metoprolol (DIM) were 90.37 ± 2.69, 33.32 ± 1.92, 16.93 ± 1.70 and 7.96 ± 0.94 ng/mL, respectively.",An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006091/),[ng] / [ml],7.96,202308,DB00683,Midazolam
,12911366,area under the curve,Atorvastatin patients demonstrated a greater area under the curve (889.4 (standard deviation 388.6) ng-h.ml-1) vs. control patients (629.1 (standard deviation 197.2) ng-h.ml-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[ng-h] / [ml],889.4,203185,DB00683,Midazolam
,12911366,area under the curve,Atorvastatin patients demonstrated a greater area under the curve (889.4 (standard deviation 388.6) ng-h.ml-1) vs. control patients (629.1 (standard deviation 197.2) ng-h.ml-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[ng-h] / [ml],629.1,203186,DB00683,Midazolam
,12911366,clearance,Patients taking atorvastatin also demonstrated a decreased clearance (0.18 (standard deviation 0.08) l-kg. h-1) vs. control patients (0.27 (standard deviation 0.08) l-kg.h-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[l-kg] / [h],0.18,203187,DB00683,Midazolam
,12911366,clearance,Patients taking atorvastatin also demonstrated a decreased clearance (0.18 (standard deviation 0.08) l-kg. h-1) vs. control patients (0.27 (standard deviation 0.08) l-kg.h-1) (p < 0.05).,The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911366/),[l-kg] / [h],0.27,203188,DB00683,Midazolam
,15522714,flow-rate,"The mobile phase for separation consisted of phosphate buffer (0.02 M, pH 4.6), perchloric acid (60%) and acetonitrile (57.9:0.1:42, v/v/v) and was delivered at a flow-rate of 0.6 ml/min.",Sensitive determination of midazolam and 1'-hydroxymidazolam in plasma by liquid-liquid extraction and column-switching liquid chromatography with ultraviolet absorbance detection and its application for measuring CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522714/),[ml] / [min],0.6,203426,DB00683,Midazolam
,22253270,Bispectral Index-IC(50),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),[μg] / [ml],0.26,203472,DB00683,Midazolam
,22253270,Bispectral Index-IC(50),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),[μg] / [ml],0.07,203473,DB00683,Midazolam
,22253270,γ,"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),,1.6,203474,DB00683,Midazolam
,22253270,γ,"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),,8.6,203475,DB00683,Midazolam
,22253270,k(e0),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),1/[min],0.14,203476,DB00683,Midazolam
,22253270,k(e0),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),1/[min],0.053,203477,DB00683,Midazolam
,22253270,I(MAX),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),,39,203478,DB00683,Midazolam
,22253270,I(MAX),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),,19,203479,DB00683,Midazolam
,22253270,IC(50),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),[μg] / [ml],0.4,203480,DB00683,Midazolam
,22253270,IC(50),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),[μg] / [ml],0.08,203481,DB00683,Midazolam
,22253270,γ,"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),,1.4,203482,DB00683,Midazolam
,22253270,γ,"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),,3.4,203483,DB00683,Midazolam
,22253270,k(e0),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),1/[min],0.25,203484,DB00683,Midazolam
,22253270,k(e0),"The 2 models were used to simulate the arterial concentrations required for the pharmacodynamic models of sedation (Bispectral Index and Modified Observer's Assessment of Alertness/Sedation [MOAA/S]) and gave population mean pharmacodynamic parameters as follows: Bispectral Index-IC(50): 0.26, 0.07 μg/mL; γ: 1.6, 8.6; k(e0): 0.14, 0.053 min(-1); I(MAX): 39, 19, and MOAA/S-IC(50): 0.4, 0.08 μg/mL; γ: 1.4, 3.4; k(e0): 0.25, 0.050 min(-1) for remimazolam and midazolam, respectively.","A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22253270/),1/[min],0.050,203485,DB00683,Midazolam
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,2.80,203765,DB00683,Midazolam
,19801894,inhibitory constants (Ki),"The inhibitory constants (Ki) of KTZ were 2.80 +/- 0.70 and 115 +/- 28 microM for MDZ1'H and MDZ4H, respectively.","Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19801894/),μM,115,203766,DB00683,Midazolam
,9686884,recovery,Sample (1 ml plasma) preparation involved a simple solvent extraction step with a recovery of approximately 90% for both compounds.,Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9686884/),%,90,204458,DB00683,Midazolam
,9686884,flow-rate,The flow-rate of the mobile phase was 16 microl/min and the eluate was monitored by UV detection.,Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9686884/),[μl] / [min],16,204459,DB00683,Midazolam
,29745466,intrinsic clearance,"On the basis of midazolam and 1-OH-midazolam concentrations from 37 preterm neonates (gestational age 26-34 weeks) receiving midazolam orally and/or via a 30-minute intravenous infusion, intrinsic clearance in the gut wall and liver were found to be very low, with lower values in the gut wall (0.0196 and 6.7 L/h, respectively).",First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29745466/),[l] / [h],0.0196,205431,DB00683,Midazolam
,29745466,intrinsic clearance,"On the basis of midazolam and 1-OH-midazolam concentrations from 37 preterm neonates (gestational age 26-34 weeks) receiving midazolam orally and/or via a 30-minute intravenous infusion, intrinsic clearance in the gut wall and liver were found to be very low, with lower values in the gut wall (0.0196 and 6.7 L/h, respectively).",First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29745466/),[l] / [h],6.7,205432,DB00683,Midazolam
,29745466,total oral bioavailability,"This results in a highly variable and high total oral bioavailability of 92.1% (range, 67-95%) in preterm neonates, whereas this is around 30% in adults.",First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29745466/),%,92.1,205433,DB00683,Midazolam
,29745466,total oral bioavailability,"This results in a highly variable and high total oral bioavailability of 92.1% (range, 67-95%) in preterm neonates, whereas this is around 30% in adults.",First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29745466/),%,30,205434,DB00683,Midazolam
,8598183,area under the plasma concentration-time curve (AUC),"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[min·μg] / [ml],0.60,206565,DB00683,Midazolam
,8598183,area under the plasma concentration-time curve (AUC),"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[min·μg] / [ml],10.5,206566,DB00683,Midazolam
,8598183,peak midazolam concentration,"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[ng] / [ml],5.2,206567,DB00683,Midazolam
,8598183,peak midazolam concentration,"In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001).",Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),[ng] / [ml],70.4,206568,DB00683,Midazolam
,8598183,elimination half-life (t l/2),The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001).,Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),h,1.3,206569,DB00683,Midazolam
,8598183,elimination half-life (t l/2),The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001).,Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598183/),h,3.1,206570,DB00683,Midazolam
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),min,20-90,206677,DB00683,Midazolam
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.3,206678,DB00683,Midazolam
,2842128,bio-availability,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,16,206679,DB00683,Midazolam
,2842128,half-life,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.7-1.3,206680,DB00683,Midazolam
,2842128,plasma,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206681,DB00683,Midazolam
,2842128,blood clearance,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206682,DB00683,Midazolam
,2842128,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,40,206683,DB00683,Midazolam
,2842128,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),kg,0.6-1,206684,DB00683,Midazolam
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,350,206834,DB00683,Midazolam
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,11,206835,DB00683,Midazolam
,8010043,T1/2 alpha,"Pharmacokinetic parameters were: T1/2 alpha = 6.8 +2- 2.5 min, T1/2 beta = 118 +/- 27 min, Vc = 25 +/- 7 L, Cl = 393 +/- 79 ml.min-1, Vdss = 59 +/- 13 L, AUC0-infinity = 39.6 +/- 8.6 g.min.L-1.",Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010043/),min,6.8,207341,DB00683,Midazolam
,8010043,T1/2 beta,"Pharmacokinetic parameters were: T1/2 alpha = 6.8 +2- 2.5 min, T1/2 beta = 118 +/- 27 min, Vc = 25 +/- 7 L, Cl = 393 +/- 79 ml.min-1, Vdss = 59 +/- 13 L, AUC0-infinity = 39.6 +/- 8.6 g.min.L-1.",Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010043/),min,118,207342,DB00683,Midazolam
,8010043,Vc,"Pharmacokinetic parameters were: T1/2 alpha = 6.8 +2- 2.5 min, T1/2 beta = 118 +/- 27 min, Vc = 25 +/- 7 L, Cl = 393 +/- 79 ml.min-1, Vdss = 59 +/- 13 L, AUC0-infinity = 39.6 +/- 8.6 g.min.L-1.",Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010043/),l,25,207343,DB00683,Midazolam
,8010043,Cl,"Pharmacokinetic parameters were: T1/2 alpha = 6.8 +2- 2.5 min, T1/2 beta = 118 +/- 27 min, Vc = 25 +/- 7 L, Cl = 393 +/- 79 ml.min-1, Vdss = 59 +/- 13 L, AUC0-infinity = 39.6 +/- 8.6 g.min.L-1.",Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010043/),[ml] / [min],393,207344,DB00683,Midazolam
,8010043,Vdss,"Pharmacokinetic parameters were: T1/2 alpha = 6.8 +2- 2.5 min, T1/2 beta = 118 +/- 27 min, Vc = 25 +/- 7 L, Cl = 393 +/- 79 ml.min-1, Vdss = 59 +/- 13 L, AUC0-infinity = 39.6 +/- 8.6 g.min.L-1.",Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010043/),l,59,207345,DB00683,Midazolam
,8010043,AUC0-infinity,"Pharmacokinetic parameters were: T1/2 alpha = 6.8 +2- 2.5 min, T1/2 beta = 118 +/- 27 min, Vc = 25 +/- 7 L, Cl = 393 +/- 79 ml.min-1, Vdss = 59 +/- 13 L, AUC0-infinity = 39.6 +/- 8.6 g.min.L-1.",Midazolam pharmacokinetics and electroencephalographic changes in eight Chinese men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010043/),[g·min] / [l],39.6,207346,DB00683,Midazolam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.44,208117,DB00683,Midazolam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.47,208118,DB00683,Midazolam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],9.6,208119,DB00683,Midazolam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],7.1,208120,DB00683,Midazolam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.96,208121,DB00683,Midazolam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],1.08,208122,DB00683,Midazolam
,26202517,systemic clearance,"One year after bariatric surgery, systemic clearance of midazolam was higher [0.65 (7%) versus 0.39 (11%) L/min, mean ± RSE (P < 0.01), respectively] and mean oral transit time (MTT) was faster [23 (20%) versus 51 (15%) minutes (P < 0.01)], while oral bioavailability was unchanged (0.54 (9%)).",The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202517/),[l] / [min],0.65,208327,DB00683,Midazolam
,26202517,systemic clearance,"One year after bariatric surgery, systemic clearance of midazolam was higher [0.65 (7%) versus 0.39 (11%) L/min, mean ± RSE (P < 0.01), respectively] and mean oral transit time (MTT) was faster [23 (20%) versus 51 (15%) minutes (P < 0.01)], while oral bioavailability was unchanged (0.54 (9%)).",The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202517/),[l] / [min],0.39,208328,DB00683,Midazolam
,26202517,oral transit time (MTT),"One year after bariatric surgery, systemic clearance of midazolam was higher [0.65 (7%) versus 0.39 (11%) L/min, mean ± RSE (P < 0.01), respectively] and mean oral transit time (MTT) was faster [23 (20%) versus 51 (15%) minutes (P < 0.01)], while oral bioavailability was unchanged (0.54 (9%)).",The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202517/),min,23,208329,DB00683,Midazolam
,26202517,oral transit time (MTT),"One year after bariatric surgery, systemic clearance of midazolam was higher [0.65 (7%) versus 0.39 (11%) L/min, mean ± RSE (P < 0.01), respectively] and mean oral transit time (MTT) was faster [23 (20%) versus 51 (15%) minutes (P < 0.01)], while oral bioavailability was unchanged (0.54 (9%)).",The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202517/),min,51,208330,DB00683,Midazolam
,26202517,oral bioavailability,"One year after bariatric surgery, systemic clearance of midazolam was higher [0.65 (7%) versus 0.39 (11%) L/min, mean ± RSE (P < 0.01), respectively] and mean oral transit time (MTT) was faster [23 (20%) versus 51 (15%) minutes (P < 0.01)], while oral bioavailability was unchanged (0.54 (9%)).",The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202517/),,0.54,208331,DB00683,Midazolam
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1,208483,DB00683,Midazolam
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.4,208484,DB00683,Midazolam
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.0,208485,DB00683,Midazolam
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2,208486,DB00683,Midazolam
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,0.9,208487,DB00683,Midazolam
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.0,208488,DB00683,Midazolam
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.2,208489,DB00683,Midazolam
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.3,208490,DB00683,Midazolam
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,3.6,208491,DB00683,Midazolam
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,5.3,208492,DB00683,Midazolam
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.8,208493,DB00683,Midazolam
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.9,208494,DB00683,Midazolam
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.9,208495,DB00683,Midazolam
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.4,208496,DB00683,Midazolam
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.5,208497,DB00683,Midazolam
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,6.9,208498,DB00683,Midazolam
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.8,208499,DB00683,Midazolam
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.9,208500,DB00683,Midazolam
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.9,208501,DB00683,Midazolam
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.31,209092,DB00683,Midazolam
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.76,209093,DB00683,Midazolam
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],24.1,209094,DB00683,Midazolam
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],22.8,209095,DB00683,Midazolam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,24 to 48,209320,DB00683,Midazolam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,"4,5",209321,DB00683,Midazolam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,"2,5",209322,DB00683,Midazolam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],30,209323,DB00683,Midazolam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],250,209324,DB00683,Midazolam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],450,209325,DB00683,Midazolam
,6114680,V1,"On the other hand, all three drugs were found to have nearly the same volumes of distribution (V1: 25 l, VdSS: 80-100 l).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),l,25,209326,DB00683,Midazolam
,6114680,VdSS,"On the other hand, all three drugs were found to have nearly the same volumes of distribution (V1: 25 l, VdSS: 80-100 l).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),l,80-100,209327,DB00683,Midazolam
,6114680,biological halflife,"Of the 3 benzodiazepines investigated, diazepam reveals extremely complex pharmacokinetic effects which vary the duration of pharmacological responses very widely; besides drug interaction, enzyme induction and -inhibition it gives rise to the active metabolite N-desmethyl-diazepam (biological halflife 50 to 120 hours).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,50 to 120,209328,DB00683,Midazolam
,25660717,flow rate,"The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1mm×50mm, 1.7μm) with the mobile phase of acetonitrile and 1% formic acid in water with gradient elution at a flow rate of 0.40mL/min.",Rapid determination of ruscogenin in rat plasma with application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660717/),[ml] / [min],0.40,209767,DB00683,Midazolam
,25660717,matrix effect,The matrix effect was 92.4-107.3% for ruscogenin.,Rapid determination of ruscogenin in rat plasma with application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660717/),%,92.4-107.3,209768,DB00683,Midazolam
,25660717,recovery,The recovery ranged from 75.4% to 86.3%.,Rapid determination of ruscogenin in rat plasma with application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660717/),%,75.4,209769,DB00683,Midazolam
,25660717,recovery,The recovery ranged from 75.4% to 86.3%.,Rapid determination of ruscogenin in rat plasma with application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660717/),%,86.3,209770,DB00683,Midazolam
,9422893,maximum arterial plasma concentrations,"After an i.n. dose of 0.15 mg kg-1, maximum arterial plasma concentrations were 192 (SD 48) micrograms litre-1 at 14 (2) min.",Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422893/),[μg] / [l],192,210082,DB00683,Midazolam
,9422893,bioavailability,Uptake of midazolam was rapid and bioavailability was 83 (15)%.,Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422893/),%,83,210083,DB00683,Midazolam
,9422893,bioavailability,Routinely administering i.n. midazolam under the assumption that the bioavailability is approximately 50% (as reported previously in the literature) may lead to overdosing in some patients.,Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422893/),%,50,210084,DB00683,Midazolam
,9725490,elimination half life,"The mean values of elimination half life and volume of distribution, 4.5 +/- 5.4 h and 1.7 +/- 0.7 l/kg respectively, were higher than those reported in healthy subjects.",Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725490/),h,4.5,210566,DB00683,Midazolam
,9725490,volume of distribution,"The mean values of elimination half life and volume of distribution, 4.5 +/- 5.4 h and 1.7 +/- 0.7 l/kg respectively, were higher than those reported in healthy subjects.",Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725490/),[l] / [kg],1.7,210567,DB00683,Midazolam
,31023150,Partial metabolic clearance,Partial metabolic clearance of midazolam in palliative care patients was 31.7 ± 32.1 L/h.,Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31023150/),[l] / [h],31.7,210923,DB00683,Midazolam
,16861415,bioavailabilities,"The mean midazolam bioavailabilities and % coefficient of variation were 72.5 (12) and 93.4 (12) after the IN and IM doses, respectively.",Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861415/),,72.5,211110,DB00683,Midazolam
,16861415,% coefficient,"The mean midazolam bioavailabilities and % coefficient of variation were 72.5 (12) and 93.4 (12) after the IN and IM doses, respectively.",Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861415/),,72.5,211111,DB00683,Midazolam
,16861415,% coefficient,"The mean midazolam bioavailabilities and % coefficient of variation were 72.5 (12) and 93.4 (12) after the IN and IM doses, respectively.",Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861415/),,93.4,211112,DB00683,Midazolam
,16861415,time to maximum concentration,Median time to maximum concentration was 10 min for IN doses.,Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861415/),min,10,211113,DB00683,Midazolam
,30336720,volume of distribution,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[l] / [kg],0.69,211785,DB00683,Midazolam
,30336720,elimination half-life,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),h,13.6,211786,DB00683,Midazolam
,30336720,peak,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],7.4,211787,DB00683,Midazolam
,30336720,trough concentrations,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],3.7,211788,DB00683,Midazolam
,30336720,trough,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],5-10,211789,DB00683,Midazolam
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB00683,Midazolam
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB00683,Midazolam
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB00683,Midazolam
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB00683,Midazolam
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB00683,Midazolam
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB00683,Midazolam
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.41,212573,DB00683,Midazolam
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.39,212574,DB00683,Midazolam
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.57,212575,DB00683,Midazolam
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.24,212576,DB00683,Midazolam
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.21,212577,DB00683,Midazolam
,17575239,maximum clearance (Cl(max)),"Both drugs were metabolized primarily by CYP3A4, CYP3A5, and CYP1A1, with respective maximum clearance (Cl(max)) values for metabolism of 0.41, 0.39, and 0.57 mL/min/nmol for gefitinib and 0.24, 0.21, 0.31 mL/min/nmol for erlotinib.",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.31,212578,DB00683,Midazolam
,17575239,Cl(max),"CYP2D6 was involved in gefitinib metabolism (Cl(max), 0.63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0.15 mL/min/nmol).",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.63,212579,DB00683,Midazolam
,17575239,Cl(max),"CYP2D6 was involved in gefitinib metabolism (Cl(max), 0.63 mL/min/nmol) to a large extent, whereas CYP1A2 was considerably involved in erlotinib metabolism (Cl(max), 0.15 mL/min/nmol).",Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575239/),[ml] / [min·nM],0.15,212580,DB00683,Midazolam
,1643892,elimination half-life,The elimination half-life was prolonged (mean 5.4 vs. 2.3 hrs) and the volume of distribution was larger (3.1 vs. 0.9 L/kg) in patients vs. healthy volunteers.,Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643892/),h,5.4,212933,DB00683,Midazolam
,1643892,elimination half-life,The elimination half-life was prolonged (mean 5.4 vs. 2.3 hrs) and the volume of distribution was larger (3.1 vs. 0.9 L/kg) in patients vs. healthy volunteers.,Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643892/),h,2.3,212934,DB00683,Midazolam
,1643892,volume of distribution,The elimination half-life was prolonged (mean 5.4 vs. 2.3 hrs) and the volume of distribution was larger (3.1 vs. 0.9 L/kg) in patients vs. healthy volunteers.,Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643892/),[l] / [kg],3.1,212935,DB00683,Midazolam
,1643892,volume of distribution,The elimination half-life was prolonged (mean 5.4 vs. 2.3 hrs) and the volume of distribution was larger (3.1 vs. 0.9 L/kg) in patients vs. healthy volunteers.,Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643892/),[l] / [kg],0.9,212936,DB00683,Midazolam
,1643892,clearance,"The clearance did not differ between groups (6.3 vs. 4.9 mL/min/kg in patients vs. volunteers, respectively).",Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643892/),[ml] / [kg·min],6.3,212937,DB00683,Midazolam
,1643892,clearance,"The clearance did not differ between groups (6.3 vs. 4.9 mL/min/kg in patients vs. volunteers, respectively).",Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1643892/),[ml] / [kg·min],4.9,212938,DB00683,Midazolam
,19884323,K(i),"An iterative approach determined the optimum values to predict in vivo effects of clarithromycin on midazolam to be 5.3 microM for K(i) and 0.4 and 4 h(-1) for k(inact) in the liver and intestines, respectively.",Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884323/),μM,5.3,214444,DB00683,Midazolam
,19884323,k(inact),"An iterative approach determined the optimum values to predict in vivo effects of clarithromycin on midazolam to be 5.3 microM for K(i) and 0.4 and 4 h(-1) for k(inact) in the liver and intestines, respectively.",Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884323/),1/[h],0.4,214445,DB00683,Midazolam
,19884323,k(inact),"An iterative approach determined the optimum values to predict in vivo effects of clarithromycin on midazolam to be 5.3 microM for K(i) and 0.4 and 4 h(-1) for k(inact) in the liver and intestines, respectively.",Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884323/),1/[h],4,214446,DB00683,Midazolam
,21545620,maximum concentration (C(max) ),"Midazolam maximum concentration (C(max) ) was significantly lower in Mongolians than that in Hans, Uygurs, Huis and Koreans (74·9 ± 33·7, 103·1 ± 26·4, 124·8 ± 50·0, 130·0 ± 38·3 and 189·0 ± 82·1 μg/L, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),[μg] / [l],74·9,214874,DB00683,Midazolam
,21545620,maximum concentration (C(max) ),"Midazolam maximum concentration (C(max) ) was significantly lower in Mongolians than that in Hans, Uygurs, Huis and Koreans (74·9 ± 33·7, 103·1 ± 26·4, 124·8 ± 50·0, 130·0 ± 38·3 and 189·0 ± 82·1 μg/L, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),[μg] / [l],103·1,214875,DB00683,Midazolam
,21545620,maximum concentration (C(max) ),"Midazolam maximum concentration (C(max) ) was significantly lower in Mongolians than that in Hans, Uygurs, Huis and Koreans (74·9 ± 33·7, 103·1 ± 26·4, 124·8 ± 50·0, 130·0 ± 38·3 and 189·0 ± 82·1 μg/L, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),[μg] / [l],124·8,214876,DB00683,Midazolam
,21545620,maximum concentration (C(max) ),"Midazolam maximum concentration (C(max) ) was significantly lower in Mongolians than that in Hans, Uygurs, Huis and Koreans (74·9 ± 33·7, 103·1 ± 26·4, 124·8 ± 50·0, 130·0 ± 38·3 and 189·0 ± 82·1 μg/L, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),[μg] / [l],130·0,214877,DB00683,Midazolam
,21545620,maximum concentration (C(max) ),"Midazolam maximum concentration (C(max) ) was significantly lower in Mongolians than that in Hans, Uygurs, Huis and Koreans (74·9 ± 33·7, 103·1 ± 26·4, 124·8 ± 50·0, 130·0 ± 38·3 and 189·0 ± 82·1 μg/L, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),[μg] / [l],189·0,214878,DB00683,Midazolam
,21545620,time to attain C(max) (t(max) ),"The time to attain C(max) (t(max) ) for Hans was significantly longer as compared with Koreans and Uygurs (1·5 ± 0·7, 0·8 ± 0·5, 0·6 ± 0·7 h, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,1·5,214879,DB00683,Midazolam
,21545620,time to attain C(max) (t(max) ),"The time to attain C(max) (t(max) ) for Hans was significantly longer as compared with Koreans and Uygurs (1·5 ± 0·7, 0·8 ± 0·5, 0·6 ± 0·7 h, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,0·8,214880,DB00683,Midazolam
,21545620,time to attain C(max) (t(max) ),"The time to attain C(max) (t(max) ) for Hans was significantly longer as compared with Koreans and Uygurs (1·5 ± 0·7, 0·8 ± 0·5, 0·6 ± 0·7 h, respectively).",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,0·6,214881,DB00683,Midazolam
,21545620,terminal half-life (t(1/2z)),"Midazolam terminal half-life (t(1/2z)) were 3·0 ± 0·8, 2·2 ± 0·7, 1·9 ± 0·7, 3·5 ± 1·9, 3·8 ± 2·3 h for Hans, Mongolians, Uygurs, Huis and Koreans, respectively.",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,3·0,214882,DB00683,Midazolam
,21545620,terminal half-life (t(1/2z)),"Midazolam terminal half-life (t(1/2z)) were 3·0 ± 0·8, 2·2 ± 0·7, 1·9 ± 0·7, 3·5 ± 1·9, 3·8 ± 2·3 h for Hans, Mongolians, Uygurs, Huis and Koreans, respectively.",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,2·2,214883,DB00683,Midazolam
,21545620,terminal half-life (t(1/2z)),"Midazolam terminal half-life (t(1/2z)) were 3·0 ± 0·8, 2·2 ± 0·7, 1·9 ± 0·7, 3·5 ± 1·9, 3·8 ± 2·3 h for Hans, Mongolians, Uygurs, Huis and Koreans, respectively.",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,1·9,214884,DB00683,Midazolam
,21545620,terminal half-life (t(1/2z)),"Midazolam terminal half-life (t(1/2z)) were 3·0 ± 0·8, 2·2 ± 0·7, 1·9 ± 0·7, 3·5 ± 1·9, 3·8 ± 2·3 h for Hans, Mongolians, Uygurs, Huis and Koreans, respectively.",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,3·5,214885,DB00683,Midazolam
,21545620,terminal half-life (t(1/2z)),"Midazolam terminal half-life (t(1/2z)) were 3·0 ± 0·8, 2·2 ± 0·7, 1·9 ± 0·7, 3·5 ± 1·9, 3·8 ± 2·3 h for Hans, Mongolians, Uygurs, Huis and Koreans, respectively.",Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21545620/),h,3·8,214886,DB00683,Midazolam
,31994022,time to reach the maximum plasma concentration,ACT-709478 was absorbed with a time to reach the maximum plasma concentration of 3.5-4.0 h and eliminated with a half-life of 45-53 h.,"Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994022/),h,3.5-4.0,215456,DB00683,Midazolam
,31994022,half-life,ACT-709478 was absorbed with a time to reach the maximum plasma concentration of 3.5-4.0 h and eliminated with a half-life of 45-53 h.,"Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31994022/),h,45-53,215457,DB00683,Midazolam
,18956271,IC(50),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.2,215833,DB00683,Midazolam
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,0.5,215834,DB00683,Midazolam
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215835,DB00683,Midazolam
,18956271,(K(i)),"The apparent K(m) and V(max) of beauvericin in HLM were determined by substrate depletion approach and its inhibitory effects on cytochromes P450 (CYP) activities were evaluated using probe substrates, with IC(50) and the (K(i)) values were 1.2 microM (0.5 microM) and 1.3 microM (1.9 microM), respectively for CYP3A4/5 (midazolam) and CYP2C19 (mephenytoin).",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.9,215836,DB00683,Midazolam
,18956271,IC(50),"Similarly, beauvericin was also a potent inhibitor for CYP3A1/2 (IC(50): 1.3 microM) in RLM.",An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18956271/),μM,1.3,215837,DB00683,Midazolam
,15845749,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) of intravenously administered midazolam (30 mg/kg) was 2.2-fold decreased in the transgenic mice compared with wild-type (5.45 +/- 0.21 versus 11.7 +/- 0.46 microg . h ml(-1); P < 0.01), and early formation of the primary metabolite 1-hydroxymidazolam was about 2-fold increased, demonstrating the functionality of CYP3A4 in the liver.",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),[h·μg] / [ml],5.45,216180,DB00683,Midazolam
,15845749,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) of intravenously administered midazolam (30 mg/kg) was 2.2-fold decreased in the transgenic mice compared with wild-type (5.45 +/- 0.21 versus 11.7 +/- 0.46 microg . h ml(-1); P < 0.01), and early formation of the primary metabolite 1-hydroxymidazolam was about 2-fold increased, demonstrating the functionality of CYP3A4 in the liver.",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),[h·μg] / [ml],11.7,216181,DB00683,Midazolam
,15845749,plasma AUC,"Similarly, following intravenous administration of cyclosporin A (20 mg/kg), CYP3A4 transgenic mice displayed a reduced plasma AUC compared with wild-type (24.3 +/- 0.66 versus 35.8 +/- 0.53 microg . h ml(-) (1); P < 0.01).",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),(1)·h·ml(-)·μg,24.3,216182,DB00683,Midazolam
,15845749,plasma AUC,"Similarly, following intravenous administration of cyclosporin A (20 mg/kg), CYP3A4 transgenic mice displayed a reduced plasma AUC compared with wild-type (24.3 +/- 0.66 versus 35.8 +/- 0.53 microg . h ml(-) (1); P < 0.01).",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),(1)·h·ml(-)·μg,35.8,216183,DB00683,Midazolam
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],382.8,216447,DB00683,Midazolam
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],63.0,216448,DB00683,Midazolam
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],84.5,216449,DB00683,Midazolam
,25453994,AUC,"Midazolam AUC was significantly higher in the HD group (382.8 h·ng/mL) than in the healthy-control (63.0 h·ng/mL; P<0.001), NDD-CKD (84.5 h·ng/mL; P=0.002), and PD (47.4 h·ng/mL; P<0.001) groups.",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],47.4,216450,DB00683,Midazolam
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"2,950",216451,DB00683,Midazolam
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"2,327",216452,DB00683,Midazolam
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"2,095",216453,DB00683,Midazolam
,25453994,AUC,"Fexofenadine AUC was significantly higher in each of the NDD-CKD (2,950 h·ng/mL; P=0.003), HD (2,327 h·ng/mL; P=0.01), and PD (2,095 h·ng/mL; P=0.04) groups compared with healthy controls (1,008 h·ng/mL).",Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25453994/),[h·ng] / [ml],"1,008",216454,DB00683,Midazolam
,3179150,clearance,"Mean clearance was 512 ml kg-1 h-1 and mean elimination half-lives were 3.3 h following CPB, with a tendency to a higher clearance in those children who had not undergone bypass.",A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179150/),[ml] / [h·kg],512,216492,DB00683,Midazolam
,3179150,elimination half-lives,"Mean clearance was 512 ml kg-1 h-1 and mean elimination half-lives were 3.3 h following CPB, with a tendency to a higher clearance in those children who had not undergone bypass.",A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179150/),h,3.3,216493,DB00683,Midazolam
,3179150,plasma midazolam concentrations,Mean plasma midazolam concentrations consistent with adequate sedation were 80-100 ng ml-1 during the infusion.,A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179150/),[ng] / [ml],80-100,216494,DB00683,Midazolam
,8549036,area under the plasma midazolam concentration-time curve,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[min·μg] / [ml],10.2,216786,DB00683,Midazolam
,8549036,area under the plasma midazolam concentration-time curve,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[min·μg] / [ml],0.42,216787,DB00683,Midazolam
,8549036,maximum concentration,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[ng] / [ml],55,216788,DB00683,Midazolam
,8549036,maximum concentration,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[ng] / [ml],3.5,216789,DB00683,Midazolam
,8549036,elimination half-life,The elimination half-life of midazolam was decreased from 3.1 +/- 0.2 to 1.3 +/- 0.2 hours by rifampin (p < 0.001).,Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),h,3.1,216790,DB00683,Midazolam
,8549036,elimination half-life,The elimination half-life of midazolam was decreased from 3.1 +/- 0.2 to 1.3 +/- 0.2 hours by rifampin (p < 0.001).,Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),h,1.3,216791,DB00683,Midazolam
,9673833,half-life,"Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg.",Clinical pharmacology of midazolam in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673833/),h,0.8 to 1.8,217533,DB00683,Midazolam
,9673833,clearance,"Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg.",Clinical pharmacology of midazolam in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673833/),[ml] / [kg·min],4.7 to 19.7,217534,DB00683,Midazolam
,19884365,area under the concentration-time curve over a dosing interval (AUC(0-tau)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[h·μg] / [ml],16.7,217960,DB00683,Midazolam
,19884365,area under the concentration-time curve over a dosing interval (AUC(0-tau)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[h·μg] / [ml],76.8,217961,DB00683,Midazolam
,19884365,maximum concentration of the drug in plasma (C(max)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],1.5,217962,DB00683,Midazolam
,19884365,maximum concentration of the drug in plasma (C(max)),"The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC(0-tau)) and maximum concentration of the drug in plasma (C(max)) ranged from 16.7 microg.h/ml (coefficient of variation [CV], 15%) and 1.5 microg/ml (CV, 24%) at a 10-mg dose to 76.8 microg.h/ml (CV, 19%) and 6.2 microg/ml (CV, 15%) at a 50-mg dose, respectively.","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],6.2,217963,DB00683,Midazolam
,19884365,steady-state concentration at the end of the dosing interval (C(tau)),"The geometric mean steady-state concentration at the end of the dosing interval (C(tau)) with a 50-mg dose was 1.6 microg/ml, approximately 25-fold higher than the protein-adjusted 90% inhibitory concentration (0.064 microg/ml).","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],1.6,217964,DB00683,Midazolam
,19884365,90% inhibitory concentration,"The geometric mean steady-state concentration at the end of the dosing interval (C(tau)) with a 50-mg dose was 1.6 microg/ml, approximately 25-fold higher than the protein-adjusted 90% inhibitory concentration (0.064 microg/ml).","Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),[μg] / [ml],0.064,217965,DB00683,Midazolam
,19884365,half-life,The half-life was approximately 15 h.,"Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19884365/),h,15,217966,DB00683,Midazolam
,7955817,half-life,"Flumazenil exhibited a rapid onset (the half-life of equilibration between drug concentration in the blood and drug effect was 3.3 minutes) and short duration of action (the flumazenil plasma concentration causing half-maximal effect was 7.4 ng/ml, which was reached about 1 hour after dosing).",The pharmacokinetic-pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955817/),min,3.3,218041,DB00683,Midazolam
,7955817,plasma concentration causing half-maximal effect,"Flumazenil exhibited a rapid onset (the half-life of equilibration between drug concentration in the blood and drug effect was 3.3 minutes) and short duration of action (the flumazenil plasma concentration causing half-maximal effect was 7.4 ng/ml, which was reached about 1 hour after dosing).",The pharmacokinetic-pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955817/),[ng] / [ml],7.4,218042,DB00683,Midazolam
,7199322,biological half-life in the terminal phase (beta),The biological half-life in the terminal phase (beta) ranges between 1 1/2 and 2 1/2 h.,[Pharmacokinetics of midazolam after i.v. administration (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199322/),h,1 1/2,218299,DB00683,Midazolam
,7199322,biological half-life in the terminal phase (beta),The biological half-life in the terminal phase (beta) ranges between 1 1/2 and 2 1/2 h.,[Pharmacokinetics of midazolam after i.v. administration (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199322/),h,2 1/2,218300,DB00683,Midazolam
,7199322,total plasma clearance,The total plasma clearance is 300-350 ml/min.,[Pharmacokinetics of midazolam after i.v. administration (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199322/),[ml] / [min],300-350,218301,DB00683,Midazolam
,15914101,flow-rate,"The chromatographic separation was performed on a reversed-phase HyPURITY Elite C18 (5 microm particle size; 100 mm x 2.1mm i.d.) analytical column using an acidic (pH 2.8) mobile phase (water-acetonitrile; 75:25% (v/v) containing formic acid (0.1%, v/v)) delivered at a flow-rate of 200 microl/min.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),[μl] / [min],200,219591,DB00683,Midazolam
,15914101,limits of detection,"The limits of detection and quantification were 2 and 5 ng/ml, respectively, for both MDZ and 1'-OHM.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),[ng] / [ml],2,219592,DB00683,Midazolam
,15914101,limits of detection,"The limits of detection and quantification were 2 and 5 ng/ml, respectively, for both MDZ and 1'-OHM.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),[ng] / [ml],5,219593,DB00683,Midazolam
,15914101,relative recoveries,"The mean relative recoveries at 40 and 600 ng/ml (MDZ) were 79.4+/-3.1% (n = 6) and 84.2+/-4.7% (n = 8), respectively; for 1'-OHM at 30 and 200 ng/ml the values were 89.9+/-7.2% (n = 6) and 86.9+/-5.6% (n = 8), respectively.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),%,79.4,219594,DB00683,Midazolam
,15914101,relative recoveries,"The mean relative recoveries at 40 and 600 ng/ml (MDZ) were 79.4+/-3.1% (n = 6) and 84.2+/-4.7% (n = 8), respectively; for 1'-OHM at 30 and 200 ng/ml the values were 89.9+/-7.2% (n = 6) and 86.9+/-5.6% (n = 8), respectively.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),%,84.2,219595,DB00683,Midazolam
,15914101,relative recoveries,"The mean relative recoveries at 40 and 600 ng/ml (MDZ) were 79.4+/-3.1% (n = 6) and 84.2+/-4.7% (n = 8), respectively; for 1'-OHM at 30 and 200 ng/ml the values were 89.9+/-7.2% (n = 6) and 86.9+/-5.6% (n = 8), respectively.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),%,89.9,219596,DB00683,Midazolam
,15914101,relative recoveries,"The mean relative recoveries at 40 and 600 ng/ml (MDZ) were 79.4+/-3.1% (n = 6) and 84.2+/-4.7% (n = 8), respectively; for 1'-OHM at 30 and 200 ng/ml the values were 89.9+/-7.2% (n = 6) and 86.9+/-5.6% (n = 8), respectively.",Determination of midazolam and its major metabolite 1'-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15914101/),%,86.9,219597,DB00683,Midazolam
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB00683,Midazolam
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB00683,Midazolam
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB00683,Midazolam
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB00683,Midazolam
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB00683,Midazolam
,23256899,peak plasma concentrations,"Arithmetic mean values ± SD for midazolam peak plasma concentrations were 0.86 ± 0.36 μg/mL (C0) and 0.20 ± 0.06 μg/mL (Cmax), following IV and IM administration, respectively.","The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23256899/),[μg] / [ml],0.86,221166,DB00683,Midazolam
,23256899,C0,"Arithmetic mean values ± SD for midazolam peak plasma concentrations were 0.86 ± 0.36 μg/mL (C0) and 0.20 ± 0.06 μg/mL (Cmax), following IV and IM administration, respectively.","The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23256899/),[μg] / [ml],0.86,221167,DB00683,Midazolam
,23256899,Cmax,"Arithmetic mean values ± SD for midazolam peak plasma concentrations were 0.86 ± 0.36 μg/mL (C0) and 0.20 ± 0.06 μg/mL (Cmax), following IV and IM administration, respectively.","The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23256899/),[μg] / [ml],0.20,221168,DB00683,Midazolam
,23256899,Time to peak concentration (Tmax ),Time to peak concentration (Tmax ) after IM administration was 7.8 ± 2.4 min with a bioavailability of 50 ± 16%.,"The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23256899/),min,7.8,221169,DB00683,Midazolam
,23256899,bioavailability,Time to peak concentration (Tmax ) after IM administration was 7.8 ± 2.4 min with a bioavailability of 50 ± 16%.,"The pharmacokinetics of midazolam after intravenous, intramuscular, and rectal administration in healthy dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23256899/),%,50,221170,DB00683,Midazolam
,11802661,absolute bioavailability,The absolute bioavailability of midazolam in the nasal formulation was determined to be 64 +/- 19% (mean +/- standard deviation).,Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802661/),%,64,221204,DB00683,Midazolam
,11802661,peak serum concentration,"The peak serum concentration from nasal application, 42 +/- 11 ng ml-1, was reached within 10-15 min following administration and clinical sedative effects were observed within 5 to 10 min and lasted for about 40 min.",Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802661/),[ng] / [ml],42,221205,DB00683,Midazolam
,20831533,AUC,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[h·μg] / [ml],2.01,222176,DB00683,Midazolam
,20831533,peak level,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.47,222177,DB00683,Midazolam
,20831533,peak level,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.82,222178,DB00683,Midazolam
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),,0.186,222179,DB00683,Midazolam
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[h·μg] / [ml],6.13,222180,DB00683,Midazolam
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.82,222181,DB00683,Midazolam
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.458,222182,DB00683,Midazolam
,25757445,Tmax,"For digoxin, the median Tmax decreased from 40 minutes at baseline to 30 and 20 minutes at 3 and 12 months, respectively.",Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25757445/),min,40,222683,DB00683,Midazolam
,25757445,Tmax,"For digoxin, the median Tmax decreased from 40 minutes at baseline to 30 and 20 minutes at 3 and 12 months, respectively.",Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25757445/),min,30,222684,DB00683,Midazolam
,25757445,Tmax,"For digoxin, the median Tmax decreased from 40 minutes at baseline to 30 and 20 minutes at 3 and 12 months, respectively.",Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25757445/),min,20,222685,DB00683,Midazolam
,1817958,half-life (t 1/2 alpha),After intravenous administration initial distribution was rapid with a mean half-life (t 1/2 alpha) of 0.06 +/- 0.03 h followed by a terminal half-life (t 1/2 beta or gamma) of 1.5 +/- 0.3 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,0.06,222906,DB00683,Midazolam
,1817958,terminal half-life (t 1/2 beta or,After intravenous administration initial distribution was rapid with a mean half-life (t 1/2 alpha) of 0.06 +/- 0.03 h followed by a terminal half-life (t 1/2 beta or gamma) of 1.5 +/- 0.3 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,1.5,222907,DB00683,Midazolam
,1817958,gamma),After intravenous administration initial distribution was rapid with a mean half-life (t 1/2 alpha) of 0.06 +/- 0.03 h followed by a terminal half-life (t 1/2 beta or gamma) of 1.5 +/- 0.3 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,1.5,222908,DB00683,Midazolam
,1817958,Volume of distribution,Volume of distribution was 0.62 +/- 0.27 l/kg.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),[l] / [kg],0.62,222909,DB00683,Midazolam
,1817958,terminal half-life,Mean terminal half-life was 2.8 +/- 1.7 h.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),h,2.8,222910,DB00683,Midazolam
,1817958,absolute bioavailability,The absolute bioavailability of intramuscular midazolam was calculated in 11 patients as 87 +/- 18%.,A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817958/),%,87,222911,DB00683,Midazolam
,24689515,clearance,"The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),[l] / [h],36,223191,DB00683,Midazolam
,24689515,intercompartmental clearance,"The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),[l] / [h],29·2,223192,DB00683,Midazolam
,24689515,intercompartmental clearance,"The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),l,169,223193,DB00683,Midazolam
,24689515,central,"The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),[l] / [h],29·2,223194,DB00683,Midazolam
,24689515,central,"The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),l,169,223195,DB00683,Midazolam
,24689515,peripheral volume,"The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),l,392,223196,DB00683,Midazolam
,24689515,clearance,"Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),[l] / [h],62·7,223197,DB00683,Midazolam
,24689515,intercompartmental clearance,"Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),[l] / [h],34·7,223198,DB00683,Midazolam
,24689515,intercompartmental clearance,"Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),l,133,223199,DB00683,Midazolam
,24689515,central,"Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),[l] / [h],34·7,223200,DB00683,Midazolam
,24689515,central,"Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),l,133,223201,DB00683,Midazolam
,24689515,peripheral volume,"Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),l,146,223202,DB00683,Midazolam
,24689515,mean transit time,"The estimated mean transit time for induction of the CYP3A4 enzyme was 197 h, with 57% IIV.",Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24689515/),h,197,223203,DB00683,Midazolam
less,32738202,Ki,The Ki values in this study were less than 8.32 μM.,Evaluation of acacetin inhibition potential against cytochrome P450 in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738202/),μM,8.32,223492,DB00683,Midazolam
,17322140,50% inhibitory concentrations (IC(50)),"In human liver microsomes, the mean 50% inhibitory concentrations (IC(50)) for PJ and GFJ versus CYP3A (triazolam alpha-hydroxylation) were 0.61% and 0.55%, (v/v) respectively, without preincubation of inhibitor with microsomes.","Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322140/),%,0.61,223506,DB00683,Midazolam
,17322140,50% inhibitory concentrations (IC(50)),"In human liver microsomes, the mean 50% inhibitory concentrations (IC(50)) for PJ and GFJ versus CYP3A (triazolam alpha-hydroxylation) were 0.61% and 0.55%, (v/v) respectively, without preincubation of inhibitor with microsomes.","Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322140/),%,0.55,223507,DB00683,Midazolam
,15083070,Cmax,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[ng] / [ml],0.30,223833,DB00683,Midazolam
,15083070,Cmax,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[ng] / [ml],0.31,223834,DB00683,Midazolam
,15083070,Cmax,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[ng] / [ml],0.31,223835,DB00683,Midazolam
,15083070,Apparent clearance,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[l] / [h],122,223836,DB00683,Midazolam
,15083070,Apparent clearance,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[l] / [h],156,223837,DB00683,Midazolam
,15083070,Apparent clearance,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[l] / [h],111,223838,DB00683,Midazolam
,15083070,t1/2,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),h,1.9,223839,DB00683,Midazolam
,15083070,t1/2,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),h,1.6,223840,DB00683,Midazolam
,15083070,t1/2,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),h,1.7,223841,DB00683,Midazolam
,21943317,area under the concentration-time curve from 0 to 36 h (AUC 0-36),"Co-administration of genistein decreased the area under the concentration-time curve from 0 to 36 h (AUC 0-36) (143.65 ± 55.40 ng h/mL versus 126.10 ± 40.14 ng h/mL, p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC 0-∞) (209.18 ± 56.61 ng h/mL versus 180.59 ± 43.03 ng h/mL, p < 0.05), and also maximum concentration (Cmax) of midazolam (48.86 ± 20.21 ng/mL versus 36.25 ± 14.35 ng/mL p < 0.05).",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],143.65,223859,DB00683,Midazolam
,21943317,area under the concentration-time curve from 0 to 36 h (AUC 0-36),"Co-administration of genistein decreased the area under the concentration-time curve from 0 to 36 h (AUC 0-36) (143.65 ± 55.40 ng h/mL versus 126.10 ± 40.14 ng h/mL, p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC 0-∞) (209.18 ± 56.61 ng h/mL versus 180.59 ± 43.03 ng h/mL, p < 0.05), and also maximum concentration (Cmax) of midazolam (48.86 ± 20.21 ng/mL versus 36.25 ± 14.35 ng/mL p < 0.05).",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],126.10,223860,DB00683,Midazolam
,21943317,area under the concentration-time curve from zero to infinity (AUC 0-∞),"Co-administration of genistein decreased the area under the concentration-time curve from 0 to 36 h (AUC 0-36) (143.65 ± 55.40 ng h/mL versus 126.10 ± 40.14 ng h/mL, p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC 0-∞) (209.18 ± 56.61 ng h/mL versus 180.59 ± 43.03 ng h/mL, p < 0.05), and also maximum concentration (Cmax) of midazolam (48.86 ± 20.21 ng/mL versus 36.25 ± 14.35 ng/mL p < 0.05).",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],209.18,223861,DB00683,Midazolam
,21943317,area under the concentration-time curve from zero to infinity (AUC 0-∞),"Co-administration of genistein decreased the area under the concentration-time curve from 0 to 36 h (AUC 0-36) (143.65 ± 55.40 ng h/mL versus 126.10 ± 40.14 ng h/mL, p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC 0-∞) (209.18 ± 56.61 ng h/mL versus 180.59 ± 43.03 ng h/mL, p < 0.05), and also maximum concentration (Cmax) of midazolam (48.86 ± 20.21 ng/mL versus 36.25 ± 14.35 ng/mL p < 0.05).",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],180.59,223862,DB00683,Midazolam
,21943317,maximum concentration (Cmax),"Co-administration of genistein decreased the area under the concentration-time curve from 0 to 36 h (AUC 0-36) (143.65 ± 55.40 ng h/mL versus 126.10 ± 40.14 ng h/mL, p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC 0-∞) (209.18 ± 56.61 ng h/mL versus 180.59 ± 43.03 ng h/mL, p < 0.05), and also maximum concentration (Cmax) of midazolam (48.86 ± 20.21 ng/mL versus 36.25 ± 14.35 ng/mL p < 0.05).",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[ng] / [ml],48.86,223863,DB00683,Midazolam
,21943317,maximum concentration (Cmax),"Co-administration of genistein decreased the area under the concentration-time curve from 0 to 36 h (AUC 0-36) (143.65 ± 55.40 ng h/mL versus 126.10 ± 40.14 ng h/mL, p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC 0-∞) (209.18 ± 56.61 ng h/mL versus 180.59 ± 43.03 ng h/mL, p < 0.05), and also maximum concentration (Cmax) of midazolam (48.86 ± 20.21 ng/mL versus 36.25 ± 14.35 ng/mL p < 0.05).",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[ng] / [ml],36.25,223864,DB00683,Midazolam
,21943317,AUC 0-36,"Similarly, AUC 0-36 (2490.282 ± 668.79 ng h/mL versus 2114.46 ± 861.11 ng h/mL, p < 0.05), AUC 0-∞ (2980.45 ± 921.09 ng h/mL versus 2626.92 ± 1003.78 ng h/mL, p < 0.05) and Cmax of talinolol (326.58 ± 197.67 ng/mL versus 293.42 ± 127.19 ng/mL, p < 0.05) were reduced by genistein co-administration.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],2490.282,223865,DB00683,Midazolam
,21943317,AUC 0-36,"Similarly, AUC 0-36 (2490.282 ± 668.79 ng h/mL versus 2114.46 ± 861.11 ng h/mL, p < 0.05), AUC 0-∞ (2980.45 ± 921.09 ng h/mL versus 2626.92 ± 1003.78 ng h/mL, p < 0.05) and Cmax of talinolol (326.58 ± 197.67 ng/mL versus 293.42 ± 127.19 ng/mL, p < 0.05) were reduced by genistein co-administration.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],2114.46,223866,DB00683,Midazolam
,21943317,AUC 0-∞,"Similarly, AUC 0-36 (2490.282 ± 668.79 ng h/mL versus 2114.46 ± 861.11 ng h/mL, p < 0.05), AUC 0-∞ (2980.45 ± 921.09 ng h/mL versus 2626.92 ± 1003.78 ng h/mL, p < 0.05) and Cmax of talinolol (326.58 ± 197.67 ng/mL versus 293.42 ± 127.19 ng/mL, p < 0.05) were reduced by genistein co-administration.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],2980.45,223867,DB00683,Midazolam
,21943317,AUC 0-∞,"Similarly, AUC 0-36 (2490.282 ± 668.79 ng h/mL versus 2114.46 ± 861.11 ng h/mL, p < 0.05), AUC 0-∞ (2980.45 ± 921.09 ng h/mL versus 2626.92 ± 1003.78 ng h/mL, p < 0.05) and Cmax of talinolol (326.58 ± 197.67 ng/mL versus 293.42 ± 127.19 ng/mL, p < 0.05) were reduced by genistein co-administration.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[h·ng] / [ml],2626.92,223868,DB00683,Midazolam
,21943317,Cmax,"Similarly, AUC 0-36 (2490.282 ± 668.79 ng h/mL versus 2114.46 ± 861.11 ng h/mL, p < 0.05), AUC 0-∞ (2980.45 ± 921.09 ng h/mL versus 2626.92 ± 1003.78 ng h/mL, p < 0.05) and Cmax of talinolol (326.58 ± 197.67 ng/mL versus 293.42 ± 127.19 ng/mL, p < 0.05) were reduced by genistein co-administration.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[ng] / [ml],326.58,223869,DB00683,Midazolam
,21943317,Cmax,"Similarly, AUC 0-36 (2490.282 ± 668.79 ng h/mL versus 2114.46 ± 861.11 ng h/mL, p < 0.05), AUC 0-∞ (2980.45 ± 921.09 ng h/mL versus 2626.92 ± 1003.78 ng h/mL, p < 0.05) and Cmax of talinolol (326.58 ± 197.67 ng/mL versus 293.42 ± 127.19 ng/mL, p < 0.05) were reduced by genistein co-administration.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),[ng] / [ml],293.42,223870,DB00683,Midazolam
,21943317,oral clearance,"The oral clearance of midazolam (1.68 ± 0.85 h-1 versus 3.98 ± 0.59 h-1, p < 0.05) and talinolol (3.34 ± 1.24 h-1 versus 3.79 ± 1.55 h-1, p<0.05) were increased by genistien significantly.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),1/[h],1.68,223871,DB00683,Midazolam
,21943317,oral clearance,"The oral clearance of midazolam (1.68 ± 0.85 h-1 versus 3.98 ± 0.59 h-1, p < 0.05) and talinolol (3.34 ± 1.24 h-1 versus 3.79 ± 1.55 h-1, p<0.05) were increased by genistien significantly.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),1/[h],3.98,223872,DB00683,Midazolam
,21943317,oral clearance,"The oral clearance of midazolam (1.68 ± 0.85 h-1 versus 3.98 ± 0.59 h-1, p < 0.05) and talinolol (3.34 ± 1.24 h-1 versus 3.79 ± 1.55 h-1, p<0.05) were increased by genistien significantly.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),1/[h],3.34,223873,DB00683,Midazolam
,21943317,oral clearance,"The oral clearance of midazolam (1.68 ± 0.85 h-1 versus 3.98 ± 0.59 h-1, p < 0.05) and talinolol (3.34 ± 1.24 h-1 versus 3.79 ± 1.55 h-1, p<0.05) were increased by genistien significantly.",Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943317/),1/[h],3.79,223874,DB00683,Midazolam
,19797607,degradation half-life,A physiologically based pharmacokinetic model of the interaction between ERY and MDZ predicted a 2.6-fold decrease in CYP3A activity after repeated ERY treatment using in vitro-estimated enzyme inhibition parameters and in vivo degradation half-life of the enzyme (20 + or - 6 h).,Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19797607/),h,20,224101,DB00683,Midazolam
,7954994,Times to awakening,"Times to awakening were longer in Group H: 3.1 +/- 3.4 hr, than in Group L: 1.1 +/- 0.8 h, P < 0.05.",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,3.1,224529,DB00683,Midazolam
,7954994,Times to awakening,"Times to awakening were longer in Group H: 3.1 +/- 3.4 hr, than in Group L: 1.1 +/- 0.8 h, P < 0.05.",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,1.1,224530,DB00683,Midazolam
,7954994,t1/2 beta,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),h,4.4,224531,DB00683,Midazolam
,7954994,CL,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),[ml] / [kg·min],5.94,224532,DB00683,Midazolam
,7954994,Vd,"Mean values were t1/2 beta = 4.4 +/- 1.5 hr, CL = 5.94 +/- 1.69 mL.min-1.kg-1, Vd = 3.13 +/- 1.07 L.kg-1.(ABSTRACT TRUNCATED AT 400 WORDS)",Optimizing sedation following major vascular surgery: a double-blind study of midazolam administered by continuous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7954994/),[l] / [kg],3.13,224533,DB00683,Midazolam
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,10.6,224594,DB00683,Midazolam
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,170,224595,DB00683,Midazolam
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,0.180,224596,DB00683,Midazolam
,7639354,Metabolic clearance,Metabolic clearance was 361 +/- 97 mL/min.,Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),[ml] / [min],361,225826,DB00683,Midazolam
,7639354,intercompartmental clearance,"Rapid intercompartmental clearance was 2197 +/- 997 mL/min and slow intercompartmental clearance, 481 +/- 225 mL/min.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),[ml] / [min],2197,225827,DB00683,Midazolam
,7639354,intercompartmental clearance,"Rapid intercompartmental clearance was 2197 +/- 997 mL/min and slow intercompartmental clearance, 481 +/- 225 mL/min.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),[ml] / [min],481,225828,DB00683,Midazolam
,7639354,volume of the central compartment (Vc),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vdss) were 5.8 +/- 5.3 L and 118.2 +/- 70.4 L, respectively.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),l,5.8,225829,DB00683,Midazolam
,7639354,volume of distribution at steady state (Vdss),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vdss) were 5.8 +/- 5.3 L and 118.2 +/- 70.4 L, respectively.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),l,118.2,225830,DB00683,Midazolam
,7639354,elimination half-life,"The elimination half-life was 6.3 +/- 3.6 h, 1.5- to 3-fold longer than has been previously reported in patients undergoing surgery.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),h,6.3,225831,DB00683,Midazolam
less,3345618,serum elimination half-life,In only one patient was midazolam serum elimination half-life less than 2 hours and in six patients the half-life was greater than 10 hours.,"Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345618/),h,2,226129,DB00683,Midazolam
greater,3345618,half-life,In only one patient was midazolam serum elimination half-life less than 2 hours and in six patients the half-life was greater than 10 hours.,"Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345618/),h,10,226130,DB00683,Midazolam
,3345618,serum concentration ratio,The serum concentration ratio of midazolam/alpha-hydroxymidazolamglucuronide at the end of the infusion varied from 0.03 to 15.6.,"Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345618/),,0.03 to 15.6,226131,DB00683,Midazolam
,20393696,AUC(0-infinity),"The geometric mean (geometric coefficient of variation) for the AUC(0-infinity) of midazolam in the placebo group was 196.4 ng x h/ml (30.3%) and after glycyrrhizin treatment, 151.3 ng x h/ml (34.7%).",Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20393696/),[h·ng] / [ml],196.4,226429,DB00683,Midazolam
,20393696,AUC(0-infinity),"The geometric mean (geometric coefficient of variation) for the AUC(0-infinity) of midazolam in the placebo group was 196.4 ng x h/ml (30.3%) and after glycyrrhizin treatment, 151.3 ng x h/ml (34.7%).",Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20393696/),[h·ng] / [ml],151.3,226430,DB00683,Midazolam
,33587239,zeta potential,The optimized midazolam nano-suspension (containing 76% TMC and 24% TP) had a mean particle size of 197 ± 7 nm and a zeta potential of 31 ± 4 (mV).,"Preparation, optimization, and evaluation of midazolam nanosuspension: enhanced bioavailability for buccal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33587239/),mv,31,226582,DB00683,Midazolam
,2567646,volume of distribution,The volume of distribution of alprazolam and triazolam is approximately 1L.,Pharmacokinetics of the newer benzodiazepines. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),l,1,228435,DB00683,Midazolam
,2567646,elimination half-life,"Mean alprazolam elimination half-life in healthy adult subjects ranges from 9.5 to 12 hours; liver disease prolongs alprazolam elimination, but renal insufficiency does not.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,9.5 to 12,228436,DB00683,Midazolam
,2567646,elimination half-life,"The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,1.8 and 5.9,228437,DB00683,Midazolam
,2567646,elimination half-life,"The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours.",Pharmacokinetics of the newer benzodiazepines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2567646/),h,3.8,228438,DB00683,Midazolam
,11381567,brain:plasma partition coefficient,"For diazepam, the estimated brain:plasma partition coefficient was 2.67, and the first and second compartments filled with half-lives of 2.2 and 0.5 min, respectively.",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),,2.67,228911,DB00683,Midazolam
,11381567,half-lives,"For diazepam, the estimated brain:plasma partition coefficient was 2.67, and the first and second compartments filled with half-lives of 2.2 and 0.5 min, respectively.",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,2.2,228912,DB00683,Midazolam
,11381567,half-lives,"For diazepam, the estimated brain:plasma partition coefficient was 2.67, and the first and second compartments filled with half-lives of 2.2 and 0.5 min, respectively.",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,0.5,228913,DB00683,Midazolam
,11381567,half-lives,"The changes in cerebral blood flow were best described by a previously published a dynamic model that incorporated long half-lives for drug dissociation from the benzodiazepine receptor (13.3 and 5.5 min for midazolam and diazepam, respectively).",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,13.3,228914,DB00683,Midazolam
,11381567,half-lives,"The changes in cerebral blood flow were best described by a previously published a dynamic model that incorporated long half-lives for drug dissociation from the benzodiazepine receptor (13.3 and 5.5 min for midazolam and diazepam, respectively).",In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11381567/),min,5.5,228915,DB00683,Midazolam
,23698259,IC₅₀,"In RHM, GTE inhibited MDZ 1'-hydroxylation with IC₅₀ and K(i)(app) values of 12.5 and 18.8 µg/mL, respectively, in a noncompetitive manner.",Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698259/),[μg] / [ml],12.5,230414,DB00683,Midazolam
,23698259,K(i)(app),"In RHM, GTE inhibited MDZ 1'-hydroxylation with IC₅₀ and K(i)(app) values of 12.5 and 18.8 µg/mL, respectively, in a noncompetitive manner.",Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698259/),[μg] / [ml],18.8,230415,DB00683,Midazolam
,28785981,clearance,The population mean midazolam clearance was significantly higher in obese adolescents than in morbidly obese adults [0.71 (7%) vs. 0.44 (11%) L/min; p < 0.01].,Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28785981/),[l] / [min],0.71,230857,DB00683,Midazolam
,28785981,clearance,The population mean midazolam clearance was significantly higher in obese adolescents than in morbidly obese adults [0.71 (7%) vs. 0.44 (11%) L/min; p < 0.01].,Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28785981/),[l] / [min],0.44,230858,DB00683,Midazolam
,6114686,volume of central compartment,"Mean (+/- SE) kinetic variables for midazolam were: volume of central compartment, 0.37 (+/ 0.06 l/kg; total volume of distribution, 1.72 (+/- 0.05) l/kg: initial distribution half-life, 7.2 (+/- 1.6) min; elimination half-life, 2.5 (+/- 0.2) h; total clearance, 8.1 (+/- 0.52) ml.min-1.kg-1.",Automated gas chromatography for studies of midazolam pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114686/),[l] / [kg],0.37,231743,DB00683,Midazolam
,6114686,total volume of distribution,"Mean (+/- SE) kinetic variables for midazolam were: volume of central compartment, 0.37 (+/ 0.06 l/kg; total volume of distribution, 1.72 (+/- 0.05) l/kg: initial distribution half-life, 7.2 (+/- 1.6) min; elimination half-life, 2.5 (+/- 0.2) h; total clearance, 8.1 (+/- 0.52) ml.min-1.kg-1.",Automated gas chromatography for studies of midazolam pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114686/),[l] / [kg],1.72,231744,DB00683,Midazolam
,6114686,initial distribution half-life,"Mean (+/- SE) kinetic variables for midazolam were: volume of central compartment, 0.37 (+/ 0.06 l/kg; total volume of distribution, 1.72 (+/- 0.05) l/kg: initial distribution half-life, 7.2 (+/- 1.6) min; elimination half-life, 2.5 (+/- 0.2) h; total clearance, 8.1 (+/- 0.52) ml.min-1.kg-1.",Automated gas chromatography for studies of midazolam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114686/),min,7.2,231745,DB00683,Midazolam
,6114686,elimination half-life,"Mean (+/- SE) kinetic variables for midazolam were: volume of central compartment, 0.37 (+/ 0.06 l/kg; total volume of distribution, 1.72 (+/- 0.05) l/kg: initial distribution half-life, 7.2 (+/- 1.6) min; elimination half-life, 2.5 (+/- 0.2) h; total clearance, 8.1 (+/- 0.52) ml.min-1.kg-1.",Automated gas chromatography for studies of midazolam pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114686/),h,2.5,231746,DB00683,Midazolam
,6114686,total clearance,"Mean (+/- SE) kinetic variables for midazolam were: volume of central compartment, 0.37 (+/ 0.06 l/kg; total volume of distribution, 1.72 (+/- 0.05) l/kg: initial distribution half-life, 7.2 (+/- 1.6) min; elimination half-life, 2.5 (+/- 0.2) h; total clearance, 8.1 (+/- 0.52) ml.min-1.kg-1.",Automated gas chromatography for studies of midazolam pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114686/),[ml] / [kg·min],8.1,231747,DB00683,Midazolam
,17578905,clearance,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg·min],68.3,232196,DB00683,Midazolam
,17578905,intercompartmental clearance,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg·min],80,232197,DB00683,Midazolam
,17578905,central compartment volume,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg],91.7,232198,DB00683,Midazolam
,17578905,peripheral compartment volume,"For a typical child with a body weight of 10.5 kg, clearance was 68.3 ml kg(-1) min(-1), intercompartmental clearance was 80 ml kg(-1) min(-1), the central compartment volume was 91.7 ml kg(-1), and the peripheral compartment volume was 141 ml kg(-1).",Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17578905/),[ml] / [kg],141,232199,DB00683,Midazolam
,11675908,Plasma concentrations (EC50),"Plasma concentrations (EC50) of SS 5, estimated by logistic regression analysis, varied among patients (mean 194 ng/ml).",Midazolam for continuous sedation in Japanese critical care patients: phase II study. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11675908/),[ng] / [ml],194,232217,DB00683,Midazolam
,6711257,distribution phase half-life,"The rapid but short-lasting action can be explained by the pharmacokinetic parameters of midazolam: a short distribution phase half-life (4.19 min), and a short elimination phase half-life (67.85 min) due to a high clearance value (13.18 ml/min/kg) and a moderate distribution volume (1.20 l/kg).",Pharmacokinetics and sedative effect of midazolam in connection with caesarean section performed under epidural analgesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6711257/),min,4.19,232578,DB00683,Midazolam
,6711257,elimination phase half-life,"The rapid but short-lasting action can be explained by the pharmacokinetic parameters of midazolam: a short distribution phase half-life (4.19 min), and a short elimination phase half-life (67.85 min) due to a high clearance value (13.18 ml/min/kg) and a moderate distribution volume (1.20 l/kg).",Pharmacokinetics and sedative effect of midazolam in connection with caesarean section performed under epidural analgesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6711257/),min,67.85,232579,DB00683,Midazolam
,6711257,clearance,"The rapid but short-lasting action can be explained by the pharmacokinetic parameters of midazolam: a short distribution phase half-life (4.19 min), and a short elimination phase half-life (67.85 min) due to a high clearance value (13.18 ml/min/kg) and a moderate distribution volume (1.20 l/kg).",Pharmacokinetics and sedative effect of midazolam in connection with caesarean section performed under epidural analgesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6711257/),[ml] / [kg·min],13.18,232580,DB00683,Midazolam
,6711257,distribution volume,"The rapid but short-lasting action can be explained by the pharmacokinetic parameters of midazolam: a short distribution phase half-life (4.19 min), and a short elimination phase half-life (67.85 min) due to a high clearance value (13.18 ml/min/kg) and a moderate distribution volume (1.20 l/kg).",Pharmacokinetics and sedative effect of midazolam in connection with caesarean section performed under epidural analgesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6711257/),[l] / [kg],1.20,232581,DB00683,Midazolam
,22452501,time to peak concentration,"Mean ± SD time to peak concentration was 11.70 ± 2.63 minutes (gel IN), 17.50 ± 2.64 minutes (solution IN), and 39 ± 14.49 minutes (solution rectally).",Bioavailability of a novel midazolam gel after intranasal administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452501/),min,11.70,233144,DB00683,Midazolam
,22452501,time to peak concentration,"Mean ± SD time to peak concentration was 11.70 ± 2.63 minutes (gel IN), 17.50 ± 2.64 minutes (solution IN), and 39 ± 14.49 minutes (solution rectally).",Bioavailability of a novel midazolam gel after intranasal administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452501/),min,17.50,233145,DB00683,Midazolam
,22452501,time to peak concentration,"Mean ± SD time to peak concentration was 11.70 ± 2.63 minutes (gel IN), 17.50 ± 2.64 minutes (solution IN), and 39 ± 14.49 minutes (solution rectally).",Bioavailability of a novel midazolam gel after intranasal administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452501/),min,39,233146,DB00683,Midazolam
,22452501,bioavailability,"Mean bioavailability of midazolam was 70.4% (gel IN), 52.0% (solution IN), and 49.0% (solution rectally).",Bioavailability of a novel midazolam gel after intranasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452501/),%,70.4,233147,DB00683,Midazolam
,22452501,bioavailability,"Mean bioavailability of midazolam was 70.4% (gel IN), 52.0% (solution IN), and 49.0% (solution rectally).",Bioavailability of a novel midazolam gel after intranasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452501/),%,52.0,233148,DB00683,Midazolam
,22452501,bioavailability,"Mean bioavailability of midazolam was 70.4% (gel IN), 52.0% (solution IN), and 49.0% (solution rectally).",Bioavailability of a novel midazolam gel after intranasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452501/),%,49.0,233149,DB00683,Midazolam
,18288078,CL/F(unbound),"Midazolam CL/F(unbound) (593 +/- 237 l/min vs. 345 +/- 103 l/min; P = 0.007), digoxin CL(Renal, unbound) (272 +/- 45 ml/min vs. 183 +/- 37 ml/min; P < 0.002) and digoxin CL(secretion,) (unbound) (109 +/- 34 ml/min vs. 58 +/- 22 ml/min; P < 0.002) were higher during pregnancy than postpartum.",Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288078/),[l] / [min],593,233964,DB00683,Midazolam
,18288078,CL/F(unbound),"Midazolam CL/F(unbound) (593 +/- 237 l/min vs. 345 +/- 103 l/min; P = 0.007), digoxin CL(Renal, unbound) (272 +/- 45 ml/min vs. 183 +/- 37 ml/min; P < 0.002) and digoxin CL(secretion,) (unbound) (109 +/- 34 ml/min vs. 58 +/- 22 ml/min; P < 0.002) were higher during pregnancy than postpartum.",Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288078/),[l] / [min],345,233965,DB00683,Midazolam
,18288078,"CL(Renal, unbound)","Midazolam CL/F(unbound) (593 +/- 237 l/min vs. 345 +/- 103 l/min; P = 0.007), digoxin CL(Renal, unbound) (272 +/- 45 ml/min vs. 183 +/- 37 ml/min; P < 0.002) and digoxin CL(secretion,) (unbound) (109 +/- 34 ml/min vs. 58 +/- 22 ml/min; P < 0.002) were higher during pregnancy than postpartum.",Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288078/),[ml] / [min],272,233966,DB00683,Midazolam
,18288078,"CL(Renal, unbound)","Midazolam CL/F(unbound) (593 +/- 237 l/min vs. 345 +/- 103 l/min; P = 0.007), digoxin CL(Renal, unbound) (272 +/- 45 ml/min vs. 183 +/- 37 ml/min; P < 0.002) and digoxin CL(secretion,) (unbound) (109 +/- 34 ml/min vs. 58 +/- 22 ml/min; P < 0.002) were higher during pregnancy than postpartum.",Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288078/),[ml] / [min],183,233967,DB00683,Midazolam
,18288078,"CL(secretion,) (unbound)","Midazolam CL/F(unbound) (593 +/- 237 l/min vs. 345 +/- 103 l/min; P = 0.007), digoxin CL(Renal, unbound) (272 +/- 45 ml/min vs. 183 +/- 37 ml/min; P < 0.002) and digoxin CL(secretion,) (unbound) (109 +/- 34 ml/min vs. 58 +/- 22 ml/min; P < 0.002) were higher during pregnancy than postpartum.",Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288078/),[ml] / [min],109,233968,DB00683,Midazolam
,18288078,"CL(secretion,) (unbound)","Midazolam CL/F(unbound) (593 +/- 237 l/min vs. 345 +/- 103 l/min; P = 0.007), digoxin CL(Renal, unbound) (272 +/- 45 ml/min vs. 183 +/- 37 ml/min; P < 0.002) and digoxin CL(secretion,) (unbound) (109 +/- 34 ml/min vs. 58 +/- 22 ml/min; P < 0.002) were higher during pregnancy than postpartum.",Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18288078/),[ml] / [min],58,233969,DB00683,Midazolam
,32060866,clearance,"After yohimbine 5 mg, the clearance ranged from 25.3 to 15,864 mL/min and after yohimbine 50 µg, the clearance ranged from 39.6 to 38,822 mL/min.",Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060866/),[ml] / [min],"25.3 to 15,864",234197,DB00683,Midazolam
,32060866,clearance,"After yohimbine 5 mg, the clearance ranged from 25.3 to 15,864 mL/min and after yohimbine 50 µg, the clearance ranged from 39.6 to 38,822 mL/min.",Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060866/),[ml] / [min],"39.6 to 38,822",234198,DB00683,Midazolam
,24696691,volume of distribution (Vd),The volume of distribution (Vd) is 1.1 L/kg both in neonates and adults.,Clinical pharmacology of midazolam in neonates and children: effect of disease-a review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24696691/),[l] / [kg],1.1,234861,DB00683,Midazolam
,12183684,clearance,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),[ml] / [kg·min],79 to 55,234910,DB00683,Midazolam
,12183684,clearance,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),[ml] / [kg·min],1051 to 237,234911,DB00683,Midazolam
,12183684,absolute bioavailability,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),,0.11,234912,DB00683,Midazolam
,12183684,absolute bioavailability,"Ketoconazole (total dose of 15 mg/kg intraperitoneally) reduced clearance of intravenous midazolam (5 mg/kg) from 79 to 55 ml/min/kg (p < 0.05) and clearance of intragastric midazolam (15 mg/kg) from 1051 to 237 ml/min/kg (p < 0.05), increasing absolute bioavailability from 0.11 to 0.36 (p < 0.05).","In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183684/),,0.36,234913,DB00683,Midazolam
,6638545,plasma-free drug fraction,CRF patients had a significantly higher (P less than 0.005) plasma-free drug fraction (6.5% +/- 0.7) compared with the control patients (3.9% +/- 0.1).,The pharmacokinetics of midazolam in chronic renal failure patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),%,6.5,235520,DB00683,Midazolam
,6638545,plasma-free drug fraction,CRF patients had a significantly higher (P less than 0.005) plasma-free drug fraction (6.5% +/- 0.7) compared with the control patients (3.9% +/- 0.1).,The pharmacokinetics of midazolam in chronic renal failure patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),%,3.9,235521,DB00683,Midazolam
,6638545,volume of distribution,"Total (bound plus unbound) kinetics differed in the two groups: volume of distribution 3.8 +/- .3 1/kg in CRF patients versus 2.2 +/- .2 1/kg in controls (P less than 0.001), and clearance 11.4 +/- 1.6 ml X min-1 X kg-1 in CRF patients versus 6.7 +/- 0.9 ml X min-1 X kg-1 in controls (P less than 0.02).",The pharmacokinetics of midazolam in chronic renal failure patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[1] / [kg],3.8,235522,DB00683,Midazolam
,6638545,volume of distribution,"Total (bound plus unbound) kinetics differed in the two groups: volume of distribution 3.8 +/- .3 1/kg in CRF patients versus 2.2 +/- .2 1/kg in controls (P less than 0.001), and clearance 11.4 +/- 1.6 ml X min-1 X kg-1 in CRF patients versus 6.7 +/- 0.9 ml X min-1 X kg-1 in controls (P less than 0.02).",The pharmacokinetics of midazolam in chronic renal failure patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[1] / [kg],2.2,235523,DB00683,Midazolam
,6638545,clearance,"Total (bound plus unbound) kinetics differed in the two groups: volume of distribution 3.8 +/- .3 1/kg in CRF patients versus 2.2 +/- .2 1/kg in controls (P less than 0.001), and clearance 11.4 +/- 1.6 ml X min-1 X kg-1 in CRF patients versus 6.7 +/- 0.9 ml X min-1 X kg-1 in controls (P less than 0.02).",The pharmacokinetics of midazolam in chronic renal failure patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[ml] / [kg·min],11.4,235524,DB00683,Midazolam
,6638545,clearance,"Total (bound plus unbound) kinetics differed in the two groups: volume of distribution 3.8 +/- .3 1/kg in CRF patients versus 2.2 +/- .2 1/kg in controls (P less than 0.001), and clearance 11.4 +/- 1.6 ml X min-1 X kg-1 in CRF patients versus 6.7 +/- 0.9 ml X min-1 X kg-1 in controls (P less than 0.02).",The pharmacokinetics of midazolam in chronic renal failure patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[ml] / [kg·min],6.7,235525,DB00683,Midazolam
,6638545,unbound volume of distribution,"When kinetic parameters were corrected for protein binding, CRF patients unbound volume of distribution (63.5 +/- 6.8 1/kg) and free drug clearance (189 +/- 29 ml X min-1 X kg-1) were not different from the control group's volume of distribution (55.6 +/- 5.7 1/kg) and free drug clearance (176 +/- 24 ml X min-1 X kg-1).",The pharmacokinetics of midazolam in chronic renal failure patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[1] / [kg],63.5,235526,DB00683,Midazolam
,6638545,free drug clearance,"When kinetic parameters were corrected for protein binding, CRF patients unbound volume of distribution (63.5 +/- 6.8 1/kg) and free drug clearance (189 +/- 29 ml X min-1 X kg-1) were not different from the control group's volume of distribution (55.6 +/- 5.7 1/kg) and free drug clearance (176 +/- 24 ml X min-1 X kg-1).",The pharmacokinetics of midazolam in chronic renal failure patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[ml] / [kg·min],189,235527,DB00683,Midazolam
,6638545,volume of distribution,"When kinetic parameters were corrected for protein binding, CRF patients unbound volume of distribution (63.5 +/- 6.8 1/kg) and free drug clearance (189 +/- 29 ml X min-1 X kg-1) were not different from the control group's volume of distribution (55.6 +/- 5.7 1/kg) and free drug clearance (176 +/- 24 ml X min-1 X kg-1).",The pharmacokinetics of midazolam in chronic renal failure patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[1] / [kg],55.6,235528,DB00683,Midazolam
,6638545,free drug clearance,"When kinetic parameters were corrected for protein binding, CRF patients unbound volume of distribution (63.5 +/- 6.8 1/kg) and free drug clearance (189 +/- 29 ml X min-1 X kg-1) were not different from the control group's volume of distribution (55.6 +/- 5.7 1/kg) and free drug clearance (176 +/- 24 ml X min-1 X kg-1).",The pharmacokinetics of midazolam in chronic renal failure patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6638545/),[ml] / [kg·min],176,235529,DB00683,Midazolam
,2288837,plasma clearance,The mean plasma clearance of morphine was 29 ml min-1 kg-1 and the plasma ratios of morphine-6-glucuronide to morphine were similar to those previously reported in children.,"Long term high dose morphine, ketamine and midazolam infusion in a child with burns. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288837/),[ml] / [kg·min],29,235738,DB00683,Midazolam
,2288837,plasma clearance,The mean plasma clearance of ketamine was 32 ml min-1 kg-1 which is greater than that previously reported in older children and adults.,"Long term high dose morphine, ketamine and midazolam infusion in a child with burns. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2288837/),[ml] / [kg·min],32,235739,DB00683,Midazolam
,2919760,elimination half-life,The population average of elimination half-life in neonates was 6.3 hours for midazolam and 14.7 hours for thiopental.,A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: III. Placental transfer and elimination in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919760/),h,6.3,235743,DB00683,Midazolam
,2919760,elimination half-life,The population average of elimination half-life in neonates was 6.3 hours for midazolam and 14.7 hours for thiopental.,A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: III. Placental transfer and elimination in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919760/),h,14.7,235744,DB00683,Midazolam
,15601346,Plasma concentrations,Plasma concentrations [mean +/- sd] of s-ketamine in group IN peaked at 355 +/- 172 ng x ml(-1) within 18 +/- 13 min vs. 1860 +/- 883 ng x ml(-1) within 3 +/- 1 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],355,235889,DB00683,Midazolam
,15601346,Plasma concentrations,Plasma concentrations [mean +/- sd] of s-ketamine in group IN peaked at 355 +/- 172 ng x ml(-1) within 18 +/- 13 min vs. 1860 +/- 883 ng x ml(-1) within 3 +/- 1 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],1860,235890,DB00683,Midazolam
,15601346,Plasma concentrations,Plasma concentrations of s-norketamine in group IN peaked at 90 +/- 128 ng x ml(-1) within 50 +/- 11 min vs. 429 +/- 277 ng x ml(-1) within 40 +/- 16 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],90,235891,DB00683,Midazolam
,15601346,Plasma concentrations,Plasma concentrations of s-norketamine in group IN peaked at 90 +/- 128 ng x ml(-1) within 50 +/- 11 min vs. 429 +/- 277 ng x ml(-1) within 40 +/- 16 min in group IV (P < 0.01).,S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],429,235892,DB00683,Midazolam
,15601346,peak plasma concentration,"One child in group IN experienced rapid and high level s-ketamine absorption with a peak plasma concentration of 732 ng x ml(-1) after 2 min, which decreased to 274 ng x ml(-1) after 60 min.",S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],732,235893,DB00683,Midazolam
,15601346,peak plasma concentration,"One child in group IN experienced rapid and high level s-ketamine absorption with a peak plasma concentration of 732 ng x ml(-1) after 2 min, which decreased to 274 ng x ml(-1) after 60 min.",S-ketamine and s-norketamine plasma concentrations after nasal and i.v. administration in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601346/),[ng] / [ml],274,235894,DB00683,Midazolam
,2764268,Cmax,"The median Cmax values were 35.3 ng/ml (group 1), 103 ng/ml (group 2) and 123.5 ng/ml (group 3).",[The pharmacokinetics of midazolam following intramuscular administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764268/),[ng] / [ml],35.3,236996,DB00683,Midazolam
,2764268,Cmax,"The median Cmax values were 35.3 ng/ml (group 1), 103 ng/ml (group 2) and 123.5 ng/ml (group 3).",[The pharmacokinetics of midazolam following intramuscular administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764268/),[ng] / [ml],103,236997,DB00683,Midazolam
,2764268,Cmax,"The median Cmax values were 35.3 ng/ml (group 1), 103 ng/ml (group 2) and 123.5 ng/ml (group 3).",[The pharmacokinetics of midazolam following intramuscular administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764268/),[ng] / [ml],123.5,236998,DB00683,Midazolam
,2764268,tmax,The duration of tmax was between 12 and 36 min (means = 27 min).,[The pharmacokinetics of midazolam following intramuscular administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764268/),min,27,236999,DB00683,Midazolam
,8969394,infusion rate,Patients were anesthetized using a continuous infusion of alfentanil (mean infusion rate: 1 microgram/kg/min) and propofol administered by TCI.,Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8969394/),[μg] / [kg·min],1,237365,DB00683,Midazolam
,8969394,target concentrations,"In the period during and after bypass, the mean target concentrations required to maintain anesthesia was 2.22 micrograms/mL.",Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8969394/),[μg] / [ml],2.22,237366,DB00683,Midazolam
,32427354,maximum inactivation rate constant kinact,"A model including mechanism-based inactivation of the metabolizing enzymes (maximum inactivation rate constant kinact , 2.83 h-1 ; dissociation rate constant K I , 9.33 μM) described the pharmacokinetics of VRZ well.",A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32427354/),1/[h],2.83,237459,DB00683,Midazolam
,32427354,dissociation rate constant K I,"A model including mechanism-based inactivation of the metabolizing enzymes (maximum inactivation rate constant kinact , 2.83 h-1 ; dissociation rate constant K I , 9.33 μM) described the pharmacokinetics of VRZ well.",A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32427354/),μM,9.33,237460,DB00683,Midazolam
,19546252,AUC(0-infinity),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[h·μg] / [ml],152.41,237784,DB00683,Midazolam
,19546252,AUC(0-infinity),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[h·μg] / [ml],129.25,237785,DB00683,Midazolam
,19546252,CL,"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[l] / [h],3.28,237786,DB00683,Midazolam
,19546252,CL,"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[l] / [h],3.89,237787,DB00683,Midazolam
,19546252,Vd,"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),l,31.38,237788,DB00683,Midazolam
,19546252,Vd,"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),l,29.74,237789,DB00683,Midazolam
,19546252,t((1/2)),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),h,6.79,237790,DB00683,Midazolam
,19546252,t((1/2)),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),h,5.56,237791,DB00683,Midazolam
,19546252,AUC(0-infinity),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[h·μg] / [ml],167.20,237792,DB00683,Midazolam
,19546252,AUC(0-infinity),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[h·μg] / [ml],139.08,237793,DB00683,Midazolam
,19546252,CL,"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[l] / [h],2.99,237794,DB00683,Midazolam
,19546252,CL,"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[l] / [h],3.59,237795,DB00683,Midazolam
,19546252,t((1/2)),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),h,6.15,237796,DB00683,Midazolam
,19546252,t((1/2)),"The following differences (Wilcoxon test, P < or = .05) were observed between the (S)-(-) and (R)-(+) enantiomers: AUC(0-infinity) 152.41 vs 129.25 microg.h/mL, CL 3.28 vs 3.89 L/h, Vd 31.38 vs 29.74 L, and t((1/2)) 6.79 vs 5.56 h for group 1 and AUC(0-infinity) 167.20 vs 139.08 microg.h/mL, CL 2.99 vs 3.59 L/h, and t((1/2)) 6.15 vs 4.99 h for group 2.",Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),h,4.99,237797,DB00683,Midazolam
,19546252,clearance,No significant relationship was observed between midazolam clearance (2.92-16.40 mL/min.kg) and clearance of each CYC enantiomer.,Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546252/),[ml] / [kg·min],2.92-16.40,237798,DB00683,Midazolam
,16300167,waiting time,National guidelines advise a waiting time of 12 hours.,Midazolam and its metabolites in brain death diagnosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300167/),h,12,237940,DB00683,Midazolam
,8876024,volume of distribution of the central compartment,"The mean volume of distribution of the central compartment and clearance were 0.77 l/kg and 2.03 l/h per keg, respectively.","Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),[l] / [kg],0.77,238040,DB00683,Midazolam
,8876024,clearance,"The mean volume of distribution of the central compartment and clearance were 0.77 l/kg and 2.03 l/h per keg, respectively.","Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),[l] / [h·keg],2.03,238041,DB00683,Midazolam
,8876024,elimination half-lives,"Midazolam elimination half-lives for the four routes of administration ranged from 23.1 to 49.5 min, and metabolites could not be detected.","Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),min,23.1 to 49.5,238042,DB00683,Midazolam
,8876024,absolute bioavailability,The mean absolute bioavailability was route-dependent: 39.3% (s.c.) 19.2% (i.p.) and 4.6% (p.o.).,"Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),%,39.3,238043,DB00683,Midazolam
,8876024,absolute bioavailability,The mean absolute bioavailability was route-dependent: 39.3% (s.c.) 19.2% (i.p.) and 4.6% (p.o.).,"Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),%,19.2,238044,DB00683,Midazolam
,8876024,absolute bioavailability,The mean absolute bioavailability was route-dependent: 39.3% (s.c.) 19.2% (i.p.) and 4.6% (p.o.).,"Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),%,4.6,238045,DB00683,Midazolam
,8876024,oral bioavailability,The markedly low oral bioavailability found in food-limited rats contrasted to the value reported for free-feeding rates (45%).,"Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876024/),%,45,238046,DB00683,Midazolam
,15145968,50% maximum effective concentration,"Analysis of all three infusion trials together yielded the following mean estimates: maximum EEG effect, 16.3% over baseline; 50% maximum effective concentration, 31 ng/mL; and an apparent rate constant for drug disappearance from the effect compartment which approached infinity.","Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145968/),[ng] / [ml],31,238341,DB00683,Midazolam
,3230199,mean,The optimal level was reached in a mean time of 61 +/- 26 min and the mean corresponding midazolam plasma concentration was 163 +/- 62 ng.,Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),,61,238956,DB00683,Midazolam
,3230199,plasma concentration,The optimal level was reached in a mean time of 61 +/- 26 min and the mean corresponding midazolam plasma concentration was 163 +/- 62 ng.,Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),ng,163,238957,DB00683,Midazolam
,3230199,elimination half life,"Estimations of the main pharmacokinetic parameters (elimination half life: 230 +/- 102 min, total body clearance: 520 +/- 283 ml.min-1, total volume of distribution: 2.23 +/- 1.15 l.kg-1) showed no marked differences with normal patients.",Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),min,230,238958,DB00683,Midazolam
,3230199,total body clearance,"Estimations of the main pharmacokinetic parameters (elimination half life: 230 +/- 102 min, total body clearance: 520 +/- 283 ml.min-1, total volume of distribution: 2.23 +/- 1.15 l.kg-1) showed no marked differences with normal patients.",Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),[ml] / [min],520,238959,DB00683,Midazolam
,3230199,total volume of distribution,"Estimations of the main pharmacokinetic parameters (elimination half life: 230 +/- 102 min, total body clearance: 520 +/- 283 ml.min-1, total volume of distribution: 2.23 +/- 1.15 l.kg-1) showed no marked differences with normal patients.",Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),[l] / [kg],2.23,238960,DB00683,Midazolam
,3230199,loading dose,The mean loading dose was 0.33 +/- 0.18 mg.,Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),mg,0.33,238961,DB00683,Midazolam
,3230199,plasma concentration,The mean midazolam plasma concentration during infusion was 215 +/- 61 ng.,Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),ng,215,238962,DB00683,Midazolam
,3230199,plasma concentration,"ml-1, and the mean midazolam plasma concentration at the end of infusion was 199 +/- 93 ng.",Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),ng,199,238963,DB00683,Midazolam
,3230199,time for,"After discontinuation of infusion, the mean time for normalization of the mental state was 97 min.",Midazolam infusion for basal sedation in intensive care: absence of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230199/),min,97,238964,DB00683,Midazolam
,1767626,infusion rate,The mean infusion rate of midazolam was similar (9.4 vs 8.7 mg/h) in the control patients and those with ARF.,The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767626/),[mg] / [h],9.4,239094,DB00683,Midazolam
,1767626,infusion rate,The mean infusion rate of midazolam was similar (9.4 vs 8.7 mg/h) in the control patients and those with ARF.,The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767626/),[mg] / [h],8.7,239095,DB00683,Midazolam
,1767626,renal clearance,The renal clearance of 1-hydroxymethylmidazolam glucuronide was much lower in the ARF group than in the control group (3.9 vs 136 ml/min).,The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767626/),[ml] / [min],3.9,239096,DB00683,Midazolam
,1767626,renal clearance,The renal clearance of 1-hydroxymethylmidazolam glucuronide was much lower in the ARF group than in the control group (3.9 vs 136 ml/min).,The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767626/),[ml] / [min],136,239097,DB00683,Midazolam
,1767626,half-life,"However, the half-life of midazolam itself was also significantly longer in patients with ARF than in the control group (13.2 vs 7.6 h).",The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767626/),h,13.2,239098,DB00683,Midazolam
,1767626,half-life,"However, the half-life of midazolam itself was also significantly longer in patients with ARF than in the control group (13.2 vs 7.6 h).",The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767626/),h,7.6,239099,DB00683,Midazolam
,2792170,terminal half-life,The average terminal half-life was 10.6 h.,Pharmacokinetics of midazolam in patients recovering from cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792170/),h,10.6,239100,DB00683,Midazolam
,2792170,metabolic clearance,The prolonged elimination was mainly due to a decrease in its metabolic clearance (0.25 l.min-1).,Pharmacokinetics of midazolam in patients recovering from cardiac surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792170/),[l] / [min],0.25,239101,DB00683,Midazolam
,1873415,tmax,This finding is in keeping with pharmacokinetics showing a tmax of intranasal midazolam of 11 minutes and a bioavailability of 51% in children (10).,[Intranasal premedication of young children using midazolam (Dormicum). Clinical experience]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1873415/),min,11,240299,DB00683,Midazolam
,1873415,bioavailability,This finding is in keeping with pharmacokinetics showing a tmax of intranasal midazolam of 11 minutes and a bioavailability of 51% in children (10).,[Intranasal premedication of young children using midazolam (Dormicum). Clinical experience]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1873415/),%,51,240300,DB00683,Midazolam
,17034653,bioavailabilities,"Mean bioavailabilities were 0.68-0.71, and Tmax 15 min for the sprays, which also were bioequivalent (ratio geometric means (90%) CI: 97.6% (90% CI 83.5; 113.9)).",Intranasal midazolam: a comparison of two delivery devices in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034653/),,0.68-0.71,241483,DB00683,Midazolam
,17034653,Tmax,"Mean bioavailabilities were 0.68-0.71, and Tmax 15 min for the sprays, which also were bioequivalent (ratio geometric means (90%) CI: 97.6% (90% CI 83.5; 113.9)).",Intranasal midazolam: a comparison of two delivery devices in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17034653/),min,15,241484,DB00683,Midazolam
,32178858,time to full alertness,The end-of-infusion injection of flumazenil shortened the median time to full alertness to 3.5 min and effectively reversed psychomotor and cardiovascular dysfunction.,Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32178858/),min,3.5,242074,DB00683,Midazolam
,25880724,plasma Cmax,Lanicemine reached a plasma Cmax of 1.51 μg/mL after 150 mg daily dosing to steady state.,Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880724/),[μg] / [ml],1.51,242629,DB00683,Midazolam
,25880724,CL,"The geometric mean CL, Vss, and t1/2 of lanicemine were 8.1 L/h, 122.0 L, and 10.4 hours, respectively.",Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880724/),[l] / [h],8.1,242630,DB00683,Midazolam
,25880724,Vss,"The geometric mean CL, Vss, and t1/2 of lanicemine were 8.1 L/h, 122.0 L, and 10.4 hours, respectively.",Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880724/),l,122.0,242631,DB00683,Midazolam
,25880724,t1/2,"The geometric mean CL, Vss, and t1/2 of lanicemine were 8.1 L/h, 122.0 L, and 10.4 hours, respectively.",Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880724/),h,10.4,242632,DB00683,Midazolam
,16415110,K(s),"Despite these differences in metabolism, all four ITZ stereoisomers induced a type II binding spectrum with CYP3A4, characteristic of coordination of the triazole nitrogen to the heme iron (K(s) 2.2-10.6 nM).",Stereochemical aspects of itraconazole metabolism in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415110/),nM,2.2-10.6,242694,DB00683,Midazolam
,16415110,IC(50),All four stereoisomers of ITZ inhibited the CYP3A4-catalyzed hydroxylation of midazolam with high affinity (IC(50) 3.7-14.8 nM).,Stereochemical aspects of itraconazole metabolism in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415110/),nM,3.7-14.8,242695,DB00683,Midazolam
,20099988,C(max),"The multiple-dose pharmacokinetic profile of telavancin with concomitant administration of midazolam (C(max) 97 microg/ml, concentration 24 hrs after completion of telavancin infusion 9 microg/ml, terminal-phase elimination half-life 8.9 hrs, clearance 13.3 ml/hr/kg) was consistent with data from earlier studies.","Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099988/),[μg] / [ml],97,242997,DB00683,Midazolam
,20099988,terminal-phase elimination half-life,"The multiple-dose pharmacokinetic profile of telavancin with concomitant administration of midazolam (C(max) 97 microg/ml, concentration 24 hrs after completion of telavancin infusion 9 microg/ml, terminal-phase elimination half-life 8.9 hrs, clearance 13.3 ml/hr/kg) was consistent with data from earlier studies.","Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099988/),h,8.9,242998,DB00683,Midazolam
,20099988,clearance,"The multiple-dose pharmacokinetic profile of telavancin with concomitant administration of midazolam (C(max) 97 microg/ml, concentration 24 hrs after completion of telavancin infusion 9 microg/ml, terminal-phase elimination half-life 8.9 hrs, clearance 13.3 ml/hr/kg) was consistent with data from earlier studies.","Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099988/),[ml] / [h·kg],13.3,242999,DB00683,Midazolam
,12891225,half-life,The midazolam half-life values increased from 1.7 hours (prestudy) to 3.3 hours on both day 1 and day 5.,Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891225/),h,1.7,245082,DB00683,Midazolam
,12891225,half-life,The midazolam half-life values increased from 1.7 hours (prestudy) to 3.3 hours on both day 1 and day 5.,Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891225/),h,3.3,245083,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 4.13 - (PEEP - 5) x 0.42 l h-1, and 0.74 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],4.13,246815,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 4.13 - (PEEP - 5) x 0.42 l h-1, and 0.74 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.42,246816,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 4.13 - (PEEP - 5) x 0.42 l h-1, and 0.74 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.74,246817,DB00683,Midazolam
,14748812,volume of distribution,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,0.74,246818,DB00683,Midazolam
,14748812,steady state volume of distribution,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,56,246819,DB00683,Midazolam
,14748812,steady state volume of distribution,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,2.1,246820,DB00683,Midazolam
,14748812,intercompartmental clearance,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],10,246821,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],11.3,246822,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.14,246823,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],7.27,246824,DB00683,Midazolam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.14,246825,DB00683,Midazolam
,14748812,volume of distribution,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,7.15,246826,DB00683,Midazolam
,14748812,steady state volume of distribution,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,431,246827,DB00683,Midazolam
,14748812,intercompartmental clearance,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],40.8,246828,DB00683,Midazolam
,14748812,intercompartmental clearance,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],2.75,246829,DB00683,Midazolam
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],12,247239,DB00683,Midazolam
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],45,247240,DB00683,Midazolam
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],35,247241,DB00683,Midazolam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],68,247242,DB00683,Midazolam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],101,247243,DB00683,Midazolam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],208,247244,DB00683,Midazolam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],304,247245,DB00683,Midazolam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],375,247246,DB00683,Midazolam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],34,247247,DB00683,Midazolam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],51,247248,DB00683,Midazolam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],104,247249,DB00683,Midazolam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],152,247250,DB00683,Midazolam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],188,247251,DB00683,Midazolam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,3.6,247252,DB00683,Midazolam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,14.9,247253,DB00683,Midazolam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,11.9,247254,DB00683,Midazolam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,31.1,247255,DB00683,Midazolam
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00683,Midazolam
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00683,Midazolam
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00683,Midazolam
,17471182,passive diffusion rate constant,The passive diffusion rate constant was 0.0014 min(-1).,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),1/[min],0.0014,249309,DB00683,Midazolam
,17471182,active efflux rate constant,The active efflux rate constant decreased from 0.0195 min(-1) to 0.0113 min(-1) in the presence of GF120918.,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),1/[min],0.0195,249310,DB00683,Midazolam
,17471182,active efflux rate constant,The active efflux rate constant decreased from 0.0195 min(-1) to 0.0113 min(-1) in the presence of GF120918.,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),1/[min],0.0113,249311,DB00683,Midazolam
,17471182,maximum transport (N(max)/V(ecf)),The active influx was insensitive to GF120918 and had a maximum transport (N(max)/V(ecf)) of 0.66 ng min(-1) ml(-1) and was saturated at low concentrations of morphine (C(50)=9.9 ng ml(-1)).,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),[ng] / [min·ml],0.66,249312,DB00683,Midazolam
,17471182,C(50),The active influx was insensitive to GF120918 and had a maximum transport (N(max)/V(ecf)) of 0.66 ng min(-1) ml(-1) and was saturated at low concentrations of morphine (C(50)=9.9 ng ml(-1)).,Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17471182/),[ng] / [ml],9.9,249313,DB00683,Midazolam
,19398603,area,"Furthermore, the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0 to 10 hours showed no significant differences among 3 statins (simvastatin: 0.32 +/- 0.09, atorvastatin: 0.31 +/- 0.09, and pitavastatin: 0.31 +/- 0.12).",Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19398603/),,0,249583,DB00683,Midazolam
,12614388,steady-state plasma concentration,Infusion of MDL resulted in a mean steady-state plasma concentration of 66 +/- 3 ng/ml.,Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614388/),[ng] / [ml],66,249817,DB00683,Midazolam
,12614388,clearance,MDL inhibited TGB clearance by 20 +/- 7 ml/min/kg from the original value of 89 +/- 6 ml/min/kg.,Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614388/),[ml] / [kg·min],20,249818,DB00683,Midazolam
,12614388,clearance,MDL inhibited TGB clearance by 20 +/- 7 ml/min/kg from the original value of 89 +/- 6 ml/min/kg.,Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614388/),[ml] / [kg·min],89,249819,DB00683,Midazolam
,12614388,Emax,"The pharmacodynamic parameter estimates of TGB were: Emax = 327 +/- 10 microV, EC50 = 392 +/- 20 ng/ml, and nH = 3.1 +/- 0.3.",Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614388/),μv,327,249820,DB00683,Midazolam
,12614388,EC50,"The pharmacodynamic parameter estimates of TGB were: Emax = 327 +/- 10 microV, EC50 = 392 +/- 20 ng/ml, and nH = 3.1 +/- 0.3.",Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614388/),[ng] / [ml],392,249821,DB00683,Midazolam
,12614388,nH,"The pharmacodynamic parameter estimates of TGB were: Emax = 327 +/- 10 microV, EC50 = 392 +/- 20 ng/ml, and nH = 3.1 +/- 0.3.",Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12614388/),,3.1,249822,DB00683,Midazolam
,20082577,inactivation constant (K(I)),"For human CYP3A, the inactivation constant (K(I)) is 12 microM, and the maximum inactivation rate (k(inact)) is 0.037 min(-1).",Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20082577/),μM,12,249994,DB00683,Midazolam
,20082577,maximum inactivation rate (k(inact)),"For human CYP3A, the inactivation constant (K(I)) is 12 microM, and the maximum inactivation rate (k(inact)) is 0.037 min(-1).",Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20082577/),1/[min],0.037,249995,DB00683,Midazolam
,17495878,AUC(0-infinity),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[h·ng] / [ml],107.9,252431,DB00683,Midazolam
,17495878,AUC(0-infinity),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[h·ng] / [ml],175.3,252432,DB00683,Midazolam
,17495878,Cl/F/kg,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[l] / [h·kg],1.26,252433,DB00683,Midazolam
,17495878,Cl/F/kg,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[l] / [h·kg],0.81,252434,DB00683,Midazolam
,17495878,T(1/2),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),h,2.01,252435,DB00683,Midazolam
,17495878,T(1/2),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),h,3.15,252436,DB00683,Midazolam
,17495878,Cmax,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[ng] / [ml],50.6,252437,DB00683,Midazolam
,17495878,Cmax,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[ng] / [ml],71.2,252438,DB00683,Midazolam
,28105513,area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h),"Following a single dose of GMI (Day 8) the area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h) of GA, GB and GK (arithmetic ± standard deviation) was 4.10 ± 1.06, 4.61 ± 1.31 and 0.127 ± 0.102 h μg/mL, respectively; the corresponding values following multiple doses of GMI (Day 19) were 3.94 ± 1.16, 5.00 ± 1.55 and 0.118 ± 0.096 h μg/mL, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),[h·μg] / [ml],4.10,252793,DB00683,Midazolam
,28105513,area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h),"Following a single dose of GMI (Day 8) the area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h) of GA, GB and GK (arithmetic ± standard deviation) was 4.10 ± 1.06, 4.61 ± 1.31 and 0.127 ± 0.102 h μg/mL, respectively; the corresponding values following multiple doses of GMI (Day 19) were 3.94 ± 1.16, 5.00 ± 1.55 and 0.118 ± 0.096 h μg/mL, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),[h·μg] / [ml],4.61,252794,DB00683,Midazolam
,28105513,area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h),"Following a single dose of GMI (Day 8) the area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h) of GA, GB and GK (arithmetic ± standard deviation) was 4.10 ± 1.06, 4.61 ± 1.31 and 0.127 ± 0.102 h μg/mL, respectively; the corresponding values following multiple doses of GMI (Day 19) were 3.94 ± 1.16, 5.00 ± 1.55 and 0.118 ± 0.096 h μg/mL, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),[h·μg] / [ml],0.127,252795,DB00683,Midazolam
,28105513,area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h),"Following a single dose of GMI (Day 8) the area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h) of GA, GB and GK (arithmetic ± standard deviation) was 4.10 ± 1.06, 4.61 ± 1.31 and 0.127 ± 0.102 h μg/mL, respectively; the corresponding values following multiple doses of GMI (Day 19) were 3.94 ± 1.16, 5.00 ± 1.55 and 0.118 ± 0.096 h μg/mL, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),[h·μg] / [ml],3.94,252796,DB00683,Midazolam
,28105513,area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h),"Following a single dose of GMI (Day 8) the area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h) of GA, GB and GK (arithmetic ± standard deviation) was 4.10 ± 1.06, 4.61 ± 1.31 and 0.127 ± 0.102 h μg/mL, respectively; the corresponding values following multiple doses of GMI (Day 19) were 3.94 ± 1.16, 5.00 ± 1.55 and 0.118 ± 0.096 h μg/mL, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),[h·μg] / [ml],5.00,252797,DB00683,Midazolam
,28105513,area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h),"Following a single dose of GMI (Day 8) the area under the concentration-timecurve from zero to 24 h after administration (AUC0-24h) of GA, GB and GK (arithmetic ± standard deviation) was 4.10 ± 1.06, 4.61 ± 1.31 and 0.127 ± 0.102 h μg/mL, respectively; the corresponding values following multiple doses of GMI (Day 19) were 3.94 ± 1.16, 5.00 ± 1.55 and 0.118 ± 0.096 h μg/mL, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),[h·μg] / [ml],0.118,252798,DB00683,Midazolam
,28105513,accumulation ratios,"The mean accumulation ratios were 0.95, 1.08 and 0.89 for GA, GB and GK, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),,0.95,252799,DB00683,Midazolam
,28105513,accumulation ratios,"The mean accumulation ratios were 0.95, 1.08 and 0.89 for GA, GB and GK, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),,1.08,252800,DB00683,Midazolam
,28105513,accumulation ratios,"The mean accumulation ratios were 0.95, 1.08 and 0.89 for GA, GB and GK, respectively.","Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28105513/),,0.89,252801,DB00683,Midazolam
,18094422,area under the curve,"In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) microg.h/mL and 41.2 (32.1-53.1) microg.h/mL, respectively (P = 0.65).",Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094422/),[h·μg] / [ml],42.6,252966,DB00683,Midazolam
,18094422,area under the curve,"In 11 evaluable patients, the geometric mean (95% confidence interval) area under the curve of imatinib on days 1 and 4 were 42.6 (33.0-54.9) microg.h/mL and 41.2 (32.1-53.1) microg.h/mL, respectively (P = 0.65).",Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094422/),[h·μg] / [ml],41.2,252967,DB00683,Midazolam
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],22.2,253697,DB00683,Midazolam
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],27.2,253698,DB00683,Midazolam
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],26.0,253699,DB00683,Midazolam
,27891611,clearance,"Mean morphine clearance was as follows: 22.2, 27.2, 26.0 and 23.4 l/h per kg in the saline-saline, saline-midazolam, saline-morphine and midazolam-morphine groups, respectively.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],23.4,253700,DB00683,Midazolam
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],32.8,253701,DB00683,Midazolam
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],23.0,253702,DB00683,Midazolam
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],22.2,253703,DB00683,Midazolam
,27891611,clearances,"Corresponding midazolam clearances were 32.8, 23.0, 22.2 and 31.1 l/h per kg.",Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27891611/),[l] / [h·kg],31.1,253704,DB00683,Midazolam
,1350744,Emax,"Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy.",Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350744/),1/[μvs],73,254600,DB00683,Midazolam
,1350744,Emax,"Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy.",Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350744/),1/[μvs],19,254601,DB00683,Midazolam
,1350744,Emax,"Large differences in maximal effect of midazolam (Emax = 73 +/- 2 microVs-1), bretazenil (Emax = 19 +/- 1 microVs-1) and Ro 19-4603 (Emax = -6.5 +/- 0.4 microVs-1) were observed, reflecting their differences in intrinsic efficacy.",Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350744/),1/[μvs],-6.5,254602,DB00683,Midazolam
,26888941,IC50,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,295,255854,DB00683,Midazolam
,26888941,KI,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,216,255855,DB00683,Midazolam
,26888941,kinact,FA was a weak reversible (IC50= 295 ± 1.0μM) and time-dependent (KI= 216 ± 41μM and kinact= 0.0179 ± 0.001 min(-1)) inhibitor of CYP3A4-catalyzed midazolam-1'-hydroxylase activity in human liver microsomes.,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),1/[min],0.0179,255856,DB00683,Midazolam
,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,157,255857,DB00683,Midazolam
>,26888941,IC50,FA demonstrated inhibition of multidrug resistant protein 1-mediated digoxin transport with an IC50 value of 157 ± 1.0μM and was devoid of breast cancer resistance protein inhibition (IC50> 500μM).,The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,500,255858,DB00683,Midazolam
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,1.59,255859,DB00683,Midazolam
,26888941,IC50,"In contrast, FA showed potent inhibition of OATP1B1- and OATP1B3-specific rosuvastatin transport with IC50 values of 1.59μM and 2.47μM, respectively.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.47,255860,DB00683,Midazolam
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,2.26,255861,DB00683,Midazolam
,26888941,IC50,"Furthermore, coadministration of oral rosuvastatin and FA to rats led to an approximately 19.3-fold and 24.6-fold increase in the rosuvastatin maximum plasma concentration and area under the plasma concentration-time curve, respectively, which could be potentially mediated through inhibitory effects of FA on rat Oatp1a4 (IC50= 2.26μM) and Oatp1b2 (IC50= 4.38μM) transporters, which are responsible for rosuvastatin uptake in rat liver.",The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26888941/),μM,4.38,255862,DB00683,Midazolam
,23748748,ID50,Ritonavir administered as a single oral dose produced a dose-dependent CYP3A inhibition with an ID50 of 3.4 mg.,Concentration effect relationship of CYP3A inhibition by ritonavir in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748748/),mg,3.4,256706,DB00683,Midazolam
,23748748,IC50,Using the measured ritonavir concentrations an exposure-inhibition effect curve was established with an IC50 of 600 h pmol/L (AUC2-4).,Concentration effect relationship of CYP3A inhibition by ritonavir in humans. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748748/),[h·pM] / [l],600,256707,DB00683,Midazolam
,31093992,Clearance,Clearance was 73.7 mL/h for a neonate weighing 1.1 kg and changed nonlinearly with body weight (exponent 1.69).,Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31093992/),[ml] / [h],73.7,256795,DB00683,Midazolam
,31093992,Volume of distribution,Volume of distribution increased linearly with body weight and was 1.03 L for a neonate weighing 1.1 kg.,Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31093992/),l,1.03,256796,DB00683,Midazolam
,31093992,steady-state concentrations,"To reach similar steady-state concentrations of 400 µg/mL (±100 µg/mL), a dose of 0.03 mg/(kg·h) is adequate for neonates ≥1 kg and ≤2 kg but would have to be reduced to 0.02 mg/(kg·h) (-33%) in neonates <1 kg and increased to 0.04 mg/(kg·h) (+33%) in neonates weighing >2 kg and ≤2.5 kg.",Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31093992/),[μg] / [ml],400,256797,DB00683,Midazolam
,24288267,midazolam concentration,We found a high interindividual variability of serum midazolam concentrations in asphyxiated neonates with therapeutic hypothermia; median midazolam concentration was 369.3 ng/ml (minimum 36.6; maximum 3 218.6 ng/ml).,Disposition of midazolam in asphyxiated neonates receiving therapeutic hypothermia--a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24288267/),[ng] / [ml],369.3,258007,DB00683,Midazolam
,24288267,clearance,"The population pharmacokinetic model revealed a midazolam clearance of 2.57 ml/kg/min, comparable to midazolam clearances observed in normothermic critically ill neonates.",Disposition of midazolam in asphyxiated neonates receiving therapeutic hypothermia--a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24288267/),[ml] / [kg·min],2.57,258008,DB00683,Midazolam
,7946365,target concentrations,Patients were anesthetized using a variable-rate infusion of alfentanil combined with midazolam in an attempt to achieve and maintain target concentrations of 100 ng/ml or 500 ng/ml.,Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ng] / [ml],100,258250,DB00683,Midazolam
,7946365,target concentrations,Patients were anesthetized using a variable-rate infusion of alfentanil combined with midazolam in an attempt to achieve and maintain target concentrations of 100 ng/ml or 500 ng/ml.,Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ng] / [ml],500,258251,DB00683,Midazolam
lower,7946365,clearance,"Two of the selected data sets of midazolam, with a clearance lower than 5 ml/kg/min, were very accurate (MDAPE less than 20%) in predicting low or high prebypass concentrations of midazolam in adult patients with good left ventricular function.",Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ml] / [kg·min],5,258252,DB00683,Midazolam
,23523258,Ki,The results indicated that Sch B significantly dose-dependently inhibited rat hepatic microsomal CYP3A activity with Ki value of 16.64 mg/kg and showed the characteristic of a noncompetitive inhibitor.,In vivo effect of Schisandrin B on cytochrome P450 enzyme activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523258/),[mg] / [kg],16.64,258262,DB00683,Midazolam
,15470333,systemic clearance,"However, mean values differed markedly between the drugs, with the systemic clearance of midazolam being almost double that of triazolam (383 +/- 73 mL/min versus 222 +/- 54 mL/min).","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],383,258662,DB00683,Midazolam
,15470333,systemic clearance,"However, mean values differed markedly between the drugs, with the systemic clearance of midazolam being almost double that of triazolam (383 +/- 73 mL/min versus 222 +/- 54 mL/min).","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],222,258663,DB00683,Midazolam
,15470333,Oral clearances,"Oral clearances were even more dissimilar: alprazolam, 75 +/- 36 mL/min; triazolam, 360 +/- 195 mL/min; and midazolam, 533 +/- 759 mL/min.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],75,258664,DB00683,Midazolam
,15470333,Oral clearances,"Oral clearances were even more dissimilar: alprazolam, 75 +/- 36 mL/min; triazolam, 360 +/- 195 mL/min; and midazolam, 533 +/- 759 mL/min.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],360,258665,DB00683,Midazolam
,15470333,Oral clearances,"Oral clearances were even more dissimilar: alprazolam, 75 +/- 36 mL/min; triazolam, 360 +/- 195 mL/min; and midazolam, 533 +/- 759 mL/min.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),[ml] / [min],533,258666,DB00683,Midazolam
,15470333,oral bioavailability,"Estimates of CYP3A-mediated extraction by the intestine and liver indicated approximately equal contributions by both organs but larger values for midazolam than for triazolam, and these differences accounted for the differences in oral bioavailability, 30% +/- 13% versus 55% +/- 20%, respectively.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),%,30,258667,DB00683,Midazolam
,15470333,oral bioavailability,"Estimates of CYP3A-mediated extraction by the intestine and liver indicated approximately equal contributions by both organs but larger values for midazolam than for triazolam, and these differences accounted for the differences in oral bioavailability, 30% +/- 13% versus 55% +/- 20%, respectively.","In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15470333/),%,55,258668,DB00683,Midazolam
,22177374,AUC(0-8),The mean (SD) 1-OH-MID AUC(0-8) was significantly greater in the TT homozygotes compared with the CT heterozygotes after intravenous (86.15 [24.34] vs 53.21 [31.36] ng/mL/h; P = 0.026) but not oral (126.36 [31.60] vs 103.09 [31.00] ng/mL/h; P = 0.159) MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [h·ml],86.15,258785,DB00683,Midazolam
,22177374,AUC(0-8),The mean (SD) 1-OH-MID AUC(0-8) was significantly greater in the TT homozygotes compared with the CT heterozygotes after intravenous (86.15 [24.34] vs 53.21 [31.36] ng/mL/h; P = 0.026) but not oral (126.36 [31.60] vs 103.09 [31.00] ng/mL/h; P = 0.159) MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [h·ml],53.21,258786,DB00683,Midazolam
,22177374,AUC(0-8),The mean (SD) 1-OH-MID AUC(0-8) was significantly greater in the TT homozygotes compared with the CT heterozygotes after intravenous (86.15 [24.34] vs 53.21 [31.36] ng/mL/h; P = 0.026) but not oral (126.36 [31.60] vs 103.09 [31.00] ng/mL/h; P = 0.159) MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [h·ml],126.36,258787,DB00683,Midazolam
,22177374,AUC(0-8),The mean (SD) 1-OH-MID AUC(0-8) was significantly greater in the TT homozygotes compared with the CT heterozygotes after intravenous (86.15 [24.34] vs 53.21 [31.36] ng/mL/h; P = 0.026) but not oral (126.36 [31.60] vs 103.09 [31.00] ng/mL/h; P = 0.159) MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [h·ml],103.09,258788,DB00683,Midazolam
,22177374,C(max),Mean 1-OH-MID C(max) was significantly greater in the TT homozygotes (51.40 [10.72] ng/mL) compared with the CC homozygotes (31.47 [11.54] ng/mL; P = 0.002) and CT heterozygotes (30.12 [9.21] ng/mL; P = 0.001) after intravenous MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [ml],51.40,258789,DB00683,Midazolam
,22177374,C(max),Mean 1-OH-MID C(max) was significantly greater in the TT homozygotes (51.40 [10.72] ng/mL) compared with the CC homozygotes (31.47 [11.54] ng/mL; P = 0.002) and CT heterozygotes (30.12 [9.21] ng/mL; P = 0.001) after intravenous MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [ml],31.47,258790,DB00683,Midazolam
,22177374,C(max),Mean 1-OH-MID C(max) was significantly greater in the TT homozygotes (51.40 [10.72] ng/mL) compared with the CC homozygotes (31.47 [11.54] ng/mL; P = 0.002) and CT heterozygotes (30.12 [9.21] ng/mL; P = 0.001) after intravenous MID administration.,"Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177374/),[ng] / [ml],30.12,258791,DB00683,Midazolam
,21280267,area under the plasma concentration-time curve (AUC),"T] allele showed a significant decrease in fexofenadine in the area under the plasma concentration-time curve (AUC) compared with c.[1457C] + c[= ] subjects (1110 ± 347 vs. 1762 ± 542 ng . h/ml, P< 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],1110,258865,DB00683,Midazolam
,21280267,area under the plasma concentration-time curve (AUC),"T] allele showed a significant decrease in fexofenadine in the area under the plasma concentration-time curve (AUC) compared with c.[1457C] + c[= ] subjects (1110 ± 347 vs. 1762 ± 542 ng . h/ml, P< 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],1762,258866,DB00683,Midazolam
,21280267,AUC,"When administered with apple juice, a significant decrease in the fexofenadine AUC was observed compared with water (1342 ± 519 vs. 284 ± 79.2 ng . h/ml, P < 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],1342,258867,DB00683,Midazolam
,21280267,AUC,"When administered with apple juice, a significant decrease in the fexofenadine AUC was observed compared with water (1342 ± 519 vs. 284 ± 79.2 ng . h/ml, P < 0.05).",The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280267/),[h·ng] / [ml],284,258868,DB00683,Midazolam
,20642546,oral midazolam clearance,"In a cross-over study, healthy volunteers (n = 9) phenotyped as extensive metabolizers of CYP2C19 and CYP2D6 and with an oral midazolam clearance ranging from 10.9 to 149.3 ml min(-1) kg(-1) received a single dose of racemic CITA (20 mg orally) in combination or not with omeprazole (20 mg day(-1) for 18 days).",Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642546/),[ml] / [kg·min],10.9 to 149.3,259312,DB00683,Midazolam
,31469454,terminal half-lives,"The mean ± SD terminal half-lives of IC and IM midazolam were 12.04 ± 3.25 hr and 16.54 ± 7.10 hr, respectively.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),h,12.04,259323,DB00683,Midazolam
,31469454,terminal half-lives,"The mean ± SD terminal half-lives of IC and IM midazolam were 12.04 ± 3.25 hr and 16.54 ± 7.10 hr, respectively.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),h,16.54,259324,DB00683,Midazolam
,31469454,area under the concentration-time curve extrapolated to infinity,"The area under the concentration-time curve extrapolated to infinity, clearance, and apparent volume of distribution in steady-state of IC midazolam were 19,112.3 ± 3,095.9 ng*hr/ml, 0.053 ± 0.008 L hr-1 kg-1 , and 0.865 ± 0.289 L/kg, respectively.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),[h·ng] / [ml],"19,112.3",259325,DB00683,Midazolam
,31469454,clearance,"The area under the concentration-time curve extrapolated to infinity, clearance, and apparent volume of distribution in steady-state of IC midazolam were 19,112.3 ± 3,095.9 ng*hr/ml, 0.053 ± 0.008 L hr-1 kg-1 , and 0.865 ± 0.289 L/kg, respectively.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),[l] / [h·kg],0.053,259326,DB00683,Midazolam
,31469454,apparent volume of distribution in steady-state,"The area under the concentration-time curve extrapolated to infinity, clearance, and apparent volume of distribution in steady-state of IC midazolam were 19,112.3 ± 3,095.9 ng*hr/ml, 0.053 ± 0.008 L hr-1 kg-1 , and 0.865 ± 0.289 L/kg, respectively.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),[l] / [kg],0.865,259327,DB00683,Midazolam
,31469454,bioavailability,The bioavailability of IM midazolam was estimated at 89%.,Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),%,89,259328,DB00683,Midazolam
,31469454,Maximum plasma concentrations,"Maximum plasma concentrations following an IM administration were reached 2.33 ± 0.98 hr and 24.00 ± 14.12 hr postinjection for midazolam and 1-hydroxymidazolam, respectively, and 22.33 ± 20.26 hr postinjection for 1-hydroxymidazolam following IC administration.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),h,2.33,259329,DB00683,Midazolam
,31469454,Maximum plasma concentrations,"Maximum plasma concentrations following an IM administration were reached 2.33 ± 0.98 hr and 24.00 ± 14.12 hr postinjection for midazolam and 1-hydroxymidazolam, respectively, and 22.33 ± 20.26 hr postinjection for 1-hydroxymidazolam following IC administration.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),h,24.00,259330,DB00683,Midazolam
,31469454,Maximum plasma concentrations,"Maximum plasma concentrations following an IM administration were reached 2.33 ± 0.98 hr and 24.00 ± 14.12 hr postinjection for midazolam and 1-hydroxymidazolam, respectively, and 22.33 ± 20.26 hr postinjection for 1-hydroxymidazolam following IC administration.",Pharmacokinetics of midazolam and its major metabolite 1-hydroxymidazolam in the ball python (Python regius) after intracardiac and intramuscular administrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31469454/),h,22.33,259331,DB00683,Midazolam
,7603305,constant plasma alcohol concentration,Ethanol infusion resulted in a constant plasma alcohol concentration of 0.44 +/- 0.04 g/l (Mean +/- SE) and had no effect on the baseline value of the EEG effect parameter.,Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603305/),[g] / [l],0.44,259444,DB00683,Midazolam
,21870106,T(max),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.03,259984,DB00683,Midazolam
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.66,259985,DB00683,Midazolam
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.66,259986,DB00683,Midazolam
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.99,259987,DB00683,Midazolam
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.25,261184,DB00683,Midazolam
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.02,261185,DB00683,Midazolam
,2935051,elimination half-life,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,2.05,261186,DB00683,Midazolam
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.13,261187,DB00683,Midazolam
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.14,261188,DB00683,Midazolam
,2935051,volume of distribution,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[l] / [kg],2.16,261189,DB00683,Midazolam
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],10.8,261190,DB00683,Midazolam
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],12.2,261191,DB00683,Midazolam
,2935051,total clearance,"Analysis of variance indicated no significant differences in mean values for trials a, b, and c in midazolam elimination half-life (2.25 vs 2.02 vs 2.05 hr), volume of distribution (2.13 vs 2.14 vs 2.16 L/kg) or total clearance (10.8 vs 12.2 vs 12.3 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],12.3,261192,DB00683,Midazolam
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],90,261193,DB00683,Midazolam
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],95,261194,DB00683,Midazolam
,2935051,peak plasma level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ng] / [ml],117,261195,DB00683,Midazolam
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,0.65,261196,DB00683,Midazolam
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,1.45,261197,DB00683,Midazolam
,2935051,time of peak level,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,0.90,261198,DB00683,Midazolam
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.04,261199,DB00683,Midazolam
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.38,261200,DB00683,Midazolam
,2935051,elimination half-life,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),h,3.30,261201,DB00683,Midazolam
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],16.2,261202,DB00683,Midazolam
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],14.3,261203,DB00683,Midazolam
,2935051,apparent oral clearance,"Again, there were no significant differences among trials a, b, and c in midazolam peak plasma level (90 vs 95 vs 117 ng/ml), time of peak level (0.65 vs 1.45 vs 0.90 hr after dose), elimination half-life (3.04 vs 3.38 vs 3.30 hr), or apparent oral clearance (16.2 vs 14.3 vs 13.8 ml . min-1 . kg-1).",Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2935051/),[ml] / [kg·min],13.8,261204,DB00683,Midazolam
,25418605,AUC(inf),"In the repeated-dose study, the values for AUC(inf) and C(max) were 2.6 (90%CI, 2.1-3.3) and 2.0 (90%CI, 1.7-2.4), respectively.",Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25418605/),,2.6,261284,DB00683,Midazolam
,25418605,C(max),"In the repeated-dose study, the values for AUC(inf) and C(max) were 2.6 (90%CI, 2.1-3.3) and 2.0 (90%CI, 1.7-2.4), respectively.",Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25418605/),,2.0,261285,DB00683,Midazolam
,19046855,t(max),"Midazolam was rapidly absorbed following i.n. administration, with a median t(max) of 10 min; dose proportionate increases for C(max) and AUC; t(1/2) of 4 h; and, 60% (+/-23) nasal administration bioavailability compared to the i.v. dose.","A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046855/),min,10,261670,DB00683,Midazolam
,19046855,t(1/2),"Midazolam was rapidly absorbed following i.n. administration, with a median t(max) of 10 min; dose proportionate increases for C(max) and AUC; t(1/2) of 4 h; and, 60% (+/-23) nasal administration bioavailability compared to the i.v. dose.","A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046855/),h,4,261671,DB00683,Midazolam
,19046855,bioavailability,"Midazolam was rapidly absorbed following i.n. administration, with a median t(max) of 10 min; dose proportionate increases for C(max) and AUC; t(1/2) of 4 h; and, 60% (+/-23) nasal administration bioavailability compared to the i.v. dose.","A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046855/),%,60,261672,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5370,262206,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5246,262207,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.43,262208,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.87,262209,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.23,262210,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.11,262211,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],677.9,262212,DB00683,Midazolam
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],466.9,262213,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,207",262214,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,688",262215,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],34.85,262216,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],37.27,262217,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],92.07,262218,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],93.04,262219,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1428,262220,DB00683,Midazolam
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1499,262221,DB00683,Midazolam
,3161528,elimination half-life,"The short elimination half-life of midazolam (2.4 h in patients less than 50 yr undergoing minor surgery) was significantly, although not markedly, prolonged with age (4.1 h in patients greater than 50 yr undergoing minor procedures) and by the nature of the operation (3.8 h after major operative procedures).",Age and nature of operation influence the pharmacokinetics of midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161528/),h,2.4,262749,DB00683,Midazolam
,3161528,elimination half-life,"The short elimination half-life of midazolam (2.4 h in patients less than 50 yr undergoing minor surgery) was significantly, although not markedly, prolonged with age (4.1 h in patients greater than 50 yr undergoing minor procedures) and by the nature of the operation (3.8 h after major operative procedures).",Age and nature of operation influence the pharmacokinetics of midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161528/),h,4.1,262750,DB00683,Midazolam
,3161528,elimination half-life,"The short elimination half-life of midazolam (2.4 h in patients less than 50 yr undergoing minor surgery) was significantly, although not markedly, prolonged with age (4.1 h in patients greater than 50 yr undergoing minor procedures) and by the nature of the operation (3.8 h after major operative procedures).",Age and nature of operation influence the pharmacokinetics of midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3161528/),h,3.8,262751,DB00683,Midazolam
,15370957,apparent K(m),"2. Midazolam was mainly metabolized by CYP3A in DEX-treated female rat liver microsomes from an immuno-inhibition study, and the apparent K(m) was 1.8 microM, similar to that in human microsomes.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,1.8,262842,DB00683,Midazolam
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,0.088,262843,DB00683,Midazolam
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,91.2,262844,DB00683,Midazolam
,27236320,Bioavailability,Bioavailability of voriconazole 50 mg was 39 % compared with 86 % of the 400 mg dose.,Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236320/),%,39,263467,DB00683,Midazolam
,27236320,Bioavailability,Bioavailability of voriconazole 50 mg was 39 % compared with 86 % of the 400 mg dose.,Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236320/),%,86,263468,DB00683,Midazolam
,27236320,area under the concentration-time curve extrapolated to infinity (AUC∞),"Voriconazole area under the concentration-time curve extrapolated to infinity (AUC∞) was 416 and 16,700 h·ng/mL for the 50 and 400 mg oral doses, respectively, and 1110 and 19,760 h·ng/mL for the 50 and 400 mg intravenous doses, respectively.",Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236320/),[h·ng] / [ml],416,263469,DB00683,Midazolam
,27236320,area under the concentration-time curve extrapolated to infinity (AUC∞),"Voriconazole area under the concentration-time curve extrapolated to infinity (AUC∞) was 416 and 16,700 h·ng/mL for the 50 and 400 mg oral doses, respectively, and 1110 and 19,760 h·ng/mL for the 50 and 400 mg intravenous doses, respectively.",Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236320/),[h·ng] / [ml],"16,700",263470,DB00683,Midazolam
,27236320,area under the concentration-time curve extrapolated to infinity (AUC∞),"Voriconazole area under the concentration-time curve extrapolated to infinity (AUC∞) was 416 and 16,700 h·ng/mL for the 50 and 400 mg oral doses, respectively, and 1110 and 19,760 h·ng/mL for the 50 and 400 mg intravenous doses, respectively.",Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236320/),[h·ng] / [ml],1110,263471,DB00683,Midazolam
,27236320,area under the concentration-time curve extrapolated to infinity (AUC∞),"Voriconazole area under the concentration-time curve extrapolated to infinity (AUC∞) was 416 and 16,700 h·ng/mL for the 50 and 400 mg oral doses, respectively, and 1110 and 19,760 h·ng/mL for the 50 and 400 mg intravenous doses, respectively.",Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236320/),[h·ng] / [ml],"19,760",263472,DB00683,Midazolam
,16580904,elimination half-life,Voriconazole reduced the clearance of intravenous midazolam by 72% (P < .001) and increased its elimination half-life from 2.8 to 8.3 hours (P < .001).,Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580904/),h,2.8,263753,DB00683,Midazolam
,16580904,elimination half-life,Voriconazole reduced the clearance of intravenous midazolam by 72% (P < .001) and increased its elimination half-life from 2.8 to 8.3 hours (P < .001).,Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580904/),h,8.3,263754,DB00683,Midazolam
,16580904,bioavailability,The bioavailability of oral midazolam was increased from 31% to 84% (P < .001).,Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580904/),%,31,263755,DB00683,Midazolam
,16580904,bioavailability,The bioavailability of oral midazolam was increased from 31% to 84% (P < .001).,Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580904/),%,84,263756,DB00683,Midazolam
,22849770,t1/2,"Following single doses of ACT-178882, t1/2 and tmax varied from 18.7 to 24.7 h and from 3 to 5 h, respectively, and food had no significant effect.","Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849770/),h,18.7 to 24.7,264352,DB00683,Midazolam
,22849770,tmax,"Following single doses of ACT-178882, t1/2 and tmax varied from 18.7 to 24.7 h and from 3 to 5 h, respectively, and food had no significant effect.","Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849770/),h,3 to 5,264353,DB00683,Midazolam
,23584886,AUC ratio,"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,8,264678,DB00683,Midazolam
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,0.97,264679,DB00683,Midazolam
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,17,264680,DB00683,Midazolam
,23584886,f(m)),"For midazolam, model 2 predicted a maximal midazolam AUC ratio of 8 and a hepatic fraction metabolized by CYP3A (f(m)) of 0.97, whereas model 1 predicted 17 and 0.90, respectively, which are more consistent with observed data.",Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23584886/),,0.90,264681,DB00683,Midazolam
,26332539,time to Cmax (Tmax,"Increasing USL261 dose corresponded with increases in midazolam area under the concentration time curve (AUC) and maximum observed plasma concentration (Cmax ), with all doses demonstrating rapid median time to Cmax (Tmax ; 10-12 min).","Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332539/),min,10-12,265521,DB00683,Midazolam
,26332539,relative bioavailability,"USL261 also demonstrated increased absorption, with a 134% relative bioavailability, compared with the same MDZ-inj IN dose.","Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26332539/),%,134,265522,DB00683,Midazolam
,29891212,Heart rate,Heart rate was significantly higher from 20 to 90 minutes after MBM-MK.,Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,20 to 90,266340,DB00683,Midazolam
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,23,266341,DB00683,Midazolam
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,11,266342,DB00683,Midazolam
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,32,266343,DB00683,Midazolam
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,18,266344,DB00683,Midazolam
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],95.6,267028,DB00683,Midazolam
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],160.4,267029,DB00683,Midazolam
less,32250458,ki,All three compounds showed a strong reversible inhibition on CYP2C8 enzyme with ki of less than 0.5 μmol L-1 .,"Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),[μM] / [l],0.5,267402,DB00683,Midazolam
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.0,267403,DB00683,Midazolam
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.1,267404,DB00683,Midazolam
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.4,267405,DB00683,Midazolam
,32250458,AUC ratio,"The PBPK simulation predicted that at recommended dosing regimens of S. sphenanthera, co-administration would result in an increase in bosutinib exposure (AUC ratio 3.0) but not in imatinib exposure.","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,3.0,267406,DB00683,Midazolam
,3512140,elimination half-life,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,149,268206,DB00683,Midazolam
,3512140,clearance,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.3,268207,DB00683,Midazolam
,3512140,elimination half-life,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,83 to 137,268208,DB00683,Midazolam
,3512140,clearance,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],4.37 to 6.47,268209,DB00683,Midazolam
,3512140,distribution,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,28,268210,DB00683,Midazolam
,3512140,terminal elimination half-lives,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,273 to 330,268211,DB00683,Midazolam
,3512140,clearance,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.6 to 25,268212,DB00683,Midazolam
,3512140,half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,2.1,268213,DB00683,Midazolam
,3512140,elimination half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,47,268214,DB00683,Midazolam
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],71.7,268712,DB00683,Midazolam
,27940077,t1/2,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),min,116,268713,DB00683,Midazolam
,27940077,clearance,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ml] / [kg·min],6.25,268714,DB00683,Midazolam
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],191,268715,DB00683,Midazolam
,27940077,Cmax,"When measured up to 4 h in venous blood, the training dose resulted in the following mean pharmacokinetic parameters: nicotine Cmax = 71.7 ng/ml, t1/2 = 116 min, and clearance = 6.25 ml/min/kg; cotinine Cmax = 191 ng/ml; and 3OH-cotinine Cmax = 63 ng/ml.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[ng] / [ml],63,268716,DB00683,Midazolam
,27940077,ED50,The ED50 value of nicotine to produce discriminative stimulus effects was 0.013 mg/kg.,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.013,268717,DB00683,Midazolam
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.00015,268718,DB00683,Midazolam
,27940077,ED50,"Epibatidine and varenicline increased drug-lever responding to 97% and 95%, respectively (ED50 values = 0.00015 and 0.031 mg/kg, respectively), whereas cocaine, midazolam, and morphine produced no more than 28% drug-appropriate responding.",The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),[mg] / [kg],0.031,268719,DB00683,Midazolam
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.58,268720,DB00683,Midazolam
,27940077,apparent pA2,DHβE (0.1 and 0.32) produced rightward shifts of the nicotine and varenicline dose-response functions; Schild plots fitted through individual data resulted in slopes that were not different from unity; the apparent pA2 calculated for DHβE did not significantly differ in the presence of nicotine (6.58) or varenicline (6.45).,The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27940077/),,6.45,268721,DB00683,Midazolam
,18581106,hydroxylation index,"The volunteers genotyped as CYP2C19*1*17, CYP2C19*17*17, CYP2C19*1*1 (n = 8), or CYP2C19*17*2 (n = 1) presented a median hydroxylation index (omeprazole/hydroxyomeprazole) of 1.35, indicating that all of them were extensive metabolizers of CYP2C19.",Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18581106/),,1.35,270175,DB00683,Midazolam
,18581106,oral clearance of midazolam,"The volunteers (n = 9) presented a 0.12 log of the omeprazole/sulfone ratio and a median oral clearance of midazolam of 17.89 ml min(-1) kg(-1), suggesting normal CYP3A activity.",Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18581106/),[ml] / [kg·min],17.89,270176,DB00683,Midazolam
,20305886,plasma concentration,"A pharmacokinetic study provided dexmedetomidine plasma concentration, set to be 3.0 ng*mL(-1).",Hemodynamics and bispectral index (BIS) of dogs anesthetized with midazolam and ketamine associated with medetomidine or dexmedetomidine and submitted to ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305886/),[ng] / [ml],3.0,270806,DB00683,Midazolam
,12837492,plasma clearance (Cl),"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[ml] / [kg·min],79,270865,DB00683,Midazolam
,12837492,plasma clearance (Cl),"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[ml] / [kg·min],92,270866,DB00683,Midazolam
,12837492,blood Cl,"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[ml] / [kg·min],64,270867,DB00683,Midazolam
,12837492,blood Cl,"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[ml] / [kg·min],75,270868,DB00683,Midazolam
,12837492,volume of distribution (V(d)),"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[l] / [kg],4.0,270869,DB00683,Midazolam
,12837492,volume of distribution (V(d)),"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[l] / [kg],3.6,270870,DB00683,Midazolam
,12837492,area under the plasma concentration-time curve (AUC(t0-tinf)),"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[h·ng] / [ml],1062,270871,DB00683,Midazolam
,12837492,area under the plasma concentration-time curve (AUC(t0-tinf)),"MDZ exhibited a high plasma clearance (Cl) of 79 and 92 ml/min/kg (corresponding to a blood Cl of 64 and 75 ml/min/kg), a high volume of distribution (V(d)) of 4.0 and 3.6 l/kg, and an area under the plasma concentration-time curve (AUC(t0-tinf)) of 1062 and 932 h.ng/ml in the control group and in the Solutol HS 15-treated group, respectively.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[h·ng] / [ml],932,270872,DB00683,Midazolam
below,12837492,excreted,The amount of MDZ excreted unchanged into urine was below 0.01% with both dosing vehicles.,Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),%,0,270873,DB00683,Midazolam
,12837492,AUC(t0-tinf),AUC(t0-tinf) in the control group was 12.3 h.ng/ml for 1'OH-MDZ and 38.8 h.ng/ml 4OH-MDZ.,Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[h·ng] / [ml],12.3,270874,DB00683,Midazolam
,12837492,AUC(t0-tinf),AUC(t0-tinf) in the control group was 12.3 h.ng/ml for 1'OH-MDZ and 38.8 h.ng/ml 4OH-MDZ.,Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[h·ng] / [ml],38.8,270875,DB00683,Midazolam
,12837492,AUC(t0-tinf),"In the Solutol HS 15-treated group, AUC(t0-tinf) was 14 h.ng/ml for 1'OH-MDZ and 35.4 h.ng/ml for 4OH-MDZ.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[h·ng] / [ml],14,270876,DB00683,Midazolam
,12837492,AUC(t0-tinf),"In the Solutol HS 15-treated group, AUC(t0-tinf) was 14 h.ng/ml for 1'OH-MDZ and 35.4 h.ng/ml for 4OH-MDZ.",Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12837492/),[h·ng] / [ml],35.4,270877,DB00683,Midazolam
,12847388,Total body clearance,"Total body clearance, apparent volume distribution in terminal phase, and plasma elimination half-life were (mean +/- sd, n = 18): 5.0 +/- 3.9 mL/kg/min, 1.7 +/- 1.1 L/kg, and 5.5 +/- 3.5 hrs, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),[ml] / [kg·min],5.0,272118,DB00683,Midazolam
,12847388,apparent volume distribution in terminal phase,"Total body clearance, apparent volume distribution in terminal phase, and plasma elimination half-life were (mean +/- sd, n = 18): 5.0 +/- 3.9 mL/kg/min, 1.7 +/- 1.1 L/kg, and 5.5 +/- 3.5 hrs, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),[l] / [kg],1.7,272119,DB00683,Midazolam
,12847388,plasma elimination half-life,"Total body clearance, apparent volume distribution in terminal phase, and plasma elimination half-life were (mean +/- sd, n = 18): 5.0 +/- 3.9 mL/kg/min, 1.7 +/- 1.1 L/kg, and 5.5 +/- 3.5 hrs, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),h,5.5,272120,DB00683,Midazolam
,12847388,ratio,"The mean 1-OH-midazolam/midazolam ratio and (1-OH-midazolam + 1-OH-midazolam-glucuronide)/midazolam ratio were 0.14 +/- 0.21 and 1.4 +/- 1.1, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),,0.14,272121,DB00683,Midazolam
,12847388,ratio,"The mean 1-OH-midazolam/midazolam ratio and (1-OH-midazolam + 1-OH-midazolam-glucuronide)/midazolam ratio were 0.14 +/- 0.21 and 1.4 +/- 1.1, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),,1.4,272122,DB00683,Midazolam
,7072920,minimal plasma level,The minimal plasma level producing a deep hypnotic effect with an EEG-median of less than 5 s-1 was about 0.5 microgram/ml.,[A microprocessor controlled infusion scheme for midazolam to achieve constant plasma levels (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7072920/),[μg] / [ml],0.5,272512,DB00683,Midazolam
,12621386,apparent inhibition constant (K(i)),"Although not a substrate for P-glycoprotein, cisapride inhibited P-glycoprotein with an apparent inhibition constant (K(i)) of 16.1 micromol/L.",Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621386/),[μM] / [l],16.1,272585,DB00683,Midazolam
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],60.47,272796,DB00683,Midazolam
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],30.56,272797,DB00683,Midazolam
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],98.74,272798,DB00683,Midazolam
,32463566,area under the curve (AUC),"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[h·ng] / [ml],49.21,272799,DB00683,Midazolam
,32463566,apparent total clearance,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[l] / [h],330.7,272800,DB00683,Midazolam
,32463566,apparent total clearance,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),[l] / [h],654.5,272801,DB00683,Midazolam
,32463566,apparent volume of distribution,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),l,"2,609",272802,DB00683,Midazolam
,32463566,apparent volume of distribution,"The uncontrolled SLE group showed higher area under the curve (AUC) for ATV (60.47 (43.76-83.56) vs. 30.56 (22.69-41.15) ng⋅hour/mL) and its inactive metabolite ATV-lactone (98.74 (74.31-131.20) vs. 49.21 (34.89-69.42) ng⋅hour/mL), and lower apparent total clearance (330.7 (239.30-457.00) vs. 654.5 (486.00-881.4) L/hour) and apparent volume of distribution (2,609 (1,607-4,234) vs. 7,159 (4,904-10,450) L), when compared to the healthy subjects group (geometric mean and 95% confidence interval).",Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463566/),l,"7,159",272803,DB00683,Midazolam
,3122596,plasma elimination half-life,"The plasma elimination half-life of midazolam and its main metabolite, 1-OH-midazolam glucuronide, after stopping the infusion varied from 4-12 hours.",Clinical pharmacokinetics of long-term infusion of midazolam in critically ill patients--preliminary results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3122596/),h,4-12,272835,DB00683,Midazolam
,2044332,initial volume of distribution,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),l,16,272930,DB00683,Midazolam
,2044332,volume of distribution at steady-state,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),l,64.8,272931,DB00683,Midazolam
,2044332,total body clearance,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),[l] / [h],53.8,272932,DB00683,Midazolam
,2044332,distribution half-life,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),min,4.1,272933,DB00683,Midazolam
,2044332,elimination half-life,"The pharmacokinetic parameters were (mean +/- SD): initial volume of distribution, 16 +/- 5.7L; volume of distribution at steady-state, 64.8 +/- 12.5L; total body clearance, 53.8 +/- 1.2 L/h; distribution half-life, 4.1 +/- 1.3 min; and elimination half-life, 70.2 +/- 9.9 min.",Pharmacokinetics and EEG effects of flumazenil in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2044332/),min,70.2,272934,DB00683,Midazolam
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,9.4,273896,DB00683,Midazolam
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,6.2,273897,DB00683,Midazolam
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,1.7-26.8,273898,DB00683,Midazolam
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,3.9,273899,DB00683,Midazolam
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,3.8,273900,DB00683,Midazolam
,23230007,metabolic ratio,"CYP3A4 activities were not significantly different between the two groups (midazolam metabolic ratio: 9.4 ± 8.2; 6.2; 1.7-26.8 vs 3.9 ± 2.3; 3.8; 1.5-7.6, in the normal dose group as compared to the high dose group, respectively, NS).",Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230007/),,1.5-7.6,273901,DB00683,Midazolam
